

~~PCT/US2005/027239~~

moving from start (N-terminus or 5') to end (C-terminus or 3'), such that for an alignment that extends to p monomers (where $p > x$) there are $p-x+1$ such windows, each window has at least $x \cdot y$ identical aligned monomers, where: x is selected from 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200; y is selected from 0.50, 0.60, 0.70, 0.75, 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99; and if $x \cdot y$ is not an integer then it is rounded up to the nearest integer. The preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm [Needlman & Wunsch (1970) *J. Mol. Biol.* 48, 443-453], using default parameters (e.g., with Gap opening penalty = 10.0, and with Gap extension penalty = 0.5, using the EBLOSUM62 scoring matrix). This algorithm is conveniently implemented in the *needle* tool in the EMBOSS package [Rice et al. (2000) *Trends Genet.* 16:276-277].

The nucleic acids and polypeptides of the invention may additionally have further sequences to the N-terminus/5' and/or C-terminus/3' of these sequences (a) to (d).

All of the Gram positive bacterial sequences referenced herein are publicly available through PubMed on GenBank.

Streptococcus pneumoniae Adhesin Island Sequences

As discussed above, a *S. pneumoniae* AI sequence is present in the TIGR4 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences are set forth below.

SrtD (Sp0468) is a sortase. An example of an amino acid sequence of SrtD is set forth in SEQ ID NO: 80.

SEQ ID NO: 80

MSRTRKLRALLGYLLMLVACLIPYICFGQMVLSLQVKGHATFVKSMTTEMYQEQQNHSLAYNQRLASQNRIVDP
FLAEGYEVNYQVSDDDPAVYGYLSIPSLEIMEPVYLGADYHHLGMLAHVDGTPPLDGTGIRSVIAGHRAEPSH
VFFRHLQKLVGDALYDNGQEIIVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFGLFVLWKLARLLRGK

SrtC (Sp0467) is a sortase. An example of an amino acid sequence of SrtC is set forth in SEQ ID NO: 81.

SEQ ID NO: 81

MSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAFNATLKPSEILDPFTEQEKKKGVSEYANMLKVHERIG
YVEIPAIHQEIPMYVGTSEDILQKGAGLLEGASLPVGGENTHTVITAHRGLPTAELFSQLDKMKKGDIFYLHVLD
QVLAYQVDQIVTVEPNDPEPVLIQHGEDIATLLTCTPYMINSHRLLVVRGKRIPTYAPIAERNRAVRERGFWLWL
LLGAMAVILLLLRYRVRNRRIKVGLEKQLEGRHVKD

SrtB (SP0466) is a sortase. An example of an amino acid sequence of SrtB is set forth in SEQ ID NO: 82.

SEQ ID NO: 82

MAVMAYPLVSRLYRVEESNQIADFDKEKATLDEADIDERMKLAQAFNDSLNNVSGDPWSEEMKKKGRAEYARM
LEIHERMGHVEIPVIDVDLVPYAGTAEVQLQAGHLEGTSPLPIGGNSTHAVITAHGLPTAKMFTDLTKLVGD
KFYVHNIKEVMAYQVDQVKVIEPTNFDDLIVPGHDYVTLTCTPYMINTHRLLVVRGHRIPYVAEVEVEEFIAANK
LSHLRYLFFYAVGLIVILLWIIIRLRKRRKQPEKALKALKAAARKEVKVEDGQQ

Sp0465 is a hypothetical protein. An example of an amino acid sequence of Sp0465 is set forth in SEQ ID NO: 83.

SEQ ID NO: 83

MFLPFLSASLYLQTHHFTAFPNRQSYLLRETRKSHFFLIHHPF

5 RrgC (SP0464) is a cell wall surface anchor family protein. RrgC contains a sortase substrate motif VPXTG (SEQ ID NO: 137), shown in italics in SEQ ID NO: 84.

SEQ ID NO: 84

MISRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQLPSRDGHRLOVWKLDDSSYSYDDRQIVRDLHS
 WDENKLSFFKKT SFEMTFLENQIEVSHIPNGLYYVRSIIQTDAVSYPAEFLFEMTDQTVPEPLVIVAKKTDMTTK
 10 VKLIKVDQDHNRLLEGVGFKLVS VARDVSEKEVPLIGEYRYS SSGQVGR TLYTDKNGE I FVTNLPLGNYRFKEVEP
 LAGYAVTTLD TDVLDHQLVITIVVNQK LPRGNVDFMKVDGR TNTSLQ GAMFKVMKEESGHYTPVLQNGKEVVV
 TSGKDGRFRVEGLE YGTYLWELQAPTGYVQLTSPV SFTI GKDRKELVTVVKNNKRPRIDVPDTGEETLYILML
 VAILLFGSGYYLT KKPNN

15 RrgB (Sp0463) is a cell wall surface anchor protein. RrgB contains a sortase substrate motif IPXTG (SEQ ID NO: 133), shown in italics in SEQ ID NO: 85.

SEQ ID NO: 85

MKSINKFLTMLAALLTASSLFSAA TVFAAGTTTT SVTVHKLLATDGDMDKIANELETGNYAGNKVGVLPANAKE
 IAGVMFVWNTNNEI IDENGO TLGVNIDPQTFKLSGAMPATAMK KLTEAEGAKFNTANLPA AKYKIYEIHSLS TY
 20 VGEDGATLTGSKAVPIEIE LPLNDVDAHVYPKNTEAKPKIDKDFKGANPDTPRVDKDTPVNHQVGDVVEYEV
 TKIPALANYATANWSDRMTEGLAFNKGTVKVTVDVVALEAGDYALTEVATGF DLKLT DAGLAKVNDQNAEKT VKI
 TYSATLNDKAI VEVPESNDVTFNYGNPNPDHGNTPKPNKPNENGLD LTKTWV DATGAPI PAGAEATFDLVNAQTG
 KVVQTVTLT DKN TVTVNGLDKNTEYKFVERS IKGYSADYQEI TTAGEI AVKNW K DENPKPLDPTEPKVV TYGKK
 FVKVNDKDNRLAGAE FVI ANADNAGQYLARKADKVSQEEKQLVVTTKDALDRAVAAYNALTAQQQTQOEKEKVDK
 25 AQAAYNAAVIAANNAFEWVADKDNENNVKLVSDAQGRFEITG LLAGTYYLEETKQPAGYALLTSRQKFEVTATSY
 SATGGQIEYTAGSGKDDATKVVNKKITIPQTGGIGITII FAVAGAAIMGIAVYAVVKNNKDEDQLA

30 RrgA (Sp0462) is a cell wall surface anchor protein. RrgA contains a sortase substrate motif YPXTG (SEQ ID NO: 186), indicated in italics in SEQ ID NO: 86.

SEQ ID NO: 86

MLNRETHMKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETS PAIGKVVIKETGEGGALLGDAVFELKNNTDG
 30 TTVSQRTEAQTGEAIFSNIKPGTYTLTEAQP PVGYKPS TKQWTV EVEKNGR TTVQGEQVENREALS DQYPQTGT
 YPDVQTPYQI IKVDGSEKNGQHKALNPNPYERVI PEGT LSKRIYQVNNLDDNQYGIELTVSGKTVYEQKDKSVPL
 DVVILLDNSNSMSNIRKNARRAERAGEATRSLIDKITSDSEN RVALV TYASTI FDGTEFTVEKGVADKNGKRLN
 DSLFWNYDQTSFTTNTKDYSYLKLTNDKNDIVELKNKVPTEAEDHDGNRLMYQFGATFTQKALMKADEILTQQR
 35 QNSQKVI FHI TDGVP TMSYPINFENHATFAPS YQNQLNAFFSKSPNKDGILLSDFITQATS GEHTIVRGDGSYQM
 FTDKTVYEKGAPAAFPVKPEKYS EMKAAGYAVIGDPINGGYI WLNWRESILAYPFNSNTAKI TNHGDPTRWYNG
 NIAPDGYDVFTVGI GINGDPGTDEATATSFMQSISSK PENYTNVTD TTKILEQLNRYFHTIVTEKKS IENGTITD
 PMGELIDLQLGTDGRFPADYTLTANDGSRLENGQAVGGPQNDGGLLKNKAVLYDTTEKRIRV TGLYLGTD EKVT
 40 LTYNVRLNDEFVSNKPYDTNGR TTHLPKEVEQNTVRDFPI PKIRDVRKYPEITISKEK KLGDI EFIKVNKNDKKP
 LRGA VFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLT FKNLSDGK YRLFENSEPAGYKPVQNKPIVAFQIVN
 GEVRDVT SIVPQDI PAGYEFTNDKHYITNEPI PKREYPR TGGIGMLPFY LIGCMMMGGVLLYTRKHP

45 RlrA (Sp0461) is a transcriptional regulator. An example of an amino acid sequence for RlrA is set forth in SEQ ID NO: 87.

SEQ ID NO: 87

MLNKYIEKRITDKITILNILLDIRSIEDELSTLTS LQSKSLLSILQELQET FEEELTFNLDTQQVQLIEHSHQ
 50 TNYFFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYI SIATGYRVRQKCGLLRSVGLDLVKNQVVGPEYRIRF
 LIALLQFHFGIEIYDLNDGSM DWVTHMIVQSNSQLSHELLEITPDEYVHF SIVALTWKRREFFLEFPESKEFEK
 LKNLFMYPILMEHCQTYLEPHANMTFTQEBLDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILOHTRGKHL LSKF
 KNILGNDISNSLSFLTALTF LTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAIVQEWMEHQKIEGVIDQHR
 LYLFSLYLTETIFSSLP AIPFI FII LNNQADVNLIKS IILRNFTDKVASVTGYNILISPPP EEEHLTEPLIIITTK
 EYLPYVKKQYPK GKHHFLTIALDLHVSQQRLIYQTI VDIRKEAFDKRVAMI AKKAHYLL

55 As discussed above, a *S. pneumoniae* AI sequence is present in the *S. pneumoniae* strain 670 genome. Examples of *S. pneumoniae* AI sequences are set forth below.

~~PCT/US2005/027239~~
Orf1_670 is a transposase. An example of an amino acid sequence of orf1_670 is set forth in SEQ ID NO: 171.

SEQ ID NO: 171

MEHINHTLLIGIKDKNITLTKAIQHDTHIEVFATLDYHPPCKKHCKGKQIKYDFQKPSKIPFIEIGGFPSLIHL
5 KKRRFQCKSCRKVTVAETTLVQKNCQISEMVRQKIAQLLLNREALTHIASKLAI STSTSTVYRKLKQHFQEDYT
TLPEILSWDEFSYQKGLAFIAQDFNTKKIMTILDNRROTTRNHFFKYSKEARKKVKVVTVDMSGSYIPLIKKL
FPNAKIVLDRFHIVQHMSRALNQTRINIMKQFDDKSLEYRALKYWKFKLSDSRKLSLKPFIYARTFRETLPREC
LKKIFTLPELKDYYDLYQLLLEFHLQEKNTDQFWGLIQDTLPHLNRTFKTTLSTFCYKNYITNAIELPYSNAKL
10 EATNKLIKDIKRNAFGFRNFENFKRIFIALNIKKERTKFLVLSRA

Orf2_670 is a transcriptional regulator. An example of an amino acid sequence of Orf2_670 is set forth in SEQ ID NO: 172.

SEQ ID NO: 172

MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLSQSKSLLSILOELQETFEELTFNLDTQQVQLIEHHSQ
15 TNYFFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYISIATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
LIALLQFHFGIEIYDLNDGSMWVTHMIVQSNQSLSHELLEITPDEYVHFSILVALTWKRREFPLEFPESKEFEK
LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSFSKDKWNQEKKHTHTIQLIILQHTRGKHLSSKF
KNILGNDISNSLSFLTALTFLTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAIVQEWMTQKIEGVLDQHR
20 LYLFSLYLTETIFSSLPAPIFIFILNNQADVNLIKSIIILRNFTDKVASVTGYNILISPPPSEEHLEPLIIITTK
EYLPYVKKQYPRGKHHFLTIALDLHVSQORLIYQTIIVDIRKEAFDKRVAMIAKKAHYLL

Orf3_670 is a cell wall surface anchor family proten. An example of an amino acid sequence of Orf3_670 is set forth in SEQ ID NO: 173.

SEQ ID NO: 173

MLNRETHMKKVRKI FQKAVAGLCCISQLTAFSSIVALAETPETSPAIGKVVIKETGEGGALLGDVAVFELKNNTDG
25 TTVSQRTEAQTGEAIFSNIKPGTYTLTEAQPVGYPKSTKQWTVVEVEKNGRITVQGEQVENREEALSQYPQTGT
YPDVQTPYQI IKVDGSEKNGQHAKALNPNPYERVIPEGTSLSKRIYQVNNLDDNQYGIELTVSGKTIVETKEASTPL
DVVILLDNSNSMSNIRHNHAHRAEKAGEATRALVDKITSNPDNRVALVTYGSTIFDGSEATVEKGVADANGKILN
30 DSALWTFDRTFFTA KTYNYSFLNLTSDPTDIQTIKDRIPSDAEELNKDKLMYQFATFTQKALMTADDILTQKAR
PNSKKVIFHITDGVPTMSYPINFKYTGTTQSYRTQLNNEFKAKTPNSSGILLEDFVWTSADGEHKKIVRGDGESYQM
FTKKPVTDQYGVHQILSITSMEQRAKLVSAGYRFYGTDLYLWRDSILAYPFNSSTDWITNHGDPTTWYNGNMA
QDGYDVFTVGVGVNGDPTDEATATRFMQSISSSPDNYTNVADPSQILQELNRYFYTIVNEKKSIENTITDPMG
ELIDFQLGADGRFDPADYTLTANDGSSLVNNVPTGGPQNDGGLLKNKAVFYDTTEKRI RVTGLYLGTGEKVTLTY
45 NVRLNDQFVSNKFYDTNGRITLHPKEVEKNTVRDFPIPKIRDVRKYPEITIPEKPKLGEIEFIFKINKNDKKPLRD
AVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSGDKYRFLFENSEPAGYKPVQNKPIVAFQIVNGEV
35 RDVTSIVPQDIPAGYEFTNDKHYITNEPIPKREYPRTEGGIGMLPFYILIGCMMMGVLLYTRKHP

Orf4_670 is a cell wall surface anchor family protein. An example of an amino acid sequence of orf4_670 is set forth in SEQ ID NO: 174.

SEQ ID NO: 174

MKSINKFLTMLAALLLTASSLFSAAVFAADNVSTAPDAVTKTLTIHKLLESEDDLKTWDTNPGKYDGTQSSLK
40 DLTGVAEEIPNVYFELQKYNLTDGKEKENLKDDSKWTTVHGGLTTKDGLKIESTLKGVYRIRREDRTKTTYVGP
NGQVLTGSKAVPALVTLPLVNNNGTVIDAHVFPKNSYNKPVVDKRIADTLNNDQNGLSIGTKI PYVNTTIPSN
ATFATSFWSDEMTEGLTYNEDVTITLNNVAMDQADYEVTKGNNGFNLKLTEAGLAKINGKDADQKIQTITYSATLN
45 SLAVADI PESNDITYHYGNHQDHGNTPKPTKPNNGQITVTKTWDSQPAPEGVKATVQLVNAKTGEKVGAPVELSE
NNWFTYTWGLDNSIEYKVEEYNGYSAEYTVESKGLGVKNWKNNDNPAIPNPEEPRVKTYGKFKVKVDQKDRLE
NAQFVVKKADS NKYIAFKSTAQQAADKAAATAKQKLDAAVAAYTNAADKQAAQALVDQAQQEYNVAYKEAKFGY
VEVAGKDEAMVLTSDNTDGFQISGLAAGTYKLEEKI KAPEGFAKIDDFEVVGVAGSWNQEFNYLKDVKQNDATKV
50 VNKKITIPQTGGIGITII FAVAGAAIMGI AVYAVYVKNKDEDQLA

Orf5_670 is a cell wall surface anchor family protein. An example of an amino acid sequence of orf5_670 is set forth in SEQ ID NO: 175.

SEQ ID NO: 175

MTMQKMQKMISRIFFVMALCFSLVGAHAVQAQEDHTLVLQLENYQEVVSQLP SRDGHRLQVWKLDDSYSDDRV
55 QIVRDLHSW DENKLSFKKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDAVSYPAEFLFEMTDQTVPEPLVI VAK

KTDTMTTKVKLIRVDQDHNRLTEGVGFKLVSVARLDGSEKEVPLIGEYRYSSSGQVGRITLYTDKNGEIVFVNLPLGN
YRFKEVEPLAGYAVTFLDLDVQLVDHQLVTTIVVNQKLPGRNVDFMKVDGRTNTSLQGAMFKVMKEESGHYTPVL
QNGKEVVVTSKDGFRFRVEGLEGTYYLWELQAPTGYVQLTSPVSTIGKDRKELVTVVKNNKRPRIDVDPDTGE
ETLYILMLVAILLFGSGYLLTKKPNN

5

Orf6_670 is a sortase. An example of an amino acid sequence of orf6_670 is set forth in SEQ ID NO: 176.

SEQ ID NO: 176

MLIKMVKTKKQKRNLLLVVFFIGMAVMAYPLVSRLYRVEVSNQQIADFDKEKATLDEADI DERMKLAQAFNDS
LNNVVGDPWSEEMKKKGRAEYARMLEIHERMGHVEI PVIDVDLPVYAGTAEVVLQAGHLEGTSPIGGNSTH
AVITAHTGLPTAKMFTDLTKLKVGDKFVYVHNIKEVMAYQVDQVKVIEPTNFDDLLIVPGHDYVTLTCTPYMINT
HRLLRVGRHIPYVAEVEEFIAANKLSHLYRYLFYVAUGLIVILLWIIIRLRKKKKQPEKALKALKAAARKEVKVE
DGQQ

10

Orf7_670 is a sortase. An example of an amino acid sequence of orf7_670 is set forth in SEQ ID NO: 177.

SEQ ID NO: 177

VSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQA FNATLKPSEILDPFTEQEKKKG VSEYANMLKVHERIG
YVEIPAI DQEI PMYVGTSEEILQKGAGLLEGASLPVGGENTHTVVTAHRLPTAELFSQLDKMKKGDV FYLHVLD
QVLAYQVDQILTVEPNDFEPVLIQHGEDYATLLTCTPYMINSHRLLVRGKRI PYTAPIAERNRAVRERGOFWLWL
LLAALVMILVLSYGVYRHRRI VKGLEKQLEEHVKG

15

20

Orf8_670 is a sortase. An example of an amino acid sequence of orf8_670 is set forth in SEQ ID NO: 178.

SEQ ID NO: 178

MSKAKLQKLLGYLLMLVALVIPVYCFGQMVLSLQVQVKGHEIFSESVTADSYQEQLQRSLDYNQRLDSQNRIVDP
FLAEGYEVNYQVSDDPDAVYGYLSIPSLEIMEPVYLGADYHHLAMGLAHVDGTPLPVEGKGI RSVIAGHRAEPSH
VFFRHL DQLKVG DALYYDNGQEIVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVA V
YQKSDPQTA AVARVAFTKEGQSVSRVATSQWLYRGLVVLAF LGILFVLWKLARLLRGK

25

30

As discussed above, a *S. pneumoniae* AI sequence is present in the 19A Hungary 6 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences from 19A Hungary 6 are set forth below.

ORF2_19AH is a transcriptional regulator. An example of an amino acid sequence of ORF2_19AH is set forth in SEQ ID NO: 187.

35

SEQ ID NO: 187

MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLQSKSLLSILQELQETFEHEELTFNLD TQQVQLIEHHSQ
TNYFFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYIS IATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
LIALLQFHFGIEIYDLNDGSM DWVTHMIVQSNSQLSHELLEITPDEYVHFSILVALTWKRREFPLEFPESKEFEK
LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQILIQHTRGKHL LSKF
KNILGNDISNSLSFLTALTFLTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAI VQEWMTQKIEGVIDQHR
LYLFSLYLTETIFSSLPAPIFIILNNAQDVNLIKSIILRNFTDKVASVTGYNILISPPPSEEHLTEPLIIITTK
EYLPYVKKQYPKGGKHHFLTIALDLHVSQQRLIYQTI VDIRKEAFDKRVAMI AKKAHYLL

40

ORF3_19AH is a cell wall surface protein. An example of an amino acid sequence of

ORF3_19AH is set forth in SEQ ID NO: 188.

45

SEQ ID NO: 188

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETS PAIGKVVIKETGEGGALLGD AVFELKNNTDGTTVSQRT
EAQTGEAIFSNIKPGTYTLTEAQP PVGYPSTKQWTVVEVEKNGRTTVQGEQVENREEALS DQYPQTGTYPDVQTF
YQIKVDGSEKNGQH KALNPNPYERVIPEGT LSKRIYQVNNLDDNQYGIELTVSGKTTVETKEASTPLDVVILLD
NSNSMSNIRHNH ARAEKAGEATRALVDKITSNPDNRVALV TYGSTIFDGSEATVEKGVADANGKILNDSALWTF
DRTFTEAKTYNYSFLNLTSDPTDIQTIKDRIPSDAEELNKDKL MYQFGATFTQKALMTADDILT KQARPN SKKVI
FHITDGVPTMSYPINFKYTGTTQSYRTQLN NFKA KTPNSSGILLED FVTVSADGEHKIVRGDGE SYQMFTKKPV T

50

DYGVHQLSFLSMTSMBORAKLVSAGYRFRYGTDLLYLYWRDSILAYPFNSSTDWITNHGDPTTWYYNGNMAQDGYDVE
 TVGVGVNGDPGTDEATATRFMQSISSSPDNYTNVADPSQILQELNRYFYTIVNEKKSIENTGITDPMGELIDFQL
 GADGRFDPADYTLTANDGSSLVNNVPTGGPQNDGGLLKNKAKVFYDTTEKRIRVTGLYLGTGEKVTLTYNVRINDQ
 FVSNKFYDTNGRITLHPKEVEKNTVRDFPIPKIRDVRKYPEITIPEKELGEIEFKINKNDKKPLRDAVFSLQK
 5 QHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTISV
 PQDIPAGYEFTNDKHYITNEPIPPKREYPRRTGGIGMLPFYILIGCMMMGGVLLYTRKNP

ORF4_19AH is a cell wall surface protein. An example of an amino acid sequence of
 ORF4_19AH is set forth in SEQ ID NO: 189.

SEQ ID NO: 189

MKSINKFLTMLAALLLTASSLFSAAVFAADNVSTAPDAVTKTLTIHKLLLEDLKTWDTNPKGYDGTQSSLK
 DLTGVAEEIIPNVYFELQKYNLTDGKEKENLKDSSKWTTVHGGLTKDGLKIETSTLKGVIYRIREDRTKTYVGP
 NGQVLTGSKAVPALVTLPLVNNNGTVIDAHVFPKNSYNKPVVDKRIADTLNYNDQNGLSIGTKIPYVNTTIPSN
 ATFATSFWSDEMTEGLTYNEDVTTILNNVAMDQADYEVTKGXNGFNLKLTEAGLAKINGKDADQKIQITYSATLN
 15 SLAVADIPESNDITYHYGNHQDHGNTPKPTKPNNGQITVTKTWSQPAPEGVKATVQLVNAKTGEKVGAPVELSE
 NNWYTTWSGLDNSIEYKVEEYNGYSAEYTVESKGLGVKNWKDNNPAPINPEEPRVKTYGKFFVKVDQKDRLE
 NAQFVVKKADSNKYIAFKSTAQQAADEKAAATAKQKLDAAVAAYTNAADKQAAQALVDQAQQEYNVAYKEAKFGY
 VEVAGKDEAMVLTSTNDGQFQISGLAAGTYKLEEIKAPEGFAKIDDVEFVVGAGSWNQGEFNYLKDQVKNATKV
 VNKKITIPQTGGIGTIIFAVAGAAIMGIAYVAYVKNKDEDQLA

ORF5_19AH is a cell wall surface protein. An example of an amino acid sequence of
 ORF5_19AH is set forth in SEQ ID NO: 190.

SEQ ID NO: 190

MTMQKMQKMSIRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQVPSRDGHRQLQVWKLDDSSYSYDDRV
 25 QIVRDLHSWDENKLSFFKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDVAVSYPAEFLFEMTDQTVPLVIVAK
 KTDMTTKVLIKVDQDHNRLGEGVGFKLVSVDGSEKEVPLIGERYSSSGQVGRITLYTDKNGEIVFVNLPLGN
 YRFKEVEPLAGYAVTTLDTDVQLVDHQLVTTIVVNQKLPRGNVDFMKVDGRTNTSLQGAMFKVMKEESGHYTPVL
 QNGKEVVVTSKDGFRFRVEGLEYGTYLWELQAPTGYVQLTSPVSEFTIGKDRKELVTVVKNNKRPRIDVDPDTGE
 30 ETLYILMLVAIILFGSGYYLTKKPNN

ORF6_19AH is a putative sortase. An example of an amino acid sequence of ORF6_19AH is
 set forth in SEQ ID NO: 191.

SEQ ID NO: 191

MLIKMVKTKKQRNLLLVGVVFFIGMAVMAYPLVSRLYYRVESNQIADFDKEKATLDEADI DERMKLAQAFNDS
 35 LNNVVSGDPWSEEMKKKGRABYARMLEIHERMGHVEIPIVIDVLPVYAGTAEVLOQGAGHLEGTSLPIGGNSTH
 AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAVQVDQVKVIEPTNFDDLLIVPGHDYVLLTCTPYMINT
 HRLLRVGRHRIPIYVAEVEEFAANKLSHLYRYLFYVAVGLIVILLWIIIRLRKRRKQPEKALKALKAAARKEVKVE
 DGQQ

ORF7_19AH is a putative sortase. An example of an amino acid sequence of ORF7_19AH is
 set forth in SEQ ID NO: 192.

SEQ ID NO: 192

MDNSRRSRKGTKKKHPILLLLIFLVGFAVAIYPLVSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAF
 45 NATLKPSEILDPEFTEQEKKGVSEYANMLKVHERIGYVEI PAIDQEI PMYVGTSEEILQKAGLLEGASLPVGGE
 NTHTVVTAHRGLPTAELFSQLDKMKKGDVYFLHVLVDQVLAQVDQILTVEPNDFEPVLIQHGEDYATLLTCTPYM
 INSHRLLRGKRIPYTAPIAERNRAVRERQFVWLWLLAALVMILVLSYGVYRHRRIKVGLEKQLEEHVKG

ORF8_19AH is a putative sortase. An example of an amino acid sequence of ORF8_19AH is
 set forth in SEQ ID NO: 193.

SEQ ID NO: 193

MSKAKLQKLLGYLLMLVALVIPVYCFGQMVLSLQVKGHEIFSESVTADSYQEQLQRSLDYNQRLDSQNRIVDP
 50 FLAEGYEVNYQVSDDPDAVYGYLSIPSLIMEPVYLGADYHLLAMGLAHVDGTPLPVEGKGIKRSVIAGHRAEPSH
 VFFRHLQDLKVGDALYYDNGQEIIVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFMGILFVLWKLARLLRGK

As discussed above, a *S. pneumoniae* AI sequence is present in the 6B Finland 12 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences from 6B Finland 12 are set forth below.

ORF2_6BF is a transcriptional regulator. An example of an amino acid sequence of

5 ORF2_6BF is set forth in SEQ ID NO: 194.

SEQ ID NO: 194

MLNKYIEKRITDKTITILNILLDIRSIELDELSTLTSLQSKSLLSILQELQETFEELTFNLDTQVQLIEHHSHQ
 TNYFFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYISIAATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
 LIALLQFHFGIETIYDLNDGSMWVTHMIVQSNLSHELLEITPDEYVHFSILVALTWKRREFPLEFPESKEFEK
 10 LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILQHTRGKHLLSKF
 KNILGNDISNLSFLTALTFLTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAIQEWMTQEKIEGVLDQHR
 LYLFSLYLTETIFSSLPAPIPIFIILNNQADVNLIKSIIILRNFTDKVASVTGYNILISPPPSEEHLEPLIIITTK
 EYLPYVKKQYPKGGKHHFLTIALDLHVSQORLIYQTIIVDIRKEAFDKRVAMIAKKAHYLL

15 ORF3_6BF is a cell wall surface protein. An example of an amino acid sequence of

ORF3_6BF is set forth in SEQ ID NO: 195.

SEQ ID NO: 195

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSPAIGKVVIKETGEGGALLGDVAVFELKNNTDGTTVSQRT
 EAQTGEAIFSNIKPGTYTLTEAQPVGYPKSTKQWTVVEKNGRTTVQGEQVENREEALSQYPPQTGTYPDVQTP
 20 YQIIKVDGSEKNGQHKALNPNPYERVIEPGLTKRIYQVNNLDDNQYGIELTVSGKTTVETKEASTPLDQVILLDD
 NSNSMSNIRHNHRAEKAGEATRALVDKITSNPDNRVALVTYGSTIFDGSEATVEKGVADANGKILNDSALWTF
 DRTTFTAKTYNSFLNLTSDPTDIQTIKDRIPSDAEELNKDKLMYQFGATFTQKALMTADDILTKQARNSKKVI
 FHITDGVPTMSYPINFKYTGTTQSYRTQLNFKAKTPNSSGILLEDFTWSADGEHKKIVRGDGESYQMFTKKPV
 25 DQYGVHQLSITSMQRAKLVSAGYRFYGTDLVLYWRDILAYPFNSSTDWITNHGDPPTWYNGNMAQDGYDVF
 TVGVGVNGDPTDEATATRFMQSISSSPDNYTNVADPSQILQELNRYFYTIIVNEKKSIENTITDPMGELIDFQL
 GADGRFDPADYTLTANDGSSLVNNVPTGGPQNDGGLLNKNAKFYDTTEKRIRVTGLYLGTGEKVTLYNVRINDQ
 FVSNKFYDTNGRTTLHPKEVEKNTVRDFPIPKIRVRYPEITIPKEKKLGEIEFIKINKNDKKPLRDAVFSLOK
 QHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYLRFENSEPAGYKPVQNKPIVAFQIVNGEVRDVT
 30 PQDIPAGYEFTNDKHITNEPIPPKREYPRGGIGMLPFYILGMMMGVLLYTRKHP

ORF4_6BF is a cell wall surface protein. An example of an amino acid sequence of

ORF4_6BF is set forth in SEQ ID NO: 196.

SEQ ID NO: 196

MKSINKFLTMLAALLLTASSLFSAAVFAADNVSTAPDAVTKTLTIHKLLSEDDLKTWDTNGPKGYDGTQSSLK
 35 DLTGVVAEEIPNVYFELQKYNLTDGKEKENLKDSSKWTTVHGGLTTKDGLKIETSTLKGVYRIRREDRTKTTYVGP
 NGQVLTGSKAVPALVTLPLVNNNGTVIDAHVFPKNSYNKPVVDKRIADTLNNDQNGLSIGTKIPYVNTTIPSN
 ATFATSFWSDEMTEGLTYNEDVTITLNNVAMDQADYEVTKGNNGFNLKLEAGLAKINGKDADQKIQITYSATLN
 SLAVADIPESNDITYHYGNHQDHGNTPKPTKPNNGQITVTKTWDSQPAPEGVKATVQLVNAKTGEKVGAPVELSE
 NNWYTYWGLDNSIEYKVEEYNGYSAEYTVESKGLGVKNWKNPAPINPEEPRVKTYGKKFVKVDQKDRLE
 40 NAQFVVKKADSNKYIAFKSTAQQAADKAAATAKQKLDAAVAAYTNAADKQAAQALVDQAQOEYNVAYKEAKFGY
 VEVAGKDEAMVLTSTNDGQFQISGLAAGTYKLEEKAPGFAKIDDDVEFVVGAGSWNQGEFNYLKDQVQKNDATKV
 VNKKITIPQTGGIGTIIFAVAGAAIMGIAVYAVKNNKDEDQLA

ORF5_6BF is a cell wall surface protein. An example of an amino acid sequence of

45 ORF5_6BF is set forth in SEQ ID NO: 197.

SEQ ID NO: 197

MTMQKMQKMSRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQVPSRDGHRQLQVWKLDDSYSDDRV
 QIVRDLHSWDENKLSFFKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDVAVSYPAEFLFEMTDQTVPLVIVAK
 50 KTDMTTKVKLIKVDQDHNRLGEGVFKLVSVARDGSEKEVPLIGEYRYSSSGQVGRTLTYTDKNGEIVFTNLPLGN
 YRFKEVEPLAGYAVTTLDTDVQLVDHQLVTITVVNQKLPRGNVDFMKVDGRINTSLQGAMFKVMKEESGHYTPVL
 QNGKEVVVTSKGDGRFRVEGLEYGTYLWELQAPTGYVQLTSPVSTIGKTRKELVTVVKNKRPRIDVPDTGE
 ETLYILMLVAILLFGSGYYLTKKPN

ORF6_6BF is a putative sortase. An example of an amino acid sequence of ORF6_6BF is set forth in SEQ ID NO: 198.

SEQ ID NO: 198

5 MLIKMVKTKKQKRNNLLLVVFFIGMAVMAYPLVSRLYRVEESNOQIADFDEKATLDEADI DERMKLAQAFNDS
LNNVVSGDPWSEEMKKKGRAEYARMLEIHERMGHVEIPVIDVDLPVYAGTAEVVLQQGAGHLEGTSLPIGGNSTH
AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAYQVDQVKVIEPTNFDDLLIVPGHDYVTLTCTPYMINT
HRLLRVGRHRI PYVAEVEVEEFIAANKLSHLYRYLFYVAVGLIVILLWII RRLRKKKKQPEKALKALKAAARKEVKVE
DGQQ

10 ORF7_6BF is a putative sortase. An example of an amino acid sequence of ORF7_6BF is set forth in SEQ ID NO: 199.

SEQ ID NO: 199

15 MDNSRRSRKKGTKKKKHPILLILLIFLVGFAVAIYPLVSRYYYRIESNEVIKEFDETQVSDMDKAELEERWRLAQAF
NATLKPSEILDPFTEQEKKKGVSEYANMLKVHERIGYVEIPAIHQEIPMYVGTSEEILQKAGLLEGASLPVGGE
NTHTVVTAHRGLPTAELFSQLDKMKKGDVFFYLHVLDQVLAYQVDQILTVEPNDFEPVLIQHGEDYATLLTCTPYM
INSHRLLRVGRKRI PYTAPIAERNRAVREREGQFWLWLLLAALVMI LVLVSYGVYRHRIRIVKGLEKQLEHHVKG

ORF8_6BF is a putative sortase. An example of an amino acid sequence of ORF8_6BF is set forth in SEQ ID NO: 200.

SEQ ID NO: 200

20 MSKAKLQKLLGYLLMLVALVIPVYCFGQMVLSLQVQKGEI FSESVTADSYQEQLQRSLDYNQRLLDSQNRIVDP
FLAEGYEVNYQVSDDDAVYGYLSIPSLEIMEPVYLGADYHHLAMGLAHVDGTPLPVEGKGRSIVIAGHRAEPPSH
VFFRHLDDQLKVGDALYDNGQEIVEYQMMDEI ILLPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFILGILFVLWKLARLLRGK

25 As discussed above, a S. pneumoniae AI sequence is present in the 6B Spain 2 S. pneumoniae genome. Examples of S. pneumoniae AI sequences from 6B Spain 2 are set forth below.

ORF2_6BSP is a transcriptional regulator. An example of an amino acid sequence of ORF2_6BSP is set forth in SEQ ID NO: 201.

SEQ ID NO: 201

30 MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLQSKSLLSILQELQETFEELTFNLDTQQVQLIEHHSHQ
TNYFFHQLYNQSTILKLLRFFLLQGNQSFNEFTQKEYISIAATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
LIALLQFHFGIEIYDLNDGSMWVTHMIVQSNQSLSHELLEITPDEYVHFSSILVALTWKRREFPLEFPESKEFEK
35 LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILQHTRGKHLLSKF
KNILGNDISNSLSFTALTFLTRTFLEGLQNLVPPYNYEYHYGIESDKPLYHISKAI VQEWMTQKIEGVIDQHR
LYLFSLYLTETIFSSLPAPIFIFILNNAQADVNLIKSII LRNFQDKVASVTGYNILISPPPSEEHLEPLIIITTK
EYLPYVKKQYPKGGKHHFLTIALDLHVSQQRLIYQTI VDIRKEAFDKRVAMI AKKAHYLL

ORF3_6BSP is a cell wall surface protein. An example of an amino acid sequence of

40 ORF3_6BSP is set forth in SEQ ID NO: 202.

SEQ ID NO: 202

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETS PAIGKVVIKETGEGGALLGDAVFELKNNTDGTTVSQRT
EAQTGEAIFSNIKPGTYTLTEAQPVGYPSTKQWTVVEVEKNGRTTVQGEQVENREEALSDQYPTGTYPDVQTP
YQIIKVDGSEKNGQHAKALNPNPYERVIPEGTLSKRIYQVNNLDDNQYGIELTVSGKTTVETKEASTPLDVVILLD
45 NSNSMSNIRHNHAHRAEKAGEATRALVDKITSNPDRVALVTYGSTIFDGSEATVEKGVADANGKILNDSALWTF
DRTTFTAQTYNYSFLNLTSDPTDIQTIKDRI PSDAEELNKDKLQMYQFGATFTQKALMTADDILTQARPNSKKVI
FHITDGVPTMSYPINFKYTGTTQSYRTQLNNEFAKTPNSSGILLEDFVTVSADGEHKKIVRGDGE SYQMFTKKPVT
DQYGVHQLSITSMEQRAKLVSAGYRFYGTDLVLYWRDSILAYFPNSSDWTNHGDPPTWYNGNMAQDGYDVF
TVGVGVNGDPGTDEATATRFMQSISSSPDNYTNVADPSQILQELNRYFYTIVNEKKSIENTGITDPMGELIDFQL
50 GADGRFPADYTLTANDGSSLVNVPPTGGPQNDGGLLNKAKVYDTEKRI RVTGLYLGTEKVTLTYNVRLNDQ
FVSNKFYDTNGRITLHPKEVEKNTVRDFPIPKIRDVRKYPEITIPKEKKLGEIEFIKINKNDKKPLRDAVFSLOK
QHPDYDPIYGAIQNGTYQNVRTGEDGKLT FKNLSDGKYLRFENSEPAGYKPVQNKPIVAFQIVNGEVRDVT SIV
PQDIPAGYEFTNDKHYITNEPIPPKREYPRGTGGIGMLPFYLI GMMMGGVLLYTRKHP

~~PCT/US2005/027239~~

ORF4_6BSP is a cell wall surface protein. An example of an amino acid sequence of ORF4_6BSP is set forth in SEQ ID NO: 203.

SEQ ID NO: 203

5 MKSINKFLTMLAALLLTASSLFSAAATVFAADNVSTAPDAVTKTLTIHKLLSEDDLKTWDTNGPKGYDGTQSSLK
DLTGVAEEI PNVYFELQKYNLTGKKEKENLKDDSKWTTVHGGLTKDGLKIETSTLKGVYRIREDRTKTYVGP
NGQVLTGSKAVPALVTLPLVNNNGTVIDAHVFPKNSYNKPVVDKRIADTLNNDQNGLSIGTKIPYVNTTIPSN
ATFATSFWSDTEGLTYNEDVTITLNNVAMDQADYEVTKGNNGFNLKLEAGLAKINGKDDAQKIQITYSATLN
10 SLAVADIPESNDITYHYGNHQDHGNTPKPTKPNNGQITVTKTWDSQPAPEGVKATVQLVNAKTGEKVGAPVELSE
NNWYTWSGLDNSIEYKVEEYNGYSAEYTVESKGLGKVNKNDNPPAPINPEEPRVKTYGKKFVKVDQKDRLE
NAQFVVKKADSNKYIAFKSTAQQAADEKAAATAKQKLDAAVAAYTNAADKQAAQALVDQAAQQEYNVAYKEAKFGY
VEVAGKDEAMVLTSTNDGQFQISGLAAGTYKLEEKAPGFAKIDDFEVVVGAGSWNQGEFNYLKDVKNDATKV
VNKKITIPQTGGIGTIIFAVAGAAIMGIAVYAYVKNNKDEDQLA

ORF5_6BSP is a cell wall surface protein. An example of an amino acid sequence of

15 ORF5_6BSP is set forth in SEQ ID NO: 204.

SEQ ID NO: 204

16 MTMQKMQKMSRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQLPSRDGHRLOQVWKLDDSYSDRRV
QIVRDLHSWDENKLSFFKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDAVSYPAEFLFEMTDQTVPLVIVAK
KTDTMTTKVKLIKVDQDHNRLLEGVGFKLVSARDGSEKEVPLIGEYRYSSTGQVGRITLYTDKNGEIVFTNLPLGN
20 YRFEVEPLAGYAVTTLDTDVQLVDHQLVTTIVVNQKLRGNVDFMKVDGRTNTSLQGAMFKVMKEESGHYTPVL
QNGKEVVVTSGKDRFRVEGLEYGTYLWELQAPTGYVQLTSPVSFTIGKDRKELVTVVKNNRPRIDVPTGE
ETLYILMLVAILLFGSGYYLTKKPN

ORF6_6BSP is a putative sortase. An example of an amino acid sequence of ORF6_6BSP is
25 set forth in SEQ ID NO: 205.

SEQ ID NO: 205

26 MLIKMVKTKKQKRNNLLLVVFFIGMAVMAYPLVSRLYRVESNQQIADFDKEKATLDEADI DERMKLAQAFNDS
LNNVSGDPWSEEMKKKGRAEYARMLEIHERMGHVEIPVIDVLPVYAGTAEVVLQAGHLEGTSLPIGGNSTH
30 AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAYQVDQVKVIEPTNFDDLLIVPGHDYVTLTCTPYMINT
HRLLRGRHIPYVAEVEEFTAAKLSHLRYLYFVAVGLIVILLWIIIRLRKRRKQPEKALKALKAAARKEVKVE
DGQQ

ORF7_6BSP is a putative sortase. An example of an amino acid sequence of ORF7_6BSP is
35 set forth in SEQ ID NO: 206.

SEQ ID NO: 206

36 MDNSRRSRKKGTKKKKHPILLIIFLVGFVAIVPLVSRYRYRIESNEVIKEFDETVSQMDKAELEERWRLAQA
NATLKPSEILDPTFEQEKKGVSSEYANMLKVHERIGYVEIPAIHQEIPMYVGTSEEILQKAGLLEGASLPVGG
40 NTHTVVTAHRGLPTAELFSQLDKMKKGDVYFYLHVLQVLAQVDQILTVPEPNDFEPVLIQHGEDYATLLTCTPYM
INSHRLLVRGKRIPYTAPIAERNRAVRERGFWLWLLLAALVMILVLSYGVYRHRRIVKGLEKQLEEHVKG

ORF8_6BSP is a putative sortase. An example of an amino acid sequence of ORF8_6BSP is
45 set forth in SEQ ID NO: 207.

SEQ ID NO: 207

46 MSKAKLQKLLGYLLMLVALVIPVYCFGQMVLSLQVQKGEIFSESVTADSYQEQLQRSLDYNQRLDSQNRIVDP
FLAEGYEVNYQVSDDPDAVYGYLSIPSLIEMEPVYLGADYHLLAMGLAHVDGTPLPVEGKGI RSVIAGHRAEPSH
50 VFFRHLQDLKVGDALYYDNGQEIIVEYQMMDETEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFGLILFVLWKLARLLRGK

As discussed above, a *S. pneumoniae* AI sequence is present in the 9V Spain 3 *S. pneumoniae*
55 genome. Examples of *S. pneumoniae* AI sequences from 9V Spain 3 are set forth below.

ORF2_9VSP is a transcriptional regulator. An example of an amino acid sequence of
ORF2_9VSP is set forth in SEQ ID NO: 208.

SEQ ID NO: 208

MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLSQSKSLLSILQELQETFFEEELTFNLDTQOVQLIEHSHQ
TNYFFHQLYNQSTILKILRFLLQGNQSFNEFTQKEYISIATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
LIALLQFHFGIEIYDLNDGSMWVTHMIVQSNQLSHELLEITPDEYVHFSILVALTWKRREFPLEFPESKEFEK
LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILOHTRGKHLKSKF
KNILGNDISNSLSFLTALTFLTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAIVQEWMTQEKIEGVIDQHR
LYLFSLYLTETIFSSLPAPIFIILNNQADVNLIKSIIILRNFTDKVASVTGYNILISPPPSEEHLTEPLIIITTK
EYLPYVKKQYPKGKHHFLTIALDLHVSQORLIYQTIIVDIRKEAFDKRVAMIAKKAHYLL

10 ORF3_9VSP is a cell wall surface protein. An example of an amino acid sequence of
ORF3_9VSP is set forth in SEQ ID NO: 209.

SEQ ID NO: 209

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSIPAIGKVVIKETGEGGALLGDVAVFELKNNNTNGTTVSQRT
EAQTGEAIFSNIKPGTYLTLTEAQPVPVGYKPKSTKQRTVEVEKNGRTTVQGEQVENREEALSQYPQTGYTYPDVQTP
YQIIKVDGSEKNGQHKALNPNPYERVIPEGTLKRIYQVNNLDDNQYGIELTVSGKTVYERKDKSVPLDVVILLD
NSNSMSNIRNKNARRAERAGEATRSLIDKITSDPENRVALVTYASTIFDGTFTVEKGVADKNGKRLNDSLFWNY
DQTSFTTNTKDYSLKLTNDKNDIVELKNKVPTAEADHDGNRLMYQFGATFTQKALMKADEILTQQARQNSQKVI
FHITDGVPTMSYPINFNHATFAPSYQNQLNAFFSKSPNKDGIILSDFITQATSGEHTIVRGDQSYQMFDTKTVY
EKGAPAAFPVKPEKYSEMKAAGYAVIGDPINGGYIWLNWRESILAYPFNSNTAKITNHGDPTRWYNGNIAPDGY
DVFTVGIINGDPGTDEATATSEMQSISSEKPENYTNVTDTTKILEQLNRYFHTIVTEKKSIEGTTIDPMDGELID
LQLGTDGRFDPADYTLTANDGSRLENGQAVGGPQNDGGLLKNAKVFDYDTEKRIRVGTGLYLTGKVTLYNVRL
NDQFVSNKFYDTNGRITLHPKEVEKNTVRDFPIPKIRDVRKYPAITIAKEKLGIEEFIKINKNDKKPLRDAVFS
LQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVT
SIVPQDIPAGYEFTNDKHYYITNEPIPPKREYPRGTGGIGMLLFYLI GCMMMGGVLLYTRKHP

25 ORF4_9VSP is a cell wall surface protein. An example of an amino acid sequence of
ORF4_9VSP is set forth in SEQ ID NO: 210.

SEQ ID NO: 210

MKSINKFLTMLAALLLTASSLFSAAVFAAGTTTTSVTVHKLATDGDMDKIANELETGNYAGNKVGVLPANAKE
IAGVMFVWNTNNEI I DENGQTLGVNIDPQTFKLSGAMPATAMKKLTEAEGAKFNTANLPAKYKIYEIHSSTY
VGEDGATLTGSKAVPIEIELEPLNDVVDAHVPKNTAKPKIDKDFKGANPDTPRVDKDTPVNHQVGDVVEYEIV
TKIPALANYATANWSDRMTEGLAFNKGTVKVTVDVALEAGDYALTEVATGFDLKLT DAGLAKVNDQNAEKT VKI
TYSATLNDKAI VEVPE SNDVT FNYGNPDHGNTPKPNKPNENGDLT LTKTWV DATGAPI PAGAEATFDLVNAQTG
KVVQTVTLT DKNITVTVNGLDKNTEYKFVERS IKGYSADYQEITTAGETIAVKNWKDENPKPLDPTPKVVTYGGK
FVKVNDKDNRLGAEFVIANADNAGQYLARKADKVSQEEKQLVVTTKDALDRAVAAYNALTAQQQTQOEKEKVDK
AQAAYNAAVIAANNAFEWVADKDNENVKLVSDAQGRFEITGLLAGTYYLEETKQPAGYALLTSRQKFEV TATS Y
SATGQGI EYTAGSGKDDATKVVNKKITIPQTGGIGIT IFAVAGAVIMGIAYVYVKNKDEQDLA

40 ORF5_9VSP is a cell wall surface protein. An example of an amino acid sequence of
ORF5_9VSP is set forth in SEQ ID NO: 211.

SEQ ID NO: 211

MTMQKMQKMQKMQKMQKMSRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQPSRDGHR LQVW
KLDDSYSYDNRVQIVRDLHSWDENKLSSEFKKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDVAVSYPAEFLFEMT
DQTVPEPLVI VAKKADTVTTKVKLIKVDQDHNRLLEGVGFKLVSVDARGSEKEVPLIGEYRYS SSGQVGR TLYTDKN
GEIVVTNLPLGTYRFEVEPLAGYTVTMDTDVQLVDHQLVTITVVNQKLPRGNVDFMKVDGRNTSLQGAMFKV
MKEENGHYTPVLQNGKEVVVASGKDRFRVEGLEYGTYLWELQAPTGYVQLTSPVFTIGKDRKELVTVVKNN
KRPRIDVPDTGEETLYILMLVAILLFGSGYYLTKKTFNN

50 ORF6_9VSP is a putative sortase. An example of an amino acid sequence of ORF6_9VSP is
set forth in SEQ ID NO: 212.

SEQ ID NO: 212

MLIKMAKTKKQKRNNLLLGVVFFIGIAVMAYPLVSRLYYRVESNQIADFDKEKATLDEADIDERMKLAQAFNDS
LNNVVSQDPWSEEMKKKGRAEYARMLEIHERMGHVEIPAI DVDLVPYAGTAEV LQQGAGHLEGTSLPIGGNSTH
AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAYQVDQVKVIEPTNFDDLIVPGHDYVTLTCTPYMINT
HRLLRGHRIPYVAEVEEEFIAANKLSHLRYLFYVAVGLIVILLWIIIRLRKKKRQSERALKALKEATKEVKVE
DE

PCT/US05/27239

ORF7_9VSP is a putative sortase. An example of an amino acid sequence of ORF7_9VSP is set forth in SEQ ID NO: 213.

SEQ ID NO: 213

MKSKRSYRKKSVKKNKPFILLIIFLVGLAVAMYPLVSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAF
 NATLKPSEILDPFTEQEKKKGVSEYANMLKVHERIGYVEIPAIHQEIPMYVGTSEEILQKGAGLLEGASLPVGGG
 NTHTVVTAHRGLPTAELFSQLDKMKKGGDI FYLHVLDQVLAYQVDQIVTVEPNDFEPVLIQHGEDYATLLTCTPYM
 INSHRLLVRGKRI PYTAPIAERNRAVRERGGQFWLWLLLGAMAVILLLLYRVYRNRRIKVGLEKQLEGRHVKD

ORF8_9VSP is a putative sortase. An example of an amino acid sequence of ORF8_9VSP is set forth in SEQ ID NO: 214.

SEQ ID NO: 214

MSRTRKLRALLGYLLMLVACLIPYICFGQMVLSLQVQKGHATFVKSMTTEMYQEQQNHSLAYNQRLASQNRIVDP
 FLAEGYEVNYQVSDPDPAVYGYLSIPSLEIMEPVYLGADYHHLGMGLAHVDGTPLPLDGTGIRSVIAGHRAEPSH
 VFFRHLDQLKVGDALYDNGQEIIVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFILGILFVLWKLARLLRGK

As discussed above, a *S. pneumoniae* AI sequence is present in the 14 CSR 10 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences from 14 CSR 10 are set forth below.

ORF2_14CSR is a transcriptional regulator. An example of an amino acid sequence of ORF2_14CSR is set forth in SEQ ID NO: 215.

SEQ ID NO: 215

MLNKYIEKRTDKITILNILLDIRSIELDELSTLTSLSQSKSLLSILQELQETFEELTFNLDTQQVQLIEHHSHQ
 TNYFFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYISIATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
 LIALLQHFHFGIEIYDLNDGSMWVTHMIVQNSQLSHELLEITPDEYVHFHSILVALTWKRREFPLEFPESKEFEK
 LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKHTIQLILQHTRGKHLLSKF
 KNILGNDISNSLSFLTALTFLTRTFLEGLQNLVPPYNYEYHYGIESDKPLYHISKAIQVEWMTQKIEGVIDQHR
 LYLFSLYLTETIFSSLPAPIFIIILNNQADVNLIKSIIILRNFTDKVASVTGYNILISPPPSEHLEPLIITTK
 EYLPYVKKQYPKGKHHFLTIALDLHVSQQRLIYQTTIVDIRKEAFDKRVAMIAKKAHYLL

ORF3_14CSR is a cell wall surface protein. An example of an amino acid sequence of ORF3_14CSR is set forth in SEQ ID NO: 216.

SEQ ID NO: 216

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSIPAIGKVVIKETGEGGALLGDAVFELKNNTDGTTVSQRT
 EAQTGEAIFSNIKPGTYTLTEAQPVGYPSTKQWTVVEVEKNGRTTVQGEQVENREALSQDQYPQTGYTPDVQTP
 YQIIVKVDGSEKNGQHKALNPNPYERVPEGLTSKRIYQVNNLDDNQYGIELTVSGKTTVETKEASTPLDVVILLD
 NSNSMSNIRHNAHRAEKAGEATRALVDKITSNPDNRVALVTYGSTIFDGESEATVEKGVADANGKILNDSALWTF
 DRRTTFAKTYNYSFLNLTSDPTDIQTIKDRI PSDAEELNKDKLMYQFGATFTQKALMTADDILTQARPNSKKVI
 FHI TDGVPTMSYPINFKYTGTTQSYRTQLNNEFAKTPNSGILLEDFVTVSADGEHKIVRGDGESYQMFTKKPV
 DQYGVHQILSITSMEQRAKLVSAGYRFYGTDLYLWRDSILAYPFNSSTDWITNHGDPTTWYNGNMAQDGYDVF
 TVGVVNGDPGTDEATATRFMQSISSSPDNYTNVADPSQILQELNRYFYTVNEKKSIENTITDPMGELIDFQL
 GADGRFDPADYTLTANDGSSLVNVP TGGPQNDGGLLKNKAVFYDTTEKRI RVTGLYLGTGEKVTLTYNVRINDQ
 FVSNKFYDTNGRITLHPKEVEKNTVRDFPIPKIRDVRKYPEITIPKEKKLGEIEFIKINKNDKKPLRDAVFSLQK
 QHPDYDPIYGAIDQNGTYQNVRTGEDGKLTFFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTISV
 PQDIPAGYEFTNDKHYITNEPIPPKREYPRGTGGIGMLPFYLI GCMGGVLLYTRKHP

ORF4_14CSR is a cell wall surface protein. An example of an amino acid sequence of ORF4_14CSR is set forth in SEQ ID NO: 217.

SEQ ID NO: 217

MKSINKFLTMLAALLLTASSLFSAAVFAADNVSTAPDAVTKTLTIHKLLLSSEDDLKTWDTNPGKYDGTQSSLK
 DLTFGVAAEIPNVYFELQKYNLTDGKEKENLKDSSKWTTVHGGLLTKDGLKIETSTLKGVYRIREDRTKTTYVGP
 NGQVLTGSKAVPALVTLPLVNNNGTVIDAHVFPKNSYNKPVVDKRIADTLNNDQNGLSIGTKIPYVNTTIPSN
 ATFATSFWSDEMTEGLTYNEDVTITLNNVAMDQADYEVTKGNNGFNLKLTAEAGLAKINGKDADQKIQITYSATLN
 SLAVADIPESNDITYHYGNHQDHGNTPKPTKPNNGQITVTKTWDSQPAPEGVKATVQLVNAKTGEKVGAPVELSE

NNNWLYTWSGLDLSSTLSEYKVEEHLNNGYSAEYTVESKGLGVKNWKDNNPAPINPEEPRVKTYGKKFVKVDQKDTRLE
 NAQFVVKKADSNKYIAFKSTAQQAADEKAAATAKQKLDAAVAAYTNAADKQAAQALVDQAQQEYNVAYKEAKFGY
 VEVAGKDEAMVLTSTNDGQFQISGLAAGTYKLEEIKAPEGFAKIDDFEVFVVGAGSWNQGEFNYLKDVKQKNDATKV
 VNKKITIPQTGGIGITIIFAVAGAAIMGIAVYAYVKNNKDEDQLA

5

ORF5_14CSR is a cell wall surface protein. An example of an amino acid sequence of ORF5_14CSR is set forth in SEQ ID NO: 218.

SEQ ID NO: 218

MTMQKMQKMSIRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQLPSRDGHRLOVWKLDDSYSDDRV
 QIVRDLHSWDENKLSSEFKKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDAVSYPAEFLFEMTDQTVFPLVIVAK
 KTDMTTKVKLIKVDQDHNRLLEGVGFKLVSVDGSEKEVPLIGEYRYSQVGRITLYTDKNGEIVFVNLPLGN
 YRFKEVEPLAGYAVTTLDTDVQLVDHQLVTTIVVNQKLPGRNVDFMKVDGRTNTSLQGAMFKVMKEESGHYTPVL
 QNGKEVVVTSKGDGRFRVGELEYGTYYLWELQAPTGYVQLTSPVSFTIGKDRKELVTVVKNNKRPRIDVPDTGE
 ETLYILMLVAILLFGSGYYLTKKPN

10

15

ORF6_14CSR is a putative sortase. An example of an amino acid sequence of ORF6_14CSR is set forth in SEQ ID NO: 219.

SEQ ID NO: 219

MLIKMKVTKKKQRNLLLVGVFFIGMAVMAYPLVSRLYRVEVSNQQIADFDKEKATLDEADI DERMKLAQAFNDS
 LNNVSGDPWSEEMKKKGRAEYARMLEIHERMGHVEI PVIDVDLPVYAGTAEVVLQOGAGHLEGTSLPIGGNSTH
 AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAYQVDQVKVIEPTNFDDLLIVPGHDYVTLTCTPYMINT
 HRLLVGRHRI PYVAEVEEFIAANKLSHLYRLYFVAVGLIVILLWII RRLRKKKKQPEKALKALKAAARKEVKVE
 DGQQ

20

25

ORF7_14CSR is a putative sortase. An example of an amino acid sequence of ORF7_14CSR is set forth in SEQ ID NO: 220.

SEQ ID NO: 220

MDNSRRSRKKGTKKKKHPILLLLIFLVGFAVAIYPLVSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAF
 NATLKPSEILDPFTEQEKKGVSSEYANMLKVHERIGYVEI PAIDQEI PMYVGTSEEILQKGAGLLEGASLPVGGGE
 NTHTVVTAHRGLPTAELFSQLDKMKKGDV FYLVLDQV LAYQVDQILTVPEPNDFEPVLIQHGEDYATLLTCTPYM
 INSHRLLVGRKRI PYTAPIAERNRAVREERGQFWLWLLLAALVMILVLSYGVYRHRRI VKGLEKQLEEHVKG

30

ORF8_14CSR is a putative sortase. An example of an amino acid sequence of ORF8_14CSR is set forth in SEQ ID NO: 221.

SEQ ID NO: 221

MSKAKLQKLLGYLLMLVALVIPVYCFGQMVLSLQGVKGEHIFSESVTADSYQEQLQRSLDYNQRLDSQNRIVDP
 FLAEGYEVNYQVSDDDPDAVYGYLSIPSLIMEPVYLGADYHHLAMGLAHVDGTPLPVEGKGRSIVIAGHRAEPSH
 VFFRHLDQLKVGDALYYDNGQEI VEYQMMDTBI ILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFGLILFVLWKLARLLRKG

40

As discussed above, a *S. pneumoniae* AI sequence is present in the 19F Taiwan 14 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences from 19F Taiwan 14 are set forth below.

ORF2_19FTW is a transcriptional regulator. An example of an amino acid sequence of

ORF2_19FTW is set forth in SEQ ID NO: 222.

SEQ ID NO: 222

MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLSQSKSLLSILQELQETFEELTFNLDTQQVQLIEHSHQ
 TNYFHLQYLNQSTILKILRFFLLQGNQSFNEFTQKEYISIAATGYRVRQKCGLLRSVGLDLVKNQVVGPEYRIRF
 LIALLQFHFGIEIYDLNDGSMWVTHMIVQSNLSHELLEITPDEYVHFSILVALTWKRREFFLEFPESKEFEK
 LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILQHTRGHLLSKF
 KNILGNDISNSLSFLTALTFLTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAIQEWMTQKIEGVIDQHR
 LYLFSLYLTETIFSSLPAPIFII LNQADVNLKSIILRNFTDKVASVTGYNILISPPPSEEHLTEPLIITTK
 EYLPYVKKQYPKGGKHHFLTIALDLHVSQORLIYQITVIDIRKEAFDKRVAMI AKKAHYLL

50

PCT/US05/27239

ORF3_19FTW is a cell wall surface protein. An example of an amino acid sequence of

ORF3_19FTW is set forth in SEQ ID NO: 223.

SEQ ID NO: 223

5 MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETS PAIGKVVIKETGEGGALLGDAVFELKNNTDGTTVSQR
 EAQTGEAIFSNIKPGTYTLTEAOPPVGYPSTKQWTVVEVEKNGRITVQGEQVENREEALS DQYPQTGYPDVQTP
 YQIIKVDGSEKNGQHKALNPNPYERVIPEGTL SKRIYQVNNLDDNQYGIELTVSGKTVYERKDKSVPLDVVILL
 NSNSMSNIRNKNARRAERAGEATRSLIDKITS DPENRVALVYASTIFDGTEFTVEKGVADKNGKRLNDSLFWNY
 10 DQTSFTTNTKDYSYLKLTNDKNDIVELKKNKVPTEAEDHDGNRLMYQFGATFTQKALMKADEILTQARQNSQKVI
 FHITDGVPTMSYPINFNHATFAPSYQNQLNAFFSKSPNKDGLLSDFITQATS GEHTIVRGDQGSYQMFDTKTVY
 EKGAPAAFPVKPEKYSEMKA VGYAVIGDPINGGYIWLNWRESILAYPFNSNTAKITNHGAPTRWYNGNIAPDGY
 DVFTVIGIGINGDPGTDEATAT SFMQSIS SKPENYTNVTDTTKILEQLNRYFHTIVTEKKS IENGTITDPMGELID
 LQLGTDGRFPADYTLTANDGSRLENGQAVGGPQNDGGLLKNKAVFYDTEKRIRV TGLYLGTEKVTLTYNVRL
 15 NDQFVSNKIFYDTNGR TLLHPKEVEKNTVRDFPIPKIRDVRKYPAITIAKEKKLGEIEFIKINKNDKKPLRDAVFS
 LQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLT FKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVT
 SIVPQDI PAGYEFTNDKHYITNEPIPPKREYPR TGGIGMLPFYILGCM MMGGVLLYTRKHP

ORF4_19FTW is a cell wall surface protein. An example of an amino acid sequence of

ORF4_19FTW is set forth in SEQ ID NO: 224.

SEQ ID NO: 224

20 MKSINKFLTMLAALLLTASSLFSAA TVFAAGTTTT SVTVHKL LATDGDMDKIANELETGNYAGNKVGVLPANAKE
 IAGVMFVWNTNNEI I DENGQTLGVNIDPQTFKLSGAMPATAMKKL TEAEGAKFNTANLPA AKYKIYEIHSLS TY
 VGEDGATLTGSKAVPIE IELPLNDVVD AHVYPKNT EAKPKIDKDFK GKANPDT PRVDKDT PVNHQSGVDVVEY EIV
 TKIPALANYATANWS DRMTEGLAFNKGTVKVT VDDVALEAGDYALTEVATGF DLKLT DAGLAKVNDQNAEKT VKI
 25 TYSATLNDKAI VEVPESNDVTFNYGN NP DHGNTPKPNKPN ENGD LTLTKTWV DATGAPI PAGAEATFDLVNAQTG
 KVVQTVTLT TDKNTVT VNGLDKNT EYK FVERS IKGYSADYQELTTAGE IAVKNWK DENPKPLDPTEPKVVTY GKK
 FVKVNDKDNRLAGAEFVIANADNAGQYLARKADKVS QEEKQLVVTTKDALDR AVAAYNALTAQQQTQQEKEKVDK
 AQAAYNAAVIAANNAFEWVADKDNEN VVKLVSDAQGRFEITGLLAGTYYLEETKQPAGYALLTSRQKFEVTATSY
 30 SATGQGI EYTAGSGKDDATKVVNKKITIPQ TGGIGTII FAVAGAVIMGI AVYAYVKNNKDEDQLA

ORF5_19FTW is a cell wall surface protein. An example of an amino acid sequence of

ORF5_19FTW is set forth in SEQ ID NO: 225.

SEQ ID NO: 225

35 MTMQKMQKMSRIFFVMALCFSLVWG AHAVQAQEDHTLV LQLENYQEVVSQLPSRDGHR LQVWKLDDSYSDNRV
 QIVRDLHSWDENKLSSEFKKTSFEMT FLENQIEVSHI PNGLYYVRSIIQTD AVSYPAEFLFEMTDQTV EPLVIVAK
 KADTVTTKVKLIKVDQDHNRL EGVGFKLVSVARDGSEKEVPLIGEYRYS SSGQVGR TLYTDKNGEIVVTNLPLGT
 YRFKEVEPLAGYTVTMDT DVQLVDHQLV TITVVNQKLP RGNVDFM KVDGRTNTSLQGAMFKVMKEENGHYTPVL
 QNGKEVVVASGKDRFRVEGLE YGTYLWELQAPTGYVQLTSPV SFTIGKDRKELVT VVKNNKRPRIDVPDTGE
 40 ETLYILMLVAILLFGSGYYLTKKTNN

ORF6_19FTW is a putative sortase. An example of an amino acid sequence of

ORF6_19FTW is set forth in SEQ ID NO: 226.

SEQ ID NO: 226

45 MLIKMAKTKKQKRNNLLLG VVFFIGMAVMAYPLVSR LYYRVESNQIADFDKEKATLDEADI DERMKLAQAFNDS
 LNNVSGDPWSEEMKKKGRAEYARMLEI HERMGHVEI PAIDVDLPVYAGTAEV LQQGAGHLEGTSLPIGGNSTH
 AVITAHTGLPTAKMFTDLTKLKVGD KFYVHNIKEVMAYQVDQVKVIEPTNFDDL IVPGHDYVTLTCTPYMINT
 HRLLVRGHRI PYVAEVEEFIAANKLSHLYR LFYVAVGLIVILLWII RRLRKKKRQSERALKALKEATKEVKVE
 DE

ORF7_19FTW is a putative sortase. An example of an amino acid sequence of

ORF7_19FTW is set forth in SEQ ID NO: 227.

SEQ ID NO: 227

50 MSKSRYSRKKSVKKKKNPFILLI FLVGLAVAMYPLVSR YYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAF
 NATLKPSEILD PFTDQEKKQGVSEYANMLKVHERIGYVEI PAIEQEI PMYVGTSEDI LQKGAGLLEGASLPVGG E

MSRTRKLRALLGYLLMLVACLIPYICFGQMVLSLQSLGQVKGHATFVKSMTTEMYQEQQNHSLAYNQRLASQNRIVDP
 FLAEGYEVNYSVDDPDAVYGYLSIPSLIEMEPVYLGADYHHLGMGLAHVDGTPPLDGTGIRSVIAGHRAEPSPH
 VFFRHLDLQKVGDALYDNGQEIIVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFILGILFVLWKLARLLRGK

ORF8_19FTW is a putative sortase. An example of an amino acid sequence of

5 ORF8_19FTW is set forth in SEQ ID NO: 228.

SEQ ID NO: 228

MSRTRKLRALLGYLLMLVACLIPYICFGQMVLSLQSLGQVKGHATFVKSMTTEMYQEQQNHSLAYNQRLASQNRIVDP
 FLAEGYEVNYSVDDPDAVYGYLSIPSLIEMEPVYLGADYHHLGMGLAHVDGTPPLDGTGIRSVIAGHRAEPSPH
 VFFRHLDLQKVGDALYDNGQEIIVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFILGILFVLWKLARLLRGK

As discussed above, a *S. pneumoniae* AI sequence is present in the 23F Taiwan 15 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences from 23F Taiwan 15 are set forth below.

15 ORF2_23FTW is a transcriptional regulator. An example of an amino acid sequence of ORF2_23FTW is set forth in SEQ ID NO: 229.

SEQ ID NO: 229

MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLQSKSLLSILQELQETFEELTFNLDTQQVQLIEHHSQ
 TNYVYFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYISISATGYRVRQKCGLLLRVGLDLVKNQVVGPEYRIRF
 LIALLQFHFQGIETYDLNDGSMDWVTHMIVQSNQSLSEHELEITPDEYVHFSILVALTWKRREFPLEFPESKEFEK
 LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILQHTRGKHLKSKF
 KNILGNDISNSLSFLTALTFLTRTFLFGLQNLVPPYNYEYHYGIESDKPLYHISKAVQEWMTQEKIEGVIDQHR
 LYLFSLYLTETIFSSLPAPIPIFIILNNQADVNLIKSILRNFTDKVASVTGYNILISPPPSEHLETEPLIIITTK
 EYLPYVKKQYPRKGGHFLTIALDLHVSQQRLIYQTIIVDIRKEAFDKRVAMIAKKAHYLL

ORF3_23FTW is a cell wall surface protein. An example of an amino acid sequence of ORF3_23FTW is set forth in SEQ ID NO: 230.

SEQ ID NO: 230

MKKVRKIFQKAVAGLCCISQLTAFSSIVALAETPETSIPAIGKVVIKETGEGGALLGDAVFELKNNTDGTTVSQR
 EAQTGEAIFSNIEKPGTYTLTEAQQPVGYKPKSTKQWTVVEKNGRTTVQGEQVENREEALSQYPTGTYPDVQTP
 YQIIKVDGSEKNGQHKALNPNPYERVIPEGTSLKRIYQVNNLDDNQYGIELTVSGKTVYEQDKKSVPLDVVILLD
 NSNSMSNIRNKNARRAERAGEATRSLIDKITSDPENRVALVTYASTIFDGTFTVEKGVADKNGKRLNDSLFWNY
 DQTSFTTNTKDYSLKLTNDKNDIVELKNKVPTAEADHDGNRLMYQFGATFTQKALMKADEILTQQARQNSQKVI
 FHITDGVPTMSYPINFNHATFAPSYQNQLNAFFSKSPNKDGIILSDFITQATSGEHTIVRGDQGSYQMFDTKTVY
 EKGAPAAFPVKPEKYSEMKAAGYAVIGDPINGGYIWLNWRESILAYPFNSNTAKITNHGDPTRWYNGNIAPDGY
 DVFTVGIINGDPTDEATATSFMQSISSKPENYTNVDTTKILEQLNRYFHTIVTEKKSIEGNTITDPMGELID
 LQLGTDGRFDPADYTLTANDGSRLENGQAVGGPQNDGGLLKNKAVLYDTTEKRIRVGTGLYLGTDKVTLYTNVRL
 NDEFVSNKFYDNTGRITLHPKEVEQNTVRDFPIPKIRDVRKYPEITISKEKKGDIETIKVNKNDDKPLRDAVFS
 LQKQHPDYPIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVT
 SIVPQDIPAGYEFNDKHITNEPIPKREYPRTGIGMLPFYILGMMMGGVLLYTRKHP

ORF4_23FTW is a cell wall surface protein. An example of an amino acid sequence of ORF4_23FTW is set forth in SEQ ID NO: 231.

SEQ ID NO: 231

MKSINKFLTILAAALLLVSSLSAATVFAAEQKTKTLTVHKLLMTDQELDAWNSDAITTAGYDGSQNFQFKQLQ
 GVPQGVTEISGVAFELQSYTGPQKQENLNDVAVWTAVNKGVTETGKVFDEVLQGTYRLVEVRKESTYVGNP
 GKVLTMKAVPALITLPLVNQNGVVENAHVYPKNSDKPTATKTFDAAAGFVDPGEKGLAIGTKVPYIVTTTIK
 NSTLATAFWSDEMTEGLDYNQDGVVNYNGQPLDNSHYTLEAGHNGFILKLNKGLEAINGKDAEATITLKYTATL
 NALAVADVPEANDVTFHYGNPFGHNTPKPNKPKNGELTITKTWADAKDAPIAGVEVTFDLVNAQTGEVVKVPGH
 ETGIVLNQTNNTFTATGLDNNTEYKFVERTIKGYSADYQTIITETGKIAVKNWKDENPEPINPEEPRVKTYGKKF
 VKVDQKDERLKEAQFVVKNEQGGKYLALKSAAQAVNEKAAAEAKQALDAAIAAYTNAADKNAQAQVVDAAQKTYN
 DNYRAARFGYVEVERKEDALVLTSTNDGQFQISGLAAGSYTLEETKAPEGFAKLGDVVKFEVVGAGSWNQDFNYLK
 DVQKNDATKVVNKKITIPQTGGIGTIIIFAVAGAVIMGIAVYAVVKNKDEQDLA

ORF5_23FTW is a cell wall surface protein. An example of an amino acid sequence of ORF5_23FTW is set forth in SEQ ID NO: 232.

SEQ ID NO: 232

MTMQMKQKMISRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVVSQLPSRDGHRQLQVWKLDDSYSDNRV
 5 QIVRDLHSWDENKLSSEFKKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDAVSYPAEFLFEMTDQTVPLVIVAK
 KADTVTTKVKLIKVDQDHNRLLEGVGFKLVSVDARGSEKEVPLIGEYRYSSESSGQVGRTRTYTDKNGEIVVTNLPPLGT
 YRFKEVEPLAGYTVTTMDTVDVQLVDHQLVTITVVNQKLRGNVDFMKVDGRNTNTSLQGAMFKVMKEENGHYTPVL
 QNGKEVVVASGKDGFRFRVEGLEYGTYLLWELQAPTGYVQLTSPVSFTIGKDKTRKELVTVVKNNKRPRIDVDPDTGE
 10 ETLYLMLLVAILLFGSGYYLTKKTTNN

ORF6_23FTW is a putative sortase. An example of an amino acid sequence of ORF6_23FTW is set forth in SEQ ID NO: 233.

SEQ ID NO: 233

MLIKMVKTKKQKRNNLLLGVVFFIGMAVMAYPLVSRLYRVEVSNQQIADFDKEKATLDEADI DERMKLAQAFNDS
 15 LNNVVSGDPWSEEMKKKGRAEYARMLEIHERMGHVEIPVIDVDLPVYAGTAAEEVLQQGAGQLEGTSLPIGGNSTH
 AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAYQVDQVKVIEPTNFDDLIVPGHDYVTLTCTPYMINT
 HRLLRGRHIPYVAEVEEFIAANKLSHLRYLYFYAVGLIVILLWII RRLRKKKKQPEKALKALKAAARKEVKVE
 DGQQ

ORF7_23FTW is a putative sortase. An example of an amino acid sequence of ORF7_23FTW is set forth in SEQ ID NO: 234.

SEQ ID NO: 234

MDNSRRSRKKGTKKKKHPLILLI FLVGFVAIAIYPLVSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAF
 25 NATLKPSEILDPFTEQEKKKGVSEYANMLKVHERIGYVEIPAI DQEIPMYVGTSEEILQKAGLLEGASLPVGGE
 NTHTVVTAHRGLPTAELFSQLDKMKKGDV FYLHVLDQVLA YQVDQILTVEPNDFEPVLIQHGDYATLLTCTPYM
 INSHRLLVRGKRI PYTAPIAERNRAVREREGQFWLWLLLAALVMILVLSYGVYRHRRI VKGLEKQLEEHVKG

ORF8_23FTW is a putative sortase. An example of an amino acid sequence of ORF8_23FTW is set forth in SEQ ID NO: 235.

SEQ ID NO: 235

MSKAKLQKLLGYLLMLVALVIPVYCFGQMVLSLQSLGQVKGHEIFSESVTADSYQEQLQSRSLDYNQRLDSQNRIVDP
 30 FLAEGYEVNYQVSDDDPAVYGYLSIP SLEIMEPVYLGADYHHLAMGLAHVDGTPLPVEGKGRSVIAGHRAEPSH
 VFFRHLDQLKVGDALYDNGQEI VEYQMM DTEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 35 YQKSDPQTA AVARVAFTKEGQSVSRVATSQWLYRGLVVLAF LGILFVLWKLARLLRGK

As discussed above, a *S. pneumoniae* AI sequence is present in the 23F Poland 16 *S. pneumoniae* genome. Examples of *S. pneumoniae* AI sequences from 23F Poland 16 are set forth below.

ORF2_23FP is a transcriptional regulator. An example of an amino acid sequence of ORF2_23FP is set forth in SEQ ID NO: 236.

SEQ ID NO: 236

MLNKYIEKRITDKITILNILLDIRSIELDELSTLTSLSQSKSLLSILQELQETFEELTFNLD TQQVQLIEHHS HQ
 45 TNYFFHQLYNQSTILKILRFFLLQGNQSFNEFTQKEYIS IATGYRVRQKCGLLRSVGLDLVKNQVVGPEYRIRF
 LIALLQFHFGIEIYDLNDGSM DWVTHMIVQSNSQLSHELLEITPDEYVHFSILVALTWKRREFPLEFPESKEFEK
 LKNLFMYPILMEHCQTYLEPHANMTFTQEELDYIFLVYCSANSSFSKDKWNQEKKTHTIQLILQHTRGKHL LSKF
 KNILGNDISNSLSFLTALTFLTRTF LFGQLNLPYNYEYHYGIESDKPLYHISKAI VQEWMT EQKIEGVIDQHR
 LYLFSLYL TETIFSSLP AIPIFIILN NQADVNLIKSIILRNFTDKVASVTGYNILISPPPSEEHLTEPLIIITTK
 EYLPYVKKQYPKGGKHHFLTIALDLHVSQQRLIYQTI VDIRKEAFDKRVAMI AKKAHYLL

ORF3_23FP is a cell wall surface protein. An example of an amino acid sequence of ORF3_23FP is set forth in SEQ ID NO: 237.

SEQ ID NO: 237

MKKVRRKLEQKAVALELCCISQHTAFSSLVALLAETPETSIPAIGKVVIKETGEGGALLGDVAFELKNNTDGGTTVSQRT
 EAQTGEAIFSNIKPGTYTLTEAQPVPVGYKPKSTKQWTVVEVEKNGRRTTVOGEQVENREEALSQYFPQTGTYPDVQTP
 YQIIKVDGSEKNGQHKALNPNPYERVIPEGTLISKRIYQVNNLDDNQYGIELTVSGKTTVETKEASTPLDVVILLD
 NSNSMSNIRHNHAEKAGEATRALVDKITSNPNRVALVTYGSTIFDGSEATVEKGVADANGKILNDSALWTF
 5 DRTTFTAKTYNYSFLNLTSDPTDIQTIKDRIPSDAEELNKDKLMYQFGATFTQKALMTADDILTQARPNSKKVI
 FHITDGVPTMSYPINEKYTGTTQSYRTQLNFKAKTPNSSGILLEDFVTWSADGEHKIVRGDGESYQMFTKKPVT
 DQYGVHQILSITSMEQRAKLVSAGYRFYGTDLVLYWRDSILAYPFNSSTDWITNHGDPPTWYNGNMAQDGYDVF
 TVGVGVNDPGTDEATATRFMQSISSSPDNYTNVADPSQILQELNRYFYTIVNEKKSIENTITDPMGELIDFQL
 10 GADGRFDPADYTLTANDGSSLVNNVPTGGPQNDGGLLKNKAKVFDYDTEKRIRVTGLYLGTGEKVTLTYNVRINDQ
 FVSNKFYDNTGRITLHPKEVEKNTVRDFPIPKIRDVRKYPEITIPKEKKLGEIEFIKINKNDKKPLRDAVFSLOK
 QHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYRLFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTISIV
 PQDIPAGYEFTNDKHYITNEPIPPKREYPRGGIGMLPFYILGCMGGVLLYTRKNP

ORF4_23FP is a cell wall surface protein. An example of an amino acid sequence of

ORF4_23FP is set forth in SEQ ID NO: 238.

15 **SEQ ID NO: 238**

MKSINKFLTMLAALLLTASSLFSAAATVFAADNVSTAPDAVTKTLTIHKLLLSDDLKTWDTNGPKGYDGTQSSLK
 DLTGVVAEEIPNVYFELQKYNLTDGKEKENLKDSDKWTTVHGGLTTKDGLKIETSTLKGVYRIRREDRTKTTYVGP
 NGQVLTGSKAVPALVTLPLVNNNGTVIDAHVFPKNSYNKPVVDKRIADTLNNDQNGLSIGTKIPYVVNTTIPSN
 ATFATSFSDTEGLTYNEDVTITLNNVAMDQADYEVTKGINGFNLKLTEAGLAKINGKDAQKIQITYSATLN
 20 SLAVADIPESNDITYHYGNHQDHGNTPKPTKPNNGQITVTKTWDSQPAPEGVKATVQLVNAKTGEKVGAPVELSE
 NNWYTWGSLDINSIEYKVEEYNGYSAEYTVESKGLGVKNWKNNPAPINLEEPVKTYGKKFVKVDQKDRLE
 NAQFVVKKADSNKYIAFKSTAQQAADKAAATAKQKLDAAVAAYTNAADKQAAQALVDQAQQEYNVAYKEAKFGY
 VEVAGKDEAMVLTSTNDGQFQISGLAAGTYKLEEIKAPEGFAKIDDFEVVVGAGSWNQGEFNYLKDVQKNDATKV
 VNKKITIPQTGGIGTIFAVAGAVIMGIAVYAVVKNKDEDQLA

ORF5_23FP is a cell wall surface protein. An example of an amino acid sequence of

ORF5_23FP is set forth in SEQ ID NO: 239.

30 **SEQ ID NO: 239**

MTMQMKQKMSRIFFVMALCFSLVWGAHAVQAQEDHTLVLQLENYQEVSQVPSRDGHRVQVWKLDDSYSYDNRV
 QIVRDLHSWDENKLSSEFKKTSFEMTFLENQIEVSHIPNGLYYVRSIIQTDAVSYPAEFLFEMTDQTVPEPLVIVAK
 35 KADTVTTKVKLIKVDQDHNRLGEGVFKLVSVARDGSEKEVPLIGEYRYSQVGRVTLTKNGEIVVTNLPLGT
 YRFKEVEPLAGYAVTMDTDVQLVDHQLVTITVNVNQLPRGNVDFMKVDGRTNTSLQGAMFKVMKEENGHYTPVL
 QNGKEVVVASGKDGFRFRVEGLEYGTYLWELQAPTGYVQLTSPVSTIGKDRKELVTVVKNKRPRIDVPDTGE
 ETLYILMLVAILLFGSGYYLTTKTNN

ORF6_23FP is a putative sortase. An example of an amino acid sequence of ORF6_23FP is
 set forth in SEQ ID NO: 240.

40 **SEQ ID NO: 240**

MLIKMAKTKKQKRNNLLGVVFFIGIAVMAYPLVSRLYRVEVSNQIADDFDKEKATLDEADI DERMKLAQAFNDS
 LNNVSGDPWSEEMKKKGRAEYARMLEIHERMGHVEIPAIIDVDLPVYAGTAEVVLQGGAGHLEGTSLPIGGNSTH
 45 AVITAHTGLPTAKMFTDLTKLVGDKFYVHNIKEVMAYQVDQVKVIEPTNFDDLLIVPGHDVYVTLTCTPYMINT
 HRLLRVGRHIPYVAEVEEFIAANKLSHLYRYLFYVAVGLIVILLWIIIRLRKKKRQSERALKALKEATKEVKVE
 DE

ORF7_23FP is a putative sortase. An example of an amino acid sequence of ORF7_23FP is
 set forth in SEQ ID NO: 241.

50 **SEQ ID NO: 241**

MSKSRYSRKKSVKKNPFILLIFLVGLAVAMYPLVSRYYYRIESNEVIKEFDETVSQMDKAELEERWRLAQAF
 NATLKPSEILDPTFEQEKKKGVSEYANMLKVHERIGYVEIPAIIDQEIIPMYVGTSEEILQKAGLLEGASLPVGGG
 55 NTHTVVTAHRGLPTAELFSQLDKMKKGDIFYLHVLDQVLAQVDQIVTVEPNDFEPVLIQHGEDYATLLTCTPYM
 INSHRLLVRGKRIPYTAPIAERNRAVRERGGFWLWLLLGAMAVILLVYRVRNRRIVKGLEKQLEGRHVKD

ORF8_23FP is a putative sortase. An example of an amino acid sequence of ORF8_23FP is
 set forth in SEQ ID NO: 242.

SEQ ID NO: 245 05 / 27 239

MSRRTKLRALLGYLLMLVACLIPICYCFGQMVLSLQGVKGHATFVKSMTTEMYQEQQNHSLAYNQRLASQNRIVDP
 FLAEGYEVNYQVSDDDPAVYGYLSIPSEIMEPVYLGADYHHLGMGLAHVDGTPLPLDGTGIRSVIAGHRAEPSH
 VFFRHLQDLKVGDALYYDNGQEIVEYQMMDTEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAV
 YQKSDPQTAAVARVAFTKEGQSVSRVATSQWLYRGLVVLAFGLILFVLWKLARLLRGK

5

Immunogenic compositions of the invention comprising AI antigens may further comprise one or more antigenic agents. Preferred antigens include those listed below. Additionally, the compositions of the present invention may be used to treat or prevent infections caused by any of the below-listed microbes. Antigens for use in the immunogenic compositions include, but are not limited to, one or more of the following set forth below, or antigens derived from one or more of the following set forth below:

Bacterial Antigens

N. meningitides: a protein antigen from *N. meningitides* serogroup A, C, W135, Y, and/or B (1-7); an outer-membrane vesicle (OMV) preparation from *N. meningitides* serogroup B. (8, 9, 10, 11); a saccharide antigen, including LPS, from *N. meningitides* serogroup A, B, C W135 and/or Y, 10 such as the oligosaccharide from serogroup C (see PCT/US99/09346; PCT IB98/01665; and PCT IB99/00103);

Streptococcus pneumoniae: a saccharide or protein antigen, particularly a saccharide from *Streptococcus pneumoniae*;

Streptococcus agalactiae: particularly, Group B streptococcus antigens;

15 *Streptococcus pyogenes*: particularly, Group A streptococcus antigens;

Enterococcus faecalis or *Enterococcus faecium*: Particularly a trisaccharide repeat or other *Enterococcus* derived antigens provided in US Patent No. 6,756,361;

Helicobacter pylori: including: Cag, Vac, Nap, HopX, HopY and/or urease antigen;

20 *Bordetella pertussis*: such as pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) from *B. pertussis*, optionally also combination with pertactin and/or agglutinogens 2 and 3 antigen;

Staphylococcus aureus: including *S. aureus* type 5 and 8 capsular polysaccharides optionally conjugated to nontoxic recombinant *Pseudomonas aeruginosa* exotoxin A, such as StaphVAX™, or antigens derived from surface proteins, invasins (leukocidin, kinases, hyaluronidase), surface factors that inhibit phagocytic engulfment (capsule, Protein A), carotenoids, catalase production, Protein A, 25 coagulase, clotting factor, and/or membrane-damaging toxins (optionally detoxified) that lyse eukaryotic cell membranes (hemolysins, leukotoxin, leukocidin);

Staphylococcus epidermis: particularly, *S. epidermidis* slime-associated antigen (SAA);

Staphylococcus saprophyticus: (causing urinary tract infections) particularly the 160 kDa hemagglutinin of *S. saprophyticus* antigen;

30 *Pseudomonas aeruginosa*: particularly, endotoxin A, Wzz protein, *P. aeruginosa* LPS, more particularly LPS isolated from PAO1 (O5 serotype), and/or Outer Membrane Proteins, including Outer Membrane Proteins F (OprF) (*Infect Immun.* 2001 May; 69(5): 3510-3515);

~~Bacillus anthracis~~ (anthrax): such as *B. anthracis* antigens (optionally detoxified) from A-components (lethal factor (LF) and edema factor (EF)), both of which can share a common B-component known as protective antigen (PA);

Moraxella catarrhalis: (respiratory) including outer membrane protein antigens (HMW-OMP), C-antigen, and/or LPS;

Yersinia pestis (plague): such as F1 capsular antigen (*Infect Immun.* 2003 Jan; 71(1)): 374-383, LPS (*Infect Immun.* 1999 Oct; 67(10): 5395), *Yersinia pestis* V antigen (*Infect Immun.* 1997 Nov; 65(11): 4476-4482);

Yersinia enterocolitica (gastrointestinal pathogen): particularly LPS (*Infect Immun.* 2002 August; 70(8): 4414);

Yersinia pseudotuberculosis: gastrointestinal pathogen antigens;

Mycobacterium tuberculosis: such as lipoproteins, LPS, BCG antigens, a fusion protein of antigen 85B (Ag85B) and/or ESAT-6 optionally formulated in cationic lipid vesicles (*Infect Immun.* 2004 October; 72(10): 6148), *Mycobacterium tuberculosis* (Mtb) isocitrate dehydrogenase associated antigens (*Proc Natl Acad Sci U S A.* 2004 Aug 24; 101(34): 12652), and/or MPT51 antigens (*Infect Immun.* 2004 July; 72(7): 3829);

Legionella pneumophila (Legionnaires' Disease): *L. pneumophila* antigens -- optionally derived from cell lines with disrupted *asd* genes (*Infect Immun.* 1998 May; 66(5): 1898);

Rickettsia: including outer membrane proteins, including the outer membrane protein A and/or B (OmpB) (*Biochim Biophys Acta.* 2004 Nov 1;1702(2):145), LPS, and surface protein antigen (SPA) (*J Autoimmun.* 1989 Jun;2 Suppl:81);

E. coli: including antigens from enterotoxigenic *E. coli* (ETEC), enteroaggregative *E. coli* (EAaggEC), diffusely adhering *E. coli* (DAEC), enteropathogenic *E. coli* (EPEC), and/or enterohemorrhagic *E. coli* (EHEC);

Vibrio cholerae: including proteinase antigens, LPS, particularly lipopolysaccharides of *Vibrio cholerae* II, O1 Inaba O-specific polysaccharides, *V. cholera* O139, antigens of IEM108 vaccine (*Infect Immun.* 2003 Oct;71(10):5498-504), and/or Zonula occludens toxin (Zot);

Salmonella typhi (typhoid fever): including capsular polysaccharides preferably conjugates (Vi, i.e. vax-TyVi);

Salmonella typhimurium (gastroenteritis): antigens derived therefrom are contemplated for microbial and cancer therapies, including angiogenesis inhibition and modulation of flk;

Listeria monocytogenes (systemic infections in immunocompromised or elderly people, infections of fetus): antigens derived from *L. monocytogenes* are preferably used as carriers/vectors for intracytoplasmic delivery of conjugates/associated compositions of the present invention;

Porphyromonas gingivalis: particularly, *P. gingivalis* outer membrane protein (OMP);

Tetanus: such as tetanus toxoid (TT) antigens, preferably used as a carrier protein in conjunction/conjugated with the compositions of the present invention;

~~For Diphtheria, such as a diphtheria toxin, preferably CRM₁₉₇, additionally antigens capable of modulating, inhibiting or associated with ADP ribosylation are contemplated for combination/co-administration/conjugation with the compositions of the present invention, the diphtheria toxoids are preferably used as carrier proteins;~~

5 *Borrelia burgdorferi* (Lyme disease): such as antigens associated with P39 and P13 (an integral membrane protein, *Infect Immun.* 2001 May; 69(5): 3323-3334), VlsE Antigenic Variation Protein (*J Clin Microbiol.* 1999 Dec; 37(12): 3997);

Haemophilus influenzae B: such as a saccharide antigen therefrom;

10 *Klebsiella*: such as an OMP, including OMP A, or a polysaccharide optionally conjugated to tetanus toxoid;

Neisseria gonorrhoeae: including, a Por (or porin) protein, such as PorB (*see Zhu et al., Vaccine* (2004) 22:660 – 669), a transferring binding protein, such as TbpA and TbpB (*See Price et al., Infection and Immunity* (2004) 71(1):277 – 283), a opacity protein (such as Opa), a reduction-modifiable protein (Rmp), and outer membrane vesicle (OMV) preparations (*see Plante et al., J Infectious Disease* (2000) 182:848 – 855), also see *e.g.* WO99/24578, WO99/36544, WO99/57280, WO02/079243);

Chlamydia pneumoniae: particularly *C. pneumoniae* protein antigens;

20 *Chlamydia trachomatis*: including antigens derived from serotypes A, B, Ba and C are (agents of trachoma, a cause of blindness), serotypes L₁, L₂ & L₃ (associated with Lymphogranuloma venereum), and serotypes, D-K;

Treponema pallidum (Syphilis): particularly a TmpA antigen; and

Haemophilus ducreyi (causing chancroid): including outer membrane protein (DsrA).

25 Where not specifically referenced, further bacterial antigens of the invention may be capsular antigens, polysaccharide antigens or protein antigens of any of the above. Further bacterial antigens may also include an outer membrane vesicle (OMV) preparation. Additionally, antigens include live, attenuated, split, and/or purified versions of any of the aforementioned bacteria. The bacterial or microbial derived antigens of the present invention may be gram-negative or gram-positive and aerobic or anaerobic.

30 Additionally, any of the above bacterial-derived saccharides (polysaccharides, LPS, LOS or oligosaccharides) can be conjugated to another agent or antigen, such as a carrier protein (for example CRM₁₉₇). Such conjugation may be direct conjugation effected by reductive amination of carbonyl moieties on the saccharide to amino groups on the protein, as provided in US Patent No. 5,360,897 and *Can J Biochem Cell Biol.* 1984 May;62(5):270-5. Alternatively, the saccharides can be conjugated through a linker, such as, with succinamide or other linkages provided in *Bioconjugate*
35 *Techniques*, 1996 and *CRC, Chemistry of Protein Conjugation and Cross-Linking*, 1993.

~~Patent Abstracts of International~~
Viral Antigens

Influenza: including whole viral particles (attenuated), split, or subunit comprising hemagglutinin (HA) and/or neuraminidase (NA) surface proteins, the influenza antigens may be derived from chicken embryos or propagated on cell culture, and/or the influenza antigens are derived from influenza type A, B, and/or C, among others;

Respiratory syncytial virus (RSV): including the F protein of the A2 strain of RSV (*J Gen Virol.* 2004 Nov; 85(Pt 11):3229) and/or G glycoprotein;

Parainfluenza virus (PIV): including PIV type 1, 2, and 3, preferably containing hemagglutinin, neuraminidase and/or fusion glycoproteins;

Poliovirus: including antigens from a family of picornaviridae, preferably poliovirus antigens such as OPV or, preferably IPV;

Measles: including split measles virus (MV) antigen optionally combined with the Protollin and or antigens present in MMR vaccine;

Mumps: including antigens present in MMR vaccine;

Rubella: including antigens present in MMR vaccine as well as other antigens from Togaviridae, including dengue virus;

Rabies: such as lyophilized inactivated virus (RabAvert™);

Flaviviridae viruses: such as (and antigens derived therefrom) yellow fever virus, Japanese encephalitis virus, dengue virus (types 1, 2, 3, or 4), tick borne encephalitis virus, and West Nile virus;

Caliciviridae; antigens therefrom;

HIV: including HIV-1 or HIV-2 strain antigens, such as gag (p24gag and p55gag), env (gp160 and gp41), pol, tat, nef, rev vpu, miniproteins, (preferably p55 gag and gp140v delete) and antigens from the isolates HIV_{IIIb}, HIV_{SF2}, HIV_{LAV}, HIV_{LAI}, HIV_{MN}, HIV-1_{CM235}, HIV-1_{US4}, HIV-2; simian immunodeficiency virus (SIV) among others;

Rotavirus: including VP4, VP5, VP6, VP7, VP8 proteins (*Protein Expr Purif.* 2004 Dec;38(2):205) and/or NSP4;

Pestivirus: such as antigens from classical porcine fever virus, bovine viral diarrhoea virus, and/or border disease virus;

Parvovirus: such as parvovirus B19;

Coronavirus: including SARS virus antigens, particularly spike protein or proteases therefrom, as well as antigens included in WO 04/92360;

Hepatitis A virus: such as inactivated virus;

Hepatitis B virus: such as the surface and/or core antigens (sAg), as well as the presurface sequences, pre-S1 and pre-S2 (formerly called pre-S), as well as combinations of the above, such as sAg/pre-S1, sAg/pre-S2, sAg/pre-S1/pre-S2, and pre-S1/pre-S2, (see, e.g., AHBV Vaccines - *Human Vaccines and Vaccination*, pp. 159-176; and U.S. Patent Nos. 4,722,840, 5,098,704, 5,324,513;

Beanes et al., *J. Virol.* (1995) 69:6833-6838, Birnbaum et al., *J. Virol.* (1990) 64:3319-3330; and Zhou et al., *J. Virol.* (1991) 65:5457-5464);

Hepatitis C virus: such as E1, E2, E1/E2 (see, Houghton et al., *Hepatology* (1991) 14:381), NS345 polyprotein, NS 345-core polyprotein, core, and/or peptides from the nonstructural regions (International Publication Nos. WO 89/04669; WO 90/11089; and WO 90/14436);

Delta hepatitis virus (HDV): antigens derived therefrom, particularly δ -antigen from HDV (see, e.g., U.S. Patent No. 5,378,814);

Hepatitis E virus (HEV); antigens derived therefrom;

Hepatitis G virus (HGV); antigens derived therefrom;

Varicella zoster virus: antigens derived from varicella zoster virus (VZV) (*J. Gen. Virol.* (1986) 67:1759);

Epstein-Barr virus: antigens derived from EBV (Baer et al., *Nature* (1984) 310:207);

Cytomegalovirus: CMV antigens, including gB and gH (*Cytomegaloviruses* (J.K. McDougall, ed., Springer-Verlag 1990) pp. 125-169);

Herpes simplex virus: including antigens from HSV-1 or HSV-2 strains and glycoproteins gB, gD and gH (McGeoch et al., *J. Gen. Virol.* (1988) 69:1531 and U.S. Patent No. 5,171,568);

Human Herpes Virus: antigens derived from other human herpesviruses such as HHV6 and HHV7; and

HPV: including antigens associated with or derived from human papillomavirus (HPV), for example, one or more of E1 – E7, L1, L2, and fusions thereof, particularly the compositions of the invention may include a virus-like particle (VLP) comprising the L1 major capsid protein, more particular still, the HPV antigens are protective against one or more of HPV serotypes 6, 11, 16 and/or 18.

Further provided are antigens, compositions, methods, and microbes included in *Vaccines*, 4th Edition (Plotkin and Orenstein ed. 2004); *Medical Microbiology* 4th Edition (Murray et al. ed. 2002); *Virology*, 3rd Edition (W.K. Joklik ed. 1988); *Fundamental Virology*, 2nd Edition (B.N. Fields and D.M. Knipe, eds. 1991), which are contemplated in conjunction with the compositions of the present invention.

Additionally, antigens include live, attenuated, split, and/or purified versions of any of the aforementioned viruses.

Fungal Antigens

Fungal antigens for use herein, associated with vaccines include those described in: U.S. Pat. Nos. 4,229,434 and 4,368,191 for prophylaxis and treatment of trichopytosis caused by Trichophyton mentagrophytes; U.S. Pat. Nos. 5,277,904 and 5,284,652 for a broad spectrum dermatophyte vaccine for the prophylaxis of dermatophyte infection in animals, such as guinea pigs, cats, rabbits, horses and lambs, these antigens comprises a suspension of killed *T. equinum*, *T. mentagrophytes* (var. granulare), *M. canis* and/or *M. gypseum* in an effective amount optionally combined with an adjuvant;

U.S. Pat. Nos. 5,453,275 and 6,132,735 for a ringworm vaccine comprising an effective amount of a homogenized, formaldehyde-killed fungi, i.e., *Microsporum canis* culture in a carrier; U.S. Pat. No. 5,948,413 involving extracellular and intracellular proteins for pythiosis. Additional antigens identified within antifungal vaccines include Ringvac bovis LTF-130 and Bioveta.

5 Further, fungal antigens for use herein may be derived from Dermatophytes, including: *Epidermophyton floccosum*, *Microsporum audouini*, *Microsporum canis*, *Microsporum distortum*, *Microsporum equinum*, *Microsporum gypsum*, *Microsporum nanum*, *Trichophyton concentricum*, *Trichophyton equinum*, *Trichophyton gallinae*, *Trichophyton gypseum*, *Trichophyton megnini*, *Trichophyton mentagrophytes*, *Trichophyton quinckeanum*, *Trichophyton rubrum*, *Trichophyton schoenleini*, *Trichophyton tonsurans*, *Trichophyton verrucosum*, *T. verrucosum* var. album, var. discoides, var. ochraceum, *Trichophyton violaceum*, and/or *Trichophyton faviforme*.

10 Fungal pathogens for use as antigens or in derivation of antigens in conjunction with the compositions of the present invention comprise *Aspergillus fumigatus*, *Aspergillus flavus*, *Aspergillus niger*, *Aspergillus nidulans*, *Aspergillus terreus*, *Aspergillus sydowi*, *Aspergillus flavatus*, *Aspergillus glaucus*, *Blastoschizomyces capitatus*, *Candida albicans*, *Candida enolase*, *Candida tropicalis*, *Candida glabrata*, *Candida krusei*, *Candida parapsilosis*, *Candida stellatoidea*, *Candida kusei*, *Candida parakwsei*, *Candida lusitanae*, *Candida pseudotropicalis*, *Candida guilliermondi*, *Cladosporium carrionii*, *Coccidioides immitis*, *Blastomyces dermatidis*, *Cryptococcus neoformans*, *Geotrichum clavatum*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Paracoccidioides*
15 *brasiliensis*, *Pneumocystis carinii*, *Pythium insidiosum*, *Pityrosporum ovale*, *Sacharomyces cerevisiae*, *Saccharomyces boulardii*, *Saccharomyces pombe*, *Scedosporium apiosperum*, *Sporothrix schenckii*, *Trichosporon beigeli*, *Toxoplasma gondii*, *Penicillium marneffe*, *Malassezia* spp., *Fonsecaea* spp., *Wangiella* spp., *Sporothrix* spp., *Basidiobolus* spp., *Conidiobolus* spp., *Rhizopus* spp., *Mucor* spp., *Absidia* spp., *Mortierella* spp., *Cunninghamella* spp., and *Saksenaea* spp.

25 Other fungi from which antigens are derived include *Alternaria* spp., *Curvularia* spp., *Helminthosporium* spp., *Fusarium* spp., *Aspergillus* spp., *Penicillium* spp., *Monolinia* spp., *Rhizoctonia* spp., *Paecilomyces* spp., *Pithomyces* spp., and *Cladosporium* spp.

Processes for producing a fungal antigens are well known in the art (see US Patent No. 6,333,164). In a preferred method a solubilized fraction extracted and separated from an insoluble
30 fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed, characterized in that the process comprises the steps of: obtaining living fungal cells; obtaining fungal cells of which cell wall has been substantially removed or at least partially removed; bursting the fungal cells of which cell wall has been substantially removed or at least partially removed; obtaining an insoluble fraction; and extracting and separating a solubilized fraction
35 from the insoluble fraction.

STD Antigens

In particular embodiments, microbes (bacteria, viruses and/or fungi) against which the present compositions and methods can be implemented include those that cause sexually transmitted diseases (STDs) and/or those that display on their surface an antigen that can be the target or antigen composition of the invention. In a preferred embodiment of the invention, compositions are combined with antigens derived from a viral or bacterial STD. Antigens derived from bacteria or viruses can be administered in conjunction with the compositions of the present invention to provide protection against at least one of the following STDs, among others: chlamydia, genital herpes, hepatitis (particularly HCV), genital warts, gonorrhoea, syphilis and/or chancroid (See, WO00/15255).

In another embodiment the compositions of the present invention are co-administered with an antigen for the prevention or treatment of an STD.

Antigens derived from the following viruses associated with STDs, which are described in greater detail above, are preferred for co-administration with the compositions of the present invention: hepatitis (particularly HCV), HPV, HIV, or HSV.

Additionally, antigens derived from the following bacteria associated with STDs, which are described in greater detail above, are preferred for co-administration with the compositions of the present invention: *Neisseria gonorrhoeae*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Treponema pallidum*, or *Haemophilus ducreyi*.

Respiratory Antigens

The antigen may be a respiratory antigen and could further be used in an immunogenic composition for methods of preventing and/or treating infection by a respiratory pathogen, including a virus, bacteria, or fungi such as respiratory syncytial virus (RSV), PIV, SARS virus, influenza, *Bacillus anthracis*, particularly by reducing or preventing infection and/or one or more symptoms of respiratory virus infection. A composition comprising an antigen described herein, such as one derived from a respiratory virus, bacteria or fungus is administered in conjunction with the compositions of the present invention to an individual which is at risk of being exposed to that particular respiratory microbe, has been exposed to a respiratory microbe or is infected with a respiratory virus, bacteria or fungus. The composition(s) of the present invention is/are preferably co-administered at the same time or in the same formulation with an antigen of the respiratory pathogen. Administration of the composition results in reduced incidence and/or severity of one or more symptoms of respiratory infection.

Pediatric/Geriatric Antigens

In one embodiment the compositions of the present invention are used in conjunction with an antigen for treatment of a pediatric population, as in a pediatric antigen. In a more particular embodiment the pediatric population is less than about 3 years old, or less than about 2 years, or less than about 1 years old. In another embodiment the pediatric antigen (in conjunction with the composition of the present invention) is administered multiple times over at least 1, 2, or 3 years.

In another embodiment the compositions of the present invention are used in conjunction with an antigen for treatment of a geriatric population, as in a geriatric antigen.

Other Antigens

Other antigens for use in conjunction with the compositions of the present include hospital
5 acquired (nosocomial) associated antigens.

In another embodiment, parasitic antigens are contemplated in conjunction with the compositions of the present invention. Examples of parasitic antigens include those derived from organisms causing malaria and/or Lyme disease.

In another embodiment, the antigens in conjunction with the compositions of the present
10 invention are associated with or effective against a mosquito born illness. In another embodiment, the antigens in conjunction with the compositions of the present invention are associated with or effective against encephalitis. In another embodiment the antigens in conjunction with the compositions of the present invention are associated with or effective against an infection of the nervous system.

In another embodiment, the antigens in conjunction with the compositions of the present
15 invention are antigens transmissible through blood or body fluids.

Antigen Formulations

In other aspects of the invention, methods of producing microparticles having adsorbed antigens are provided. The methods comprise: (a) providing an emulsion by dispersing a mixture comprising (i) water, (ii) a detergent, (iii) an organic solvent, and (iv) a
20 biodegradable polymer selected from the group consisting of a poly(α -hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate. The polymer is typically present in the mixture at a concentration of about 1% to about 30% relative to the organic solvent, while the detergent is typically present in the mixture at a weight-to-weight detergent-to-polymer ratio of from about 0.00001:1 to about 0.1:1 (more typically about 0.0001:1 to
25 about 0.1:1, about 0.001:1 to about 0.1:1, or about 0.005:1 to about 0.1:1); (b) removing the organic solvent from the emulsion; and (c) adsorbing an antigen on the surface of the microparticles. In certain embodiments, the biodegradable polymer is present at a concentration of about 3% to about 10% relative to the organic solvent.

Microparticles for use herein will be formed from materials that are
30 sterilizable, non-toxic and biodegradable. Such materials include, without limitation, poly(α -hydroxy acid), polyhydroxybutyric acid, polycaprolactone, polyorthoester, polyanhydride, PACA, and polycyanoacrylate. Preferably, microparticles for use with the present invention are derived from a poly(α -hydroxy acid), in particular, from a poly(lactide) ("PLA") or a copolymer of D,L-lactide and glycolide or glycolic acid, such as a poly(D,L-lactide-co-glycolide) ("PLG" or "PLGA"), or a
35 copolymer of D,L-lactide and caprolactone. The microparticles may be derived from any of various polymeric starting materials which have a variety of molecular weights and, in the case of the copolymers such as PLG, a variety of lactide:glycolide ratios, the selection of which will be largely a

matter of choice, depending in part on the coadministered macromolecule. These parameters are discussed more fully below.

Further antigens may also include an outer membrane vesicle (OMV) preparation.

Additional formulation methods and antigens (especially tumor antigens) are provided in U.S.

5 Patent Serial No. 09/581,772.

Antigen References

The following references include antigens useful in conjunction with the compositions of the present invention:

- 10 1 International patent application WO99/24578
 2 International patent application WO99/36544.
 3 International patent application WO99/57280.
 4 International patent application WO00/22430.
 5 Tettelin et al. (2000) Science 287:1809-1815.
 15 6 International patent application WO96/29412.
 7 Pizza et al. (2000) Science 287:1816-1820.
 8 PCT WO 01/52885.
 9 Bjune et al. (1991) Lancet 338(8775).
 10 Fuskasawa et al. (1999) Vaccine 17:2951-2958.
 20 11 Rosenqist et al. (1998) Dev. Biol. Strand 92:323-333.
 12 Constantino et al. (1992) Vaccine 10:691-698.
 13 Constantino et al. (1999) Vaccine 17:1251-1263.
 14 Watson (2000) Pediatr Infect Dis J 19:331-332.
 15 Rubin (2000) Pediatr Clin North Am 47:269-285, v.
 25 16 Jedrzejjas (2001) Microbiol Mol Biol Rev 65:187-207.
 17 International patent application filed on 3rd July 2001 claiming priority from GB-
 0016363.4; WO 02/02606; PCT IB/01/00166.
 18 Kalman et al. (1999) Nature Genetics 21:385-389.
 19 Read et al. (2000) Nucleic Acids Res 28:1397-406.
 30 20 Shirai et al. (2000) J. Infect. Dis 181(Suppl 3):S524-S527.
 21 International patent application WO99/27105.
 22 International patent application WO00/27994.
 23 International patent application WO00/37494.
 24 International patent application WO99/28475.
 35 25 Bell (2000) Pediatr Infect Dis J 19:1187-1188.
 26 Iwarson (1995) APMIS 103:321-326.
 27 Gerlich et al. (1990) Vaccine 8 Suppl:S63-68 & 79-80.
 28 Hsu et al. (1999) Clin Liver Dis 3:901-915.
 29 Gastofsson et al. (1996) N. Engl. J. Med. 334:349-355.
 40 30 Rappuoli et al. (1991) TIBTECH 9:232-238.
 31 Vaccines (1988) eds. Plotkin & Mortimer. ISBN 0-7216-1946-0.
 32 Del Giudice et al. (1998) Molecular Aspects of Medicine 19:1-70.
 33 International patent application WO93/018150.
 34 International patent application WO99/53310.
 45 35 International patent application WO98/04702.
 36 Ross et al. (2001) Vaccine 19:135-142.
 37 Sutter et al. (2000) Pediatr Clin North Am 47:287-308.
 38 Zimmerman & Spann (1999) Am Fam Physician 59:113-118, 125-126.
 39 Dreensen (1997) Vaccine 15 Suppl"S2-6.
 50 40 MMWR Morb Mortal Wkly rep 1998 Jan 16:47(1):12, 9.
 41 McMichael (2000) Vaccine 19 Suppl 1:S101-107.

- 42 Schuchat (1999) *Lancet* 353(9146):51-6.
43 GB patent applications 0026333.5, 0028727.6 & 0105640.7.
44 Dale (1999) *Infect Disclin North Am* 13:227-43, viii.
45 Ferretti et al. (2001) *PNAS USA* 98: 4658-4663.
5 46 Kuroda et al. (2001) *Lancet* 357(9264):1225-1240; see also pages 1218-1219.
47 Ramsay et al. (2001) *Lancet* 357(9251):195-196.
48 Lindberg (1999) *Vaccine* 17 Suppl.2:S28-36.
49 Buttery & Moxon (2000) *J R Coil Physicians Long* 34:163-168.
50 Ahmad & Chapnick (1999) *Infect Dis Clin North Am* 13:113-133, vii.
10 51 Goldblatt (1998) *J. Med. Microbiol.* 47:663-567.
52 European patent 0 477 508.
53 U.S. Patent No. 5,306,492.
54 International patent application WO98/42721.
55 Conjugate Vaccines (eds. Cruse et al.) ISBN 3805549326, particularly vol. 10:48-114.
15 56 Hermanson (1996) *Bioconjugate Techniques* ISBN: 012323368 & 012342335X.
57 European patent application 0372501.
58 European patent application 0378881.
59 European patent application 0427347.
60 International patent application WO93/17712.
20 61 International patent application WO98/58668.
62 European patent application 0471177.
63 International patent application WO00/56360.
64 International patent application WO00/67161.

25 The contents of all of the above cited patents, patent applications and journal articles are incorporated by reference as if set forth fully herein.

There may be an upper limit to the number of Gram positive bacterial proteins which will be in the compositions of the invention. Preferably, the number of Gram positive bacterial proteins in a composition of the invention is less than 20, less than 19, less than 18, less than 17, less than 16, less
30 than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, or less than 3. Still more preferably, the number of Gram positive bacterial proteins in a composition of the invention is less than 6, less than 5, or less than 4. Still more preferably, the number of Gram positive bacterial proteins in a composition of the invention is 3.

35 The Gram positive bacterial proteins and polynucleotides used in the invention are preferably isolated, *i.e.*, separate and discrete, from the whole organism with which the molecule is found in nature or, when the polynucleotide or polypeptide is not found in nature, is sufficiently free of other biological macromolecules so that the polynucleotide or polypeptide can be used for its intended purpose.

40 Fusion Proteins: GBS AI sequences

The GBS AI proteins used in the invention may be present in the composition as individual separate polypeptides, but it is preferred that at least two (*i.e.* 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) of the antigens are expressed as a single polypeptide chain (a "hybrid" or "fusion" polypeptide). Such fusion polypeptides offer two principal advantages: first, a polypeptide that may
45 be unstable or poorly expressed on its own can be assisted by adding a suitable fusion partner that

overcomes the problem, second, commercial manufacture is simplified as only one expression and purification need be employed in order to produce two polypeptides which are both antigenically useful.

The fusion polypeptide may comprise one or more AI polypeptide sequences. Preferably, the fusion comprises an AI surface protein sequence. Preferably, the fusion polypeptide includes one or more of GBS 80, GBS 104, and GBS 67. Most preferably, the fusion peptide includes a polypeptide sequence from GBS 80. Accordingly, the invention includes a fusion peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first and second amino acid sequences are selected from a GBS AI surface protein or a fragment thereof. Preferably, the first and second amino acid sequences in the fusion polypeptide comprise different epitopes.

Hybrids (or fusions) consisting of amino acid sequences from two, three, four, five, six, seven, eight, nine, or ten GBS antigens are preferred. In particular, hybrids consisting of amino acid sequences from two, three, four, or five GBS antigens are preferred.

Different hybrid polypeptides may be mixed together in a single formulation. Within such combinations, a GBS antigen may be present in more than one hybrid polypeptide and/or as a non-hybrid polypeptide. It is preferred, however, that an antigen is present either as a hybrid or as a non-hybrid, but not as both.

Hybrid polypeptides can be represented by the formula $\text{NH}_2\text{-A-}\{-\text{X-L}\}_n\text{-B-COOH}$, wherein: X is an amino acid sequence of a GBS AI protein or a fragment thereof; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; and n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

If a -X- moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in the hybrid protein. In some embodiments, the leader peptides will be deleted except for that of the -X- moiety located at the N-terminus of the hybrid protein *i.e.* the leader peptide of X_1 will be retained, but the leader peptides of $X_2 \dots X_n$ will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of X_1 as moiety -A-.

For each n instances of $\{-\text{X-L}\}$, linker amino acid sequence -L- may be present or absent. For instance, when $n=2$ the hybrid may be $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-L}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-X}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-X}_2\text{-L}_2\text{-COOH}$, *etc.* Linker amino acid sequence(s) -L- will typically be short (*e.g.* 20 or fewer amino acids *i.e.* 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples comprise short peptide sequences which facilitate cloning, poly-glycine linkers (*i.e.* comprising Gly_n where $n = 2, 3, 4, 5, 6, 7, 8, 9, 10$ or more), and histidine tags (*i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG, with the Gly-Ser dipeptide being formed from a *Bam*HI restriction site, thus aiding cloning and manipulation, and the $(\text{Gly})_4$ tetrapeptide being a typical poly-glycine linker.

-A- is an optional N-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19,

18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include leader sequences to direct protein trafficking, or short peptide sequences which facilitate cloning or purification (e.g. histidine tags *i.e.* His_n where *n* = 3, 4, 5, 6, 7, 8, 9, 10 or more). Other suitable N-terminal amino acid sequences will be apparent to those skilled in the art. If X₁ lacks its own N-terminus methionine, -A- is preferably an oligopeptide (e.g. with 1, 2, 3, 4, 5, 6, 7 or 8 amino acids) which provides a N-terminus methionine.

-B- is an optional C-terminal amino acid sequence. This will typically be short (e.g. 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include sequences to direct protein trafficking, short peptide sequences which facilitate cloning or purification (e.g. comprising histidine tags *i.e.* His_n where *n* = 3, 4, 5, 6, 7, 8, 9, 10 or more), or sequences which enhance protein stability. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.

Most preferably, *n* is 2 or 3.

Fusion Proteins: Gram positive bacteria AI sequences

The Gram positive bacteria AI proteins used in the invention may be present in the composition as individual separate polypeptides, but it is preferred that at least two (*i.e.* 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18) of the antigens are expressed as a single polypeptide chain (a "hybrid" or "fusion" polypeptide). Such fusion polypeptides offer two principal advantages: first, a polypeptide that may be unstable or poorly expressed on its own can be assisted by adding a suitable fusion partner that overcomes the problem; second, commercial manufacture is simplified as only one expression and purification need be employed in order to produce two polypeptides which are both antigenically useful.

The fusion polypeptide may comprise one or more AI polypeptide sequences. Preferably, the fusion comprises an AI surface protein sequence. Accordingly, the invention includes a fusion peptide comprising a first amino acid sequence and a second amino acid sequence, wherein said first and second amino acid sequences are selected from a Gram positive bacteria AI protein or a fragment thereof. Preferably, the first and second amino acid sequences in the fusion polypeptide comprise different epitopes.

Hybrids (or fusions) consisting of amino acid sequences from two, three, four, five, six, seven, eight, nine, or ten Gram positive bacteria antigens are preferred. In particular, hybrids consisting of amino acid sequences from two, three, four, or five Gram positive bacteria antigens are preferred.

Different hybrid polypeptides may be mixed together in a single formulation. Within such combinations, a Gram positive bacteria AI sequence may be present in more than one hybrid polypeptide and/or as a non-hybrid polypeptide. It is preferred, however, that an antigen is present either as a hybrid or as a non-hybrid, but not as both.

Hybrid polypeptides can be represented by the formula NH₂-A-{-X-L-}_n-B-COOH, wherein: X is an amino acid sequence of a Gram positive bacteria AI sequence or a fragment thereof; L is an

optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; and n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

If a -X- moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in the hybrid protein. In some embodiments, the leader peptides will be deleted except for that of the -X- moiety located at the N-terminus of the hybrid protein *i.e.* the leader peptide of X_1 will be retained, but the leader peptides of $X_2 \dots X_n$ will be omitted. This is equivalent to deleting all leader peptides and using the leader peptide of X_1 as moiety -A-.

For each n instances of {-X-L-}, linker amino acid sequence -L- may be present or absent. For instance, when $n=2$ the hybrid may be $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-L}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-X}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-L}_1\text{-X}_2\text{-COOH}$, $\text{NH}_2\text{-X}_1\text{-X}_2\text{-L}_2\text{-COOH}$, *etc.* Linker amino acid sequence(s) -L- will typically be short (*e.g.* 20 or fewer amino acids *i.e.* 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples comprise short peptide sequences which facilitate cloning, poly-glycine linkers (*i.e.* comprising Gly_n where $n = 2, 3, 4, 5, 6, 7, 8, 9, 10$ or more), and histidine tags (*i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG, with the Gly-Ser dipeptide being formed from a *Bam*HI restriction site, thus aiding cloning and manipulation, and the $(\text{Gly})_4$ tetrapeptide being a typical poly-glycine linker.

-A- is an optional N-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include leader sequences to direct protein trafficking, or short peptide sequences which facilitate cloning or purification (*e.g.* histidine tags *i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more). Other suitable N-terminal amino acid sequences will be apparent to those skilled in the art. If X_1 lacks its own N-terminus methionine, -A- is preferably an oligopeptide (*e.g.* with 1, 2, 3, 4, 5, 6, 7 or 8 amino acids) which provides a N-terminus methionine.

-B- is an optional C-terminal amino acid sequence. This will typically be short (*e.g.* 40 or fewer amino acids *i.e.* 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples include sequences to direct protein trafficking, short peptide sequences which facilitate cloning or purification (*e.g.* comprising histidine tags *i.e.* His_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more), or sequences which enhance protein stability. Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.

Most preferably, n is 2 or 3.

Antibodies: GBS AI sequences

The GBS AI proteins of the invention may also be used to prepare antibodies specific to the GBS AI proteins. The antibodies are preferably specific to the an oligomeric or hyper-oligomeric form of an AI protein. The invention also includes combinations of antibodies specific to GBS AI proteins selected to provide protection against an increased range of GBS serotypes and strain isolates. For example, a combination may comprise a first and second antibody, wherein said first

antibody is specific to a first GBS AI protein and said second antibody is specific to a second GBS AI protein. Preferably, the nucleic acid sequence encoding said first GBS AI protein is not present in a GBS genome comprising a polynucleotide sequence encoding for said second GBS AI protein.

Preferably, the nucleic acid sequence encoding said first and second GBS AI proteins are present in the genomes of multiple GBS serotypes and strain isolates.

The GBS specific antibodies of the invention include one or more biological moieties that, through chemical or physical means, can bind to or associate with an epitope of a GBS polypeptide. The antibodies of the invention include antibodies which specifically bind to a GBS AI protein. The invention includes antibodies obtained from both polyclonal and monoclonal preparations, as well as the following: hybrid (chimeric) antibody molecules (see, for example, Winter *et al.* (1991) *Nature* 349: 293-299; and US Patent No. 4,816,567; F(ab')₂ and F(ab) fragments; F_v molecules (non-covalent heterodimers, see, for example, Inbar *et al.* (1972) *Proc Natl Acad Sci USA* 69:2659-2662; and Ehrlich *et al.* (1980) *Biochem* 19:4091-4096); single-chain F_v molecules (sFv) (see, for example, Huston *et al.* (1988) *Proc Natl Acad Sci USA* 85:5897-5883); dimeric and trimeric antibody fragment constructs; minibodies (see, *e.g.*, Pack *et al.* (1992) *Biochem* 31:1579-1584; Cumber *et al.* (1992) *J Immunology* 149B: 120-126); humanized antibody molecules (see, for example, Riechmann *et al.* (1988) *Nature* 332:323-327; Verhoeyan *et al.* (1988) *Science* 239:1534-1536; and U.K. Patent Publication No. GB 2,276,169, published 21 September 1994); and, any functional fragments obtained from such molecules, wherein such fragments retain immunological binding properties of the parent antibody molecule. The invention further includes antibodies obtained through non-conventional processes, such as phage display.

Preferably, the GBS specific antibodies of the invention are monoclonal antibodies. Monoclonal antibodies of the invention include an antibody composition having a homogeneous antibody population. Monoclonal antibodies of the invention may be obtained from murine hybridomas, as well as human monoclonal antibodies obtained using human rather than murine hybridomas. See, *e.g.*, Cote, *et al.* *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, 1985, p 77.

The antibodies of the invention may be used in diagnostic applications, for example, to detect the presence or absence of GBS in a biological sample. The antibodies of the invention may also be used in the prophylactic or therapeutic treatment of GBS infection.

Antibodies: Gram positive bacteria AI sequences

The Gram positive bacteria AI proteins of the invention may also be used to prepare antibodies specific to the Gram positive bacteria AI proteins. The antibodies are preferably specific to the an oligomeric or hyper-oligomeric form of an AI protein. The invention also includes combinations of antibodies specific to Gram positive bacteria AI proteins selected to provide protection against an increased range of Gram positive bacteria genus, species, serotypes and strain isolates.

For example, a combination may comprise a first and second antibody, wherein said first antibody is specific to a first Gram positive bacteria AI protein and said second antibody is specific to a second Gram positive bacteria AI protein. Preferably, the nucleic acid sequence encoding said first Gram positive bacteria AI protein is not present in a Gram positive bacterial genome comprising a polynucleotide sequence encoding for said second Gram positive bacteria AI protein. Preferably, the nucleic acid sequence encoding said first and second Gram positive bacteria AI proteins are present in the genomes of multiple Gram positive bacteria genus, species, serotypes or strain isolates.

As an example of an instance where the combination of antibodies provides protection against an increased range of bacteria serotypes, the first antibody may be specific to a first GAS AI protein and the second antibody may be specific to a second GAS AI protein. The first GAS AI protein may comprise a GAS AI-1 surface protein, while the second GAS AI protein may comprise a GAS AI-2 or AI-3 surface protein.

As an example of an instance where the combination of antibodies provides protection against an increased range of bacterial species, the first antibody may be specific to a GBS AI protein and the second antibody may be specific to a GAS AI protein. Alternatively, the first antibody may be specific to a GAS AI protein and the second antibody may be specific to a *S. pneumoniae* AI protein.

The Gram positive specific antibodies of the invention include one or more biological moieties that, through chemical or physical means, can bind to or associate with an epitope of a Gram positive bacteria AI polypeptide. The antibodies of the invention include antibodies which specifically bind to a Gram positive bacteria AI protein. The invention includes antibodies obtained from both polyclonal and monoclonal preparations, as well as the following: hybrid (chimeric) antibody molecules (see, for example, Winter *et al.* (1991) *Nature* 349: 293-299; and US Patent No. 4,816,567; F(ab')₂ and F(ab) fragments; F_v molecules (non-covalent heterodimers, see, for example, Inbar *et al.* (1972) *Proc Natl Acad Sci USA* 69:2659-2662; and Ehrlich *et al.* (1980) *Biochem* 19:4091-4096); single-chain F_v molecules (sFv) (see, for example, Huston *et al.* (1988) *Proc Natl Acad Sci USA* 85:5897-5883); dimeric and trimeric antibody fragment constructs; minibodies (see, *e.g.*, Pack *et al.* (1992) *Biochem* 31:1579-1584; Cumber *et al.* (1992) *J Immunology* 149B: 120-126); humanized antibody molecules (see, for example, Riechmann *et al.* (1988) *Nature* 332:323-327; Verhoevan *et al.* (1988) *Science* 239:1534-1536; and U.K. Patent Publication No. GB 2,276,169, published 21 September 1994); and, any functional fragments obtained from such molecules, wherein such fragments retain immunological binding properties of the parent antibody molecule. The invention further includes antibodies obtained through non-conventional processes, such as phage display.

Preferably, the Gram positive specific antibodies of the invention are monoclonal antibodies. Monoclonal antibodies of the invention include an antibody composition having a homogeneous antibody population. Monoclonal antibodies of the invention may be obtained from murine hybridomas, as well as human monoclonal antibodies obtained using human rather than murine

hybridomas. See, e.g., Cote, *et al. Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, 1985, p 77.

The antibodies of the invention may be used in diagnostic applications, for example, to detect the presence or absence of Gram positive bacteria in a biological sample. The antibodies of the invention may also be used in the prophylactic or therapeutic treatment of Gram positive bacteria infection.

Nucleic Acids

The invention provides nucleic acids encoding the Gram positive bacteria sequences and/or the hybrid fusion polypeptides of the invention. The invention also provides nucleic acid encoding the GBS antigens and/or the hybrid fusion polypeptides of the invention. Furthermore, the invention provides nucleic acid which can hybridise to these nucleic acids, preferably under "high stringency" conditions (e.g. 65°C in a 0.1xSSC, 0.5% SDS solution).

Polypeptides of the invention can be prepared by various means (e.g. recombinant expression, purification from cell culture, chemical synthesis, *etc.*) and in various forms (e.g. native, fusions, non-glycosylated, lipidated, *etc.*). They are preferably prepared in substantially pure form (*i.e.* substantially free from other GAS or host cell proteins).

Nucleic acid according to the invention can be prepared in many ways (e.g. by chemical synthesis, from genomic or cDNA libraries, from the organism itself, *etc.*) and can take various forms (e.g. single stranded, double stranded, vectors, probes, *etc.*). They are preferably prepared in substantially pure form (*i.e.* substantially free from other GBS or host cell nucleic acids).

The term "nucleic acid" includes DNA and RNA, and also their analogues, such as those containing modified backbones (e.g. phosphorothioates, *etc.*), and also peptide nucleic acids (PNA), *etc.* The invention includes nucleic acid comprising sequences complementary to those described above (e.g. for antisense or probing purposes).

The invention also provides a process for producing a polypeptide of the invention, comprising the step of culturing a host cell transformed with nucleic acid of the invention under conditions which induce polypeptide expression.

The invention provides a process for producing a polypeptide of the invention, comprising the step of synthesising at least part of the polypeptide by chemical means.

The invention provides a process for producing nucleic acid of the invention, comprising the step of amplifying nucleic acid using a primer-based amplification method (e.g. PCR).

The invention provides a process for producing nucleic acid of the invention, comprising the step of synthesising at least part of the nucleic acid by chemical means.

Purification and Recombinant Expression

The Gram positive bacteria AI proteins of the invention may be isolated from the native Gram positive bacteria, or they may be recombinantly produced, for instance in a heterologous host. For example, the GAS, GBS, and *S. pneumoniae* antigens of the invention may be isolated from

~~*Streptococcus agalactiae*, *S. pyogenes*, *S. pneumoniae*~~, or they may be recombinantly produced, for instance, in a heterologous host. Preferably, the GBS antigens are prepared using a heterologous host.

The heterologous host may be prokaryotic (e.g. a bacterium) or eukaryotic. It is preferably *E.coli*, but other suitable hosts include *Bacillus subtilis*, *Vibrio cholerae*, *Salmonella typhi*, *Salmonella typhimurium*, *Neisseria lactamica*, *Neisseria cinerea*, *Mycobacteria* (e.g. *M.tuberculosis*), *S. gordonii*, *L. lactis*, yeasts, etc.

Recombinant production of polypeptides is facilitated by adding a tag protein to the Gram positive bacteria AI sequence to be expressed as a fusion protein comprising the tag protein and the Gram positive bacteria antigen. For example, recombinant production of polypeptides is facilitated by adding a tag protein to the GBS antigen to be expressed as a fusion protein comprising the tag protein and the GBS antigen. Such tag proteins can facilitate purification, detection and stability of the expressed protein. Tag proteins suitable for use in the invention include a polyarginine tag (Arg-tag), polyhistidine tag (His-tag), FLAG-tag, Strep-tag, c-myc-tag, S-tag, calmodulin-binding peptide, cellulose-binding domain, SBP-tag, chitin-binding domain, glutathione S-transferase-tag (GST), maltose-binding protein, transcription termination anti-terminiation factor (NusA), *E. coli* thioredoxin (TrxA) and protein disulfide isomerase I (DsbA). Preferred tag proteins include His-tag and GST. A full discussion on the use of tag proteins can be found at Terpe et al., "Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems", Appl Microbiol Biotechnol (2003) 60:523 – 533.

After purification, the tag proteins may optionally be removed from the expressed fusion protein, i.e., by specifically tailored enzymatic treatments known in the art. Commonly used proteases include enterokinase, tobacco etch virus (TEV), thrombin, and factor X_a.

GBS polysaccharides

The compositions of the invention may be further improved by including GBS polysaccharides. Preferably, the GBS antigen and the saccharide each contribute to the immunological response in a recipient. The combination is particularly advantageous where the saccharide and polypeptide provide protection from different GBS serotypes.

The combined antigens may be present as a simple combination where separate saccharide and polypeptide antigens are administered together, or they may be present as a conjugated combination, where the saccharide and polypeptide antigens are covalently linked to each other.

Thus the invention provides an immunogenic composition comprising (i) one or more GBS AI proteins and (ii) one or more GBS saccharide antigens. The polypeptide and the polysaccharide may advantageously be covalently linked to each other to form a conjugate.

Between them, the combined polypeptide and saccharide antigens preferably cover (or provide protection from) two or more GBS serotypes (e.g. 2, 3, 4, 5, 6, 7, 8 or more serotypes). The serotypes of the polypeptide and saccharide antigens may or may not overlap. For example, the polypeptide might protect against serogroup II or V, while the saccharide protects against either serogroups Ia, Ib, or III. Preferred combinations protect against the following groups of serotypes:

(1) serotypes Ia and Ib, (2) serotypes Ia and II, (3) serotypes Ia and III, (4) serotypes Ia and IV, (5) serotypes Ia and V, (6) serotypes Ia and VI, (7) serotypes Ia and VII, (8) serotypes Ia and VIII, (9) serotypes Ib and II, (10) serotypes Ib and III, (11) serotypes Ib and IV, (12) serotypes Ib and V, (13) serotypes Ib and VI, (14) serotypes Ib and VII, (15) serotypes Ib and VIII, 16) serotypes II and III, 5 (17) serotypes II and IV, (18) serotypes II and V, (19) serotypes II and VI, (20) serotypes II and VII, (21) serotypes II and VIII, (22) serotypes III and IV, (23) serotypes III and V, (24) serotypes III and VI, (25) serotypes III and VII, (26) serotypes III and VIII, (27) serotypes IV and V, (28) serotypes IV and VI, (29) serotypes IV and VII, (30) serotypes IV and VIII, (31) serotypes V and VI, (32) serotypes V and VII, (33) serotypes V and VIII, (34) serotypes VI and VII, (35) serotypes VI and 10 VIII, and (36) serotypes VII and VIII.

Still more preferably, the combinations protect against the following groups of serotypes: (1) serotypes Ia and II, (2) serotypes Ia and V, (3) serotypes Ib and II, (4) serotypes Ib and V, (5) serotypes III and II, and (6) serotypes III and V. Most preferably, the combinations protect against serotypes III and V.

15 Protection against serotypes II and V is preferably provided by polypeptide antigens. Protection against serotypes Ia, Ib and/or III may be polypeptide or saccharide antigens.

Immunogenic compositions and medicaments

20 Compositions of the invention are preferably immunogenic compositions, and are more preferably vaccine compositions. The pH of the composition is preferably between 6 and 8, preferably about 7. The pH may be maintained by the use of a buffer. The composition may be sterile and/or pyrogen-free. The composition may be isotonic with respect to humans.

25 Vaccines according to the invention may either be prophylactic (*i.e.* to prevent infection) or therapeutic (*i.e.* to treat infection), but will typically be prophylactic. Accordingly, the invention includes a method for the therapeutic or prophylactic treatment of a Gram positive bacteria infection in an animal susceptible to such gram positive bacterial infection comprising administering to said animal a therapeutic or prophylactic amount of the immunogenic composition of the invention. For example, the invention includes a method for the therapeutic or prophylactic treatment of a *Streptococcus agalactiae*, *S. pyogenes*, or *S. pneumoniae* infection in an animal susceptible to streptococcal infection comprising administering to said animal a therapeutic or prophylactic amount 30 of the immunogenic compositions of the invention.

The invention also provides a composition of the invention for use of the compositions described herein as a medicament. The medicament is preferably able to raise an immune response in a mammal (*i.e.* it is an immunogenic composition) and is more preferably a vaccine.

35 The invention also provides the use of the compositions of the invention in the manufacture of a medicament for raising an immune response in a mammal. The medicament is preferably a vaccine.

The invention also provides kits comprising one or more containers of compositions of the invention. Compositions can be in liquid form or can be lyophilized, as can individual antigens. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes.

Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The composition may comprise a first component comprising one or more Gram positive bacteria AI proteins. Preferably, the AI proteins are surface AI proteins. Preferably, the AI surface proteins are in an oligomeric or hyperoligomeric form. For example, the first component comprises a combination of GBS antigens or GAS antigens, or *S. pneumoniae* antigens. Preferably said combination includes GBS 80. Preferably GBS 80 is present in an oligomeric or hyperoligomeric form.

5
10
The kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other buffers, diluents, filters, needles, and syringes. The kit can also comprise a second or third container with another active agent, for example an antibiotic.

15
The kit can also comprise a package insert containing written instructions for methods of inducing immunity against *S. agalactiae* and/or *S. pyogenes* and/or *S. pneumoniae* or for treating *S. agalactiae* and/or *S. pyogenes* and/or *S. pneumoniae* infections. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.

20
The invention also provides a delivery device pre-filled with the immunogenic compositions of the invention.

The invention also provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention. The immune response is preferably protective and preferably involves antibodies and/or cell-mediated immunity. This immune response will preferably induce long lasting (*e.g.*, neutralising) antibodies and a cell mediated immunity that can quickly respond upon exposure to one or more GBS and/or GAS and/or *S. pneumoniae* antigens. The method may raise a booster response.

25
30
The invention provides a method of neutralizing GBS, GAS, or *S. pneumoniae* infection in a mammal comprising the step of administering to the mammal an effective amount of the immunogenic compositions of the invention, a vaccine of the invention, or antibodies which recognize an immunogenic composition of the invention.

35
The mammal is preferably a human. Where the vaccine is for prophylactic use, the human is preferably a female (either of child bearing age or a teenager). Alternatively, the human may be elderly (*e.g.*, over the age of 50, 55, 60, 65, 70 or 75) and may have an underlying disease such as diabetes or cancer. Where the vaccine is for therapeutic use, the human is preferably a pregnant female or an elderly adult.

These uses and methods are preferably for the prevention and/or treatment of a disease caused by *Streptococcus agalactiae*, or *S. pyogenes*, or *S. pneumoniae*. The compositions may also be

effective against other streptococcal bacteria. The compositions may also be effective against other Gram positive bacteria.

One way of checking efficacy of therapeutic treatment involves monitoring Gram positive bacterial infection after administration of the composition of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses against the Gram positive bacterial antigens in the compositions of the invention after administration of the composition.

One way of checking efficacy of therapeutic treatment involves monitoring GBS infection after administration of the composition of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses against the GBS antigens in the compositions of the invention after administration of the composition.

A way of assessing the immunogenicity of the component proteins of the immunogenic compositions of the present invention is to express the proteins recombinantly and to screen patient sera or mucosal secretions by immunoblot. A positive reaction between the protein and the patient serum indicates that the patient has previously mounted an immune response to the protein in question- that is, the protein is an immunogen. This method may also be used to identify immunodominant proteins and/or epitopes.

Another way of checking efficacy of therapeutic treatment involves monitoring GBS or GAS or *S pneumoniae* infection after administration of the compositions of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses both systemically (such as monitoring the level of IgG1 and IgG2a production) and mucosally (such as monitoring the level of IgA production) against the GBS and/or GAS and/or *S pneumoniae* antigens in the compositions of the invention after administration of the composition. Typically, GBS and/or GAS and/or *S pneumoniae* serum specific antibody responses are determined post-immunization but pre-challenge whereas mucosal GBS and/or GAS and/or *S pneumoniae* specific antibody body responses are determined post-immunization and post-challenge.

The vaccine compositions of the present invention can be evaluated *in vitro* and *in vivo* animal models prior to host, *e.g.*, human, administration.

The efficacy of immunogenic compositions of the invention can also be determined *in vivo* by challenging animal models of GBS and/or GAS and/or *S pneumoniae* infection, *e.g.*, guinea pigs or mice, with the immunogenic compositions. The immunogenic compositions may or may not be derived from the same serotypes as the challenge serotypes. Preferably the immunogenic compositions are derivable from the same serotypes as the challenge serotypes. More preferably, the immunogenic composition and/or the challenge serotypes are derivable from the group of GBS and/or GAS and/or *S pneumoniae* serotypes.

In vivo efficacy models include but are not limited to: (i) A murine infection model using human GBS and/or GAS and/or *S pneumoniae* serotypes; (ii) a murine disease model which is a murine model using a mouse-adapted GBS and/or GAS and/or *S pneumoniae* strain, such as those

strains outlined above which is particularly virulent in mice and (iii) a primate model using human GBS or GAS or S pneumoniae isolates.

The immune response may be one or both of a TH1 immune response and a TH2 response.

The immune response may be an improved or an enhanced or an altered immune response.

5 The immune response may be one or both of a systemic and a mucosal immune response.

Preferably the immune response is an enhanced system and/or mucosal response.

An enhanced systemic and/or mucosal immunity is reflected in an enhanced TH1 and/or TH2 immune response. Preferably, the enhanced immune response includes an increase in the production of IgG1 and/or IgG2a and/or IgA

10 Preferably the mucosal immune response is a TH2 immune response. Preferably, the mucosal immune response includes an increase in the production of IgA.

Activated TH2 cells enhance antibody production and are therefore of value in responding to extracellular infections. Activated TH2 cells may secrete one or more of IL-4, IL-5, IL-6, and IL-10.

15 A TH2 immune response may result in the production of IgG1, IgE, IgA and memory B cells for future protection.

A TH2 immune response may include one or more of an increase in one or more of the cytokines associated with a TH2 immune response (such as IL-4, IL-5, IL-6 and IL-10), or an increase in the production of IgG1, IgE, IgA and memory B cells. Preferably, the enhanced TH2 immune response will include an increase in IgG1 production.

20 A TH1 immune response may include one or more of an increase in CTLs, an increase in one or more of the cytokines associated with a TH1 immune response (such as IL-2, IFN γ , and TNF β), an increase in activated macrophages, an increase in NK activity, or an increase in the production of IgG2a. Preferably, the enhanced TH1 immune response will include an increase in IgG2a production.

25 Immunogenic compositions of the invention, in particular, immunogenic composition comprising one or more GAS antigens of the present invention may be used either alone or in combination with other GAS antigens optionally with an immunoregulatory agent capable of eliciting a Th1 and/or Th2 response.

30 Compositions of the invention will generally be administered directly to a patient. Certain routes may be favored for certain compositions, as resulting in the generation of a more effective immune response, preferably a CMI response, or as being less likely to induce side effects, or as being easier for administration. Direct delivery may be accomplished by parenteral injection (*e.g.* subcutaneously, intraperitoneally, intradermally, intravenously, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral (*e.g.* tablet, spray), vaginal, topical, transdermal (*e.g.* see WO 99/27961) or transcutaneous (*e.g.* see WO 02/074244 and WO 02/064162), intranasal (*e.g.* see 35 WO03/028760), ocular, aural, pulmonary or other mucosal administration.

The invention may be used to elicit systemic and/or mucosal immunity.

In one particularly preferred embodiment, the immunogenic composition comprises one or more GBS or GAS or S pneumoniae antigen(s) which elicits a neutralising antibody response and one or more GBS or GAS or S pneumoniae antigen(s) which elicit a cell mediated immune response. In this way, the neutralising antibody response prevents or inhibits an initial GBS or GAS or S pneumoniae infection while the cell-mediated immune response capable of eliciting an enhanced Th1 cellular response prevents further spreading of the GBS or GAS or S pneumoniae infection. Preferably, the immunogenic composition comprises one or more GBS or GAS or S pneumoniae surface antigens and one or more GBS or GAS or S pneumoniae cytoplasmic antigens. Preferably the immunogenic composition comprises one or more GBS or GAS or S pneumoniae surface antigens or the like and one or other antigens, such as a cytoplasmic antigen capable of eliciting a Th1 cellular response.

Dosage treatment can be a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. In a multiple dose schedule the various doses may be given by the same or different routes *e.g.* a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, *etc.*

The compositions of the invention may be prepared in various forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (*e.g.* a lyophilised composition). The composition may be prepared for topical administration *e.g.* as an ointment, cream or powder. The composition may be prepared for oral administration *e.g.* as a tablet or capsule, as a spray, or as a syrup (optionally flavoured). The composition may be prepared for pulmonary administration *e.g.* as an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration *e.g.* as drops. The composition may be in kit form, designed such that a combined composition is reconstituted just prior to administration to a patient. Such kits may comprise one or more antigens in liquid form and one or more lyophilised antigens.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, such as antibiotics, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention, or increases a measurable immune response or prevents or reduces a clinical symptom. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (*e.g.* non-human primate, primate, *etc.*), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

Further Components of the Composition

The composition of the invention will typically, in addition to the components mentioned above, comprise one or more 'pharmaceutically acceptable carriers', which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes). Such carriers are well known to those of ordinary skill in the art. The vaccines may also contain diluents, such as water, saline, glycerol, *etc.* Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present. A thorough discussion of pharmaceutically acceptable excipients is available in Gennaro (2000) *Remington: The Science and Practice of Pharmacy*. 20th ed., ISBN: 0683306472.

Adjuvants

Vaccines of the invention may be administered in conjunction with other immunoregulatory agents. In particular, compositions will usually include an adjuvant. Adjuvants for use with the invention include, but are not limited to, one or more of the following set forth below:

A. Mineral Containing Compositions

Mineral containing compositions suitable for use as adjuvants in the invention include mineral salts, such as aluminum salts and calcium salts. The invention includes mineral salts such as hydroxides (*e.g.* oxyhydroxides), phosphates (*e.g.* hydroxyphosphates, orthophosphates), sulfates, *etc.* (*e.g.* see chapters 8 & 9 of *Vaccine Design...* (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.), or mixtures of different mineral compounds (*e.g.* a mixture of a phosphate and a hydroxide adjuvant, optionally with an excess of the phosphate), with the compounds taking any suitable form (*e.g.* gel, crystalline, amorphous, *etc.*), and with adsorption to the salt(s) being preferred. The mineral containing compositions may also be formulated as a particle of metal salt (WO 00/23105).

Aluminum salts may be included in vaccines of the invention such that the dose of Al^{3+} is between 0.2 and 1.0 mg per dose.

B. Oil-Emulsions

Oil-emulsion compositions suitable for use as adjuvants in the invention include squalene-water emulsions, such as MF59 (5% Squalene, 0.5% Tween 80, and 0.5% Span 85, formulated into submicron particles using a microfluidizer). See WO90/14837. See also, Podda, "The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine", *Vaccine* (2001) 19: 2673-2680; Frey et al., "Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults", *Vaccine* (2003) 21:4234-4237. MF59 is used as the adjuvant in the FLUAD™ influenza virus trivalent subunit vaccine.

Particularly preferred adjuvants for use in the compositions are submicron oil-in-water emulsions. Preferred submicron oil-in-water emulsions for use herein are squalene/water emulsions optionally containing varying amounts of MTP-PE, such as a submicron oil-in-water emulsion containing 4-5% w/v squalene, 0.25-1.0% w/v Tween 80™ (polyoxyethylsorbitan monooleate), and/or 0.25-1.0% Span 85™ (sorbitan trioleate), and, optionally, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-*sn*-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), for example, the submicron oil-in-water emulsion known as "MF59" (International Publication No. WO 90/14837; US Patent Nos. 6,299,884 and 6,451,325, incorporated herein by reference in their entireties; and Ott et al., "MF59 -- Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines" in *Vaccine Design: The Subunit and Adjuvant Approach* (Powell, M.F. and Newman, M.J. eds.) Plenum Press, New York, 1995, pp. 277-296). MF59 contains 4-5% w/v Squalene (e.g. 4.3%), 0.25-0.5% w/v Tween 80™, and 0.5% w/v Span 85™ and optionally contains various amounts of MTP-PE, formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA). For example, MTP-PE may be present in an amount of about 0-500 µg/dose, more preferably 0-250 µg/dose and most preferably, 0-100 µg/dose. As used herein, the term "MF59-0" refers to the above submicron oil-in-water emulsion lacking MTP-PE, while the term MF59-MTP denotes a formulation that contains MTP-PE. For instance, "MF59-100" contains 100 µg MTP-PE per dose, and so on. MF69, another submicron oil-in-water emulsion for use herein, contains 4.3% w/v squalene, 0.25% w/v Tween 80™, and 0.75% w/v Span 85™ and optionally MTP-PE. Yet another submicron oil-in-water emulsion is MF75, also known as SAF, containing 10% squalene, 0.4% Tween 80™, 5% pluronic-blocked polymer L121, and thr-MDP, also microfluidized into a submicron emulsion. MF75-MTP denotes an MF75 formulation that includes MTP, such as from 100-400 µg MTP-PE per dose.

Submicron oil-in-water emulsions, methods of making the same and immunostimulating agents, such as muramyl peptides, for use in the compositions, are described in detail in International Publication No. WO 90/14837 and US Patent Nos. 6,299,884 and 6,451,325, incorporated herein by reference in their entireties.

Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) may also be used as adjuvants in the invention.

C. Saponin Formulations

Saponin formulations, may also be used as adjuvants in the invention. Saponins are a heterologous group of sterol glycosides and triterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponin from the bark of the *Quillaja saponaria* Molina tree have been widely studied as adjuvants. Saponin can also be commercially obtained from *Smilax ornata* (sarsapilla), *Gypsophilla paniculata* (brides veil), and *Saponaria officianalis* (soap root). Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs.

Saponin compositions have been purified using High Performance Thin Layer Chromatography (HP-LC) and Reversed Phase High Performance Liquid Chromatography (RP-HPLC). Specific purified fractions using these techniques have been identified, including QS7, QS17, QS18, QS21, QH-A, QH-B and QH-C. Preferably, the saponin is QS21. A method of production of QS21 is disclosed in US Patent No. 5,057,540. Saponin formulations may also comprise a sterol, such as cholesterol (see WO96/33739).

Combinations of saponins and cholesterol can be used to form unique particles called Immunostimulating Complexes (ISCOMs). ISCOMs typically also include a phospholipid such as phosphatidylethanolamine or phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of Quil A, QHA and QHC. ISCOMs are further described in EP0109942, WO 96/11711 and WO 96/33739. Optionally, the ISCOMS may be devoid of additional detergent. See WO 00/07621.

A review of the development of saponin based adjuvants can be found at Barr, et al., "ISCOMs and other saponin based adjuvants", *Advanced Drug Delivery Reviews* (1998) 32:247-271. See also Sjolander, et al., "Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines", *Advanced Drug Delivery Reviews* (1998) 32:321-338.

D. Virosomes and Virus Like Particles (VLPs)

Virosomes and Virus Like Particles (VLPs) can also be used as adjuvants in the invention. These structures generally contain one or more proteins from a virus optionally combined or formulated with a phospholipid. They are generally non-pathogenic, non-replicating and generally do not contain any of the native viral genome. The viral proteins may be recombinantly produced or isolated from whole viruses. These viral proteins suitable for use in virosomes or VLPs include proteins derived from influenza virus (such as HA or NA), Hepatitis B virus (such as core or capsid proteins), Hepatitis E virus, measles virus, Sindbis virus, Rotavirus, Foot-and-Mouth Disease virus, Retrovirus, Norwalk virus, human Papilloma virus, HIV, RNA-phages, QB-phage (such as coat proteins), GA-phage, fr-phage, AP205 phage, and Ty (such as retrotransposon Ty protein p1). VLPs are discussed further in WO 03/024480, WO 03/024481, and Niikura et al., "Chimeric Recombinant Hepatitis E Virus-Like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes", *Virology* (2002) 293:273-280; Lenz et al., "Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells", *Journal of Immunology* (2001) 5246-5355; Pinto, et al., "Cellular Immune Responses to Human Papillomavirus (HPV)-16 L1 Healthy Volunteers Immunized with Recombinant HPV-16 L1 Virus-Like Particles", *Journal of Infectious Diseases* (2003) 188:327-338; and Gerber et al., "Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with Escherichia coli Heat-Labile Enterotoxin Mutant R192G or CpG", *Journal of Virology* (2001) 75(10):4752-4760. Virosomes are discussed further in, for example, Gluck et al., "New Technology Platforms in the Development of Vaccines for the Future", *Vaccine* (2002) 20:B10-B16. Immunopotentiating reconstituted influenza virosomes (IRIV) are used as the subunit antigen

E. Bacterial or Microbial Derivatives

Adjuvants suitable for use in the invention include bacterial or microbial derivatives such as:

5 (1) Non-toxic derivatives of enterobacterial lipopolysaccharide (LPS)

Such derivatives include Monophosphoryl lipid A (MPL) and 3-O-deacylated MPL (3dMPL).
3dMPL is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains. A
preferred "small particle" form of 3 De-O-acylated monophosphoryl lipid A is disclosed in EP 0 689
454. Such "small particles" of 3 dMPL are small enough to be sterile filtered through a 0.22 micron
10 membrane (see EP 0 689 454). Other non-toxic LPS derivatives include monophosphoryl lipid A
mimics, such as aminoalkyl glucosaminide phosphate derivatives e.g. RC-529. See Johnson *et al.*
(1999) *Bioorg Med Chem Lett* 9:2273-2278.

(2) Lipid A Derivatives

Lipid A derivatives include derivatives of lipid A from *Escherichia coli* such as OM-174.
15 OM-174 is described for example in Meraldi *et al.*, "OM-174, a New Adjuvant with a Potential for
Human Use, Induces a Protective Response with Administered with the Synthetic C-Terminal
Fragment 242-310 from the circumsporozoite protein of *Plasmodium berghei*", *Vaccine* (2003)
21:2485-2491; and Pajak, *et al.*, "The Adjuvant OM-174 induces both the migration and maturation of
murine dendritic cells in vivo", *Vaccine* (2003) 21:836-842.

20 (3) Immunostimulatory oligonucleotides

Immunostimulatory oligonucleotides suitable for use as adjuvants in the invention include
nucleotide sequences containing a CpG motif (a sequence containing an unmethylated cytosine
followed by guanosine and linked by a phosphate bond). Bacterial double stranded RNA or
oligonucleotides containing palindromic or poly(dG) sequences have also been shown to be
25 immunostimulatory.

The CpG's can include nucleotide modifications/analogs such as phosphorothioate
modifications and can be double-stranded or single-stranded. Optionally, the guanosine may be
replaced with an analog such as 2'-deoxy-7-deazaguanosine. See Kandimalla, *et al.*, "Divergent
synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory
30 oligodeoxyribonucleotide agents with distinct cytokine induction profiles", *Nucleic Acids Research*
(2003) 31(9): 2393-2400; WO02/26757 and WO99/62923 for examples of possible analog
substitutions. The adjuvant effect of CpG oligonucleotides is further discussed in Krieg, "CpG motifs:
the active ingredient in bacterial extracts?", *Nature Medicine* (2003) 9(7): 831-835; McCluskie, *et al.*,
"Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen
and CpG DNA", *FEMS Immunology and Medical Microbiology* (2002) 32:179-185; WO98/40100;
35 US Patent No. 6,207,646; US Patent No. 6,239,116 and US Patent No. 6,429,199.

The CpG sequence may be directed to TLR9, such as the motif GTCGTT or TTCGTT. See
Kandimalla, *et al.*, "Toll-like receptor 9: modulation of recognition and cytokine induction by novel

synthetic CpG DNAs” Biochemical Society Transactions (2003) 31 (part 3): 654-658. The CpG sequence may be specific for inducing a Th1 immune response, such as a CpG-A ODN, or it may be more specific for inducing a B cell response, such a CpG-B ODN. CpG-A and CpG-B ODNs are discussed in Blackwell, et al., “CpG-A-Induced Monocyte IFN-gamma-Inducible Protein-10
5 Production is Regulated by Plasmacytoid Dendritic Cell Derived IFN-alpha”, J. Immunol. (2003) 170(8):4061-4068; Krieg, “From A to Z on CpG”, TRENDS in Immunology (2002) 23(2): 64-65 and WO01/95935. Preferably, the CpG is a CpG-A ODN.

Preferably, the CpG oligonucleotide is constructed so that the 5' end is accessible for receptor recognition. Optionally, two CpG oligonucleotide sequences may be attached at their 3' ends to form
10 “immunomers”. See, for example, Kandimalla, et al., “Secondary structures in CpG oligonucleotides affect immunostimulatory activity”, BBRC (2003) 306:948-953; Kandimalla, et al., “Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic GpG DNAs”, Biochemical Society Transactions (2003) 31(part 3):664-658; Bhagat et al., “CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents” BBRC (2003) 300:853-861 and WO
15 03/035836.

(4) *ADP-ribosylating toxins and detoxified derivatives thereof.*

Bacterial ADP-ribosylating toxins and detoxified derivatives thereof may be used as adjuvants in the invention. Preferably, the protein is derived from *E. coli* (i.e., *E. coli* heat labile enterotoxin “LT), cholera (“CT”), or pertussis (“PT”). The use of detoxified ADP-ribosylating toxins
20 as mucosal adjuvants is described in WO95/17211 and as parenteral adjuvants in WO98/42375. Preferably, the adjuvant is a detoxified LT mutant such as LT-K63, LT-R72, and LTR192G. The use of ADP-ribosylating toxins and detoxified derivatives thereof, particularly LT-K63 and LT-R72, as adjuvants can be found in the following references, each of which is specifically incorporated by reference herein in their entirety: Beignon, et al., “The LTR72 Mutant of Heat-Labile Enterotoxin of
25 *Escherichia coli* Enhances the Ability of Peptide Antigens to Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin”, Infection and Immunity (2002) 70(6):3012-3019; Pizza, et al., “Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants”, Vaccine (2001) 19:2534-2541; Pizza, et al., “LTK63 and LTR72, two mucosal adjuvants ready for clinical trials” Int. J. Med. Microbiol (2000) 290(4-5):455-461; Scharton-Kersten et al., “Transcutaneous
30 Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits and Unrelated Adjuvants”, Infection and Immunity (2000) 68(9):5306-5313; Ryan et al., “Mutants of *Escherichia coli* Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2
35 Cells” Infection and Immunity (1999) 67(12):6270-6280; Partidos et al., “Heat-labile enterotoxin of *Escherichia coli* and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides”, Immunol. Lett. (1999) 67(3):209-216; Peppoloni et al., “Mutants of the *Escherichia coli* heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines”, Vaccines (2003) 2(2):285-293; and Pine et al., (2002) “Intranasal
-241-

immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63)" J. Control Release (2002) 85(1-3):263-270. Numerical reference for amino acid substitutions is preferably based on the alignments of the A and B subunits of ADP-ribosylating toxins set forth in Domenighini et al., Mol. Microbiol (1995) 15(6):1165-1167, specifically incorporated herein by reference in its entirety.

F. Bioadhesives and Mucoadhesives

Bioadhesives and mucoadhesives may also be used as adjuvants in the invention. Suitable bioadhesives include esterified hyaluronic acid microspheres (Singh et al. (2001) J. Cont. Rele. 70:267-276) or mucoadhesives such as cross-linked derivatives of poly(acrylic acid), polyvinyl alcohol, polyvinyl pyrrolidone, polysaccharides and carboxymethylcellulose. Chitosan and derivatives thereof may also be used as adjuvants in the invention. E.g. WO99/27960.

G. Microparticles

Microparticles may also be used as adjuvants in the invention. Microparticles (i.e. a particle of ~100nm to ~150µm in diameter, more preferably ~200nm to ~30µm in diameter, and most preferably ~500nm to ~10µm in diameter) formed from materials that are biodegradable and non-toxic (e.g. a poly(α-hydroxy acid), a polyhydroxybutyric acid, a polyorthoester, a polyanhydride, a polycaprolactone, etc.), with poly(lactide-co-glycolide) are preferred, optionally treated to have a negatively-charged surface (e.g. with SDS) or a positively-charged surface (e.g. with a cationic detergent, such as CTAB).

H. Liposomes

Examples of liposome formulations suitable for use as adjuvants are described in US Patent No. 6,090,406, US Patent No. 5,916,588, and EP 0 626 169.

I. Polyoxyethylene ether and Polyoxyethylene Ester Formulations

Adjuvants suitable for use in the invention include polyoxyethylene ethers and polyoxyethylene esters. WO99/52549. Such formulations further include polyoxyethylene sorbitan ester surfactants in combination with an octoxynol (WO01/21207) as well as polyoxyethylene alkyl ethers or ester surfactants in combination with at least one additional non-ionic surfactant such as an octoxynol (WO 01/21152).

Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether (laureth 9), polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether.

J. Polyphosphazene (PCPP)

PCPP formulations are described, for example, in Andrianov et al., "Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions", Biomaterials (1998) 19(1-3):109-115 and Payne et al., "Protein Release from Polyphosphazene Matrices", Adv. Drug. Delivery Review (1998) 31(3):185-196.

K. Muramyl peptides

Examples of muramyl peptides suitable for use as adjuvants in the invention include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-l-alanyl-d-isoglutamine (nor-MDP), and N-acetylmuramyl-l-alanyl-d-isoglutaminyl-l-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE).

L. Imidazoquinolone Compounds.

Examples of imidazoquinolone compounds suitable for use adjuvants in the invention include Imiquimod and its homologues, described further in Stanley, "Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential" Clin Exp Dermatol (2002) 27(7):571-577 and Jones, "Resiquimod 3M", Curr Opin Investig Drugs (2003) 4(2):214-218.

The invention may also comprise combinations of aspects of one or more of the adjuvants identified above. For example, the following adjuvant compositions may be used in the invention:

- (1) a saponin and an oil-in-water emulsion (WO 99/11241);
- (2) a saponin (e.g., QS21) + a non-toxic LPS derivative (e.g. 3dMPL) (see WO 94/00153);
- (3) a saponin (e.g., QS21) + a non-toxic LPS derivative (e.g. 3dMPL) + a cholesterol;
- (4) a saponin (e.g. QS21) + 3dMPL + IL-12 (optionally + a sterol) (WO 98/57659);
- (5) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions (See European patent applications 0835318, 0735898 and 0761231);
- (6) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-block polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion.
- (7) RibTM adjuvant system (RAS), (Ribi Immunochem) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DetoxTM);
- (8) one or more mineral salts (such as an aluminum salt) + a non-toxic derivative of LPS (such as 3dPML).
- (9) one or more mineral salts (such as an aluminum salt) + an immunostimulatory oligonucleotide (such as a nucleotide sequence including a CpG motif). Combination No. (9) is a preferred adjuvant combination.

M. Human Immunomodulators

Human immunomodulators suitable for use as adjuvants in the invention include cytokines, such as interleukins (e.g. IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), interferons (e.g. interferon- γ), macrophage colony stimulating factor, and tumor necrosis factor.

Aluminum salts and MF59 are preferred adjuvants for use with injectable influenza vaccines. Bacterial toxins and bioadhesives are preferred adjuvants for use with mucosally-delivered vaccines, such as nasal vaccines.

The immunogenic compositions of the present invention may be administered in combination with an antibiotic treatment regime. In one embodiment, the antibiotic is administered prior to administration of the antigen of the invention or the composition comprising the one or more of the antigens of the invention.

5 In another embodiment, the antibiotic is administered subsequent to the administration of the one or more antigens of the invention or the composition comprising the one or more antigens of the invention. Examples of antibiotics suitable for use in the treatment of the Streptococcal infections of the invention include but are not limited to penicillin or a derivative thereof or clindamycin or the like.

10 Further antigens

The compositions of the invention may further comprise one or more additional Gram positive bacterial antigens which are not associated with an AI. Preferably, the Gram positive bacterial antigens that are not associated with an AI can provide protection across more than one serotype or strain isolate. For example, a first non-AI antigen, in which the first non-AI antigen is at least 90% (*i.e.*, at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%) homologous to the amino acid sequence of a second non-AI antigen, wherein the first and the second non-AI antigen are derived from the genomes of different serotypes of a Gram positive bacteria, may be further included in the compositions. The first non-AI antigen may also be homologous to the amino acid sequence of a third non-AI antigen, such that the first non-AI antigen, the second non-AI antigen, and the third non-AI antigen are derived from the genomes of different serotypes of a Gram positive bacteria. The first non-AI antigen may also be homologous to the amino acid sequence of a fourth non-AI antigen, such that the first non-AI antigen, the second non-AI antigen, the third non-AI antigen, and the fourth non-AI antigen are derived from the genomes of different serotypes of a Gram positive bacteria.

25 The first non-AI antigen may be GBS 322. The amino acid sequence of GBS 322 across GBS strains from serotypes Ia, Ib, II, III, V, and VIII is greater than 90%. Alternatively, the first non-AI antigen may be GBS 276. The amino acid sequence of GBS 276 across GBS strain from serotypes Ia, Ib, II, III, V, and VIII is greater than 90%. Table 13 provides the percent amino acid sequence identity of GBS 322 and GBS 276 across different GBS strains and serotypes.

Table 13: Conservation of GBS 322 and GBS 276 amino acid sequences

Serotype	Strains	GBS 322		GBS 276	
		cGH	%AA identity	cGH	%AA identity
Ia	090	+	98.60	+	97.90
	A909	+	98.30	+	97.90
	515	+	98.80	+	97.50
	DK1	+		+	
	DK8	+		+	
	Davis	+		+	
Ib	7357b	+		+	
	H36B	+	98.30	+	97.80
II	18RS21	+	100.00	+	99.90
	DK21	+		+	

Serotype	Strains	GBS 322		GBS 276	
		cGH	%AA identity	cGH	%AA identity
III	NEM316	+	100.00	+	97.00
	COH31	+		+	
	D136	+		+	
	M732	+	98.00	+	100.00
	COH1	+	98.30	+	100.00
	M781	+	98.30	+	99.60
No type	CJB110	+	98.60	+	97.90
	1169NT	+	97.40	+	97.90
V	CJB111	+	100.00	+	
	2603	+	100.00	+	100.00
VIII	JM130013	+	100.00	+	97.90
	SMU014	+		+	
total		22/22	98.28+/-0.4	22/22	98.44 +/-1.094

As an example, inclusion of a non-AI protein, GBS 322, in combination with AI antigens GBS 67, GBS 80, and GBS 104 provided protection to newborn mice in an active maternal immunization assay.

5

Table 14: Active maternal immunization assay for a combination of fragments from GBS 322, GBS 80, GBS 104, and GBS 67

GBS strains	Type	FACS (Δ Mean)			MIX=322+80+104+67		PBS	
		GBS 80	GBS 67	GBS 322	alive/treated	% protection	alive/treated	% protection
515	Ia	0	409	227	39/40	97	6/40	15
7357b-	Ib	91	316	102	19/30	63	1/30	3
DK21	II	0	331	416	25/34	73	17/48	35
5401	II	170	618	135	35/40	87	3/37	8
3050	II	43	460	188	48/48	100	1/30	3
COH1	III	305	0	130	36/36	100	7/40	17
M781	III	65	0	224	30/40	75	4/39	10
2603	V	125	105	313	27/33	82	10/35	28
CJB111	V	370	481	63	25/28	89	4/46	9
JM9130013	VIII	597	83	143	37/39	95	5/40	12
JMU071	VIII	556	79	170	44/50	88	18/50	36
NT1169	NT	0	443	213	12/32	37	11/35	31

In fact, the non-AI GBS 322 antigen may itself provide protection to newborn mice in an active maternal immunization assay.

PCT/US2005/027239

Table 16: Active maternal immunization assay for each of GBS 80 and GBS 322 antigens

GBS strains	Type	GBS 80			GBS 322		
		FACS	Protection (% survival)		FACS	Protection (% survival)	
		Δ Mean	antigen	ctrl-	Δ Mean	antigen	ctrl-
CJB111	V	370	72 %	40%	63	57%	40%
COH1	III	305	76 %	10%	130	3%	10%
2603	V	82	22 %	34%	313	83 %	34%
7357b-	Ib	91	36%	34%	102	43%	34%
18RS21	II	0	15%	24%	268	84 %	24%
DK21	II	0	10%	21%	416	67 %	25%
A909	Ia	0	0%	14%			
O90	Ia	0	0%	0%			
H36B	Ib				105	34%	32%

Thus, inclusion of a non-AI protein in an immunogenic composition of the invention may provide increased protection a mammal.

The immunogenic compositions comprising *S. pneumoniae* AI polypeptides may further secondary SP protein antigens which include (a) any of the SP protein antigens disclosed in WO 02/077021 or U.S. provisional application _____, filed April 20, 2005 (Attorney Docket Number 002441.00154), (2) immunogenic portions of the antigens comprising at least 7 contiguous amino acids, (3) proteins comprising amino acid sequences which retain immunogenicity and which are at least 95% identical to these SP protein antigens (e.g., 95%, 96%, 97%, 98%, 99%, or 99.5% identical), and (4) fusion proteins, including hybrid SP protein antigens, comprising (1)-(3).

Alternatively, the invention may include an immunogenic composition comprising a first and a second Gram positive bacteria non-AI protein, wherein the polynucleotide sequence encoding the sequence of the first non-AI protein is less than 90% (i.e., less than 90, 88, 86, 84, 82, 81, 78, 76, 74, 72, 70, 65, 60, 55, 50, 45, 40, 35, or 30 percent) homologous than the corresponding sequence in the genome of the second non-AI protein.

The compositions of the invention may further comprise one or more additional non-Gram positive bacterial antigens, including additional bacterial, viral or parasitic antigens. The compositions of the invention may further comprise one or more additional non-GBS antigens, including additional bacterial, viral or parasitic antigens.

In another embodiment, the GBS antigen combinations of the invention are combined with one or more additional, non-GBS antigens suitable for use in a vaccine designed to protect elderly or immunocomprised individuals. For example, the GBS antigen combinations may be combined with an antigen derived from the group consisting of *Enterococcus faecalis*, *Staphylococcus aureus*, *Staphylococcus epidermis*, *Pseudomonas aeruginosa*, *Legionella pneumophila*, *Listeria monocytogenes*, *Neisseria meningitides*, influenza, and Parainfluenza virus ('PIV').

Where a saccharide or carbohydrate antigen is used, it is preferably conjugated to a carrier protein in order to enhance immunogenicity {e.g. Ramsay *et al.* (2001) *Lancet* 357(9251):195-196; Lindberg (1999) *Vaccine* 17 Suppl 2:S28-36; Buttery & Moxon (2000) *J R Coll Physicians Lond* 34:163-168; Ahmad & Chapnick (1999) *Infect Dis Clin North Am* 13:113-133, vii.; Goldblatt (1998) *J. Med. Microbiol.* 47:563-567; European patent 0 477 508; US Patent No. 5,306,492; International patent application WO98/42721; *Conjugate Vaccines* (eds. Cruse *et al.*) ISBN 3805549326, particularly vol. 10:48-114; and Hermanson (1996) *Bioconjugate Techniques* ISBN: 0123423368 or 012342335X}. Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria or tetanus toxoids. The CRM₁₉₇ diphtheria toxoid is particularly preferred {*Research Disclosure*, 453077 (Jan 2002)}. Other carrier polypeptides include the *N.meningitidis* outer membrane protein (EP-A-0372501), synthetic peptides (EP-A-0378881; EP-A-0427347), heat shock proteins (WO 93/17712; WO 94/03208), pertussis proteins (WO 98/58668; EP A 0471177), protein D from *H.influenzae* (WO 00/56360), cytokines (WO 91/01146), lymphokines, hormones, growth factors, toxin A or B from *C.difficile* (WO00/61761), iron-uptake proteins (WO01/72337), *etc.* Where a mixture comprises capsular saccharides from both serogroups A and C, it may be preferred that the ratio (w/w) of MenA saccharide:MenC saccharide is greater than 1 (e.g. 2:1, 3:1, 4:1, 5:1, 10:1 or higher). Different saccharides can be conjugated to the same or different type of carrier protein. Any suitable conjugation reaction can be used, with any suitable linker where necessary.

Toxic protein antigens may be detoxified where necessary e.g. detoxification of pertussis toxin by chemical and/or genetic means.

Where a diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.

Antigens in the composition will typically be present at a concentration of at least 1 µg/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.

As an alternative to using protein antigens in the composition of the invention, nucleic acid encoding the antigen may be used {e.g. refs. Robinson & Torres (1997) *Seminars in Immunology* 9:271-283; Donnelly *et al.* (1997) *Annu Rev Immunol* 15:617-648; Scott-Taylor & Dalgleish (2000) *Expert Opin Investig Drugs* 9:471-480; Apostolopoulos & Plebanski (2000) *Curr Opin Mol Ther* 2:441-447; Ilan (1999) *Curr Opin Mol Ther* 1:116-120; Dubensky *et al.* (2000) *Mol Med* 6:723-732; Robinson & Pertmer (2000) *Adv Virus Res* 55:1-74; Donnelly *et al.* (2000) *Am J Respir Crit Care Med* 162(4 Pt 2):S190-193; and Davis (1999) *Mt. Sinai J. Med.* 66:84-90}. Protein components of the compositions of the invention may thus be replaced by nucleic acid (preferably DNA e.g. in the form of a plasmid) that encodes the protein.

Definitions

PCT/US2005/027239

The term "comprising" means "including" as well as "consisting" *e.g.* a composition "comprising" X may consist exclusively of X or may include something additional *e.g.* X + Y.

The term "about" in relation to a numerical value *x* means, for example, $x \pm 10\%$.

5 References to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of *Current Protocols in Molecular Biology* (F.M. Ausubel *et al.*, eds., 1987) Supplement 30. A preferred alignment is determined by the
10 Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is disclosed in Smith & Waterman (1981) *Adv. Appl. Math.* 2: 482-489.

The invention is further illustrated, without limitation, by the following examples.

15 **EXAMPLE 1: Binding of an Adhesin Island surface protein, GBS 80, to Fibrinogen and Fibronectin.**

This example demonstrates that an Adhesin Island surface protein, GBS 80 can bind to fibrinogen and fibronectin.

20 An enzyme-linked immunosorbent assay (ELISA) was used to analyse the *in vitro* binding ability of recombinant GBS 80 to immobilized extra-cellular matrix (ECM) proteins but not to bovine serum albumin (BSA). Microtiter plates were coated with ECM proteins (fibrinogen, fibronectin, laminin, collagen type IV) and binding assessed by adding varying concentrations of a recombinant
25 form of GBS 80, over-expressed and purified from *E. coli* (FIGURE 5A). Plates were then incubated sequentially with a) mouse anti-GBS 80 primary antibody; b) rabbit anti-mouse AP-conjugated secondary antibody; c) pNPP colorimetric substrate. Relative binding was measured by monitoring
30 absorbance at 405 nm, using 595 nm as a reference wavelength. Figure 5b shows binding of recombinant GBS 80 to immobilized ECM proteins (1 μg) as a function of concentration of GBS 80. BSA was used as a negative control. Data points represent the means of OD₄₀₅ values \pm standard deviation for 3 wells.

30 Binding of GBS 80 to the tested ECM proteins was found to be concentration dependent and exhibited saturation kinetics. As is also evident from FIGURE 5, binding of GBS 80 to fibronectin and fibrinogen was greater than binding to laminin and collagen type IV at all the concentrations tested.

EXAMPLE 2: GBS 80 is required for surface localization of GBS 104.

35 This example demonstrates that co-expression of GBS 80 is required for surface localization of GBS 104.

The polycistronic nature of the Adhesin Island I mRNA was investigated through reverse transcriptase-PCR (RT-PCR) analysis employing primers designed to detect transcripts arising from contiguous genes. Total RNA was isolated from GBS cultures grown to an optical density at 600 nm

(OD₆₀₀) of 0.3 in THB (Todd-Hewitt broth) by the RNeasy Total RNA isolation method (Qiagen) according to the manufacturer's instructions. The absence of contaminating chromosomal DNA was confirmed by failure of the gene amplification reactions to generate a product detectable by agarose gel electrophoresis, in the absence of reverse transcriptase. RT-PCR analysis was performed with the
5 Access RT-PCR system (Promega) according to the manufacturer's instructions, employing PCR cycling temperatures of 60°C for annealing and 70°C for extension. Amplification products were visualized alongside 100-bp DNA markers in 2% agarose gels after ethidium bromide staining.

FIGURE 5 shows that all the genes are co-transcribed as an operon. A schematic of the AI-1 operon is shown above the agarose gel analysis of the RT-PCR products. Large rectangular arrows
10 indicate the predicted transcript direction. Primer pairs were selected such as "1-4" cross the 3' finish-5' start of successive genes and overlap each gene by at least 200 bp. Additionally, "1" crosses a putative rho-independent transcriptional terminator. "5" is an internal GBS 80 control and "6" is an unrelated control from a highly expressed gene. Lanes: "a": RNA plus RTase enzyme; "b" RNA without RTase; "c": genomic DNA control.

15 In the effort to elucidate the functions of the AI-1 proteins, in frame deletions of all of the genes within the operon have been constructed and the resulting mutants characterized with respect to surface exposure of the encoded antigens (see FIGURE 8).

Each in-frame deletion mutation was constructed by splice overlap extension PCR (SOE-PCR) essentially as described by Horton et al. [Horton R. M., Z. L. Cai, S. N. Ho, L. R. Pease (1990)
20 Biotechniques 8:528-35] using suitable primers and cloned into the temperature sensitive shuttle vector pJRS233 to replace the wild type copy by allelic exchange [Perez-Casal, J., J. A. Price, et al. (1993) Mol Microbiol 8(5): 809-19.]. All plasmid constructions utilized standard molecular biology techniques, and the identities of DNA fragments generated by PCR were verified by sequencing. Following SOE-PCR, the resulting mutant DNA fragments were digested with XhoI and EcoRI, and
25 ligated into a similarly digested pJRS233. The resulting vectors were introduced by electroporation into the chromosome of 2603 and COH1 GBS strains in a three-step process, essentially as described in Framson et al. [Framson, P. E., A. Nittayajarn, J. Merry, P. Youngman, and C. E. Rubens. (1997) Appl. Environ. Microbiol. 63(9):3539-47]. Briefly, the vector pJRS233 contains an *erm* gene encoding erythromycin resistance and a temperature-sensitive gram-positive replicon that is active at
30 30°C but not at 37°C. Initially, the constructs are electroporated into GBS electro-competent cells prepared as described by Framson et al., and transformants containing free plasmid are selected by their ability to grow at 30°C on Todd-Hewitt Broth (THB) agar plates containing 1 µg/ml erythromycin. The second step includes a selection step for strains in which the plasmid has integrated into the chromosome via a single recombination event over the homologous plasmid insert and
35 chromosome sequence by their ability to grow at 37°C on THB agar medium containing 1 mg/ml erythromycin. In the third step, GBS cells containing the plasmid integrated within the chromosome (integrants) are serially passed in broth culture in the absence of antibiotics at 30°C. Plasmid excision

from the chromosome via a second recombination event over the duplicated target gene sequence either completed the allelic exchange or reconstituted the wild-type genotype. Subsequent loss of the plasmid in the absence of antibiotic selection pressure resulted in an erythromycin-sensitive phenotype. In order to assess gene replacement a screening of erythromycin-sensitive colonies was performed by analysis of the target gene PCR amplicons.

FIGURE 7 reports a schematic of the IS-1 operon for each knock-out strain generated, along with the deletion position within the amino acidic sequence. Most data presented here concern the COH1 deletion strains, in which the expression of each of the antigens is higher by DNA microarray analysis (data not shown) as well as detectable by FACS analysis (see FIGURE 8). The double mutant in 2603 Δ 80, Δ 104 double mutant was constructed by sequential allelic exchanges of the shown alleles.

Immunization protocol

Immune sera for FACS experiments were obtained as follows.

Groups of 4 CD-1 outbred female mice 6-7 weeks old (Charles River Laboratories, Calco Italy) were immunized with the selected GBS antigens, (20 μ g of each recombinant GBS antigen), suspended in 100 μ l of PBS. Each group received 3 doses at days 0, 21 and 35. Immunization was performed through intra-peritoneal injection of the protein with an equal volume of Complete Freund's Adjuvant (CFA) for the first dose and Incomplete Freund's Adjuvant (IFA) for the following two doses. In each immunization scheme negative and positive control groups are used. Immune response was monitored by using serum samples taken on day 0 and 49.

FACS analysis

Preparation of paraformaldehyde treated GBS cells and their FACS analysis were carried out as follows.

GBS serotype COH1 strain cells were grown in Todd Hewitt Broth (THB; Difco Laboratories, Detroit, Mich.) to OD_{600nm} = 0.5. The culture was centrifuged for 20 minutes at 5000 rpm and bacteria were washed once with PBS, resuspended in PBS containing 0.05% paraformaldehyde, and incubated for 1 hours at 37 °C and then overnight at 4°C. 50 μ l of fixed bacteria (OD₆₀₀ 0.1) were washed once with PBS, resuspended in 20 μ l of Newborn Calf Serum, (Sigma) and incubated for 20 min. at room temperature. The cells were then incubated for 1 hour at 4°C in 100 μ l of preimmune or immune sera, diluted 1:200 in dilution buffer (PBS, 20% Newborn Calf Serum, 0.1% BSA). After centrifugation and washing with 200 μ l of washing buffer (0.1% BSA in PBS), samples were incubated for 1 hour at 4°C with 50 μ l of R-Phicoerytrin conjugated F(ab)₂ goat anti-mouse IgG (Jackson ImmunoResearch Laboratories; Inc.), diluted 1:100 in dilution buffer. Cells were washed with 200 μ l of washing buffer and resuspended in 200 μ l of PBS. Samples were analysed using a FACS Calibur apparatus (Becton Dickinson, Mountain View, Calif.) and data were analyzed using the Cell Quest Software (Becton Dickinson). A shift in mean fluorescence intensity of > 75 channels compared to preimmune sera from the same mice was considered positive. This cutoff

was determined from the mean plus two standard deviations of shifts obtained with control sera raised against mock purified recombinant proteins from cultures of *E. coli* carrying the empty expression vector and included in every experiment. Artifacts due to bacterial lysis were excluded using antisera raised against 6 different known cytoplasmic proteins all of which were negative

5 FACS data on COH1 single KO mutants for GBS 104 and GBS 80 indicated that GBS 80 is required for surface localization of GBS 104.

As shown in FIGURE 8, GBS 104 is not surface exposed in the Δ80 strain (second column, bottom), but is present in the whole protein extracts (see FIGURE 10). Mean shift values suggest that GBS 104 is partially responsible for GBS 80 surface exposure (Mean shift of GBS 80 is reduced to
10 ~60% wild-type levels in Δ104), and that GBS 80 is over-expressed in the complemented strain (mean shift value ~200% wild-type level). The Δ80/pGBS 80 strain contains the GBS 80 orf cloned in the shuttle-vector pAM401 (Wirth, R., F. Y. An, et al. (1986). *J Bacteriol* 165(3): 831-6). The vector alone does not alter the secretion pattern of GBS 104 (right column). FACS was performed on mid-log fixed bacteria with mouse polyclonal antibodies as indicated at left. Black peak is pre-immune
15 sera, colored peaks are sera from immunized animals.

EXAMPLE 3: Deletion of GBS 80 causes attenuation *in vivo*.

This example demonstrates that deletion of GBS 80 causes attenuation *in vivo*, suggesting that this protein contributes to bacterial virulence.

20 By using a mouse animal model, we studied the role of GBS 80 and GBS 104 in the virulence of *S. agalactiae*.

Groups of ten outbred female mice 5-6 week weeks old (Charles River Laboratories, Calco Italy) were inoculated intraperitoneally with different dilutions of the mutant strains and LD50 (lethal dose 50) were calculated according to the method of Reed and Muench [Reed, L. J. and H. Muench (1938).*The American Journal of Hygiene* 27(3): 493-7]. As presented in the table below the number
25 of colony forming units (cfu) counted for both the Δ80 and the Δ80, Δ104 double mutants is about 10 fold higher when compared to the wild type strain suggesting that inactivation of GBS 80 but not GBS 104 is responsible for an attenuation in virulence. This finding indicates that GBS 80 gene in the AI-1 might contribute to virulence.

30 Table Lethal dose 50% analysis of AI-1 mutants in the 2603 strain background. LD50s were performed by IP injection of female CD1 mice at an age of 5-6 weeks. LD50s were calculated by the method of Reed and Muench (8).

GBS strain	LD ₅₀ , cfu	Number of Experiments
Wild Type 2603	2 x 10 ⁸	4
Δ104 mutant	~2 x 10 ⁸	1
Δ80 mutant	2.6 x 10 ⁹	3
Δ80, Δ104 double mutant	~2 x 10 ⁹	1

EXAMPLE 4: Effect of Adhesin Island Sortase Deletions on Surface Antigen Presentation

This example demonstrates the effect of adhesin island sortase deletions on surface antigen presentation.

FACS analysis results set forth in FIGURE 9 show that a deletion in sortase SAG0648 prevented GBS 104 from reaching the surface and slightly reduced the surface exposure of GBS 80 (fourth panel; mean shift value ~60% wild-type COH1). In the double sortase knock-out strain, neither antigen was surface exposed (far right panel). Either sortase alone was sufficient for GBS 80 to arrive at the bacterial surface (third and fourth columns, top). No effect was seen on surface exposure of antigens GBS 80 or GBS 104 in the Δ GBS 52 strain. Antibodies derived from purified GBS 52 were either non-specific or were FACS negative for GBS 52 (data not shown). FACS analysis was performed as described above (see EXAMPLE 2).

As shown in FIGURE 10, inactivation of GBS 80 has no effect on GBS 104 expression as much as GBS 104 knock out doesn't change the total amount GBS 80 expressed. The Western blot of whole protein extracts (strains noted above lanes) probed with anti-GBS 80 antisera is shown in panel A. Arrow indicates expected size of GBS 80 (60 kDa). GBS 80 antibodies recognize a doublet, the lower band is not present in Δ GBS 80 strains. Panel B shows a Western blot of whole protein extracts probed with anti-GBS 104 antisera. Arrow indicates expected size of GBS 104 (99.4 kDa). Protein extracts were prepared from the same bacterial cultures used for FACS (FIGURES 8 and 9). In conclusion, although GBS 104 does not arrive at the surface in the Δ 80 strain by FACS (FIGURE 8, second column), it is present at approximately wild-type levels in the whole protein preps (B, second lane). Approximately 20 μ g of each protein extract was loaded per lane.

Western-blot analysis

Aliquots of total protein extract mixed with SDS loading buffer (1x: 60 mM TRIS-HCl pH 6.8, 5% w/v SDS, 10% v/v glycerin, 0.1% Bromophenol Blue, 100 mM DTT) and boiled 5 minutes at 95° C, were loaded on a 12.5% SDS-PAGE precast gel (Biorad). The gel is run using a SDS-PAGE running buffer containing 250 mM TRIS, 2.5 mM Glycine and 0.1 %SDS. The gel is electroblotted onto nitrocellulose membrane at 200 mA for 60 minutes. The membrane is blocked for 60 minutes with PBS/0.05 % Tween-20 (Sigma), 10% skimmed milk powder and incubated O/N at 4° C with PBS/0.05 % Tween 20, 1% skimmed milk powder, with the appropriate dilution of the sera. After washing twice with PBS/0.05 % Tween, the membrane is incubated for 2 hours with peroxidase-conjugated secondary anti-mouse antibody (Amersham) diluted 1:4000. The nitrocellulose is washed three times for 10 minutes with PBS/0.05 % Tween and once with PBS and thereafter developed by Opti-4CN Substrate Kit (Biorad).

Example 5: Binding of Adhesin Island proteins to epithelial cells and effect of Adhesin Island proteins on capacity of GBS to adhere to epithelial cells.

This example illustrates the binding of AI proteins to epithelial cells and the effect of AI proteins on the capacity of GBS to adhere to epithelial cells.

Applicants analysed whether recombinant AI surface proteins GBS 80 or GBS 104 would demonstrate binding to various epithelial cells in a FACS analysis. Applicants also analysed whether

deletion of AI surface proteins GBS 80 or GBS 104 would effect the capacity of GBS to adhere to and invade ME180 cervical epithelial cells.

As shown in Figure 28, deletion of GBS 80 sequence from GBS strain isolate 2603 (serotype V) did not affect the capacity of the mutated GBS to adhere to and invade ME180 cervical epithelial cells. Here ME180 cervical carcinoma epithelial cells were infected with wild type GBS 2603 or GBS 2603 Δ 80 isogenic mutant. After two hours of infection, non-adherent bacteria were washed off and infection prolonged for a further two hours and four hours. In invasion experiments, after each time point, was followed by a two hour antibiotic treatment. Cells were then lysed with 1% saponin and lysates plated on TSA plates. As shown in Figure 28, there was little difference between the percent invasion or percent adhesion of wild type and mutant strains up to the four hour time point.

Figure 30 repeats this experiment with both Δ 104 and Δ 80 mutants from a different strain isolate. Here, ME180 cervical carcinoma epithelial cells were infected with GBS strain isolate COH (serotype III) wild type or COH1 Δ GBS 104 or COH1 Δ 80 isogenic mutant. After one hour of infection, non-adherent bacteria were washed off and the cells were lysed with 1% saponin. The lysates were plated on TSA plates. As shown in Figure 30, while there was little difference in the percent invasion, there was a significant decrease in the percent association of the Δ 104 mutant compared to both the wild type and Δ 80 mutant.

The affect of AI surface proteins on the ability of GBS to translocate through an epithelial monolayer was also analysed. As shown in Figure 31, a GBS 80 knockout mutant strain partially loses the ability to translocate through an epithelial monolayer. Here epithelial monolayers were inoculated with wildtype or knockout mutant in the apical chamber of a transwell system for two hours and then non-adherent bacteria were washed off. Infection was prolonged for a further two and four hours. Samples were taken from the media of the basolateral side and the number of colony forming unities measured. Transepithelial electrical resistance measured prior to and after infection gave comparable values, indicating the maintenance of the integrity of the monolayer. By the six hour time point, the Δ 80 mutants demonstrated a reduced percent transcytosis.

A similar experiment was conducted with GBS 104 knock out mutants. Here, as shown in Figure 22, the Δ 104 mutants also demonstrated a reduced percent transcytosis, indicating that the mutant strains translocate through an epithelial monolayer less efficiently than their isogenic wild type counterparts.

Applicants also studied the effect of AI proteins on the capacity of a GBS strain to invade J774 macrophage-like cells. Here, J774 cells were infected with GBS COH1 wild type or COH1 Δ GBS104 or COH1 Δ GBS80 isogenic mutants. After one hour of infection, non-adherent bacteria were washed off and intracellular bacteria were recovered at two, four and six hours post antibiotic treatment. At each time point, cells were lysed with 0.25% Triton X-100 and lysates plated on TSA plates. As shown in Figure 32, the Δ 104 mutant demonstrated a significantly reduced percent invasion compared to both the wild type and Δ 80 mutant.

Example 6: Hyperoligomeric structures comprising AI surface proteins GBS 80 and GBS 104.

This example illustrates hyperoligomeric structures comprising AI surface proteins GBS 80 and GBS 104. A GBS isolate COH1 (serotype III) was adapted to increase expression of GBS 80. Figure 34 presents a regular negative stain electron micrograph of this mutant; no pilus or hyperoligomeric structures are distinguishable on the surface of the bacteria. When the EM stain is based on anti-GBS 80 antibodies labelled with 10 or 20 nm gold particles, the presence of GBS 80 throughout the hyperoligomeric structure is clearly indicated (Figures 36, 37 and 38). EM staining against GBS 104 (anti-GBS 104 antibodies labelled with 10 nm gold particles) also reveals the presence of GBS 104 primarily on or near the surface of the bacteria or potentially associated with bacterial peptidoglycans (Figure 39). Analysis of this same strain (over-expressing GBS 80) with a combination of both anti-GBS 80 (using 20 nm gold particles) and anti-GBS 104 (using 10 nm gold particles) reveals the presence of GBS 104 on the surface and within the hyperoligomeric structures (see Figures 40 and 41).

Example 7: GBS 80 is necessary for polymer formation and GBS 104 and sortase SAG0648 are necessary for efficient pili assembly

This example demonstrates that GBS 80 is necessary for formation of polymers and that GBS 104 and sortase SAG0648 are necessary for efficient pili assembly. GBS 80 and GBS 104 polymeric assembly was systematically analyzed in Coh1 strain single knock out mutants of each of the relevant coding genes in AI-1 (GBS 80, GBS 104, GBS 52, sag0647, and sag0648). Figure 41 provides Western blots of total protein extracts (strains noted above lanes) probed with either anti-GBS 80 (left panel) sera or anti-GBS 104 sera (right panel) for each of these Coh1 and Coh1 knock out strains. (Coh1, wild type Coh1; $\Delta 80$, Coh1 with GBS 80 knocked out; $\Delta 104$, Coh1 with GBS 104 knocked out; $\Delta 52$, Coh1 with GBS 52 knocked out; $\Delta 647$, Coh1 with SAG0647 knocked out; $\Delta 648$, Coh1 with SAG0648 knocked out, $\Delta 647-8$, Coh1 with SAG0647 and SAG0648 knocked out; $\Delta 80/pGBS80$, Coh1 with GBS 80 knocked out but complemented with a high copy number plasmid expressing GBS 80. Asterisks identify the monomer of GBS 80 and GBS 104.)

The smear of immunoreactive material observed in the wild type strain, along with its disappearance in $\Delta 80$ and $\Delta 104$ mutants, is consistent with the notion that such high molecular weight structures are composed of covalently linked (SDS-resistant) GBS 80 and GBS 104 subunits. The immunoblotting with both anti-GBS 80 (α -GBS 80) and anti-GBS 104 (α -GBS 104) revealed that deletion of sortase SAG0648 also interferes with the assembly of high molecular weight species, whereas the knock out mutant of the second sortase (SAG0647), even if somehow reduced, still maintains the ability to form polymeric structures.

Total extracts from GBS were prepared as follows. Bacteria were grown in 50 ml of Todd-Hewitt broth (Difco) to an OD_{600nm} of 0.5-0.6 and successively pelleted. After two washes in PBS the pellet was resuspended and incubated 3 hours at 37°C with mutanolisin. Cells were then lysed with at

least three freezing-thawing cycles in dry ice and a 37°C bath. The lysate was then centrifuged to eliminate the cellular debris and the supernatant was quantified. Approximately 40 µg of each protein extract was separated on SDS-PAGE. The gel was then subjected to immunoblotting with mice antisera and detected with chemiluminescence.

5

Example 8: GBS 80 is polymerized by an AI-2 sortase

This example illustrates that GBS 80 can be polymerized not only by AI-1 sortases, but also by AI-2 sortases. Figure 42 shows total cell extract immunoblots of GBS 515 strain, which lacks AI-1. The left panel, where an anti-GBS 67 sera was used, shows that GBS 67 from AI-2 is assembled into high-molecular weight-complexes, suggesting the formation of a second type of pilus. The same high molecular structure is observed when GBS 80 is highly expressed by reintroducing the gene within a plasmid (pGBS 80). By using anti-GBS 80 (right panel) sera on the same extracts, again it is observed that, with GBS 80 over expression (515/pGBS 80), a high-molecular weight structure is assembled. This implies that, in the absence of AI-1 sortases, AI-2 sortases (SAG1405 and SAG1406) can complement the lacking function, still being able to assemble GBS 80 in a pilus structure.

10
15

Example 9: Coh1 produces a high molecular weight molecule, the GBS 80 pilin

This example illustrates that Coh1 produces a high molecular weight molecule, greater than 1000 kDa, which is the GBS 80 pilin. Figure 43 provides silver-stained electrophoretic gels that show that Coh1 produces two macromolecules. One of these macromolecules disappears in the Coh1 GBS 80 knock out cells, but does not disappear in the Coh1 GBS 52 knock out mutant cells. The last two lanes on the right were loaded with 15 times the amount loaded in the other lanes. This was done in order to be able to count the bands. By doing this, a conservative size estimate of the top bands was calculated by starting at 240 kDa and considering each of 14 higher bands as the result of consecutive additions of a GBS 80 monomer.

20
25

Coh1, wild type Coh1; Δ80, Coh1 cells with GBS 80 knocked out; Δ52, Coh1 cells with GBS 52 knocked out; Δ80/pGBS 80, Coh1 cells with GBS 80 knocked out and complemented with a high copy number construct expressing GBS 80.

Example 10. GBS 52 is a minor component of the GBS pilus

This example illustrates that GBS 52 is present in the GBS pilus and is a minor component of the pilus. Figure 45 shows an immunoblot of total cell extracts from a GBS Coh1 strain and a GBS Coh1 strain knocked out for GBS 52 (Δ52). The total cell extracts were immunoblotted anti-GBS 80 antisera (left) and anti-GBS 52 antisera (right). Immunoblotting was performed using a 3-8% Tris-acetate polyacrylamide gel (Invitrogen) which provided excellent separation of large molecular weight proteins (see figure 41). When the gel was incubated with anti-GBS 80 sera, the bands from the Coh1 wild-type strain appeared shifted when compared to the Δ52 mutant. This observation

30
35

indicated a different size of the pilus polymeric components in the two strains. When the same gel was stripped and incubated with anti-GBS 52 sera the high-molecular subunits in the Coh1 wild-type strain showed similar molecular size of those in the correspondent lane in the left panel. These findings confirmed that GBS 52 is indeed associated with GBS 80 macro-molecular structures but represents a minor component of the GBS pilus.

Example 11: Pilus structures are present in the supernatant of GBS bacterial cultures

This example illustrates that the pilus structure assembled in Coh1 GBS is present in the supernatant of a bacterial cell culture. Figure 46 shows an immunoblot where the protein extract of the supernatant from cultures of different GBS mutant strains (117 = Coh1 GBS 80 knockout; 159 = Coh1 GBS 104 knockout; 202 = Coh1 GBS 52 knockout; 206 = Coh1 GBS sag0647 knockout; 208 = Coh1 GBS sag0648 knockout; 197 = Coh1 GBS sag0647/sag0648 knockout; 179 = Coh1 GBS 80 knockout complemented with a high copy plasmid expressing GBS 80). GBS 80 antisera detects the presence of pilus structures in the appropriate Coh1 strains.

The protein extract was prepared as follows. Bacteria were grown in THB to an OD_{600nm} of 0.5-0.6 and the supernatant was separated from the cells by centrifugation. The supernatant was then filtered (\varnothing 0.2 μm) and 1 ml was added with 60% TCA for protein precipitation.

GBS pili were also extracted from the fraction of surface-exposed proteins in Coh1 strain and its GBS 80 knock out mutant as described hereafter. Bacteria were grown to an OD_{600nm} of 0.6 in 50 ml of THB at 37°C. Cells were washed once with PBS and the pellet was then resuspended in 0.1 M KPO4 pH 6.2, 40% sucrose, 10 mM MgCl₂, 400U/ml mutanolysin and incubated 3 hours at 37°C.

Protoplasts were separated by centrifugation and the supernatant was recovered and its protein content measured.

In order to study the dynamics of pilus production during different growth phases, 1 ml supernatant of a culture at different OD_{600nm} was TCA precipitated and loaded onto a 3-8% SDS-PAGE as described before. Figure 47 shows the corresponding Western blot with GBS 80 anti-sera. The first group of lanes (left five sample lanes) refer to a Coh1 strain growth (OD_{600nm} are noted above the lanes) whereas the second group of lanes (right five samples) are from a GBS 80 knock out strain over expressing GBS 80. The experiment shows that pilus macromolecular structures can be found in the supernatant in all of the growth phases tested.

Example 12: In GBS strain Coh1, only GBS 80 and a sortase (sag0647 or sag0648) is required for polymerization

This example describes requirements for pilus formation in Coh1. Figure 48 shows a Western blot of total protein extracts (prepared as described before) using anti-GBS 80 sera on Coh1 clones. (Coh1, wild type Coh1; Δ 104, Coh1 knocked out for GBS 104, Δ 647, Coh1 knocked out for sag0647, Δ 648, Coh1 knocked for sag0648, Δ 647-8, Coh1 knocked out for sag0647 and sag0648; 515, wild

type bacterial strain B15, which lacks an AI-1; p80 a high copy number plasmid which expresses GBS 80.) The data show that only the double sortase mutant is unable to polymerize GBS 80 indicating that the 'conditio sine qua non' for pilus polymerization is the co-existence of GBS 80 with at least one sortase. This result leads to a reasonable assumption that SAG1405 and SAG1406 are responsible for polymerization in this strain.

Example 13: GBS 80 can be expressed in *L. lactis* under its own promoter and terminator sequences

This example demonstrates that *L. lactis*, a non-pathogenic bacterium, can express GBS AI polypeptides such as GBS 80. *L. lactis* M1363 (*J. Bacteriol.* 154 (1983):1-9) was transformed with a construct encoding GBS 80. Briefly, the construct was prepared by cloning a DNA fragment containing the gene coding for GBS 80 under its own promoter and terminator sequences into plasmid pAM401 (a shuttle vector for *E. coli* and other Gram positive bacteria; *J. Bacteriol.* 163 (1986):831-836). Total extracts of the transformed bacteria in log phase were separated on SDS-PAGE, transferred to membranes, and incubated with antiserum against GBS 80. A polypeptide corresponding to the molecular weight of GBS 80 was detected in the lanes containing total extracts of *L. lactis* transformed with the GBS 80 construct. See Figures 133A and 133B, lanes 6 and 7. This same polypeptide was not detected in the lane containing total extracts of *L. lactis* not transformed with the GBS 80 construct, lane 9. This example shows that *L. lactis* can express GBS 80 under its own promoter and terminator.

Example 14: *L. lactis* modified to express GBS AI-1 under the GBS 80 promoter and terminator sequences expresses GBS 80 in polymeric structures

This example demonstrates the ability of *L. lactis* to express GBS AI-1 polypeptides and to incorporate at least some of the polypeptides into oligomers. *L. lactis* was transformed with a construct containing the genes encoding GBS AI-1 polypeptides. Briefly, the construct was prepared by cloning a DNA fragment containing the genes for GBS 80, GBS 52, SAG0647, SAG0648, and GBS 104 under the GBS 80 promoter and terminator sequences into construct pAM401. The construct was transformed into *L. lactis* M1363. Total extracts of log phase transformed bacteria were separated on reducing SDS-PAGE, transferred to membranes, and incubated with antiserum against GBS 80. A polypeptide with a molecular weight corresponding to the molecular weight of GBS 80 was detected in the lanes containing *L. lactis* transformed with the GBS AI-1 encoding construct. See Figure 134, lane 2. In addition, the same lane also showed immunoreactivity of polypeptides having higher molecular weights than the polypeptide having the molecular weight of GBS 80. These higher molecular weight polypeptides are likely oligomers of GBS 80. Oligomers of similar molecular

weights were also observed on a Western blot of the culture supernatant of the transformed *L. lactis*. See lane 4 of Figure 135. Thus, this example shows that *L. lactis* transformed to express GBS AI-1 can efficiently polymerize GBS 80 in the form of a pilus. This pilus structure can likely be purified from either the cell culture supernatant or cell extracts.

5

Example 15: Cloning and Expression of *S. pneumoniae* Sp0462

This example describes the production of a clone encoding a Sp0462 polypeptide and expression of the clone. To produce a clone encoding Sp0462, the open reading frame encoding Sp0462 was amplified using primers that annealed within the full-length Sp0462 open reading frame sequence. Figure 150A provides a 893 amino acid sequence of Sp0462. The primers used to produce a clone encoding the Sp0462 polypeptide are shown in Figure 150B. These primers annealed to the nucleotide sequences encoding the amino acid residues indicated by underlining in Figure 150A. Amplification of the open reading frame encoding Sp0462 using these primers produced the amplicon shown at lane 2 of the agarose gel provided in Figure 160. The Sp0462 clone encodes amino acid residues 38-862 of the 893 amino acid residue Sp0462 protein; the italicized residues in Figure 150A were eliminated. Figure 151A provides a schematic depiction of the recombinant Sp0462 polypeptide. Figure 151B shows a schematic depiction of the full-length Sp0462 polypeptide. Both the recombinant Sp0462 encoded by the clone and the full-length Sp0462 protein have two collagen binding protein type B (Cna B) domains and a von Hillebrand factor A (vWA) domain. The cloned recombinant Sp0462 lacks the LPXTG motif present in the full-length Sp0462 protein. Western blot analysis for expression of the Sp0462 clone did not result in detection of polypeptides with serum obtained from *S. pneumoniae*-infected patients (Figure 152A) or GBS 80 antiserum (Figure 152B).

10

15

20

Example 16: Cloning and Expression of *S. pneumoniae* Sp0463

This example describes the production of a clone encoding a Sp0463 polypeptide and detection of recombinant Sp0463 polypeptide expressed from the clone. To produce a clone encoding Sp0463, the open reading frame encoding Sp0463 was amplified using primers that annealed within the full-length Sp0463 open reading frame sequence. Figure 153A provides a 665 amino acid sequence of Sp0463. The primers used to produce the clone encoding Sp0463 polypeptide are shown in Figure 153B. These primers annealed to the nucleotide sequences encoding the amino acid residues indicated by underlining in Figure 153A. Amplification of the open reading frame encoding Sp0463 using these primers produced the amplicon shown at lane 3 of the agarose gel provided in Figure 160. The Sp0463 clone encodes amino acid residues 23-627 of the 665 amino acid residue Sp0463 protein; the italicized residues in Figure 153A were eliminated. Figure 154A provides a schematic depiction of the recombinant Sp0463 polypeptide. Figure 154B shows a schematic depiction of the full-length Sp0463 polypeptide. Both the recombinant Sp0463 encoded by the clone and the full-length Sp0463 protein have a Cna B domain and an E box motif. The cloned recombinant

30

35

Sp0463 lacks the LPXTG motif present in the full-length Sp0463 protein. Expression of the Sp0463 clone resulted in the detection of a 60 kD polypeptide, the expected molecular weight of the recombinant Sp0463 polypeptide, by Western blot analysis. See Figure 155.

5 Example 17: Cloning and Expression of *S. pneumoniae* Sp0464

This example describes the production of a clone encoding a Sp0464 polypeptide and detection of recombinant Sp0464 polypeptide expressed from the clone. To produce a clone encoding Sp0464, the open reading frame encoding Sp0464 was amplified using primers that annealed either within the full-length Sp0464 open reading frame sequence. Figure 157A provides a 393 amino acid
10 sequence of Sp0464. The primers used to produce a clone encoding the Sp0464 polypeptide are shown in Figure 157B. These primers annealed to the nucleotide sequences encoding the amino acid residues indicated by underlining in Figure 157A. Amplification of the open reading frame encoding Sp0464 using these primers produced the amplicon shown at lane 4 of the agarose gel provided in Figure 160. The Sp0464 clone encodes amino acid residues 19-356 of the 393 amino acid residue
15 Sp0464 protein; the italicized residues in Figure 157A were eliminated. Figure 158A provides a schematic depiction of the recombinant Sp0464 polypeptide. Figure 158B shows a schematic depiction of the full-length Sp0464 polypeptide. Both the recombinant Sp0464 encoded by the clone and the full-length Sp0464 protein have two Cna B domains. The cloned recombinant Sp0464 lacks the LPXTG motif present in the full-length Sp0464 protein. Expression of the Sp0464 clone resulted
20 in the detection of a 38 kD polypeptide, the expected molecular weight of the recombinant Sp0464 polypeptide, by Western blot analysis. See Figure 159.

Example 18: Intranasal Immunization of Mice with Recombinant *L. lactis* Expressing GBS 80 and Subsequent Challenge

25 This example describes a method of intranasally immunizing mice using *L. lactis* that express GBS 80. Intranasal immunization consisted of 3 doses at days 0, 14 and 28, each dose administered in three consecutive days. Each day, groups of 3 CD-1 outbred female mice 6-7 weeks old (Charles River Laboratories, Calco Italy) were immunized intranasally with 10^9 or 10^{10} CFU of the recombinant *Lactococcus lactis* suspended in 20 μ l of PBS. In each immunization scheme negative
30 (wild-type *L. lactis*) and positive (recombinant GBS80) control groups were used. The immune response of the dams was monitored by using serum samples taken on day 0 and 49. The female mice were bred 2-7 days after the last immunization (at approximately $t = 36 - 37$), and typically had a gestation period of 21 days. Within 48 hours of birth, the pups were challenged via I.P. with GBS in a dose approximately equal to an amount which would be sufficient to kill 90 % of immunized pups (as
35 determined by empirical data gathered from PBS control groups). The GBS challenge dose is preferably administered in 50ml of THB medium. Preferably, the pup challenge takes place at 56 to 61 days after the first immunization. The challenge inocula were prepared starting from frozen

cultures diluted to the appropriate concentration with THB prior to use. Survival of pups was monitored for 5 days after challenge.

Example 19: Subcutaneous Immunization of Mice with Recombinant *L. lactis* Expressing GBS 80 and Subsequent Challenge

This example describes a method of subcutaneous immunization mice using *L. lactis* that express GBS 80. Subcutaneous immunization consists of 3 doses at days 0, 14 and 28. Groups of 3 CD-1 outbred female mice 6-7 weeks old (Charles River Laboratories, Calco Italy) were injected subcutaneously with 10^9 or 10^{10} CFU of the recombinant *Lactococcus lactis* suspended in 100 μ l of PBS. In each immunization scheme, negative (wild-type *L. lactis*) and positive (recombinant GBS80) control groups were used. The immune response of the dams was monitored by using serum samples taken on day 0 and 49. The female mice were bred 2-7 days after the last immunization (at approximately $t = 36 - 37$), and typically had a gestation period of 21 days. Within 48 hours of birth, the pups were challenged via I.P. with GBS in a dose approximately equal to an amount which would be sufficient to kill 90 % of immunized pups (as determined by empirical data gathered from PBS control groups). The GBS challenge dose is preferably administered in 50ml of THB medium. Preferably, the pup challenge takes place at 56 to 61 days after the first immunization. The challenge inocula were prepared starting from frozen cultures diluted to the appropriate concentration with THB prior to use. Survival of pups was monitored for 5 days after challenge.

Example 20: Immunization of Mice with GAS AI polypeptides and Subsequent Intranasal Challenge

This example describes a method of immunizing mice with GAS AI polypeptides and subsequently intranasally challenging the mice with GAS bacteria. Groups of 10 CD1 female mice aged between 6 and 7 weeks are immunized with a combination of GAS antigens of the invention GAS 15, GAS 16, and GAS 18, (15 μ g of each recombinant antigen, derived from M1 strain SF370) or *L. lactis* expressing the M1 strain SF370 adhesin island, suspended in 100 μ l of suitable solution. Each group receives 3 doses at days 0, 21 and 45. Immunization is performed through subcutaneous or intraperitoneal injection for the GAS 15, GAS 16, GAS 18 protein combination. The protein combination is administered with an equal volume of Complete Freund's Adjuvant (CFA) for the first dose and Incomplete Freund's Adjuvant (IFA) for the following two doses. Immunization is performed intranasally for the *L. lactis* expressing the M1 strain SF370 adhesin island. In each immunization scheme negative and positive control groups are used.

The negative control group for the mice immunized with the GAS 15, GAS 16, GAS 18 protein combination included mice immunized with PBS. The negative control group for the mice immunized with *L. lactis* expressing the M1 strain SF370 adhesin island, included mice immunized

with either wildtype *L. lactis* or *L. lactis* transformed with the pAM401 expression vector lacking any cloned adhesin island sequence.

The positive control groups included mice immunized with purified M1 strain SF370 M protein.

- 5 Immunized mice are then anaesthetized with Zoletil and challenged intranasally with a 25 μ L suspension containing 1.2×10^6 or 1.2×10^8 CFU of ISS 3348 in THB. Animals are observed daily and checked for survival.

Example 21: Active Maternal Immunization Assay

- 10 As used herein, an Active Maternal Immunization assay refers to an *in vivo* protection assay where female mice are immunized with the test antigen composition. The female mice are then bred and their pups are challenged with a lethal dose of GBS. Serum titers of the female mice during the immunization schedule are measured as well as the survival time of the pups after challenge.

15 **Mouse immunization**

- Specifically, groups of 4 CD-1 outbred female mice 6-8 weeks old (Charles River Laboratories, Calco Italy) are immunized with one or more GBS antigens, (20 μ g of each recombinant GBS antigen), suspended in 100 μ L of PBS. Each group receives 3 doses at days 0, 21 and 35. Immunization is performed through intra-peritoneal injection of the protein with an equal volume of Complete Freund's Adjuvant (CFA) for the first dose and Incomplete Freund's Adjuvant (IFA) for the following two doses. In each immunization scheme negative and positive control groups are used.

Immune response is monitored by using serum samples taken on day 0 and 49. The sera are analyzed as pools from each group of mice.

25 **Active maternal immunization**

- A maternal immunization/neonatal pup challenge model of GBS infection was used to verify the protective efficacy of the antigens in mice. The mouse protection study was adapted from Rodewald et al. (Rodewald et al. J. Infect. Diseases 166, 635 (1992)). In brief, CD-1 female mice (6-8 weeks old) were immunized before breeding, as described above. The mice received 20 μ g of protein per dose when immunized with a single antigen and 60 μ g of protein per dose (15 μ g of each antigen) when immunized with the combination of antigens. Mice were bred 2-7 days after the last immunization. Within 48 h of birth, pups were injected intraperitoneally with 50 μ L of GBS culture. Challenge inocula were prepared starting from frozen cultures diluted to the appropriate concentration with THB before use. In preliminary experiments (not shown), the challenge doses per pup for each strain tested were determined to cause 90% lethality. Survival of pups was monitored for 2 days after challenge. Protection was calculated as (percentage

$$\frac{\text{percentage deadVaccine} - \text{percentage deadControl}}{\text{percentage deadControl}}$$
 multiplied by 100. Data were evaluated for statistical significance by Fisher's exact test.

Embodiments of the Invention

The invention encompasses, but is not limited to, the embodiments enumerated below.

1. An immunogenic composition comprising a purified Group B Streptococcus (GBS) adhesin island (AI) polypeptide in oligomeric form.

2. The immunogenic composition of embodiment 1 wherein the GBS AI polypeptide is selected from a GBS AI-1.

3. The immunogenic composition of embodiment 1 wherein the GBS AI polypeptide is selected from a GBS AI-2.

1. An immunogenic composition comprising a purified Group B Streptococcus (GBS) adhesin island (AI) polypeptide in oligomeric form.

2. The immunogenic composition of embodiment 1 wherein the GBS AI polypeptide is selected from a GBS AI-1.

3. The immunogenic composition of embodiment 1 wherein the GBS AI polypeptide is selected from a GBS AI-2.

4. The immunogenic composition of any of embodiments 1-3 wherein the GBS AI polypeptide comprises a sortase substrate motif.

5. The immunogenic composition of embodiment 4 wherein the sortase substrate motif is an LPXTG motif.

6. The immunogenic composition of embodiment 5 wherein the LPXTG motif is represented by the amino acid sequence XPXTG, wherein the X at amino acid position 1 is an L, an I, or an F and the X at amino acid position 3 is any amino acid residue.

7. The immunogenic composition of any one of embodiments 1-3 wherein the GBS AI polypeptide affects the ability of GBS bacteria to adhere to epithelial cells.

8. The immunogenic composition of any one of embodiments 1-3 wherein the GBS AI polypeptide affects the ability of GBS bacteria to invade epithelial cells.

9. The immunogenic composition of any one of embodiments 1-3 wherein the GBS AI polypeptide affects the ability of GBS bacteria to translocate through an epithelial cell layer.

10. The immunogenic composition of any one of embodiments 1-3 wherein the GBS AI polypeptide is capable of associating with an epithelial cell surface.

11. The immunogenic composition of embodiment 10 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

12. The immunogenic composition of any of embodiments 1-3 wherein the GBS AI polypeptide is a full-length GBS AI protein.

13. The immunogenic composition of any of embodiments 1-3 wherein the GBS AI polypeptide is a fragment of a full-length GBS AI protein.

14. The immunogenic composition of embodiment 13 wherein the fragment comprises at least 7 contiguous amino acid residues of the GBS AI protein.

15. The immunogenic composition of embodiment 2 wherein the GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.

16. The immunogenic composition of embodiment 3 wherein the GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof.

17. The immunogenic composition of embodiment 15 wherein the GBS AI polypeptide is GBS 80.

18. The immunogenic composition of any of embodiments 1-3 or 15-17 wherein the oligomeric form is a hyperoligomer.

19. The immunogenic composition of any of embodiments 1-3, or 15-17 further comprising a Gram positive bacterium antigen not associated with an AI.

20. The immunogenic composition of embodiment 19 wherein the antigen is selected from the group consisting of GBS 322 and GBS 276.

21. The immunogenic composition of embodiment 20 wherein the antigen is GBS 322.

22. An immunogenic composition comprising a purified Gram positive bacteria adhesin island (AI) polypeptide in an oligomeric form.

23. The immunogenic composition of embodiment 22 wherein the Gram positive bacteria is of a genus selected from the group consisting of *Streptococcus*, *Enterococcus*, *Staphylococcus*, or *Listeria*.

24. The immunogenic composition of embodiment 23 wherein the Gram positive bacteria is of the genus *Streptococcus*.

25. The immunogenic composition of any of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide comprises a sortase substrate motif.

26. The immunogenic composition of embodiment 25 wherein the sortase substrate motif is an LPXTG motif.

27. The immunogenic composition of any one of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide affects the ability of Gram positive bacteria to adhere to epithelial cells.

28. The immunogenic composition of any one of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide affects the ability of Gram positive bacteria to invade epithelial cells.

29. The immunogenic composition of any one of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide affects the ability of Gram positive bacteria to translocate through an epithelial cell layer.

30. The immunogenic composition of any one of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide is capable of associating with an epithelial cell surface.

31. The immunogenic composition of embodiment 30 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

32. The immunogenic composition of any of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide is a full-length Gram positive bacteria AI protein.

33. The immunogenic composition of any of embodiments 22-24 wherein the Gram positive bacteria AI polypeptide is a fragment of a full-length Gram positive bacteria AI protein.

5 34. The immunogenic composition of embodiment 33 wherein the fragment comprises at least 7 contiguous amino acid residues of the Gram positive bacteria AI protein.

35. The immunogenic composition of embodiment 24 wherein the genus *Streptococcus* bacteria is Group A Streptococcus (GAS) bacteria and the Gram positive bacteria AI polypeptide is a GAS AI polypeptide.

10 36. The immunogenic composition of embodiment 35 wherein the GAS AI polypeptide is selected from a GAS AI-1.

37. The immunogenic composition of embodiment 35 wherein the GAS AI polypeptide is selected from a GAS AI-2.

15 38. The immunogenic composition of embodiment 35 wherein the GAS AI polypeptide is selected from a GAS AI-3.

39. The immunogenic composition of embodiment 35 wherein the GAS AI polypeptide is selected from a GAS AI-4.

40. The immunogenic composition of any of embodiments 35-39 wherein the GAS AI polypeptide comprises a sortase substrate motif.

20 41. The immunogenic composition of embodiment 40 wherein the sortase substrate motif is an LPXTG motif.

25 42. The immunogenic composition of embodiment 41 wherein the LPXTG motif is represented by XXXXG, wherein the X at the first amino acid position is an L, a V, an E, or a Q, wherein the X at the second amino acid position is P if the X at the first amino acid position is an L, the X at the second amino acid position is a V if the X at the first amino acid position is an E or a Q, or the X at the second amino acid position is a V or a P if the X at the first amino acid position is a V, wherein the X at the third amino acid position is any amino acid residue, and wherein the X at the fourth amino acid position is a T if the X at the first amino acid position is a V, an E, or a Q, or the X at the fourth amino acid position is a T, an S, or an A if the X at the first amino acid position is an L.

30 43. The immunogenic composition of any one of embodiments 35-39 wherein the GAS AI polypeptide affects the ability of GAS bacteria to adhere to epithelial cells.

44. The immunogenic composition of any one of embodiments 35-39 wherein the GAS AI polypeptide affects the ability of GAS bacteria to invade epithelial cells.

35 45. The immunogenic composition of any one of embodiments 35-39 wherein the GAS AI polypeptide affects the ability of GAS bacteria to translocate through an epithelial cell layer.

46. The immunogenic composition of any one of embodiments 35-39 wherein the GAS AI polypeptide is capable of associating with an epithelial cell surface.

47. The immunogenic composition of embodiment 46 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

48. The immunogenic composition of any of embodiments 35-39 wherein the GAS AI polypeptide is a full-length GAS AI protein.

49. The immunogenic composition of any of embodiments 35-39 wherein the GAS AI polypeptide is a fragment of a full-length GAS AI protein.

50. The immunogenic composition of embodiment 49 wherein the fragment comprises at least 7 contiguous amino acid residues of the GAS AI protein.

51. The immunogenic composition of embodiment 36 wherein the GAS AI-1 polypeptide is selected from the group consisting of M6_Spy0157, M6_Spy0159, M6_Spy0160, CDC SS 410_fimbrial, ISS3650_fimbrial, DSM2071_fimbrial, and fragments thereof.

52. The immunogenic composition of embodiment 37 wherein the GAS AI-2 polypeptide is selected from the group consisting of GAS15, GAS16, GAS18, and fragments thereof.

53. The immunogenic composition of embodiment 38 wherein the GAS AI-3 polypeptide is selected from the group consisting of SpyM3_0098, SpyM3_0100, SpyM3_0102, SpyM3_0104, SPs0100, SPs0102, SPs0104, SPs0106, orf78, orf80, orf82, orf84, spyM18_0126, spyM18_0128, spyM18_0130, spyM18_0132, SpyoM01000156, SpyoM01000155, SpyoM01000154, SpyoM01000153, SpyoM01000152, SpyoM01000151, SpyoM01000150, SpyoM01000149, ISS3040_fimbrial, ISS3776_fimbrial, ISS4959_fimbrial, and fragments thereof.

53. The immunogenic composition of embodiment 39 wherein the GAS AI-4 polypeptide is selected from the group consisting of 19224134, 19224135, 19224137, 19224139, 19224141, 20010296_fimbrial, 20020069_fimbrial, CDC SS 635_fimbrial, ISS4883_fimbrial, ISS4538_fimbrial, and fragments thereof.

54. The immunogenic composition of embodiment 24 wherein the *Streptococcus* bacteria is *Streptococcus pneumoniae* and the Gram positive bacteria AI polypeptide is a *S. pneumoniae* AI polypeptide.

55. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide comprises a sortase substrate motif.

56. The immunogenic composition of embodiment 55 wherein the sortase substrate motif is an LPXTG motif.

57. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide affects the ability of *S. pneumoniae* to adhere to epithelial cells.

58. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide affects the ability of *S. pneumoniae* to invade epithelial cells.

59. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide affects the ability of *S. pneumoniae* to translocate through an epithelial cell layer.

60. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide is capable of associating with an epithelial cell surface.

61. The immunogenic composition of embodiment 60 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

62. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide is a full-length *S. pneumoniae* AI protein.

63. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide is a fragment of a full-length *S. pneumoniae* AI protein.

64. The immunogenic composition of embodiment 63 wherein the fragment comprises at least 7 contiguous amino acid residues of the *S. pneumoniae* AI protein.

65. The immunogenic composition of embodiment 54 wherein the *S. pneumoniae* AI polypeptide is selected from the group consisting of SP0462, SP0463, SP0464, orf3_670, orf4_670, orf5_670, ORF3_14CSR, ORF4_14CSR, ORF5_14CSR, ORF3_19AH, ORF4_19AH, ORF5_19AH, ORF3_19FTW, ORF4_19FTW, ORF5_19FTW, ORF3_23FP, ORF4_23FP, ORF5_23FP, ORF3_23FTW, ORF4_23FTW, ORF5_23FTW, ORF3_6BF, ORF4_6BF, ORF5_6BF, ORF3_6BSP, ORF4_6BSP, ORF5_6BSP, ORF3_9VSP, ORF4_9VSP, ORF5_9VSP, and fragments thereof.

66. The immunogenic composition of any one of embodiments 22-24, 35-39, 51-54, or 65 wherein the oligomeric form is a hyperoligomer.

67. The immunogenic composition of any one of embodiments 22-24, 35-39, 51-54, or 65 further comprising a Gram positive bacteria antigen not associated with an AI.

68. The immunogenic composition of embodiment 67 wherein the antigen is selected from the group consisting of GBS 322 and GBS 276.

69. An immunogenic composition comprising a first and a second Group B Streptococcus (GBS) adhesin island (AI) polypeptide.

70. The immunogenic composition of embodiment 69 wherein a full-length polynucleotide sequence encoding for the first GBS AI polypeptide is not present in a GBS bacteria genome comprising a polynucleotide sequence encoding for the second GBS AI polypeptide.

71. The immunogenic composition of embodiment 69 wherein polynucleotides encoding the first and the second GBS AI polypeptide are each present in genomes of more than one GBS serotype and strain isolate.

72. The immunogenic composition of embodiment 69 wherein the first GBS AI polypeptide is encoded by a GBS AI-1.

73. The immunogenic composition of embodiment 69 wherein the first GBS AI polypeptide is encoded by a GBS AI-2.

74. The immunogenic composition of embodiment 72 wherein the second GBS AI polypeptide is encoded by a GBS AI-2.

75. The immunogenic composition of embodiment 73 wherein the second GBS AI polypeptide is encoded by a GBS AI-2.

76. The immunogenic composition of embodiment 72 wherein the second GBS AI polypeptide is encoded by a GBS AI-1.

88. The immunogenic composition of embodiment 73 wherein the second GBS AI polypeptide is encoded by a GBS AI-1.

78. The immunogenic composition of embodiment 72 wherein the first GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.

5 79. The immunogenic composition of embodiment 73 wherein the first GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof.

10 80. The immunogenic composition of embodiment 74 or 75 wherein the second GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof, and wherein the first and the second GBS AI polypeptide are not the same polypeptide.

81. The immunogenic composition of embodiment 76 or 77 wherein the second GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof, and wherein the first and the second GBS AI polypeptide are not the same polypeptide.

15 82. The immunogenic composition of any one of embodiments 69-77 wherein the first GBS AI polypeptide comprises a sortase substrate motif.

83. The immunogenic composition of embodiment 82 wherein the sortase substrate motif is an LPXTG motif.

20 84. The immunogenic composition of embodiment 83 wherein the LPXTG motif is represented by the sequence XPXTG, wherein the X at amino acid position 1 is an L, an I, or an F and the X at amino acid position 3 is any amino acid residue.

85. The immunogenic composition of any one of embodiments 69-77 wherein the first GBS AI polypeptide affects the ability of GBS bacteria to adhere to epithelial cells.

25 86. The immunogenic composition of any one of embodiments 69-77 wherein the first GBS AI polypeptide affects the ability of GBS bacteria to invade epithelial cells.

87. The immunogenic composition of any one of embodiments 69-77 wherein the first GBS AI polypeptide affects the ability of GBS bacteria to translocate through an epithelial cell layer.

88. The immunogenic composition of any one of embodiments 69-77 wherein the first GBS AI polypeptide is capable of associating with an epithelial cell surface.

30 89. The immunogenic composition of embodiment 88 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

90. The immunogenic composition of any of embodiments 69-77 wherein the first GBS AI polypeptide is a full-length GBS AI protein.

35 91. The immunogenic composition of any of embodiments 69-77 wherein the first GBS AI polypeptide is a fragment of a full-length GBS AI protein.

92. The immunogenic composition of embodiment 91 wherein the fragment comprises at least 7 contiguous amino acid residues of the first GBS AI protein.

93. The immunogenic composition of any one of embodiments 69-79 wherein the first GBS AI polypeptide is in oligomeric form.

94. The immunogenic composition of any one of embodiments 69-77 wherein the second GBS AI polypeptide is in oligomeric form.

95. The immunogenic composition of any one of embodiments 69-79 wherein the first and the second GBS AI polypeptide are associated in a single oligomeric form.

96. The immunogenic composition of embodiment 95 wherein the first and the second GBS AI polypeptides are chemically associated.

97. The immunogenic composition of embodiment 95 wherein the first and the second GBS AI polypeptides are physically associated.

98. The immunogenic composition of embodiment 93 wherein the oligomeric form is a hyperoligomer.

99. The immunogenic composition of embodiment 94 wherein the oligomeric form is a hyperoligomer.

100. The immunogenic composition of embodiment 76 wherein the first GBS AI polypeptide is GBS 80 and the second GBS AI polypeptide is GBS 104.

101. The immunogenic composition of embodiment 74 wherein the first GBS AI polypeptide is GBS 80 and the second GBS AI polypeptide is GBS 67.

102. The immunogenic composition of any one of embodiments 69-79, 100, or 101 further comprising a GBS polypeptide not associated with an AI.

103. The immunogenic composition of embodiment 102 wherein the GBS polypeptide not associated with an AI is selected from the group consisting of GBS 322 and GBS 276.

104. The immunogenic composition of embodiment 103 wherein the GBS polypeptide not associated with an AI is GBS 322.

105. An immunogenic composition comprising a first and a second Gram positive bacteria adhesin island (AI) polypeptide.

106. The immunogenic composition of embodiment 105 wherein a full length polynucleotide sequence encoding for the first Gram positive bacteria AI polypeptide is not present in a genome of a Gram positive bacteria comprising a full length polynucleotide sequence encoding for the second Gram positive bacteria AI polypeptide.

107. The immunogenic composition of embodiment 105 wherein polynucleotides encoding the first and the second Gram positive bacteria AI polypeptide are each present in genomes of more than one Gram positive bacteria serotype and strain isolate.

108. The immunogenic composition of embodiment 105 wherein the first and the second Gram positive bacteria AI polypeptides are of different Gram positive bacteria species.

109. The immunogenic composition of embodiment 105 wherein the first and the second Gram positive bacteria AI polypeptides are of the same Gram positive bacteria species.

110. The immunogenic composition of embodiment 105 wherein the first and the second Gram positive bacteria AI polypeptides are from different AI subtypes.

111. The immunogenic composition of embodiment 105 wherein the first and the second Gram positive bacteria AI polypeptides are from the same AI subtype.

5 112. The immunogenic composition of embodiment 105 wherein the first Gram positive bacteria AI polypeptide has detectable surface exposure on a first Gram positive bacteria strain or serotype but not a second Gram positive bacteria strain or subtype and the second Gram positive bacteria AI polypeptide has detectable surface exposure on the second Gram positive bacteria strain or serotype but not the first Gram positive bacteria strain or serotype.

10 113. The immunogenic composition of embodiment 105 wherein the Gram positive bacteria is *S. pneumoniae*, *S. mutans*, *E. faecalis*, *E. faecium*, *C. difficile*, *L. monocytogenes*, or *C. diphtheriae*.

114. The immunogenic composition of any of embodiments 105-113 wherein the first and the second Gram positive bacteria AI polypeptides comprise a sortase substrate motif.

15 115. The immunogenic composition of embodiment 114 wherein the sortase substrate motif is an LPXTG motif.

20 116. The immunogenic composition of embodiment 115 wherein the LPXTG motif is represented by XXXXG, wherein the X at amino acid position 1 is an L, a V, an E, an I, an F, or a Q, wherein X at amino acid position 2 is a P if X at amino acid position 1 is an L, an I, or an F, wherein X at amino acid position 2 is a V if X at amino acid position 1 is a E or a Q, wherein X at amino acid position 2 is a V or a P if X at amino acid position 1 is a V, wherein X at amino acid position 3 is any amino acid residue, wherein X at amino acid position 4 is a T if X at amino acid position 1 is a V, E, I, F, or Q, and wherein X at amino acid position 4 is a T, S, or A if X at amino acid position 1 is an L.

25 117. The immunogenic composition of embodiment 105 wherein the first Gram positive bacteria AI polypeptide is a first Group A Streptococcus (GAS) AI polypeptide.

118. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide comprises a sortase substrate motif.

119. The immunogenic composition of embodiment 118 wherein the sortase substrate motif is an LPXTG motif.

30 120. The immunogenic composition of embodiment 119 wherein the LPXTG motif is represented by XXXXG, wherein the X at the first amino acid position is an L, a V, an E, or a Q, wherein the X at the second amino acid position is P if the X at the first amino acid position is an L, the X at the second amino acid position is a V if the X at the first amino acid position is an E or a Q, or the X at the second amino acid position is a V or a P if the X at the first amino acid position is a V, wherein the X at the third amino acid position is any amino acid residue, and wherein the X at the 35 fourth amino acid position is a T if the X at the first amino acid position is a V, an E, or a Q, or the X at the fourth amino acid position is a T, an S, or an A if the X at the first amino acid position is an L.

121. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide affects the ability of GAS bacteria to adhere to epithelial cells.

122. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide affects the ability of GAS bacteria to invade epithelial cells.

123. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide affects the ability of GAS bacteria to translocate through an epithelial cell layer.

5 124. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is capable of associating with an epithelial cell surface.

125. The immunogenic composition of embodiment 117 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

10 126. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is a full-length GAS AI protein.

127. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is a fragment of a full-length GAS AI protein.

128. The immunogenic composition of embodiment 127 wherein the fragment comprises at least 7 contiguous amino acid residues of the GAS AI protein.

15 129. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is a first GAS AI-1 polypeptide.

130. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is a first GAS AI-2 polypeptide.

20 131. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is a first GAS AI-3 polypeptide.

132. The immunogenic composition of embodiment 117 wherein the first GAS AI polypeptide is a first GAS AI-4 polypeptide.

133. The immunogenic composition of any one of embodiments 117 or 129-132 wherein the second Gram positive bacteria AI polypeptide is a second GAS AI polypeptide.

25 134. The immunogenic composition of embodiment 133 wherein the second GAS AI polypeptide is a second GAS AI-1 polypeptide.

135. The immunogenic composition of embodiment 133 wherein the second GAS AI polypeptide is a second GAS AI-2 polypeptide.

30 136. The immunogenic composition of embodiment 133 wherein the second GAS AI polypeptide is a second GAS AI-3 polypeptide.

137. The immunogenic composition of embodiment 133 wherein the second GAS AI polypeptide is a second GAS AI-4 polypeptide.

35 138. The immunogenic composition of embodiment 129 wherein the first GAS AI-1 polypeptide is selected from the group consisting of M6_Spy0157, M6_Spy0159, M6_Spy0160, CDC SS 410_fimbrial, ISS3650_fimbrial, DSM2071_fimbrial, and fragments thereof.

139. The immunogenic composition of embodiment 130 wherein the first GAS AI-2 polypeptide is selected from the group consisting of GAS15, GAS16, GAS18, and fragments thereof.

140. The immunogenic composition of embodiment 131 wherein the first GAS AI-3 polypeptide is selected from the group consisting of SpyM3_0098, SpyM3_0100, SpyM3_0102, SpyM3_0104, SPs0100, SPs0102, SPs0104, SPs0106, orf78, orf80, orf82, orf84, spyM18_0126, spyM18_0128, spyM18_0130, spyM18_0132, SpyoM01000156, SpyoM01000155, SpyoM01000154, SpyoM01000153, SpyoM01000152, SpyoM01000151, SpyoM01000150, SpyoM01000149, ISS3040_fimbrial, ISS3776_fimbrial, ISS4959_fimbrial, and fragments thereof.

141. The immunogenic composition of embodiment 132 wherein the first GAS AI-4 polypeptide is selected from the group consisting of 19224134, 19224135, 19224137, 19224139, 19224141, 20010296_fimbrial, 20020069_fimbrial, CDC SS 635_fimbrial, ISS4883_fimbrial, ISS4538_fimbrial, and fragments thereof.

142. The immunogenic composition of embodiment 134 wherein the second GAS AI-1 polypeptide is selected from the group consisting of M6_Spy0157, M6_Spy0159, M6_Spy0160, CDC SS 410_fimbrial, ISS3650_fimbrial, DSM2071_fimbrial, and fragments thereof.

143. The immunogenic composition of embodiment 135 wherein the second GAS AI-2 polypeptide is selected from the group consisting of GAS15, GAS16, GAS18, and fragments thereof.

144. The immunogenic composition of embodiment 136 wherein the second GAS AI-3 polypeptide is selected from the group consisting of SpyM3_0098, SpyM3_0100, SpyM3_0102, SpyM3_0104, SPs0100, SPs0102, SPs0104, SPs0106, orf78, orf80, orf82, orf84, spyM18_0126, spyM18_0128, spyM18_0130, spyM18_0132, SpyoM01000156, SpyoM01000155, SpyoM01000154, SpyoM01000153, SpyoM01000152, SpyoM01000151, SpyoM01000150, SpyoM01000149, ISS3040_fimbrial, ISS3776_fimbrial, ISS4959_fimbrial, and fragments thereof.

145. The immunogenic composition of embodiment 137 wherein the second GAS AI-4 polypeptide is selected from the group consisting of 19224134, 19224135, 19224137, 19224139, 19224141, 20010296_fimbrial, 20020069_fimbrial, CDC SS 635_fimbrial, ISS4883_fimbrial, ISS4538_fimbrial, and fragments thereof.

146. The immunogenic composition of any one of embodiments 117-132 or 138-141 wherein the second Gram positive bacteria AI polypeptide is a Group B Streptococcus (GBS) AI polypeptide.

147. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide comprises a sortase substrate motif.

148. The immunogenic composition of embodiment 147 wherein the sortase substrate motif is an LPXTG motif.

149. The immunogenic composition of embodiment 148 wherein the LPXTG motif is represented by the amino acid sequence XPXTG, wherein the X at amino acid position 1 is an L, an I, or an F and the X at amino acid position 3 is any amino acid residue.

150. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide affects the ability of GBS bacteria to adhere to epithelial cells.

151. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide affects the ability of GBS bacteria to invade epithelial cells.

152. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide affects the ability of GBS bacteria to translocate through an epithelial cell layer.

153. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide is capable of associating with an epithelial cell surface.

5 154. The immunogenic composition of embodiment 146 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

155. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide is a full-length GBS AI protein.

10 156. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide is a fragment of a full-length GBS AI protein.

157. The immunogenic composition of embodiment 156 wherein the fragment comprises at least 7 contiguous amino acid residues of the GBS AI protein.

158. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide is a GBS AI-1 polypeptide.

15 159. The immunogenic composition of embodiment 146 wherein the GBS AI polypeptide is a GBS AI-2 polypeptide.

160. The immunogenic composition of embodiment 158 wherein the GBS AI-1 polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.

20 161. The immunogenic composition of embodiment 159 wherein the GBS AI-2 polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof.

162. The immunogenic composition of any one of embodiments 117-132 or 138-141 wherein the second Gram positive bacteria AI polypeptide is a *Streptococcus pneumoniae* AI polypeptide.

25 163. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide comprises a sortase substrate motif.

164. The immunogenic composition of embodiment 163 wherein the sortase substrate motif is an LPXTG motif.

165. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide affects the ability of *S. pneumoniae* to adhere to epithelial cells.

30 166. The immunogenic composition of embodiment 162 *S. pneumoniae* AI polypeptide affects the ability of *S. pneumoniae* to invade epithelial cells.

167. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide affects the ability of *S. pneumoniae* to translocate through an epithelial cell layer.

35 168. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide is capable of associating with an epithelial cell surface.

169. The immunogenic composition of embodiment 168 wherein the associating with an epithelial cell surface is binding to the epithelial cell surface.

170. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide is a full-length *S. pneumoniae* AI protein.

171. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide is a fragment of a full-length *S. pneumoniae* AI protein.

172. The immunogenic composition of embodiment 162 wherein the fragment comprises at least 7 contiguous amino acid residues of the *S. pneumoniae* AI protein.

173. The immunogenic composition of embodiment 162 wherein the *S. pneumoniae* AI polypeptide is selected from the group consisting of SP0462, SP0463, SP0464, orf3_670, orf4_670, orf5_670, ORF3_14CSR, ORF4_14CSR, ORF5_14CSR, ORF3_19AH, ORF4_19AH, ORF5_19AH, ORF3_19FTW, ORF4_19FTW, ORF5_19FTW, ORF3_23FP, ORF4_23FP, ORF5_23FP, ORF3_23FTW, ORF4_23FTW, ORF5_23FTW, ORF3_6BF, ORF4_6BF, ORF5_6BF, ORF3_6BSP, ORF4_6BSP, ORF5_6BSP, ORF3_9VSP, ORF4_9VSP, ORF5_9VSP, and fragments thereof.

174. The immunogenic composition of any one of embodiments 105-117 wherein the first Gram positive bacteria AI polypeptide is in oligomeric form.

175. The immunogenic composition of embodiment 174 wherein the oligomeric form is a hyperoligomer.

176. The immunogenic composition of embodiment 174 wherein the second Gram positive bacteria AI polypeptide is in oligomeric form.

177. The immunogenic composition of embodiment 176 wherein the oligomeric form is a hyperoligomer.

178. The immunogenic composition of embodiment 176 wherein the first and the second Gram positive bacteria AI polypeptide are associated in a single oligomeric form.

179. The immunogenic composition of embodiment 178 wherein the first and the second Gram positive bacteria AI polypeptide are chemically associated.

180. The immunogenic composition of embodiment 178 wherein the first and the second Gram positive bacteria AI polypeptide are physically associated.

181. The immunogenic composition of any one of embodiments 105-117 further comprising a Gram positive bacteria polypeptide not associated with an AI.

182. The immunogenic composition of embodiment 181 wherein the Gram positive bacteria polypeptide not associated with an AI is selected from the group consisting of GBS 322 and GBS 276.

183. The immunogenic composition of embodiment 182 wherein the Gram positive bacteria polypeptide not associated with an AI is GBS 322.

184. A modified Gram positive bacterium adapted to produce increased levels of AI surface protein.

185. The modified Gram positive bacterium of embodiment 184 wherein the AI surface protein is in oligomeric form.

186. The modified Gram positive bacterium of embodiment 185 wherein the oligomeric form is a hyperoligomer.

187. The modified Gram positive bacterium of any one of embodiments 184-186 which is a Group B Streptococcus bacterium.

188. The modified Gram positive bacterium of any one of embodiments 184-186 which is a Group A Streptococcus bacterium.

5 189. The modified Gram positive bacterium of any one of embodiments 184-186 which is a non-pathogenic Gram positive bacterium.

190. The modified Gram positive bacterium of embodiment 189 wherein the non-pathogenic Gram positive bacterium is *Streptococcus gordonii*.

10 191. The modified Gram positive bacterium of embodiment 189 wherein the non-pathogenic Gram positive bacterium is *Lactococcus lactis*.

192. The modified Gram positive bacterium of any one of embodiments 184-186 which has been inactivated and wherein the AI surface protein is exposed on the surface of the Gram positive bacterium.

15 193. The modified Gram positive bacterium of any one of embodiments 184-186 which has been attenuated and wherein the AI surface protein is exposed on the surface of the Gram positive bacterium.

194. The modified GBS bacterium of embodiment 187 which has been inactivated and wherein the AI surface protein is exposed on the surface of the GBS bacterium.

20 195. The modified GBS bacterium of embodiment 187 which has been attenuated and wherein the AI surface protein is exposed on the surface of the GBS bacterium.

196. The modified GAS bacterium of embodiment 188 which has been inactivated and wherein the AI surface protein is exposed on the surface of the GAS bacterium.

197. The modified GAS bacterium of embodiment 188 which has been attenuated and wherein the AI surface protein is exposed on the surface of the GAS bacterium.

25 198. The modified non-pathogenic bacterium of embodiment 189 which has been inactivated and wherein the AI surface protein is exposed on the surface of the non-pathogenic Gram positive bacterium.

30 199. The modified non-pathogenic bacterium of embodiment 189 which has been attenuated and wherein the AI surface protein is exposed on the surface of the non-pathogenic Gram positive bacterium.

200. A method for manufacturing an oligomeric adhesin island (AI) surface antigen comprising:

culturing a Gram positive bacterium that expresses an oligomeric AI surface antigen and isolating the expressed oligomeric AI surface antigen.

35 201. The method of embodiment 200 wherein the step of isolating is performed by collecting said oligomeric AI surface antigen from Gram positive bacterium secretions in the Gram positive bacterium culture.

202. The method of embodiment 200 further comprising a step of purifying.

203. The method of embodiment 202 wherein the oligomeric AI surface antigen is purified from the Gram positive bacterium cell surface.

204. The method of embodiment 200 wherein the Gram positive bacterium is adapted for increased AI protein expression.

5 205. The method of any one of embodiments 200-204 wherein the Gram positive bacterium is a Group A Streptococcus bacterium.

206. The method of any one of embodiments 200-204 wherein the Gram positive bacterium is a Group B Streptococcus bacterium.

10 207. The method of any one of embodiments 200-204 wherein the oligomeric AI surface antigen is in hyperoligomeric form.

208. The method of embodiment 200 wherein the Gram positive bacterium expresses the oligomeric AI surface antigen recombinantly.

209. The method of embodiment 208 wherein the Gram positive bacterium further manipulated expresses at least 1 AI sortase.

15 210. The modified Gram positive bacterium of any one of embodiments 184-186 which is a *S. pneumoniae* bacterium.

211. The method of any one of embodiments 200-204 wherein the Gram positive bacterium is *S. pneumoniae*.

1. An immunogenic composition comprising a purified Group B Streptococcus (GBS) adhesin island (AI) polypeptide in oligomeric form.

5 2. The immunogenic composition of claim 1 wherein the GBS AI polypeptide is selected from a GBS AI-1.

3. The immunogenic composition of claim 1 wherein the GBS AI polypeptide is selected from a GBS AI-2.

4. The immunogenic composition of claim 2 wherein the GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.

10 5. The immunogenic composition of claim 3 wherein the GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof.

6. The immunogenic composition of claim 4 wherein the GBS AI polypeptide is GBS 80.

15 7. The immunogenic composition of any of claims 1-6 wherein the oligomeric form is a hyperoligomer.

8 (22). An immunogenic composition comprising a purified Gram positive bacteria adhesin island (AI) polypeptide in an oligomeric form.

9 (23). The immunogenic composition of claim 8 wherein the Gram positive bacteria is of a genus selected from the group consisting of *Streptococcus*, *Enterococcus*, *Staphylococcus*,
20 *Clostridium*, *Corynebacterium*, or *Listeria*.

10 (24). The immunogenic composition of claim 9 wherein the Gram positive bacteria is of the genus *Streptococcus*.

11 (35). The immunogenic composition of claim 10 wherein the genus *Streptococcus* bacteria is Group A Streptococcus (GAS) bacteria and the Gram positive bacteria AI polypeptide is a
25 GAS AI polypeptide.

12 (36). The immunogenic composition of claim 11 wherein the GAS AI polypeptide is selected from a GAS AI-1.

13 (37). The immunogenic composition of claim 11 wherein the GAS AI polypeptide is selected from a GAS AI-2.

30 14 (38). The immunogenic composition of claim 11 wherein the GAS AI polypeptide is selected from a GAS AI-3.

15 (39). The immunogenic composition of claim 11 wherein the GAS AI polypeptide is selected from a GAS AI-4.

16 (66). The immunogenic composition of any one of claims 8-15 wherein the oligomeric
35 form is a hyperoligomer.

17. An immunogenic composition comprising a first and a second Group B Streptococcus (GBS) adhesin island (AI) polypeptide.

18. The immunogenic composition of claim 17 wherein the first GBS AI polypeptide is encoded by a GBS AI-1.

19. The immunogenic composition of claim 18 wherein the second GBS AI polypeptide is encoded by a GBS AI-2.

5 20. The immunogenic composition of claim 18 wherein the first GBS AI polypeptide is selected from the group consisting of GBS 80, GBS 104, GBS 52, and fragments thereof.

21. The immunogenic composition of claim 19 wherein the second GBS AI polypeptide is selected from the group consisting of GBS 59, GBS 67, GBS 150, 01521, 01523, 01524, and fragments thereof, and wherein the first and the second GBS AI polypeptide are not the same polypeptide.

10 22. The immunogenic composition of claim 19 wherein the first GBS AI polypeptide is GBS 80 and the second GBS AI polypeptide is GBS 67.

23. An immunogenic composition comprising a first and a second Gram positive bacteria adhesin island (AI) polypeptide.

15 24. The immunogenic composition of claim 23 wherein the Gram positive bacteria is *Streptococcus*, *Enterococcus*, *Staphylococcus*, *Clostridium*, *Corynebacterium*, or *Listeria*.

25. The immunogenic composition of claim 23 wherein the first Gram positive bacteria AI polypeptide is a first Group A Streptococcus (GAS) AI polypeptide.

20 26. The immunogenic composition of claim 25 wherein the first GAS AI polypeptide is a first GAS AI-1 polypeptide.

27. The immunogenic composition of claim 25 wherein the first GAS AI polypeptide is a first GAS AI-2 polypeptide.

28. The immunogenic composition of claim 25 wherein the first GAS AI polypeptide is a first GAS AI-3 polypeptide.

25 29. The immunogenic composition of claim 25 wherein the first GAS AI polypeptide is a first GAS AI-4 polypeptide.

30. The immunogenic composition of any one of claims 25-29 wherein the second Gram positive bacteria AI polypeptide is a second GAS AI polypeptide.

30 31. The immunogenic composition of claim 30 wherein the second GAS AI polypeptide is a second GAS AI-1 polypeptide.

32. The immunogenic composition of claim 30 wherein the second GAS AI polypeptide is a second GAS AI-2 polypeptide.

33. The immunogenic composition of claim 30 wherein the second GAS AI polypeptide is a second GAS AI-3 polypeptide.

35 34. The immunogenic composition of claim 30 wherein the second GAS AI polypeptide is a second GAS AI-4 polypeptide.

35. A modified Gram positive bacterium adapted to produce increased levels of AI surface protein.

36. The modified Gram positive bacterium of claim 35 wherein the AI surface protein is in oligomeric form.

37. The modified Gram positive bacterium of claim 36 wherein the oligomeric form is a hyperoligomer.

5 38. The modified Gram positive bacterium of any one of claims 35-37 which is a non-pathogenic Gram positive bacterium.

39. The modified Gram positive bacterium of claim 38 wherein the non-pathogenic Gram positive bacterium is *Lactococcus lactis*.

10 40. A method for manufacturing an oligomeric adhesin island (AI) surface antigen comprising:

culturing a Gram positive bacterium that expresses an oligomeric AI surface antigen and isolating the expressed oligomeric AI surface antigen.

PCT/US2005/027239

FIGURE 1: Adhesion Island 1





Figure 2: Conservation of AI-1 in GBS serotypes and strain isolates



PCT/US2005/027239

FIGURE 3: Correlation of AI-1 and AI-2 within GBS serotype V, strain isolate 2603 genome




Figure 4: Identification and Variance of AI-2 in Several GBS Serotypes and Strain Isolates




Figure 5: Purified gbs80 protein binds fibronectin and fibrinogen in an ELISA




Figure 6: Adhesion Island I is an operon by RT-PCR





Figure 7: In frame deletions of AI-1 genes



8/487

Figure 8: gbs80 is required for surface localization of gbs104




Figure 9: sortases 647 & 648 play a semi-redundant role in surface exposure of gbs80 and gbs104






Figure 10: Western blot of mutant strains



**FIGURE 11: Pre-embedding IEM
staining of GBS 80**



PCT/US05/27239/12/487

FIGURE 12: Predicted Secondary Structure for GBS 067


PHD SECONDARY STRUCTURE PREDICTION for GBS 067

```

10      |      20      30      40      50      60      70
MRKYQKFSKILTLFLCISQIPLNTNVLGSEIVPENGAKGLVVKTKDDQNKPLSKAIFVLKTTAHPESK
CCCCCEEEEEEcccccccccccccccccccccccccccccccccccccccccccccccccccccccc
IEKVTALTEATFDNLIPGDYTLSEETAPAGYKKTNTQWQVSENGKTTIQNSGDKNSTIGONQEBELD
hhhhhhheeecccccccccccccccccccccccccccccccccccccccccccccccccccccccc
KQFPPTGIYEDTKESYLEHVKGSVPNGKSEAKANFYSSGEHIREIPEGTLSKRISSEVGLAHNKYKI
CCCCCCEEEcccccccccccccccccccccccccccccccccccccccccccccccccccccccc
ELTVSGKTIKVPDKQKPLDVFVLDNSNSMNDGNFQRHNKAKAABALGTAVKDILGANSNDRVALV
EEEECCCEEEcccccccccccccccccccccccccccccccccccccccccccccccccccccccc
TVGSDIFDGRSDVVKGFEDDKYGLQTKFTIGTENYSHKQLTNABEIIKRIPTAPKAKWGSTINGL
Ecccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc
TPEQKKEYLISKVGETTYMKAFFMEADDILSNVTRNSQKIIIVVTDGVPTRSYAINNFKLGASYESQFEQM
CCCCCEEEcccccccccccccccccccccccccccccccccccccccccccccccccccccccc
KKNGLNKSNFLTRPEDIKNGESYFLPDSYOTQIISGNLQKLYLDLNLNYPKGTIYRNGPVRKH
HHhC'CCCCcccccccccccccccccccccccccccccccccccccccccccccccccccccccc
GTPTKLYINSLKQKNYDIFNFGIDISGFRQVYNEHYKKNQDGTQKLEEAFLKSLDGEITELMRFSFSSKP
CC'CEEEcccccccccccccccccccccccccccccccccccccccccccccccccccccccc
BYTPIVTSADTSNNELSKIQQFETILFKNSLVANGTIEDPMGDKINLQNGOITLQPSDYTLQNDG
cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc
SVMKDGIATGPNNDGILKGVKLEYIGNKLYVRGINLGEQKVLTYDVKLDLDSFISNKFYDINGRFTL
cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc
NPKSEDPNTRDFPAPKIRDVREYPTITIKNEKNGEIEFFIKVYKDNKLLKGAIFELQEFNEDYKLYL
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
PIKNNNSKVTGENKISYKDLKDGKYLLEAVSPEDYQKINPKPILTFEVKGSIKNIIVANKQISEYH
eecccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc
EEGDKHLITNTHIPPKGILPMTGGKILSPILIGGAMMSIAGGIYIWKRYKSSDMSIKKD
HhCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
Sequence length: 901

```

Alpha helix (Hh) :	148 is	16.43%	310 helix (Gg) :	0 is	0.00%
Pi helix (Ii) :	0 is	0.00%	Beta bridge (Bb) :	0 is	0.00%
Extended strand (Ee) :	243 is	26.97%	Beta turn (Tt) :	0 is	0.00%
Bend region (Ss) :	0 is	0.00%	Random coil (Cc) :	510 is	56.60%
Ambiguous states (?) :	0 is	0.00%	Other states	0 is	0.00%



PCT/US05/27239/13/487

Figure 13




Figure 14





Figure 15



PCT/US05/27239 16/487

Figure 16





Figure 17



18/487




Figure 18

19/487




FIGURE 18 A




FIGURE 18 B

Alignment Report of A1-1 alignment, using J. Hein method with Weighted residue weight table.
Thursday, July 29, 2004 5:46 PM

	Majority				
	1060	1070	1080	1090	1100
	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				
1050	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				2603_all.seq
819	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				18rs21_all.seq
1051	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				coh1_all.seq
1050	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				cjb111_all.seq
1051	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				nen316_all.seq
1051	A G G T G G T T G T C C A C A T A A T G G A C A A T A C T A T T G T A C A T T T G C T G C T T G T C				a909_all.seq
	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				
	1110	1120	1130	1140	1150
1100	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				2603_all.seq
869	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				18rs21_all.seq
1101	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				coh1_all.seq
1100	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				cjb111_all.seq
1101	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				nen316_all.seq
1101	A G A G A T G C T C T T A T T G G T T A A G G A T T C T G A A A A T C A A T A A G A G C T G C A C				a909_all.seq
	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				
	1160	1170	1180	1190	1200
1150	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				2603_all.seq
819	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				18rs21_all.seq
1151	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				coh1_all.seq
1150	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				cjb111_all.seq
1151	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				nen316_all.seq
1151	A G C G A A T T C T T G A A A C A T C A A T A A G A T C A G G A G C C T C T T C G T T T A A A G C C				a909_all.seq
	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				
	1210	1220	1230	1240	1250
1200	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				2603_all.seq
869	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				18rs21_all.seq
1201	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				coh1_all.seq
1200	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				cjb111_all.seq
1201	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				nen316_all.seq
1201	A T A T A G T G C T T T A C C A G C G C A T A A C T T T T A G C C A C A T C A G T A T T T T C C T C				a909_all.seq
	G A A A C T T A A T T C T A G T A A T T T T G T T A A G T A A A C A A C A G T T A A G T T C T T T T				
	1260	1270	1280	1290	1300
250	G A A A C T T A A T T C T A G T A A T T T T G T T A A G T A A A C A A C A G T T A A G T T C T T T T				2603_all.seq
019	G A A A C T T A A T T C T A G T A A T T T T G T T A A G T A A A C A A C A G T T A A G T T C T T T T				18rs21_all.seq
251	G A A A C T T A A T T C T A G T A A T T T T C T T A A G T A A A C A A C A G T T A A G T T C T T T T				coh1_all.seq
250	G A A A C T T A A T T C T A G T A A T T T T G T T A A G T A A A C A A C A G T T A A G T T C T T T T				cjb111_all.seq
251	G A A A C T T A A T T C T A G T A A T T T T G T T A A G T A A A C A A C A G T T A A G T T C T T T T				nen316_all.seq
251	G A A A C T T A A T T C T A G T A A T T T T G T T A A G T A A A C A A C A G T T A A G T T C T T T T				a909_all.seq
	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				
	1310	1320	1330	1340	1350
300	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				2603_all.seq
069	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				18rs21_all.seq
301	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				coh1_all.seq
300	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				cjb111_all.seq
301	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				nen316_all.seq
301	C A G C T C T T A G G G C A G G G A T T G A A G A T G A G G T A A C A C T G G A T G A T G G G A G G				a909_all.seq
	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				
	1360	1370	1380	1390	1400
350	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				2603_all.seq
119	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				18rs21_all.seq
351	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				coh1_all.seq
350	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				cjb111_all.seq
351	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				nen316_all.seq
351	C G A T T A A T T T C T T G C T T T A A C A G T T G A G T G T T A C C C A G C T T A A C G A G A T C				a909_all.seq

FIGURE 18 C




FIGURE 18 D

23/487




FIGURE 18 E

Alignment Report of AI-1... method with Weighted residue weight table.




FIGURE 18 F

25/487




FIGURE 18 G

26/487

	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T Majority				
	2810	2820	2830	2840	2850
2798	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T				2603_all.seq
2567	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T				18rs21_all.seq
2799	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T				cohl_all.seq
2799	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T				cjb111_all.seq
2801	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T				nem316_all.seq
2800	C A A A A A G T A A T G T G A G A T A C T T G T A T G T A G A A G A T T T A A A G A A T T C A C C T				a909_all.seq
	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T Majority				
	2860	2870	2880	2890	2900
2848	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T				2603_all.seq
2617	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T				18rs21_all.seq
2849	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T				cohl_all.seq
2849	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T				cjb111_all.seq
2851	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T				nem316_all.seq
2850	T C A A A C A T T A C C A A A G C T T A T G C T G T A C C G T T T G T G T T G G A A T T A C C A G T				a909_all.seq
	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A Majority				
	2910	2920	2930	2940	2950
2898	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A				2603_all.seq
2667	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A				18rs21_all.seq
2899	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A				cohl_all.seq
2899	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A				cjb111_all.seq
2901	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A				nem316_all.seq
2900	T G C T A A C T C T A C A G G T A C A G G T T T C C T T T C T G A A A T T A A T A T T T A C C C T A				a909_all.seq
	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A Majority				
	2960	2970	2980	2990	3000
2948	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A				2603_all.seq
2717	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A				18rs21_all.seq
2949	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A				cohl_all.seq
2949	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A				cjb111_all.seq
2951	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A				nem316_all.seq
2950	A A A A C G T T G T A A C T G A T G A A C C A A A A A C A G A T A A A G A T G T T A A A A A A T T A				a909_all.seq
	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T Majority				
	3010	3020	3030	3040	3050
998	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T				2603_all.seq
767	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T				18rs21_all.seq
999	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T				cohl_all.seq
999	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T				cjb111_all.seq
001	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T				nem316_all.seq
000	G G T C A G G A C C A T G C A G G T T A T A C G A T T G G T G A A G A A T T C A A A T G G T T C T T				a909_all.seq
	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A Majority				
	3060	3070	3080	3090	3100
048	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A				2603_all.seq
817	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A				18rs21_all.seq
049	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A				cohl_all.seq
249	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A				cjb111_all.seq
251	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A				nem316_all.seq
250	G A A A T C T A C A A T C C C T G C C A A T T T A G G T G A C T A T G A A A A A T T T G A A A T T A				a909_all.seq
	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G Majority				
	3110	3120	3130	3140	3150
298	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G				2603_all.seq
367	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G				18rs21_all.seq
299	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G				cohl_all.seq
299	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G				cjb111_all.seq
101	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G				nem316_all.seq
100	C T G A T A A A T T T G C A G A T G G C T T G A C T T A T A A A T C T G T T G C A A A A A T C A A G				a909_all.seq

FIGURE 18 H

27/487

ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC		Majority		
3160	3170	3180	3190	3200
148	ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC	2603_all.seq		
917	ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC	18rs21_all.seq		
149	ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC	cohl1_all.seq		
149	ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC	cjb111_all.seq		
151	ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC	nem316_all.seq		
150	ATTGGTTTCGAAAACAACACTGAAATAGAGATGAGCACTACACTATTGATGAACC	a909_all.seq		
AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT		Majority		
3210	3220	3230	3240	3250
198	AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT	2603_all.seq		
967	AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT	18rs21_all.seq		
199	AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT	cohl1_all.seq		
199	AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT	cjb111_all.seq		
201	AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT	nem316_all.seq		
200	AACAGTTGATAAACC AAAATACATTAAAAATTACGTTTAAACCAGAGAAAT	a909_all.seq		
TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA		Majority		
3260	3270	3280	3290	3300
248	TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA	2603_all.seq		
217	TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA	18rs21_all.seq		
249	TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA	cohl1_all.seq		
249	TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA	cjb111_all.seq		
251	TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA	nem316_all.seq		
250	TTAAAGAAAATTGCTGAGCTACTTAAAGGAATGACCCTTGTTAAAAATCAA	a909_all.seq		
GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA		Majority		
3310	3320	3330	3340	3350
298	GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA	2603_all.seq		
267	GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA	18rs21_all.seq		
299	GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA	cohl1_all.seq		
299	GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA	cjb111_all.seq		
301	GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA	nem316_all.seq		
300	GATGCTCTTGATAAAGCTACTGCAAATACAGATGATGCCGCATTTTTTGA	a909_all.seq		
AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA		Majority		
3360	3370	3380	3390	3400
48	AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA	2603_all.seq		
17	AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA	18rs21_all.seq		
49	AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA	cohl1_all.seq		
49	AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA	cjb111_all.seq		
51	AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA	nem316_all.seq		
50	AATTCAGTTGCAATCAACTATTAATGAAAAAGCAGTTTTTAGGAAAAGCAA	a909_all.seq		
TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC		Majority		
3410	3420	3430	3440	3450
98	TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC	2603_all.seq		
67	TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC	18rs21_all.seq		
99	TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC	cohl1_all.seq		
99	TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC	cjb111_all.seq		
01	TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC	nem316_all.seq		
00	TTGAAAAATACTTTTGAACCTTCAATATGACCATACTCCTGATAAAGCTGAC	a909_all.seq		
AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG		Majority		
3460	3470	3480	3490	3500
48	AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG	2603_all.seq		
17	AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG	18rs21_all.seq		
49	AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG	cohl1_all.seq		
49	AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG	cjb111_all.seq		
51	AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG	nem316_all.seq		
50	AATCCAAAACCATCTAATCCTCCAAAGAAAACCAGAAAGTTTCATACTGGTGG	a909_all.seq		

FIGURE 18 I

28/487

	G A A A C C A A T T T G T A A A G A A A G A C T C A A C A G A A A A C A C A A A C A C T A G G T G G T G Majority				
	3510	3520	3530	3540	3550
1498	G A A A C G A T T T G T A A A G A A A G A C T C A A C A G A A A C A C A A A C A C T A G G T G G T G				2603_ail.seq
1267	C A A A C G A T T T G T A A A G A A A G A C T C A A C A G A A A C A C A A A C A C T A G G T G G T G				18rs21_ail.seq
1499	G A A A C G A T T T G T A A A G A A A G A C T C A A C A G A A A C A C A A A C A C T A G G T G G T G				cohl_ail.seq
1499	G A A A C G A T T T G T A A A G A A A G A C T C A A C A G A A A C A C A A A C A C T A G G T G G T G				cjb111_ail.seq
1501	G A A A C G A T T T G T A A A G A A A G A C T C A A C A G A A A C A C A A A C A C T A G G T G G T G				nea316_ail.seq
1500	G A A A C G A T T T G T A A A G A A A G A C T C A A C A G A A A C A C A A A C A C T A G G T G G T G				a909_ail.seq
C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T Majority					
	3560	3570	3580	3590	3600
1548	C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T				2603_ail.seq
1317	C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T				18rs21_ail.seq
1549	C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T				cohl_ail.seq
1549	C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T				cjb111_ail.seq
1551	C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T				nea316_ail.seq
1550	C T G A G T T T G A T T T G T T G G C T T C T G A T G G G A C A G C A G T A A A A T G G A C A G A T				a909_ail.seq
G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T Majority					
	3610	3620	3630	3640	3650
598	G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T				2603_ail.seq
367	G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T				18rs21_ail.seq
599	G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T				cohl_ail.seq
599	G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T				cjb111_ail.seq
601	G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T				nea316_ail.seq
600	G C T C T T A T T A A A G C C G A A T A C T A A T A A A A A C T A T A T T G C T G G A G A A G C T G T				a909_ail.seq
T A C T G G G C A A C C A A T C A A A T T C A A A T C A C A T A C A G A C G G T A C G T T T G A G A Majority					
	3660	3670	3680	3690	3700
648	T A C T G G G C A A C C A A T C A A A T T G A A A T C A C A T A C A G A C G G T A C G T T T G A G A				2603_ail.seq
417	T A C T G G G C A A C C A A T C A A A T T G A A A T C A C A T A C A G A C G G T A C G T T T G A G A				18rs21_ail.seq
649	T A C T G G G C A A C C A A T C A A A T T G A A A T C A C A T A C A G A C G G T A C G T T T G A G A				cohl_ail.seq
649	T A C T G G G C A A C C A A T C A A A T T G A A A T C A C A T A C A G A C G G T A C G T T T G A G A				cjb111_ail.seq
651	T A C T G G G C A A C C A A T C A A A T T G A A A T C A C A T A C A G A C G G T A C G T T T G A G A				nea316_ail.seq
650	T A C T G G G C A A C C A A T C A A A T T G A A A T C A C A T A C A G A C G G T A C G T T T G A G A				a909_ail.seq
T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A Majority					
	3710	3720	3730	3740	3750
598	T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A				2603_ail.seq
467	T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A				18rs21_ail.seq
599	T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A				cohl_ail.seq
599	T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A				cjb111_ail.seq
701	T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A				nea316_ail.seq
700	T T A A A G C T T T G C C T T A T G C A G T T G A T G C G A A T G C A G A G G G T A C A G C A G T A				a909_ail.seq
A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A Majority					
	3760	3770	3780	3790	3800
748	A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A				2603_ail.seq
517	A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A				18rs21_ail.seq
749	A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A				cohl_ail.seq
749	A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A				cjb111_ail.seq
751	A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A				nea316_ail.seq
750	A C T T A C A A A T T A A A A G A A A C A A A A G C A C C A G A A G G T T A T G T A A T C C C T G A				a909_ail.seq
T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A Majority					
	3810	3820	3830	3840	3850
198	T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A				2603_ail.seq
167	T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A				18rs21_ail.seq
199	T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A				cohl_ail.seq
199	T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A				cjb111_ail.seq
301	T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A				nea316_ail.seq
300	T A A A G A A A T C G A G T T T A C A G T A T C A C A A A C A T C T T A T A A A T A C A A A A C C A A				a909_ail.seq

FIGURE 18 J

29/487




FIGURE 18 K

30/487




FIGURE 18 L

31/487

WO 2006/078318

Using a trim method with Weighted residue weight table.




FIGURE 18 M




FIGURE 18 N




FIGURE 18 O

34/487

G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A Majority				
5610	5620	5630	5640	5650
598	G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A	2603_all.seq		
367	G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A	18rs21_all.seq		
599	G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A	cohl_all.seq		
599	G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A	cjb111_all.seq		
601	G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A	nen316_all.seq		
600	G G C G G A A A G A T T G C T T A T C A G G T A G A C C A A A T C A A A G T T A T C G C C C C T G A	a909_all.seq		
T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T Majority				
5660	5670	5680	5690	5700
648	T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T	2603_all.seq		
417	T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T	18rs21_all.seq		
649	T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T	cohl_all.seq		
649	T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T	cjb111_all.seq		
651	T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T	nen316_all.seq		
650	T C A G T T A G A G G A T T T G T A C G T G A T T C A A G G A G A A G A T C A C G T C A C C C T A T	a909_all.seq		
T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C Majority				
5710	5720	5730	5740	5750
698	T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C	2603_all.seq		
467	T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C	18rs21_all.seq		
699	T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C	cohl_all.seq		
699	T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C	cjb111_all.seq		
701	T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C	nen316_all.seq		
700	T A A C T T G C A C A C C T T A T A T G A T A A A T A G T C A T C G C C T C C T C G T T C G A G G C C	a909_all.seq		
A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T Majority				
5760	5770	5780	5790	5800
748	A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T	2603_all.seq		
517	A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T	18rs21_all.seq		
749	A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T	cohl_all.seq		
749	A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T	cjb111_all.seq		
751	A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T	nen316_all.seq		
750	A A G C G A A T T C C T T A T G T G G A A A A A A C A G T G C A G A A A G A T T C A A A G A C C T T	a909_all.seq		
C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A Majority				
5810	5820	5830	5840	5850
798	C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A	2603_all.seq		
567	C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A	18rs21_all.seq		
799	C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A	cohl_all.seq		
799	C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A	cjb111_all.seq		
301	C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A	nen316_all.seq		
300	C A G G C A A C A A C A A T A C C T A A C C T A T G C T A T G T G G G T A G T C G T T G G A C T T A	a909_all.seq		
T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C G C C Majority				
5860	5870	5880	5890	5900
148	T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C G G	2603_all.seq		
317	T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C G G	18rs21_all.seq		
149	T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C G G	cohl_all.seq		
149	T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C G G	cjb111_all.seq		
151	T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C C C	nen316_all.seq		
150	T C T T G C T G T C G C T T C T C A T T T G C T T T A A A A A G A C G A A A C A G A A A A A G C G C	a909_all.seq		
A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A Majority				
5910	5920	5930	5940	5950
198	A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A	2603_all.seq		
167	A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A	18rs21_all.seq		
199	A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A	cohl_all.seq		
199	A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A	cjb111_all.seq		
101	A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A	nen316_all.seq		
100	A G A A A G A A T G A A A A A G C G G C T A G T C A A A A T A G T C A C A A T A A T T C G A A A T A	a909_all.seq		

FIGURE 18 P




FIGURE 18 Q

36/487




FIGURE 18 R

37/487

A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T		Majority			
6660	6670	6680	6690	6700	
648	A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T	2603_all.seq			
647	A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T	18rs21_all.seq			
649	A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T	cohl_all.seq			
649	A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T	cjb111_all.seq			
651	A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T	nem316_all.seq			
650	A A C C C T A C A A G A T T A T C G T T T G T C A C T A G T G T T G A A G A T A C T A C T A G T A T	a909_all.seq			
T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T		Majority			
6710	6720	6730	6740	6750	
698	T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T	2603_all.seq			
667	T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T	18rs21_all.seq			
699	T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T	cohl_all.seq			
699	T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T	cjb111_all.seq			
701	T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T	nem316_all.seq			
700	T A T T A A T T G G A C T C T T C A T C G T G A T A A T G A T G A G A A G A T G G A T G C A A C A T	a909_all.seq			
C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A C T T A T C A A A T A G G T G A C T		Majority			
6760	6770	6780	6790	6800	
748	C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A T C A A A T A G G T G A C T	2603_all.seq			
517	C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A C T T A T C A A A T A G G T G A C T	18rs21_all.seq			
749	C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A C T T A T C A A A T A G G T G A C T	cohl_all.seq			
749	C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A C T T A T C A A A T A G G T G A C T	cjb111_all.seq			
751	C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A C T T A T C A A A T A G G T G A C T	nem316_all.seq			
750	C G T C A A T A A C G A T G T T G T G A A T G G C T T A C T T A C T T A T C A A A T A G G T G A C T	a909_all.seq			
A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A		Majority			
6810	6820	6830	6840	6850	
794	A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A	2603_all.seq			
567	A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A	18rs21_all.seq			
799	A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A	cohl_all.seq			
799	A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A	cjb111_all.seq			
801	A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A	nem316_all.seq			
800	A A T G A T G A T T G T G A A T A A T G G T T A T C T A G A A G G G A G A A A A A T G A A A A A G A	a909_all.seq			
G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A		Majority			
6860	6870	6880	6890	6900	
844	G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A	2603_all.seq			
317	G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A	18rs21_all.seq			
349	G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A	cohl_all.seq			
349	G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A	cjb111_all.seq			
351	G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A	nem316_all.seq			
350	G A C A A A A A A T A T G G A G A G G G T T A T C A G T T A C T T T A C T A A T C C T G T C C C A A	a909_all.seq			
A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C		Majority			
6910	6920	6930	6940	6950	
894	A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C	2603_all.seq			
867	A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C	18rs21_all.seq			
899	A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C	cohl_all.seq			
899	A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C	cjb111_all.seq			
901	A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C	nem316_all.seq			
900	A T T C C A T T T G G T A T A T T G G T A C A A G G T G A A A C C C A A G A T A C C A A T C A A G C	a909_all.seq			
A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G		Majority			
6960	6970	6980	6990	7000	
844	A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G	2603_all.seq			
817	A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G	18rs21_all.seq			
849	A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G	cohl_all.seq			
849	A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G	cjb111_all.seq			
851	A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G	nem316_all.seq			
850	A C T T G G A A A A G T A A T T G T T A A A A A A A C G G G A G A C A A T G C T A C A C C A T T A G	a909_all.seq			

FIGURE 18 S

38/487

Alignment Report of A1-1 alignment, using J. Hein method with Weighted residue weight table.
Thursday, July 29, 2004 5:46 PM




FIGURE 18 T

39/487




FIGURE 18 U

40/487




FIGURE 18 V

41/487

A A A A C C A G G T T T A A T T C T T T T T T T A A A T A A A A T A C C A G A T A G A A G T G G T A T T Majority				
8060	8070	8080	8090	8100
1044	A A A A C C A G T T T A A T T C T T T T T T A A A T A A A A T A C C A G A T A G A A G T G G T A T T	2603_ail.seq		
1817	A A A A C C A G T T T A A T T C T T T T T T A A A T A A A A T A C C A G A T A G A A G T G G T A T T	18rs21_ail.seq		
1049	A A A A C C A G T T T A A T T C T T T T T T A A A T A A A A T A C C A G A T A G A A G T G G T A T T	coh1_ail.seq		
1051	A A A A C C A G T T T A A T T C T T T T T T A A A T A A A A T A C C A G A T A G A A G T G G T A T T	cjb111_ail.seq		
1050	A A A A C C A G T T T A A T T C T T T T T T A A A T A A A A T A C C A G A T A G A A G T G G T A T T	nem316_ail.seq		
	a909_ail.seq			
C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G Majority				
8110	8120	8130	8140	8150
1094	C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G	2603_ail.seq		
1867	C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G	18rs21_ail.seq		
1099	C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G	coh1_ail.seq		
1099	C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G	cjb111_ail.seq		
1101	C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G	nem316_ail.seq		
1100	C T C C A A G A G G A T T T T A T A A T C A A T G G T G A T G A T T A T C A A A T A G T A A A A G G	a909_ail.seq		
A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G Majority				
8160	8170	8180	8190	8200
1144	A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G	2603_ail.seq		
1917	A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G	18rs21_ail.seq		
1149	A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G	coh1_ail.seq		
1149	A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G	cjb111_ail.seq		
1151	A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G	nem316_ail.seq		
1150	A G A T G G A G A G A G T T T T A A A C T G T T T T C G G A T A G A A A A G T T C C T G T T A C T G	a909_ail.seq		
G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A Majority				
8210	8220	8230	8240	8250
194	G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A	2603_ail.seq		
967	G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A	18rs21_ail.seq		
199	G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A	coh1_ail.seq		
199	G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A	cjb111_ail.seq		
201	G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A	nem316_ail.seq		
200	G A G G A A C G A C A C A A G C A G C T T A T C G A G T A C C G C A A A A T C A A C T C T C T G T A	a909_ail.seq		
A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G Majority				
8260	8270	8280	8290	8300
244	A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G	2603_ail.seq		
017	A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G	18rs21_ail.seq		
249	A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G	coh1_ail.seq		
249	A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G	cjb111_ail.seq		
251	A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G	nem316_ail.seq		
250	A T G A G T A A T G A G G G A T A T G C A A T T A A T A G T G G A T A T A T T T A T C T C T A T T G	a909_ail.seq		
G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T Majority				
8310	8320	8330	8340	8350
294	G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T	2603_ail.seq		
067	G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T	18rs21_ail.seq		
299	G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T	coh1_ail.seq		
299	G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T	cjb111_ail.seq		
301	G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T	nem316_ail.seq		
300	G A G A G A T T A C A A C T G G G T C T A T C C A T T T G A T C C T A A G A C A A A G A A A G T T T	a909_ail.seq		
C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T Majority				
8360	8370	8380	8390	8400
344	C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T	2603_ail.seq		
117	C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T	18rs21_ail.seq		
349	C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T	coh1_ail.seq		
349	C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T	cjb111_ail.seq		
351	C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T	nem316_ail.seq		
350	C T G C A A C G A A A C A A A T C A A A A C T C A T G T G A G C C A A C A A C A T T A T A C T T T	a909_ail.seq		

FIGURE 18 W

42/487

	8410	8420	8430	8440	8450	Majority
	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					
8394	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					2603_all.seq
8167	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					18rs21_all.seq
8399	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					cohl_all.seq
8399	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					cjb111_all.seq
8401	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					nea316_all.seq
8400	A A T G C G A A A T A T A A G A C C T A A A G G T T A T G A C A T T T T T A C T G T T G G G A T T G G					a909_all.seq
	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					Majority
	8460	8470	8480	8490	8500	
8444	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					2603_all.seq
8217	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					18rs21_all.seq
8449	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					cohl_all.seq
8449	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					cjb111_all.seq
8451	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					nea316_all.seq
8450	T G T A A A C G G A G A T C C T G G T G C A A C T C C T C T T G A A G C T G A G A A A T T T A T G C					a909_all.seq
	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					Majority
	8510	8520	8530	8540	8550	
8494	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					2603_all.seq
8267	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					18rs21_all.seq
8499	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					cohl_all.seq
8499	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					cjb111_all.seq
8501	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					nea316_all.seq
8500	A A T C A A T A T C A A G T A A A A C A G A A A A T T A T A C T A A T G T T G A T G A T A C A A A T					a909_all.seq
	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					Majority
	8560	8570	8580	8590	8600	
8544	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					2603_all.seq
8317	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					18rs21_all.seq
8549	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					cohl_all.seq
8549	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					cjb111_all.seq
8551	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					nea316_all.seq
8550	A A A A T T T A T G A T G A G C T A A A T A A A T A C T T T A A A A C A A T T G T T G A G G A A A A					a909_all.seq
	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					Majority
	8610	8620	8630	8640	8650	
8594	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					2603_all.seq
8367	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					18rs21_all.seq
8599	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					cohl_all.seq
8599	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					cjb111_all.seq
8601	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					nea316_all.seq
8600	A C A T T C T A T T C T T G A T G C A A A T G T G A C T G A T C C T A T G G G A G A G A T G A T T G					a909_all.seq
	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					Majority
	8660	8670	8680	8690	8700	
8644	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					2603_all.seq
8417	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					18rs21_all.seq
8649	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					cohl_all.seq
8649	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					cjb111_all.seq
8651	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					nea316_all.seq
8650	A A T T C C A A T T A A A A A T G G T C A A A G T T T T A C A C A T G A T G A T T A C G T T T T G					a909_all.seq
	G T T G G A A A T G A T G C C A C T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					Majority
	8710	8720	8730	8740	8750	
8694	G T T G G A A A T G A T G C C A C T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					2603_all.seq
8467	G T T G G A A A T G A T G C C A G T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					18rs21_all.seq
8699	G T T G G A A A T G A T G C C A G T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					cohl_all.seq
8699	G T T G G A A A T G A T G C C A G T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					cjb111_all.seq
701	G T T G G A A A T G A T G C C A G T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					nea316_all.seq
700	G T T G G A A A T G A T G C C A G T C A A T T A A A A A T G G T G T G C C T C T T G G T G G A C C					a909_all.seq

FIGURE 18 X

43/487




FIGURE 18 Y

44/487

	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T C T G G G T A T A A G C A A T T T G T T Majority				
	9110	9120	9130	9140	9150
9094	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T T C T G G G T A T A A G C A A T T T G T T				
8867	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T T C T G G G T A T A A G C A A T T T G T T				2603_all.seq
9099	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T T C T G G G T A T A A G C A A T T T G T T				18rs21_all.seq
9099	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T T C T G G G T A T A A G C A A T T T G T T				cohl_all.seq
9101	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T T C T G G G T A T A A G C A A T T T G T T				cjb111_all.seq
9100	A G T T T C A A C T T C A G A T A G A A A A A G A T T T T T C T G G G T A T A A G C A A T T T G T T				nean316_all.seq
					a909_all.seq
C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A Majority					
	9160	9170	9180	9190	9200
9144	C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A				2603_all.seq
8917	C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A				18rs21_all.seq
9149	C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A				cohl_all.seq
9149	C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A				cjb111_all.seq
9151	C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A				nean316_all.seq
9150	C C A G A G G G A A G T G A T G T T A C A A C A A G A A T G A T G G T A A A A T T T A T T T T A A				a909_all.seq
A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C Majority					
	9210	9220	9230	9240	9250
9194	A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C				2603_all.seq
3967	A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C				18rs21_all.seq
9199	A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C				cohl_all.seq
9199	A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C				cjb111_all.seq
9201	A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C				nean316_all.seq
9200	A G C A C T T C A A G A T G G T A A C T A T A A A T T A T A T G A A A T T T C A A G T C C A G A T C				a909_all.seq
G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T Majority					
	9260	9270	9280	9290	9300
9244	G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T				2603_all.seq
9017	G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T				18rs21_all.seq
9249	G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T				cohl_all.seq
9249	G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T				cjb111_all.seq
9251	G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T				nean316_all.seq
9250	G C T A T A T A G A G G T T A A A A C G A A A C C T G T T G T G A C A T T T A C A A T T C A A A A T				a909_all.seq
G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T Majority					
	9310	9320	9330	9340	9350
294	G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T				2603_all.seq
067	G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T				18rs21_all.seq
299	G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T				cohl_all.seq
299	G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T				cjb111_all.seq
301	G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T				nean316_all.seq
300	G G A C A A G T T A C G A A C C T G A A A G C A G A T C C A A A T G C T A A T A A A A A T C A A A T				a909_all.seq
C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C Majority					
	9360	9370	9380	9390	9400
344	C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C				2603_all.seq
117	C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C				18rs21_all.seq
349	C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C				cohl_all.seq
349	C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C				cjb111_all.seq
351	C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C				nean316_all.seq
350	C G G G T A T C T T G A A G G A A A T G G T A A A C A T C T T A T T A C C A A C A C T C C C A A A C				a909_all.seq
G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T Majority					
	9410	9420	9430	9440	9450
394	G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T				2603_all.seq
167	G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T				18rs21_all.seq
399	G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T				cohl_all.seq
399	G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T				cjb111_all.seq
401	G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T				nean316_all.seq
400	G C C C A C C A G G T G T T T T T C C T A A A A C A G G G G C A A T T G G T A C A A T T G T C T A T				a909_all.seq

FIGURE 18 Z

45/487




FIGURE 18 AA

46/487

Alignment Report of AI-1 alignment, using J. Hein method with Weighted residue weight table.
Thursday, July 29, 2004 5:46 PM

G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A Majority				
9810	9820	9830	9840	9850
1794	G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A	2603_ail.seq		
1567	G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A	18rs21_ail.seq		
1799	G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A	cohl_ail.seq		
1799	G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A	cjb111_ail.seq		
1801	G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A	nem316_ail.seq		
1800	G A G A G C A G G T T G A C C A T G T G A T G A T T C C A A A A A T C A A T C A G G A T T T A C C A	a909_ail.seq		
A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T Majority				
9860	9870	9880	9890	9900
1844	A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T	2603_ail.seq		
1617	A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T	18rs21_ail.seq		
1849	A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T	cohl_ail.seq		
1849	A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T	cjb111_ail.seq		
1851	A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T	nem316_ail.seq		
1850	A T C T A C G C T G G T T C A G A A G A G G A C A A T C T G C A A C G G G G A G T T G G T C A T C T	a909_ail.seq		
A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A Majority				
9910	9920	9930	9940	9950
894	A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A	2603_ail.seq		
667	A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A	18rs21_ail.seq		
899	A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A	cohl_ail.seq		
899	A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A	cjb111_ail.seq		
901	A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A	nem316_ail.seq		
900	A G A A G G G A T A A G T T T G C C G A T T G G A G G G G C T T C T A C A C A T G C G G T C T T G A	a909_ail.seq		
G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G Majority				
9960	9970	9980	9990	10000
944	G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G	2603_ail.seq		
717	G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G	18rs21_ail.seq		
949	G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G	cohl_ail.seq		
949	G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G	cjb111_ail.seq		
951	G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G	nem316_ail.seq		
950	G C C G T C A A A G A G G T A T G C C A G C T G C T C G G T T G T T T G C G G A T T T G G A T A A G	a909_ail.seq		
A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C Majority				
10010	10020	10030	10040	10050
994	A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C	2603_ail.seq		
767	A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C	18rs21_ail.seq		
999	A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C	cohl_ail.seq		
999	A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C	cjb111_ail.seq		
0001	A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C	nem316_ail.seq		
0000	A T G A A A A A A G G T G A T T A T T T T A T G T T A C C A A T C T G A A A G A A A C C T T G G C	a909_ail.seq		
T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G Majority				
10060	10070	10080	10090	10100
0044	T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G	2603_ail.seq		
817	T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G	18rs21_ail.seq		
0049	T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G	cohl_ail.seq		
0049	T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G	cjb111_ail.seq		
0051	T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G	nem316_ail.seq		
0050	T T A T C A A G T G G A T C C T A T C A T G G T G A T T G A A C C T A G C C A A T T G G A T G C C G	a909_ail.seq		
T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T Majority				
10110	10120	10130	10140	10150
0094	T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T	2603_ail.seq		
867	T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T	18rs21_ail.seq		
0099	T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T	cohl_ail.seq		
0099	T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T	cjb111_ail.seq		
0101	T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T	nem316_ail.seq		
0100	T C A G C A T T G A A G A G G A T A A A G A T T A T G T T A C C C T T C T G A C C T G T A C A C C T	a909_ail.seq		

FIGURE 18 AB

47/487




FIGURE 18 AC

T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A		Majority			
10510	10520	10530	10540	10550	
10494	T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A	2603_all.seq			
10267	T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A	18rs21_all.seq			
10499	T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A	cohl_all.seq			
10499	T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A	cjb111_all.seq			
10501	T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A	nea316_all.seq			
10500	T A A A G G T C G G T T A T A A T A G C G G A G C T C A T C T G A G A A A A C T T T T A T A C C T C A	a909_all.seq			
A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C		Majority			
10560	10570	10580	10590	10600	
10544	A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C	2603_all.seq			
10317	A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C	18rs21_all.seq			
10549	A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C	cohl_all.seq			
10549	A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C	cjb111_all.seq			
10551	A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C	nea316_all.seq			
10550	A A G T C A G T C T A G C T T T G A T A T C A T G A A G C C A T T A G G A G T T A T T C C T T A T C	a909_all.seq			
T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A		Majority			
10610	10620	10630	10640	10650	
10594	T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A	2603_all.seq			
10367	T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A	18rs21_all.seq			
10599	T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A	cohl_all.seq			
10599	T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A	cjb111_all.seq			
10601	T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A	nea316_all.seq			
10600	T T T T A G T G G C C G C G A T C C A T A T A G T G A T A G A T C G A G A T A T T T A G A T C C A	a909_all.seq			
A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A		Majority			
10660	10670	10680	10690	10700	
10644	A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A	2603_all.seq			
10417	A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A	18rs21_all.seq			
10649	A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A	cohl_all.seq			
10649	A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A	cjb111_all.seq			
10651	A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A	nea316_all.seq			
10650	A A A G T T C T A T C A T C C T C T T T T G G C G C C T T T T T T C C A G C A G A T A A T A T T A A	a909_all.seq			
G G T A G C T T G G T C T A A C A A C T C C A G C A G T T T A T T T A C A C C A C C T A T T A A T G		Majority			
10710	10720	10730	10740	10750	
0694	G G T A G C T T G G T C T A A C A A C T C C A G C A G T T T A T T T A C A C C A C C T A T T A A T G	2603_all.seq			
0467	G G T A G C T T G G T C T A A C A A C T C C A G C A C T T T A T T T A C A C C A C C T A T T A A T G	18rs21_all.seq			
0699	G G T A G C T T G G T C T A A C A A C T C C A G C A C T T T A T T T A C A C C A C C T A T T A A T G	cohl_all.seq			
0699	G G T A G C T T G G T C T A A C A A C T C C A G C A C T T T A T T T A C A C C A C C T A T T A A T G	cjb111_all.seq			
0701	G G T A G C T T G G T C T A A C A A C T C C A G C A C T T T A T T T A C A C C A C C T A T T A A T G	nea316_all.seq			
0700	G G T A G C T T G G T C T A A C A A C T C C A G C A C T T T A T T T A C A C C A C C T A T T A A T G	a909_all.seq			
C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A		Majority			
10760	10770	10780	10790	10800	
0744	C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A	2603_all.seq			
0517	C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A	18rs21_all.seq			
0749	C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A	cohl_all.seq			
0749	C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A	cjb111_all.seq			
0751	C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A	nea316_all.seq			
0750	C A A A C T A C A C C A C T C A G A T T C A A G C T A T T C G G A C A A C G A T T A A G T C A C A A	a909_all.seq			
A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G		Majority			
10810	10820	10830	10840	10850	
0794	A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G	2603_all.seq			
0567	A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G	18rs21_all.seq			
0799	A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G	cohl_all.seq			
0799	A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G	cjb111_all.seq			
0801	A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G	nea316_all.seq			
0800	A T T C C G G A A T C G A T T T T G A C G G T T A C C G A T A A A A A G A G C A G G A A G T T C A G	a909_all.seq			

FIGURE 18 AD

49/487

C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A Majority					
10844	10860	10870	10880	10890	10900
10844	C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A				2603_all.seq
10617	C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A				18rs21_all.seq
10849	C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A				coh1_all.seq
10849	C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A				cjb111_all.seq
10851	C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A				nen316_all.seq
10850	C A T T A A C A A G A T T G A C G A A G C T A A A G A A G G C T T A G T A G G T G C G A C C T T C A				a909_all.seq
C C T T G T C T A A A C G C A C A A C A G T A G C G G C A G A T C A T C A A G T A C A A G G A G A T Majority					
10910	10920	10930	10940	10950	
10894	C C T T G T C T A A A C G C A C A A C A G T A G C G G C A G A T C A T C A A G T A C A A G G A G A T				2603_all.seq
10667	C C T T G T C T A A A C G C A C A A C A C T A G C G G C A G A T C A T C A A G T A C A A G G A G A T				18rs21_all.seq
10899	C C T T G T C T A A A C G C A C A A C A G T A G C G G C A G A T C A T C A A G T A C A A G G A G A T				coh1_all.seq
10899	C C T T G T C T A A A C G C A C A A C A G T A G C G G C A G A T C A T C A A G T A C A A G G A G A T				cjb111_all.seq
10901	C C T T G T C T A A A C G C A C A A C A C T A G C G G C A G A T C A T C A A G T A C A A G G A G A T				nen316_all.seq
10900	C C T T G T C T A A A C G C A C A A C A G T A G C G G C A G A T C A T C A A G T A C A A G G A G A T				a909_all.seq
T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T Majority					
10960	10970	10980	10990	11000	
10944	T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T				2603_all.seq
10717	T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T				18rs21_all.seq
10949	T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T				coh1_all.seq
10949	T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T				cjb111_all.seq
10951	T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T				nen316_all.seq
10950	T T C A T T C C T G T C A G C A A A G A G A C G A C A G T C G G T C G G A C A A C C C T T A C C T T				a909_all.seq
T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A Majority					
11010	11020	11030	11040	11050	
0994	T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A				2603_all.seq
0767	T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A				18rs21_all.seq
0999	T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A				coh1_all.seq
0999	T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A				cjb111_all.seq
1001	T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A				nen316_all.seq
1000	T G A C A A C C T T A A A C C T G G A T T T T A T G A C C T T A A A G A A A C G A A A G C G C C G A				a909_all.seq
A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A Majority					
11060	11070	11080	11090	11100	
1044	A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A				2603_all.seq
3817	A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A				18rs21_all.seq
1049	A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A				coh1_all.seq
1049	A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A				cjb111_all.seq
1051	A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A				nen316_all.seq
1050	A T G C T T A C G T A C T T G A T C C T A A G A C T T A T G T T G T G G T C G T T C A A A A T T C A				a909_all.seq
G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C Majority					
11110	11120	11130	11140	11150	
1094	G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C				2603_all.seq
1867	G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C				18rs21_all.seq
1099	G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C				coh1_all.seq
1099	G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C				cjb111_all.seq
1101	G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C				nen316_all.seq
1100	G G A A A A A C G A C A A T T G T G G A T G A A G C T A A C T T C A A A G A G G C T G A T T A C C C				a909_all.seq
A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A Majority					
11160	11170	11180	11190	11200	
144	A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A				2603_all.seq
917	A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A				18rs21_all.seq
149	A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A				coh1_all.seq
149	A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A				cjb111_all.seq
151	A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A				nen316_all.seq
150	A A T G C C T G A T A A T A C C A G C C A T G T G G A G T G C G T A G C C T T G C T A C A A C G A A				a909_all.seq

FIGURE 18 AE

50/487

G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T Majority					
11210	11220	11230	11240	11250	
11194	G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T				2603_all.seq
10967	G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T				18rs21_all.seq
11199	G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T				coh1_all.seq
11199	G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T				cjb111_all.seq
11201	G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T				nea316_all.seq
11200	G C A A A G G G T A A A A A T C C T T T A T T T T A A G C A C T T T T T C A A G C A T T T T G T C T				a909_all.seq
T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G Majority					
11260	11270	11280	11290	11300	
11244	T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G				2603_all.seq
11017	T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G				18rs21_all.seq
11249	T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G				coh1_all.seq
11249	T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G				cjb111_all.seq
11251	T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G				nea316_all.seq
11250	T T A T T G A A A A G A G T G A T T T T A A C A T A A A A A A G G T A T T A A A A A C A T A T T G				a909_all.seq
A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G Majority					
11310	11320	11330	11340	11350	
11294	A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G				2603_all.seq
11067	A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G				18rs21_all.seq
11299	A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G				coh1_all.seq
11299	A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G				cjb111_all.seq
11301	A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G				nea316_all.seq
11300	A C C T G A C C G T T T G T T T T G A A G T G G C T T G C G T A G A C A A A A A A T A G A T A C G				a909_all.seq
T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T Majority					
11360	11370	11380	11390	11400	
11344	T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T				2603_all.seq
11117	T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T				18rs21_all.seq
11349	T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T				coh1_all.seq
11349	T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T				cjb111_all.seq
11351	T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T				nea316_all.seq
11350	T C A G A T A A A T T T C T G G C A T T A C G A G A A C A T T T T T A G A G T G T T C T C T T T T				a909_all.seq
T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T Majority					
11410	11420	11430	11440	11450	
1394	T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T				2603_all.seq
1167	T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T				18rs21_all.seq
1399	T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T				coh1_all.seq
1399	T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T				cjb111_all.seq
1401	T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T				nea316_all.seq
1400	T T A G T T T A C G G A G G A A A A T A T A T A T G G A A A A C A G G A T T C A C G A G T T C T				a909_all.seq
C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A Majority					
11460	11470	11480	11490	11500	
1444	C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A				2603_all.seq
1217	C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A				18rs21_all.seq
1449	C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A				coh1_all.seq
1449	C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A				cjb111_all.seq
1451	C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A				nea316_all.seq
1450	C A T C C A T T G G G A G G G G A A T T C T G G G G A C A A G C T C A T T G A A C A C C A A A C C A				a909_all.seq
G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A Majority					
11510	11520	11530	11540	11550	
1494	G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A				2603_all.seq
1267	G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A				18rs21_all.seq
1499	G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A				coh1_all.seq
1499	G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A				cjb111_all.seq
1501	G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A				nea316_all.seq
1500	G C C C A A C G G G G T G G T A C T A C C A A G T C G A T C G T A G C T T T A G T C A A C C A A A A				a909_all.seq

FIGURE 18 AF

51/487




FIGURE 18 AG




FIGURE 18 AH

53/487




FIGURE 18 AI

54/487




FIGURE 18 AJ

55/487

WO 2006/078318

PCT/US2005/027239

Alignment Report of AI-1 alignment, using J. Hein method with Weighted residue weight table.
Thursday, July 29, 2004 5:46 PM

Page 38

	12960	12970	12980	12990	13000	Majority																																										
	C T A A G A A T G A T G A A G A C C C T C G T A T T G A A G A A G A A G T T G A G C A G C T A G A A																																															
12944	C	T	A	A	G	A	A	T	G	A	T	G	A	A	G	A	C	C	C	T	C	G	T	A	T	T	G	A	A	G	A	A	G	T	T	G	A	G	C	A	G	C	T	A	G	A	A	2603_all.seq
12717	C	T	A	A	G	A	A	T	G	A	T	G	A	A	G	A	C	C	C	T	C	G	T	A	T	T	G	A	A	G	A	A	G	T	T	G	A	G	C	A	G	C	T	A	G	A	A	18rs21_all.seq
12949	C	T	A	A	G	A	A	T	G	A	T	G	A	A	G	A	C	C	C	T	C	G	T	A	T	T	G	A	A	G	A	A	G	T	T	G	A	G	C	A	G	C	T	A	G	A	A	cohl_all.seq
12949	C	T	A	A	G	A	A	T	G	A	T	G	A	A	G	A	C	C	C	T	C	G	T	A	T	T	G	A	A	G	A	A	G	T	T	G	A	G	C	A	G	C	T	A	G	A	A	cjb111_all.seq
12951	C	T	A	A	G	A	A	T	G	A	T	G	A	A	G	A	C	C	C	T	C	G	T	A	T	T	G	A	A	G	A	A	G	T	T	G	A	G	C	A	G	C	T	A	G	A	A	nem316_all.seq
12950	C	T	A	A	G	A	A	T	G	A	T	G	A	A	G	A	C	C	C	T	C	G	T	A	T	T	G	A	A	G	A	A	G	T	T	G	A	G	C	A	G	C	T	A	G	A	A	a909_all.seq

G A T A A G A T

Majority

12994	G	A	T	A	A	G	A	T
12767	G	A	T	A	A	G	A	T
12999	G	A	T	A	A	G	A	T
12999	G	A						
13000	G	A						
13000	G	A	T	A	A	G	A	T

- 2603_all.seq
- 18rs21_all.seq
- cohl_all.seq
- cjb111_all.seq
- nem316_all.seq
- a909_all.seq

Decoration *Decoration #1*: Shade (with solid black) residues that differ from the Consensus.

FIGURE 18 AK

	GGCCTTGTTCGGATGTTGATCCGGATAACTCCTGGCTCATTAAATAGCCTG	Majority
	10 20 30 40 50	
1	GGCCTTGTTCGGATGTTGATCCGGATAACTCCTGGCTCATTAAATAGCCTG	2603_ai2.seq
1	GGCCTTGTTCGGATGTTGATCCGGATAACTCCTGGCTCATTAAATAGCCTG	18rs21_ai2.seq
1	GGCCTTGTTCGGATGTTGATCCGGATAACTCCTGGCTCATTAAATAGCCTG	515_ai2.seq
1	GGCCTTGTTCGGATGTTGATCCGGATAACTCCTGGCTCATTAAATAGCCTG	cjb111_ai2.seq
1	GGCCTTGTTCGGATGTTGATCCGGATAACTCCTGGCTCATTAAATAGCCTG	h36b_ai2.seq
	TTTCGTAACGCTCTTTAATTATCTCTAACTTAGCATGGGTATTGGTAAAAAT	Majority
	60 70 80 90 100	
51	TTTCGTAACGCTCTTTAATTATCTCTAACTTAGCATGGGTATTGGTAAAAAT	2603_ai2.seq
51	TTTCGTAACGCTCTTTAATTATCTCTAACTTAGCATGGGTATTGGTAAAAAT	18rs21_ai2.seq
51	TTTCGTAACGCTCTTTAATTATCTCTAACTTAGCATGGGTATTGGTAAAAAT	515_ai2.seq
51	TTTCGTAACGCTCTTTAATTATCTCTAACTTAGCATGGGTATTGGTAAAAAT	cjb111_ai2.seq
51	TTTCGTAACGCTCTTTAATTATCTCTAACTTAGCATGGGTATTGGTAAAAAT	h36b_ai2.seq
	TTTGAAAAATAGACTAAGTATTTATTAACCTCAGGCCACTTTCTATGCATG	Majority
	110 120 130 140 150	
101	TTTGAAAAATAGACTAAGTATTTATTAACCTCAGGCCACTTTCTATGCATG	2603_ai2.seq
101	TTTGAAAAATAGACTAAGTATTTATTAACCTCAGGCCACTTTCTATGCATG	18rs21_ai2.seq
101	TTTGAAAAATAGACTAAGTATTTATTAACCTCAGGCCACTTTCTATGCATG	515_ai2.seq
101	TTTGAAAAATAGACTAAGTATTTATTAACCTCAGGCCACTTTCTATGCATG	cjb111_ai2.seq
101	TTTGAAAAATAGACTAAGTATTTATTAACCTCAGGCCACTTTCTATGCATG	h36b_ai2.seq
	AAATCAATTTCTTTATAGAATTTGTTACGGAATAGGAGCTTCTGGAGCAAAC	Majority
	160 170 180 190 200	
151	AAATCAATTTCTTTATAGAATTTGTTACGGAATAGGAGCTTCTGGAGCAAAC	2603_ai2.seq
151	AAATCAATTTCTTTATAGAATTTGTTACGGAATAGGAGCTTCTGGAGCAAAC	18rs21_ai2.seq
151	AAATCAATTTCTTTATAGAATTTGTTACGGAATAGGAGCTTCTGGAGCAAAC	515_ai2.seq
151	AAATCAATTTCTTTATAGAATTTGTTACGGAATAGGAGCTTCTGGAGCAAAC	cjb111_ai2.seq
151	AAATCAATTTCTTTATAGAATTTGTTACGGAATAGGAGCTTCTGGAGCAAAC	h36b_ai2.seq
	TATAGCATCCCTGAAACCAAAAAGTGCACCCCTCCTCTAG	Majority
	210 220 230 240 250	
201	TATAGCATCCCTGAAACCAAAAAGTGCACCCCTCCTCTAG	2603_ai2.seq
201	TATAGCATCCCTGAAACCAAAAAGTGCACCCCTCCTCTAG	18rs21_ai2.seq
201	TATAGCATCCCTGAAACCAAAAAGTGCACCCCTCCTCTAG	515_ai2.seq
201	TATAGCATCCCTGAAACCAAAAAGTGCACCCCTCCTCTAG	cjb111_ai2.seq
201	TATAGCATCCCTGAAACCAAAAAGTGCACCCCTCCTCTAG	h36b_ai2.seq
	CAACTGTTCCGTCTCTGTTAGGACAGTCAAAAACCAGCATCTATAGGTAAT	Majority
	260 270 280 290 300	
251	CAACTGTTCCGTCTCTGTTAGGACAGTCAAAAACCAGCATCTATAGGTAAT	2603_ai2.seq
251	CAACTGTTCCGTCTCTGTTAGGACAGTCAAAAACCAGCATCTATAGGTAAT	18rs21_ai2.seq
251	CAACTGTTCCGTCTCTGTTAGGACAGTCAAAAACCAGCATCTATAGGTAAT	515_ai2.seq
251	CAACTGTTCCGTCTCTGTTAGGACAGTCAAAAACCAGCATCTATAGGTAAT	cjb111_ai2.seq
251	CAACTGTTCCGTCTCTGTTAGGACAGTCAAAAACCAGCATCTATAGGTAAT	h36b_ai2.seq
	TTAAATATTTTTTCTCCAAAGAGTCTCCGATAATAATCATTAAATCGCACG	Majority
	310 320 330 340 350	
301	TTAAATATTTTTTCTCCAAAGAGTCTCCGATAATAATCATTAAATCGCACG	2603_ai2.seq
301	TTAAATATTTTTTCTCCAAAGAGTCTCCGATAATAATCATTAAATCGCACG	18rs21_ai2.seq
301	TTAAATATTTTTTCTCCAAAGAGTCTCCGATAATAATCATTAAATCGCACG	515_ai2.seq
301	TTAAATATTTTTTCTCCAAAGAGTCTCCGATAATAATCATTAAATCGCACG	cjb111_ai2.seq
301	TTAAATATTTTTTCTCCAAAGAGTCTCCGATAATAATCATTAAATCGCACG	h36b_ai2.seq
	ATAACGTTTTTTCATAGGATAAATTGTATCACAATTTTAACTAAAATAAAC	Majority
	360 370 380 390 400	
351	ATAACGTTTTTTCATAGGATAAATTGTATCACAATTTTAACTAAAATAAAC	2603_ai2.seq
351	ATAACGTTTTTTCATAGGATAAATTGTATCACAATTTTAACTAAAATAAAC	18rs21_ai2.seq
351	ATAACGTTTTTTCATAGGATAAATTGTATCACAATTTTAACTAAAATAAAC	515_ai2.seq
351	ATAACGTTTTTTCATAGGATAAATTGTATCACAATTTTAACTAAAATAAAC	cjb111_ai2.seq
351	ATAACGTTTTTTCATAGGATAAATTGTATCACAATTTTAACTAAAATAAAC	h36b_ai2.seq
	TCACTACTACAATAAAAACCTAAAAAAGATTGGAACGTCAGTTAGTCCCAAT	Majority
	410 420 430 440 450	
401	TCACTACTACAATAAAAACCTAAAAAAGATTGGAACGTCAGTTAGTCCCAAT	2603_ai2.seq
401	TCACTACTACAATAAAAACCTAAAAAAGATTGGAACGTCAGTTAGTCCCAAT	18rs21_ai2.seq
401	TCACTACTACAATAAAAACCTAAAAAAGATTGGAACGTCAGTTAGTCCCAAT	515_ai2.seq
401	TCACTACTACAATAAAAACCTAAAAAAGATTGGAACGTCAGTTAGTCCCAAT	cjb111_ai2.seq
401	TCACTACTACAATAAAAACCTAAAAAAGATTGGAACGTCAGTTAGTCCCAAT	h36b_ai2.seq

Figure 19

57/487




FIGURE 19A




FIGURE 19B




FIGURE 19C

60/487




FIGURE 19D

61/487




FIGURE 19E

63/487




FIGURE 19G

64/487




FIGURE 19H




FIGURE 19I




FIGURE 19J

67/487




FIGURE 19K

68/487




FIGURE 19L

69/487




FIGURE 19M

70/487




FIGURE 19N

71/487




FIGURE 190

72/487

	7210	7220	7230	7240	7250	Majority
	TTGGTGGAAATATGCGTGTGGTAATTAATAATGCTTGTACACCTTCCTCATGA					
7152	TTGGTGGAAATATGCGTGTGGTAATTAATAATGCTTGTACACCTTCCTCATGA					2603_a12.seq
7152	TTGGTGGAAATATGCGTGTGGTAATTAATAATGCTTGTACACCTTCCTCATGA					18rs21_a12.seq
7060	TTGGTGGAAATATGCGTGTGGTAATTAATAATGCTTGTACACCTTCCTCATGA					515_a12.seq
7049	TTGGTGGAAATATGCGTGTGGTAATTAATAATGCTTGTACACCTTCCTCATGA					cjb111_a12.seq
7102	TTGGTGGAAATATGCGTGTGGTAATTAATAATGCTTGTACACCTTCCTCATGA					h36b_a12.seq
	TATTCAGAAATCTGTTTATTAACAGCTATTATATTTTTTATCGATCCTTT					Majority
	7260	7270	7280	7290	7300	
7202	TATTCAGAAATCTGTTTATTAACAGCTATTATATTTTTTATCGATCCTTT					2603_a12.seq
7202	TATTCAGAAATCTGTTTATTAACAGCTATTATATTTTTTATCGATCCTTT					18rs21_a12.seq
7110	TATTCAGAAATCTGTTTATTAACAGCTATTATATTTTTTATCGATCCTTT					515_a12.seq
7099	TATTCAGAAATCTGTTTATTAACAGCTATTATATTTTTTATCGATCCTTT					cjb111_a12.seq
7152	TATTCAGAAATCTGTTTATTAACAGCTATTATATTTTTTATCGATCCTTT					h36b_a12.seq
	AACCACTTCAAAAAGTTAAAATTGGTTTATTAGTAATTTTTTGATAATCCT					Majority
	7310	7320	7330	7340	7350	
7252	AACCACTTCAAAAAGTTAAAATTGGTTTATTAGTAATTTTTTGATAATCCT					2603_a12.seq
7252	AACCACTTCAAAAAGTTAAAATTGGTTTATTAGTAATTTTTTGATAATCCT					18rs21_a12.seq
7160	AACCACTTCAAAAAGTTAAAATTGGTTTATTAGTAATTTTTTGATAATCCT					515_a12.seq
7149	AACCACTTCAAAAAGTTAAAATTGGTTTATTAGTAATTTTTTGATAATCCT					cjb111_a12.seq
7202	AACCACTTCAAAAAGTTAAAATTGGTTTATTAGTAATTTTTTGATAATCCT					h36b_a12.seq
	CCGGCGAAACTGCTTCTATTAACCTGATATTTGCCATCTTTCAAAATCCTTG					Majority
	7360	7370	7380	7390	7400	
7302	CCGGCGAAACTGCTTCTATTAACCTGATATTTGCCATCTTTCAAAATCCTTG					2603_a12.seq
7302	CCGGCGAAACTGCTTCTATTAACCTGATATTTGCCATCTTTCAAAATCCTTG					18rs21_a12.seq
7210	CCGGCGAAACTGCTTCTATTAACCTGATATTTGCCATCTTTCAAAATCCTTG					515_a12.seq
7199	CCGGCGAAACTGCTTCTATTAACCTGATATTTGCCATCTTTCAAAATCCTTG					cjb111_a12.seq
7252	CCGGCGAAACTGCTTCTATTAACCTGATATTTGCCATCTTTCAAAATCCTTG					h36b_a12.seq
	TAAGAAATTTTGCCTTTTCTCCCGTCACTACTTTTGAATTATTATTTTT					Majority
	7410	7420	7430	7440	7450	
7352	TAAGAAATTTTGCCTTTTCTCCCGTCACTACTTTTGAATTATTATTTTT					2603_a12.seq
7352	TAAGAAATTTTGCCTTTTCTCCCGTCACTACTTTTGAATTATTATTTTT					18rs21_a12.seq
7260	TAAGAAATTTTGCCTTTTCTCCCGTCACTACTTTTGAATTATTATTTTT					515_a12.seq
7249	TAAGAAATTTTGCCTTTTCTCCCGTCACTACTTTTGAATTATTATTTTT					cjb111_a12.seq
7302	TAAGAAATTTTGCCTTTTCTCCCGTCACTACTTTTGAATTATTATTTTT					h36b_a12.seq
	TATTGGTAAATAAAGTTTATAATCTTCAATTAATTTCTTGAAGTTCAAACG					Majority
	7460	7470	7480	7490	7500	
7402	TATTGGTAAATAAAGTTTATAATCTTCAATTAATTTCTTGAAGTTCAAACG					2603_a12.seq
7402	TATTGGTAAATAAAGTTTATAATCTTCAATTAATTTCTTGAAGTTCAAACG					18rs21_a12.seq
7310	TATTGGTAAATAAAGTTTATAATCTTCAATTAATTTCTTGAAGTTCAAACG					515_a12.seq
7299	TATTGGTAAATAAAGTTTATAATCTTCAATTAATTTCTTGAAGTTCAAACG					cjb111_a12.seq
7352	TATTGGTAAATAAAGTTTATAATCTTCAATTAATTTCTTGAAGTTCAAACG					h36b_a12.seq
	TAGCTCCTTTGAGAAGCAACTTATTATTATCTTTATCAACTTTTATAAAAT					Majority
	7510	7520	7530	7540	7550	
7452	TAGCTCCTTTGAGAAGCAACTTATTATTATCTTTATCAACTTTTATAAAAT					2603_a12.seq
7452	TAGCTCCTTTGAGAAGCAACTTATTATTATCTTTATCAACTTTTATAAAAT					18rs21_a12.seq
7360	TAGCTCCTTTGAGAAGCAACTTATTATTATCTTTATCAACTTTTATAAAAT					515_a12.seq
7349	TAGCTCCTTTGAGAAGCAACTTATTATTATCTTTATCAACTTTTATAAAAT					cjb111_a12.seq
7402	TAGCTCCTTTGAGAAGCAACTTATTATTATCTTTATCAACTTTTATAAAAT					h36b_a12.seq
	TCAATTTTCACTAACTTCTTCTCGTTTTTAAATCGTTATTGTAGGATATTC					Majority
	7560	7570	7580	7590	7600	
7502	TCAATTTTCACTAACTTCTTCTCGTTTTTAAATCGTTATTGTAGGATATTC					2603_a12.seq
7502	TCAATTTTCACTAACTTCTTCTCGTTTTTAAATCGTTATTGTAGGATATTC					18rs21_a12.seq
7410	TCAATTTTCACTAACTTCTTCTCGTTTTTAAATCGTTATTGTAGGATATTC					515_a12.seq
7399	TCAATTTTCACTAACTTCTTCTCGTTTTTAAATCGTTATTGTAGGATATTC					cjb111_a12.seq
7452	TCAATTTTCACTAACTTCTTCTCGTTTTTAAATCGTTATTGTAGGATATTC					h36b_a12.seq
	TCTCACATCACGAATTTTAGGGATTGGAAAATCTCTAAAGTGTATTAGGAT					Majority
	7610	7620	7630	7640	7650	
7552	TCTCACATCACGAATTTTAGGGATTGGAAAATCTCTAAAGTGTATTAGGAT					2603_a12.seq
7552	TCTCACATCACGAATTTTAGGGATTGGAAAATCTCTAAAGTGTATTAGGAT					18rs21_a12.seq
7460	TCTCACATCACGAATTTTAGGGATTGGAAAATCTCTAAAGTGTATTAGGAT					515_a12.seq
7449	TCTCACATCACGAATTTTAGGGATTGGAAAATCTCTAAAGTGTATTAGGAT					cjb111_a12.seq
7502	TCTCACATCACGAATTTTAGGGATTGGAAAATCTCTAAAGTGTATTAGGAT					h36b_a12.seq

FIGURE 19P

73/487




FIGURE 19Q

74/487




FIGURE 19R

75/487




FIGURE 19S

76/487




FIGURE 19T

77/487

	Majority				
	9460	9470	9480	9490	9500
	TCTTTTATAAACCTTCGGGCGCTGTTCTTCTGATAAAAGTATAATCTCCA				
9402	TCTTTTATAAACCTTCGGGCGCTGTTCTTCTGATAAAAGTATAATCTCCA				
9402	TCTTTTATAAACCTTCGGGCGCTGTTCTTCTGATAAAAGTATAATCTCCA				
9310	TCTTTTATAAACCTTCGGGCGCTGTTCTTCTGATAAAAGTATAATCTCCA				
9299	TCTTTTATAAACCTTCGGGCGCTGTTCTTCTGATAAAAGTATAATCTCCA				
9337	TCTTTTATAAACCTTCGGGCGCTGTTCTTCTGATAAAAGTATAATCTCCA				
	Majority				
	9510	9520	9530	9540	9550
	CGTATGAGATTATCAAAAAGTAGCTTCACTGTTAGCTCAGCAGTTACTTT				
9452	CGTATGAGATTATCAAAAAGTAGCTTCACTGTTAGCTCAGCAGTTACTTT				
9452	CGTATGAGATTATCAAAAAGTAGCTTCACTGTTAGCTCAGCAGTTACTTT				
9360	CGTATGAGATTATCAAAAAGTAGCTTCACTGTTAGCTCAGCAGTTACTTT				
9349	CGTATGAGATTATCAAAAAGTAGCTTCACTGTTAGCTCAGCAGTTACTTT				
9387	CGTATGAGATTATCAAAAAGTAGCTTCACTGTTAGCTCAGCAGTTACTTT				
	Majority				
	9560	9570	9580	9590	9600
	TTCTATTTTACTTTCTGGATGAGCAGTAGTTTTTAAACAAGGTTAGCTT				
9502	TTCTATTTTACTTTCTGGATGAGCAGTAGTTTTTAAACAAGGTTAGCTT				
9502	TTCTATTTTACTTTCTGGATGAGCAGTAGTTTTTAAACAAGGTTAGCTT				
9410	TTCTATTTTACTTTCTGGATGAGCAGTAGTTTTTAAACAAGGTTAGCTT				
9399	TTCTATTTTACTTTCTGGATGAGCAGTAGTTTTTAAACAAGGTTAGCTT				
9437	TTCTATTTTACTTTCTGGATGAGCAGTAGTTTTTAAACAAGGTTAGCTT				
	Majority				
	9610	9620	9630	9640	9650
	TTGAAAAGTGGTTTCTGGTCACTCTGCTTTTTAAACAATAACTTTCTT				
9552	TTGAAAAGTGGTTTCTGGTCACTCTGCTTTTTAAACAATAACTTTCTT				
9552	TTGAAAAGTGGTTTCTGGTCACTCTGCTTTTTAAACAATAACTTTCTT				
9460	TTGAAAAGTGGTTTCTGGTCACTCTGCTTTTTAAACAATAACTTTCTT				
9449	TTGAAAAGTGGTTTCTGGTCACTCTGCTTTTTAAACAATAACTTTCTT				
9487	TTGAAAAGTGGTTTCTGGTCACTCTGCTTTTTAAACAATAACTTTCTT				
	Majority				
	9660	9670	9680	9690	9700
	TTAGCACCAATTTTCCGGTACGGTACTTTCCCTAAAACATTGGTATTTAAG				
9602	TTAGCACCAATTTTCCGGTACGGTACTTTCCCTAAAACATTGGTATTTAAG				
9602	TTAGCACCAATTTTCCGGTACGGTACTTTCCCTAAAACATTGGTATTTAAG				
9510	TTAGCACCAATTTTCCGGTACGGTACTTTCCCTAAAACATTGGTATTTAAG				
9499	TTAGCACCAATTTTCCGGTACGGTACTTTCCCTAAAACATTGGTATTTAAG				
9537	TTAGCACCAATTTTCCGGTACGGTACTTTCCCTAAAACATTGGTATTTAAG				
	Majority				
	9710	9720	9730	9740	9750
	CGGTATTTGCGACAAAACAAAAGACTTAAACGTCAATATTTTAGAAAATT				
9652	CGGTATTTGCGACAAAACAAAAGACTTAAACGTCAATATTTTAGAAAATT				
9652	CGGTATTTGCGACAAAACAAAAGACTTAAACGTCAATATTTTAGAAAATT				
9560	CGGTATTTGCGACAAAACAAAAGACTTAAACGTCAATATTTTAGAAAATT				
9549	CGGTATTTGCGACAAAACAAAAGACTTAAACGTCAATATTTTAGAAAATT				
9587	CGGTATTTGCGACAAAACAAAAGACTTAAACGTCAATATTTTAGAAAATT				
	Majority				
	9760	9770	9780	9790	9800
	TTTGGTATTTTCTCATTTTACAACCTCCTATTGTCGCCGAAATGTCGTTTCT				
9702	TTTGGTATTTTCTCATTTTACAACCTCCTATTGTCGCCGAAATGTCGTTTCT				
9702	TTTGGTATTTTCTCATTTTACAACCTCCTATTGTCGCCGAAATGTCGTTTCT				
9610	TTTGGTATTTTCTCATTTTACAACCTCCTATTGTCGCCGAAATGTCGTTTCT				
9599	TTTGGTATTTTCTCATTTTACAACCTCCTATTGTCGCCGAAATGTCGTTTCT				
9637	TTTGGTATTTTCTCATTTTACAACCTCCTATTGTCGCCGAAATGTCGTTTCT				
	Majority				
	9810	9820	9830	9840	9850
	AAATCTAAGATCAGATACAGAATATCCTAGAATATACAAACTATCACTTA				
9752	AAATCTAAGATCAGATACAGAATATCCTAGAATATACAAACTATCACTTA				
9752	AAATCTAAGATCAGATACAGAATATCCTAGAATATACAAACTATCACTTA				
9660	AAATCTAAGATCAGATACAGAATATCCTAGAATATACAAACTATCACTTA				
9649	AAATCTAAGATCAGATACAGAATATCCTAGAATATACAAACTATCACTTA				
9687	AAATCTAAGATCAGATACAGAATATCCTAGAATATACAAACTATCACTTA				
	Majority				
	9860	9870	9880	9890	9900
	TTATGATATCAATAATTTCTTATTATAAGGATATGGAATTTTAAATGTTTTT				
9802	TTATGATATCAATAATTTCTTATTATAAGGATATGGAATTTTAAATGTTTTT				
9802	TTATGATATCAATAATTTCTTATTATAAGGATATGGAATTTTAAATGTTTTT				
9710	TTATGATATCAATAATTTCTTATTATAAGGATATGGAATTTTAAATGTTTTT				
9699	TTATGATATCAATAATTTCTTATTATAAGGATATGGAATTTTAAATGTTTTT				
9737	TTATGATATCAATAATTTCTTATTATAAGGATATGGAATTTTAAATGTTTTT				

FIGURE 19U

78/487




FIGURE 19V

79/487




FIGURE 19W

80/487




FIGURE 19X

81/487




FIGURE 19Y

82/487

G T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G Majority

11710 11720 11730 11740 11750

11616 G T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G 2603_al2.seq
11617 G T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G 18rs21_al2.seq
11514 C A A A A A T G A C T T G A C C A T G T T C T A A A A C A A T A C T A G C T A A A T G G T G T T 515_al2.seq
11514 G T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G cjb111_al2.seq
11554 G T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G h36b_al2.seq

T A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T Majority

11760 11770 11780 11790 11800

11666 T A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T 2603_al2.seq
11667 T A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T 18rs21_al2.seq
11564 C T T T G C A A A A G A T A G C C T T T A A C G T T T A A G T G A A A A G C T T A T T A G 515_al2.seq
11564 T A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T cjb111_al2.seq
11604 T A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T h36b_al2.seq

G G A G T - - - G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A Majority

11810 11820 11830 11840 11850

11716 G G A G T - - - G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A 2603_al2.seq
11717 G G A G T - - - G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A 18rs21_al2.seq
11614 A A A T C A C A A A A T G A A T A T T T T C A T C T G A A A C A T A T T T C A C A G G T G T T 515_al2.seq
11614 G G A G T - - - G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A cjb111_al2.seq
11654 G G A G T - - - G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A h36b_al2.seq

T - - - - - C A A T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C Majority

11860 11870 11880 11890 11900

11763 T - - - - - C A A T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C 2603_al2.seq
11764 T - - - - - C A A T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C 18rs21_al2.seq
11664 T A T T C T C A A T T T T G T A A I A A T A C A I A G C G T T T C T T G A C A A T A T T T T 515_al2.seq
11661 T - - - - - C A A T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C cjb111_al2.seq
11701 T - - - - - C A A T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C h36b_al2.seq

A C T T G A A A G T A G A C C A G C T T C T A A A - - - - A T A G A G G T T G G T A A T C C C T C Majority

11910 11920 11930 11940 11950

11807 A C T T G A A A G T A G A C C A G C T T C T A A A - - - - A T A G A G G T T G G T A A T C C C T C 2603_al2.seq
11808 A C T T G A A A G T A G A C C A G C T T C T A A A - - - - A T A G A G G T T G G T A A T C C C T C 18rs21_al2.seq
11714 G T T G G T A A A G G T A A A T T T T C A A C C T T C A T C T T C A T C I A T A A T C C G T 515_al2.seq
11705 A C T T G A A A G T A G A C C A G C T T C T A A A - - - - A T A G A G G T T G G T A A T C C C T C cjb111_al2.seq
11745 A C T T G A A A G T A G A C C A G C T T C T A A A - - - - A T A G A G G T T G G T A A T C C C T C h36b_al2.seq

T G G A T A C A T T G A A G G G T A A A C A A A G A T A T C A G T C T G T - G C C A T T A A A G A C Majority

11960 11970 11980 11990 12000

11852 T G G A T A C A T T G A A G G G T A A A C A A A G A T A T C A G T C T G T - G C C A T T A A A G A C 2603_al2.seq
11853 T G G A T A C A T T G A A G G G T A A A C A A A G A T A T C A G T C T G T - G C C A T T A A A G A C 18rs21_al2.seq
11763 A A A T C A C A T G A T T A G T T G T T A C A A T A C A A C A C G G T A G C C A C G G T T A A C 515_al2.seq
11750 T G G A T A C A T T G A A G G G T A A A C A A A G A T A T C A G T C T G T - G C C A T T A A A G A C cjb111_al2.seq
11790 T G G A T A C A T T G A A G G G T A A A C A A A G A T A T C A G T C T G T - G C C A T T A A A G A C h36b_al2.seq

A T A G T C T G T T C A A A G T T T A A T T T C C C C A A A A G T T A A T C T G T T T G G A C T G Majority

12010 12020 12030 12040 12050

11901 A T A G T C T G T T C A A A G T T T A A T T T C C C C A A A A G T T A A T C T G T T T G G A C T G 2603_al2.seq
11902 A T A G T C T G T T C A A A G T T T A A T T T C C C C A A A A G T T A A T C T G T T T T G G A C T G 18rs21_al2.seq
11813 C A A A T C T G T T C A A A G T T T A A T T T C C C C A A A A G T T A A T C T G T T T G G A A G G 515_al2.seq
11799 A T A G T C T G T T C A A A G T T T A A T T T C C C C A A A A G T T A A T C T G T T T G G A C T G cjb111_al2.seq
11839 A T A G T C T G T T C A A A G T T T A A T T T C C C C A A A A G T T A A T C T G T T T G G A C T G h36b_al2.seq

A T A T T T C T C T T T C A A A T G T G C T A A T T C A G G T C C G T C T C C T G C A A T C T G T A Majority

12060 12070 12080 12090 12100

11951 A T A T T T C T C T T T C A A A T G T G C T A A T T C A G G T C C G T C T C C T G C A A T C T G T A 2603_al2.seq
11952 A T A T T T C T C T T T C A A A T G T G C T A A T T C A G G T C C G T C T C C T G C A A T C T G T A 18rs21_al2.seq
11863 G T A G A T A A T T C T G A G A A A A C A G C A C T T T T A A G C C T T A T G A T G A A G C A A 515_al2.seq
11849 A T A T T T C T C T T T C A A A T G T G C T A A T T C A G G T C C G T C T C C T G C A A T C T G T A cjb111_al2.seq
11889 A T A T T T C T C T T T C A A A T G T G C T A A T T C A G G T C C G T C T C C T G C A A T C T G T A h36b_al2.seq

A A T A A A C A T T T T C A - G A G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A Majority

12110 12120 12130 12140 12150

12001 A A T A A A C A T T T T C A - G A G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A 2603_al2.seq
12002 A A T A A A C A T T T T C A - G A G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A 18rs21_al2.seq
11913 T T T A T T C A C A T T T T C A A T A A G C C A T C T T T A A G C C T T A T G A T G A A G C A A 515_al2.seq
11899 A A T A A A C A T T T T C A - G A G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A cjb111_al2.seq
11939 A A T A A A C A T T T T C A - G A G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A h36b_al2.seq

FIGURE 19Z

82/487




FIGURE 19AA

84/487




FIGURE 19AB

85/487




FIGURE 19AC

86/487





FIGURE 19AD

87/487



Decoration 'Decoration #1': Shade (with solid black) residues that differ from the Consensus.

FIGURE 19AE

88/487




Figure 20

89/487




FIGURE 20A

90/487

	TTGTTAAAAGCTAATTGGCTACACCAATAAATGTTCTGATATCAAAGTTA	Majority
	1310 1320 1330 1340 1350	
1202	TTGTTAAAAGGTAATTGCCTACACCAATAAATGTTCTGATATCAAAGTTA	2603_ai2.seq
1301	TTGTTAAAAGGTAATTGCCTACACCAATAAATGTTCTGATATCAAAGTTA	nem316_ai2.seq
	GCAAATATAGCATACAAAGGAATCGCAAAGACATAGTTGAGAGCTACCAAT	Majority
	1360 1370 1380 1390 1400	
1252	GCAAATATAGCATACAAAGGAATCGCAAAGACATAGTTGAGAGCTACCAAT	2603_ai2.seq
1351	GCAAATATAGCATACAAAGGAATCGCAAAGACATAGTTGAGAGCTACCAAT	nem316_ai2.seq
	AGATACGGTCAAGCTAACTGTACCAAATAGACTAGCTTTAATAAAATCTTT	Majority
	1410 1420 1430 1440 1450	
1302	AGATACGGTCAAGCTAACTGTACCAAATAGACTAGCTTTAATAAAATCTTT	2603_ai2.seq
1401	AGATACGGTCAAGCTAACTGTACCAAATAGACTAGCTTTAATAAAATCTTT	nem316_ai2.seq
	TTGCACTCTCTCTATTTTTCCAGAAAATAGCGAAACTTGCCTAAAAATAAA	Majority
	1460 1470 1480 1490 1500	
1352	TTGCACTCTCTCTATTTTTCCAGAAAATAGCGAAACTTGCCTAAAAATAAA	2603_ai2.seq
1451	TTGCACTCTCTCTATTTTTCCAGAAAATAGCGAAACTTGCCTAAAAATAAA	nem316_ai2.seq
	GCTAGAGCAACCATATTCATCGGTAACCGATAAAGGTTTTCTGGACCACG	Majority
	1510 1520 1530 1540 1550	
1402	GCTAGAGCAACCATATTCATCGGTAACCGATAAAGGTTTTCTGGACCACG	2603_ai2.seq
1501	GCTAGAGCAACCATATTCATCGGTAACCGATAAAGGTTTTCTGGACCACG	nem316_ai2.seq
	ATTAGCAAAGTATAAAGTCTTAATAAGAGTACACCATAAAC	Majority
	1560 1570 1580 1590 1600	
1452	ATTAGCAAAGTATAAAGTCTTAATAAGAGTACACCATAAAC	2603_ai2.seq
1551	ATTAGCAAAGTATAAAGTCTTAATAAGAGTACACCATAAAC	nem316_ai2.seq
	TTGATTTCAAATCAAATAAAAATAAAGCAACTAACATCGGAAGGATTGAA	Majority
	1610 1620 1630 1640 1650	
1502	TTGATTTCAAATCAAATAAAAATAAAGCAACTAACATCGGAAGGATTGAA	2603_ai2.seq
1601	TTGATTTCAAATCAAATAAAAATAAAGCAACTAACATCGGAAGGATTGAA	nem316_ai2.seq
	AAATCAACCTTTAAAAAATTCTGCTCCTGGTATTAATGGAAATGAAACCAT	Majority
	1660 1670 1680 1690 1700	
1552	AAATCAACCTTTAAAAAATTCTGCTCCTGGTATTAATGGAAATGAAACCAT	2603_ai2.seq
1651	AAATCAACCTTTAAAAAATTCTGCTCCTGGTATTAATGGAAATGAAACCAT	nem316_ai2.seq
	CATCAATACAAAAGATAAGGCAGAAAGAATGGCGATTGTCAACATTTTAC	Majority
	1710 1720 1730 1740 1750	
1602	CATCAATACAAAAGATAAGGCAGAAAGAATGGCGATTGTCAACATTTTAC	2603_ai2.seq
1701	CATCAATACAAAAGATAAGGCAGAAAGAATGGCGATTGTCAACATTTTAC	nem316_ai2.seq
	GTTGATTTGTTCATAAAAAAATTCCTCCAATTTAAATAAATTGAAAGAAGC	Majority
	1760 1770 1780 1790 1800	
1652	GTTGATTTGTTCATAAAAAAATTCCTCCAATTTAAATAAATTGAAAGAAGC	2603_ai2.seq
1751	GTTGATTTGTTCATAAAAAAATTCCTCCAATTTAAATAAATTGAAAGAAGC	nem316_ai2.seq
	TCCAAAGGTAAGCGTATGTACGGCAAAAAACCTTTGTCTTCTCCCATCC	Majority
	1810 1820 1830 1840 1850	
1702	TCCAAAGGTAAGCGTATGTACGGCAAAAAACCTTTGTCTTCTCCCATCC	2603_ai2.seq
1801	TCCAAAGGTAAGCGTATGTACGGCAAAAAACCTTTGTCTTCTCCCATCC	nem316_ai2.seq
	AGACTTTACTGTCGGTTGTGGAAATCTCACACATCAGCTTTTCGCTCGCGG	Majority
	1860 1870 1880 1890 1900	
1751	AGACTTTACTGTCGGTTGTGGAAATCTCACACATCAGCTTTTCGCTCGCGG	2603_ai2.seq
1851	AGACTTTACTGTCGGTTGTGGAAATCTCACACATCAGCTTTTCGCTCGCGG	nem316_ai2.seq
	ACTGATGCTTTCACAACTGACAAAATAAGTTGGAAGCGATTACCGCCGGTCC	Majority
	1910 1920 1930 1940 1950	
1801	ACTGATGCTTTCACAACTGACAAAATAAGTTGGAAGCGATTACCGCCGGTCC	2603_ai2.seq
1901	ACTGATGCTTTCACAACTGACAAAATAAGTTGGAAGCGATTACCGCCGGTCC	nem316_ai2.seq

FIGURE 20B

91/487

GGAATTACACCCCTGCCCTGGAAGACACCTATAGCATAACAAAAAAACTTGG Majority
1960 1970 1980 1990 2000
1851 GGAATTACACCCCTGCCCTGGAAGACACCTATAGCATAACAAAAAAACTTGG 2603_ai2.seq
1951 GGAATTACACCCCTGCCCTGGAAGACACCTATAGCATAACAAAAAAACTTGG nem316_ai2.seq

CAATTGCAAGTTTTTTAATTACTAATTAGTAGTAGTGATTAAAAATCATA Majority
2010 2020 2030 2040 2050
1901 CAATTGCAAGTTTTTTAATTACTAATTAGTAGTAGTGATTAAAAATCATA 2603_ai2.seq
2001 CAATTGCAAGTTTTTTAATTACTAATTAGTAGTAGTGATTAAAAATCATA nem316_ai2.seq

TTAATACCAAATTACTATGCTGTATCGTTTCTTTTCAGATTTGCTATTTTT Majority
2060 2070 2080 2090 2100
1951 TTAATACCAAATTACTATGCTGTATCGTTTCTTTTCAGATTTGCTATTTTT 2603_ai2.seq
2051 TTAATACCAAATTACTATGCTGTATCGTTTCTTTTCAGATTTGCTATTTTT nem316_ai2.seq

AGTTTTTCTTAAAAAGATAAAACAAAATTCCCAAATAATACAACCAAGAA Majority
2110 2120 2130 2140 2150
2001 AGTTTTTCTTAAAAAGATAAAACAAAATTCCCAAATAATACAACCAAGAA 2603_ai2.seq
2101 AGTTTTTCTTAAAAAGATAAAACAAAATTCCCAAATAATACAACCAAGAA nem316_ai2.seq

TTGTCAGTCCCTCCACCAATAATCATTCCTGTTTTAGGAAGAAATGATTGT Majority
2160 2170 2180 2190 2200
2051 TTGTCAGTCCCTCCACCAATAATCATTCCTGTTTTAGGAAGAAATGATTGT 2603_ai2.seq
2151 TTGTCAGTCCCTCCACCAATAATCATTCCTGTTTTAGGAAGAAATGATTGT nem316_ai2.seq

GGAAAAAGCGGTTGTGATGGTTTAGGATTTGTTGGTGGAGGAGTTTCTTT Majority
2210 2220 2230 2240 2250
2101 GGAAAAAGCGGTTGTGATGGTTTAGGATTTGTTGGTGGAGGAGTTTCTTT 2603_ai2.seq
2201 GGAAAAAGCGGTTGTGATGGTTTAGGATTTGTTGGTGGAGGAGTTTCTTT nem316_ai2.seq

TTGTTTTCTACCTCTACTTCTGTTTATTAGCAACTACAGCAACTA Majority
2260 2270 2280 2290 2300
2151 TTGTTTTCTACCTCTACTTCTGTTTATTAGCAACTACAGCAACTA 2603_ai2.seq
2251 TTGTTTTCTACCTCTACTTCTGTTTATTAGCAACTACAGCAACTA nem316_ai2.seq

CAGCATCCTTCATAGATATACGGTAACCAAGTTAGTGCTTTTTCCTTCTCGA Majority
2310 2320 2330 2340 2350
2201 CAGCATCCTTCATAGATATACGGTAACCAAGTTAGTGCTTTTTCCTTCTCGA 2603_ai2.seq
2301 CAGCATCCTTCATAGATATACGGTAACCAAGTTAGTGCTTTTTCCTTCTCGA nem316_ai2.seq

AAAAATATACTTACCAGGTAATAAACCTTCAACCTCAATTTCTCCCTTATC Majority
2360 2370 2380 2390 2400
2251 AAAAATATACTTACCAGGTAATAAACCTTCAACCTCAATTTCTCCCTTATC 2603_ai2.seq
2351 AAAAATATACTTACCAGGTAATAAACCTTCAACCTCAATTTCTCCCTTATC nem316_ai2.seq

ATCAGTTACTAATGAAGTAATCCCATCTTGATCGGTCGTAATTCGTTCCAT Majority
2410 2420 2430 2440 2450
2301 ATCAGTTACTAATGAAGTAATCCCATCTTGATCGGTCGTAATTCGTTCCAT 2603_ai2.seq
2401 ATCAGTTACTAATGAAGTAATCCCATCTTGATCGGTCGTAATTCGTTCCAT nem316_ai2.seq

TTTTAAAGCGAACTGGCTGATTCTGGTTATCGTATAATAACAATATTACT Majority
2460 2470 2480 2490 2500
2351 TTTTAAAGCGAACTGGCTGATTCTGGTTATCGTATAATAACAATATTACT 2603_ai2.seq
2451 TTTTAAAGCGAACTGGCTGATTCTGGTTATCGTATAATAACAATATTACT nem316_ai2.seq

CCTGATAGCCTTTTCTTTATCTTTCCTTCTTTTGTATATTTAATAAGTTT Majority
2510 2520 2530 2540 2550
2401 CCTGATAGCCTTTTCTTTATCTTTCCTTCTTTTGTATATTTAATAAGTTT 2603_ai2.seq
2501 CCTGATAGCCTTTTCTTTATCTTTCCTTCTTTTGTATATTTAATAAGTTT nem316_ai2.seq

TAATCGGCCCTGTTTCAACTTTTTCGCTTAGGATTTATCTGTAATTGATTTG Majority
2560 2570 2580 2590 2600
2451 TAATCGGCCCTGTTTCAACTTTTTCGCTTAGGATTTATCTGTAATTGATTTG 2603_ai2.seq
2551 TAATCGGCCCTGTTTCAACTTTTTCGCTTAGGATTTATCTGTAATTGATTTG nem316_ai2.seq

FIGURE 20C

ATAACTTATCATCTGGTATTTCAATATAAAAAGGTACTATTGTTGAAACG Majority
 2610 2620 2630 2640 2650
 2501 **ATAACTTATCATCTGGTATTTCAATATAAAAAGGTA**CTATTGTTGAAACG 2603_a12.seq
 2601 **ATAACTTATCATCTGGTATTTCAATATAAAAAGGTA**CTATTGTTGAAACG nem316_a12.seq
CTTTGATCAGCTTTATAAGCACGACCAAAGTACGAACCATTGGGGAGTGC Majority
 2660 2670 2680 2690 2700
 2551 **CTTTGATCAGCTTTATAAGCACGACCAAAGTACGA**ACCATTGGGGAGTGC 2603_a12.seq
 2651 **CTTTGATCAGCTTTATAAGCACGACCAAAGTACGA**ACCATTGGGGAGTGC nem316_a12.seq
TATCTTTGCTCTGACCATTAGTATCAGTAGGAGAAGTCAAGATACTCTTAT Majority
 2710 2720 2730 2740 2750
 2601 **TATCTTTGCTCTGACCATTAGTATCAGTAGGAGA**AGTCAAGATACTCTTAT 2603_a12.seq
 2701 **TATCTTTGCTCTGACCATTAGTATCAGTAGGAGA**AGTCAAGATACTCTTAT nem316_a12.seq
ACTTCTGGTTCAATTCGCTATCTGTCATTTGGCTCAATAAATCAACTTTT Majority
 2760 2770 2780 2790 2800
 2651 **ACTTCTGGTTCAATTCGCTATCTGTCA**TTTGGCTCAATAAATCAACTTTT 2603_a12.seq
 2751 **ACTTCTGGTTCAATTCGCTATCTGTCA**TTTGGCTCAATAAATCAACTTTT nem316_a12.seq
AAGTTGTCAGTACAGTCCATAAACGATAAGAAATCCCCTCCTCTGTAGT Majority
 2810 2820 2830 2840 2850
 2701 **AAGTTGTCAGTACAGTCCATAAACGATAAGAA**ATCCCCTCCTCTGTAGT 2603_a12.seq
 2801 **AAGTTGTCAGTACAGTCCATAAACGATAAGAA**ATCCCCTCCTCTGTAGT nem316_a12.seq
ATTTGGCTGAAGTCCTATCTGTGTGATTGTTACTTGATTAGGGGTATCAG Majority
 2860 2870 2880 2890 2900
 2751 **ATTTGGCTGAAGTCCTATCTGTGTGATTGTTA**CTTGATTAGGGGTATCAG 2603_a12.seq
 2851 **ATTTGGCTGAAGTCCTATCTGTGTGATTGTTA**CTTGATTAGGGGTATCAG nem316_a12.seq
CATTTACACTGGCTACCGAAAAAAACGCTAATTGTACCAATCCTAAAAAG Majority
 2910 2920 2930 2940 2950
 2801 **CATTTACACTGGCTACCGAAAAAAACGCTA**ATTGTACCAATCCTAAAAAG 2603_a12.seq
 2901 **CATTTACACTGGCTACCGAAAAAAACGCTA**ATTGTACCAATCCTAAAAAG nem316_a12.seq
CAACATAGTAGAAGTCCTAAACTTTTTCTAATCTTTTTTCATTTTTTGATTT Majority
 2960 2970 2980 2990 3000
 2851 **CAACATAGTAGAAGTCCTAAACTTTTTCTA**ATCTTTTTTCATTTTTTGATTT 2603_a12.seq
 2951 **CAACATAGTAGAAGTCCTAAACTTTTTCTA**ATCTTTTTTCATTTTTTGATTT nem316_a12.seq
CCCTTTCTTTTTCTCTCTTTAAATTTTTCGTTTTAAATATAATAGTAAAGC Majority
 3010 3020 3030 3040 3050
 2901 **CCCTTTCTTTTTCTCTCTTTAAATTTTTCG**TTTTAAATATAATAGTAAAGC 2603_a12.seq
 3001 **CCCTTTCTTTTTCTCTCTTTAAATTTTTCG**TTTTAAATATAATAGTAAAGC nem316_a12.seq
GACTAATATAAGAATAAACTAGGATTGATAAGAGGAAATAAAGTTTATAGT Majority
 3060 3070 3080 3090 3100
 2951 **GACTAATATAAGAATAA**ACTAGGATTGATAAGAGGAAATAAAGTTTATAGT 2603_a12.seq
 3051 **GACTAATATAAGAATAA**ACTAGGATTGATAAGAGGAAATAAAGTTTATAGT nem316_a12.seq
GTGTTTGCAATTCTTTCATTAATAAGTTCTTTTCTTTAACAGGAGGTACA Majority
 3110 3120 3130 3140 3150
 3001 **GTGTTTGCAATTC**TTTCATTAATAAGTTCTTTTCTTTAACAGGAGGTACA 2603_a12.seq
 3101 **GTGTTTGCAATTC**TTTCATTAATAAGTTCTTTTCTTTAACAGGAGGTACA nem316_a12.seq
TACTTGATTCCGATGCCCTCTAACTAGTAAACGATGTGAATTAATCGAATA Majority
 3160 3170 3180 3190 3200
 3051 **TACTTGATTCCGATGCCCTCTAACTAGTAA**ACGATGTGAATTAATCGAATA 2603_a12.seq
 3151 **TACTTGATTCCGATGCCCTCTAACTAGTAA**ACGATGTGAATTAATCGAATA nem316_a12.seq
AGGTGTACATGTTAGCAAAGTCGCATAATCCTTACCTTTAACAAACCAATA Majority
 3210 3220 3230 3240 3250
 3101 **AGGTGTACATGTTAGCAAAGTCGCATAATC**CTTACCTTTAACAAACCAATA 2603_a12.seq
 3201 **AGGTGTACATGTTAGCAAAGTCGCATAATC**CTTACCTTTAACAAACCAATA nem316_a12.seq

FIGURE 20D

93/487




FIGURE 20E

94/487

```

CTAAAAGATTATTTTGAAGCTTGAAGCTTTTATTAAACCAAAGTAACCAAGCA Majority
          3910          3920          3930          3940          3950
3801 CTAAACGATTTTTTTGACGTTGACGTTTTTATTAAACCAAAGTAACCAAGCA 2603_a12.seq
3901 CTAAACGATTTTTTTGACGTTGACGTTTTTATTAAACCAAAGTAACCAAGCA nem316_a12.seq

ATAATAACTAAAGATATATAGAAATAGATATCTATAAATCGTGTTTAAATG Majority
          3960          3970          3980          3990          4000
3851 ATAATAACTAAAGATATATAGAAATAGATATCTATAAATCGTGTTTAAATG 2603_a12.seq
3951 ATAATAACTAAAGATATATAGAAATAGATATCTATAAATCGTGTTTAAATG nem316_a12.seq

ACCTTCTTTTTATTAATTTTTTCATCAATAGGACCTTTATAAGGGATACGAT Majority
          4010          4020          4030          4040          4050
3901 ACCCTCTTTTTATTAATTTTTTCATCAATAGGACCTTTATAAGGGATACGAT 2603_a12.seq
4001 ACCTTCTTTTTATTAATTTTTTCATCAATAGGACCTTTATAAGGGATACGAT nem316_a12.seq

GTCCCTTACTAAAAGTCTGTGTGTATTGATCATAATCGGGGTGCAAGTT Majority
          4060          4070          4080          4090          4100
3951 GTCCCTTACTAAAAGTCTGTGTGTATTGATCATAATCGGGGTGCAAGTT 2603_a12.seq
4051 GTCCCTTACTAAAAGTCTGTGTGTATTGATCATAATCGGGGTGCAAGTT nem316_a12.seq

AATAAGGTTGCATAATCATGTCAGGAACAACCAACAAATCTGAAAAGTT Majority
          4110          4120          4130          4140          4150
4001 AATAAGGTTGCATAATCATGTCAGGAACAACCAACAAATCTGAAAAGTT 2603_a12.seq
4101 AATAAGGTTGCATAATCATGTCAGGAACAACCAACAAATCTGAAAAGTT nem316_a12.seq

ATCGGGTGTAACGACTTTTTATCTGATCTACTTGATATGCTATCGTTTCTT Majority
          4160          4170          4180          4190          4200
4051 ATCGGGTGTAACGACTTTTTATCTGATCTACTTGATATGCTATCGTTTCTT 2603_a12.seq
4151 ATCGGGTGTAACGACTTTTTATCTGATCTACTTGATATGCTATCGTTTCTT nem316_a12.seq

TTATGTTTTGAATATAAAAACTTATCTCCTTTTTTTAACTTTTTTAAGGTTA Majority
          4210          4220          4230          4240          4250
4101 TTATGTTTTGAATATAAAAACTTATCTCCTTTTTTTAACTTTTTTAAGGTTA 2603_a12.seq
4201 TTATGTTTTGAATATAAAAACTTATCTCCTTTTTTTAACTTTTTTAAGGTTA nem316_a12.seq

GAAAAGAGTTCTTTATCTGGAATTCCTGAGTGGCCTGTTATAACGGTATG Majority
          4260          4270          4280          4290          4300
4151 GAAAAGAGTTCTTTATCTGGAATTCCTGAGTGGCCTGTTATAACGGTATG 2603_a12.seq
4251 GAAAAGAGTTCTTTATCTGGAATTCCTGAGTGGCCTGTTATAACGGTATG nem316_a12.seq

TGTGCTATTTTCCCTCCAATTGGGAAGAGAGGTACCTTCTAAATGCCCTGCTC Majority
          4310          4320          4330          4340          4350
4201 TGTGCTATTTTCCCTCCAATTGGGAAGAGAGGTACCTTCTAAATGCCCTGCTC 2603_a12.seq
4301 TGTGCTATTTTCCCTCCAATTGGGAAGAGAGGTACCTTCTAAATGCCCTGCTC nem316_a12.seq

CTTTAGATAGA AACTTCTTGACTTGAACCTGCCAATAATAGGGAGTTTTTGA Majority
          4360          4370          4380          4390          4400
4251 CTTTAGATAGA AACTTCTTGACTTGAACCTGCCAATAATAGGGAGTTTTTGA 2603_a12.seq
4351 CTTTAGATAGA AACTTCTTGACTTGAACCTGCCAATAATAGGGAGTTTTTGA nem316_a12.seq

CCTATCTTAGGAACCTGAAATTTGTTCCGATTTTTTTCACTTACCTCTAACAT Majority
          4410          4420          4430          4440          4450
4391 CCTATCTTAGGAACCTGAAATTTGTTCCGATTTTTTTCACTTACCTCTAACAT 2603_a12.seq
4401 CCTATCTTAGGAACCTGAAATTTGTTCCGATTTTTTTCACTTACCTCTAACAT nem316_a12.seq

ACGGGGCTACTCTGCTACCCCTTTTGAATTCGTTTTTTCTCATAAGGAT Majority
          4460          4470          4480          4490          4500
4351 ACGGGGCTACTCTGCTACCCCTTTTGAATTCGTTTTTTCTCATAAGGAT 2603_a12.seq
4451 ACGGGGCTACTCTGCTACCCCTTTTGAATTCGTTTTTTCTCATAAGGAT nem316_a12.seq

CTTCAAGATGGACATTATTTAAAGAATCATTATAAGCTTGTGCTAGAGTC Majority
          4510          4520          4530          4540          4550
4401 CTTCAAGATGGACATTATTTAAAGAATCATTATAAGCTTGTGCTAGAGTC 2603_a12.seq
4501 CTTCAAGATGGACATTATTTAAAGAATCATTATAAGCTTGTGCTAGAGTC nem316_a12.seq

```

FIGURE 20F

95/487




FIGURE 20G

96/487




FIGURE 20H

97/487

TTTTAATGACCTTTTAAATTTCTTGGCTTTTCCTGGTACCTTGTGTTGTTTTC Majority
5860 5870 5880 5890 5900

5724 TTTTAGCAACTTTTACTTTCACCTTTTGAACGCTGTAACAGGAAAGTTTACTTC 2603_ai2.seq
5824 CTTTAAATGACTTTTAAATTTCTTGGCTTTAGCTGGAACTACCTTCTTGTGGTTTCA nem316_ai2.seq

CTTTCCTTTCGTTGGTTTGTTACCATAGTCCAAATTTGATAATCATTGGTTTTTC Majority
5910 5920 5930 5940 5950

5774 AAGTCTTTTACTTGGTTTGTTACCATAGTCCAAATTTGATAATCATTGGCAATTC 2603_ai2.seq
5874 CTTTCTTTCGTTGGCTTTTATTACCATAGTCCAAATTTAAATCATTGGTTTTTC nem316_ai2.seq

TGGATTTTCAATAGTTGTTTGGCCGTTTACCGTAGCTGTGTAAGTGATTT Majority
5960 5970 5980 5990 6000

5824 TGGATTTATCAATAATTGGCTTGACCAATTAACAGTAGCACTATAAAGTCAATG 2603_ai2.seq
5924 TGGAACTTCAACAGTAGTGGAGCCCTTACCGTAGCTGAGTAAGTGATCT nem316_ai2.seq

TGATTTCAATATCTTTTTTTTTTGGCTGCTTTTTTCTACTTTTGGCCAGTCTCT Majority
6010 6020 6030 6040 6050

5874 TAAATTTCAATATCAGTTTGTTTTGGCTGCTTTTTTCTAAATTTGCCCAATCCA 2603_ai2.seq
5974 TGATTTCAAATCTTTTTTGTCTTTTTGGCAAGCTGCTACTGGTGCMAAGACCT nem316_ai2.seq

TTTGCCTTTGAATTTTAGTGTGAAACCTTGGTCACTGTCTGAGTTTGTATA Majority
6060 6070 6080 6090 6100

5924 TCAGCTGTGAATTTTAAATGTGAAACCAATGGGTCATCAATGCTAAGTTCAATA 2603_ai2.seq
6024 GTTGCATTTCAAAGGCAAGACGAAACCTTGGTCACTGTTAGGAGTTTGTATA nem316_ai2.seq

GTTTGTATCCTTAGGAAAATTTTTTGTATTTTCTGTTGCTTTAAAGTTTGT Majority
6110 6120 6130 6140 6150

5974 GTCTGTATCCTTAGCAAAAATTTTGTATTTTCTGAAAGCTTTTAAAGCTTAA 2603_ai2.seq
6074 GTTTAAAAACAGGAAAATTTTTAGCATTTCAATGTTAATTTAACTTTGT nem316_ai2.seq

TAGTTGAACCCATTGTCAAACCTTTTGTCAATCTATCTGTCCAAACCAGT Majority
6160 6170 6180 6190 6200

6024 CAGTTGAACCCATTGTCAAACCAATTTGACATTAATATCTGTCCAAACCAAG 2603_ai2.seq
6121 TGTGTTGAACAGTCAAACCTTTAGTCAATCTATCTAGTCCAAACCAGT nem316_ai2.seq

TTTTTGTATTTTGCAGCCTTTTGTGAATTTTGTTTTAACTTTGTATTGTTT Majority
6210 6220 6230 6240 6250

6074 TTTTGTATTTTGAACCTTTTGTGAATTTTGTTTTAACTTTGATAAGGAAG 2603_ai2.seq
6165 TTCTTATAATTTGAGCCTTTTAAGAATTTTGTTCGAACTATGTATTCTTT nem316_ai2.seq

TTTTTTACCGAATTTTCCGCTGTGGCAGTTTGTCTTGTACGTTGCATAATTAC Majority
6260 6270 6280 6290 6300

6124 AACTTTTACCGAATTTTCAAGTACCACTTGTCTTGTACGTTGCATAATTAC 2603_ai2.seq
6215 TTTTTCACCAATTTTCTGCTGAGCAACAACCTTTGTCTTGTCTTGTCTTGTCT nem316_ai2.seq

CATAATTTGGCCAGCTGTCAAAGTCTATTTTTCGTTTGTCAAGTGTGTC Majority
6310 6320 6330 6340 6350

6174 CATAATTTGGCCAGCTGTCAAAGTCTATTTTTCGTTTGTCAAGTGTGTC 2603_ai2.seq
6251 TTTTTCGTTTGTCAAGTATAATTC nem316_ai2.seq

AACTTGTGTTTCTTTTTTGCAAAAGTTTTTATCTATTTGTGGTTTTTTTTTCACT Majority
6360 6370 6380 6390 6400

6224 AAAATGCTTTTGTGTTTGAACAAAGTTTTTATCAATTTTGTGGTTTTTCTTCACT 2603_ai2.seq
6272 AAGATCTTTTATCTTGCAAAAGTTTTTATCTATTTGTGGTTTTTCTTCACT nem316_ai2.seq

GTTCTTTGGATAAAATGTGGGCATCTTTTAAACAACACCTTGTGTTTGTACCA Majority
6410 6420 6430 6440 6450

6274 GTTCTTTGGATAAAATGTGGGCATCTTTTAAACAACACCTTGTGTTTGTACCA 2603_ai2.seq
6320 AATCTTTGGATAAAATGTGAGCATCTTTTAAACAACACCTTGTGTTTGTACCA nem316_ai2.seq

ATGGCAGAGTGATTTTAACTGGAACTGCTTTTTGAATCAGCCAGGATGGAA Majority
6460 6470 6480 6490 6500

6324 ATGGAAGAGTGATTTTAACTGGAACTGCTTTTTGAATCAGCCAGGATGGAA 2603_ai2.seq
6370 ATGGCAGAGTGATTTTAACTGGAACTGCTTTTTGAATCAGCCAGGATGGAA nem316_ai2.seq

FIGURE 20I

98/487




FIGURE 20J

99/487

```

TTTTTCTGGAAATATATGACCTAGATTTCCTTATATCTTTTCCAAATATAAAATT Majority
          7160          7170          7180          7190          7200
7020 TTTTCTGGAAATATATCACTAGATTTCTTATACTTTTCCAAATATAAAATT 2603_a12.seq
7017 TTTTCTCTAGATATATCACTAGATTTCTTATACTTTTCCAAATATAAAATT nem316_a12.seq

CCACCTGCCAATAGACATCATAGCTCCACCTATTTAAAAATGAAAGATAGAAT Majority
          7210          7220          7230          7240          7250
7070 CCACCTGCCAATAGACATCATAGCTCCACCTATTTAAAAATGAAAGATAGAAT 2603_a12.seq
7067 CCACCTGCCAATAGACATCATAGCTCCACCTATTTAAAAATGAAAGATAGAAT nem316_a12.seq

TCCTTTCCCACTGTCATCGGAATAATTCCTTTTGGTGGAAATATGCGTGT Majority
          7260          7270          7280          7290          7300
7120 TCCTTTCCCACTGTCATCGGAATAATTCCTTTTGGTGGAAATATGCGTGT 2603_a12.seq
7117 TCCTTTCCCACTGTCATCGGAATAATTCCTTTTGGTGGAAATATGCGTGT nem316_a12.seq

TGGTAATTAATGCTTGTACCTTCCCTCATGATATTCAGAAATCTGTTTA Majority
          7310          7320          7330          7340          7350
7170 TGGTAATTAATGCTTGTACCTTCCCTCATGATATTCAGAAATCTGTTTA 2603_a12.seq
7167 TGGTAATTAATGCTTGTACCTTCCCTCATGATATTCAGAAATCTGTTTA nem316_a12.seq

TTAACAGCTATTTATATTTTTTATCGATCCTTTAACCACTTCAAAGTTAA Majority
          7360          7370          7380          7390          7400
7220 TTAACAGCTATTTATATTTTTTATCGATCCTTTAACCACTTCAAAGTTAA 2603_a12.seq
7217 TTAACAGCTATTTATATTTTTTATCGATCCTTTAACCACTTCAAAGTTAA nem316_a12.seq

AATTGGTTTTATTAGTAATTTTTTGATAATCCTTCGGCGAAACTGCTTCTA Majority
          7410          7420          7430          7440          7450
7270 AATTGGTTTTATTAGTAATTTTTTGATAATCCTTCGGCGAAACTGCTTCTA 2603_a12.seq
7267 AATTGGTTTTATTAGTAATTTTTTGATAATCCTTCGGCGAAACTGCTTCTA nem316_a12.seq

TTAACTGATATTTGCCATCTTTCAAATCTTTGTAAGAAATTTTGCCGTTT Majority
          7460          7470          7480          7490          7500
7320 TTAACAGCTATTTATATTTTTTATCGATCCTTTAACCACTTCAAAGTTAA 2603_a12.seq
7317 TTAACAGCTATTTATATTTTTTATCGATCCTTTAACCACTTCAAAGTTAA nem316_a12.seq

TCTCCCGTCACTACTTTTTGAATTAATTTTTTATTGGTAAATAAAAGTTT Majority
          7510          7520          7530          7540          7550
7370 TCTCCCGTCACTACTTTTTGAATTAATTTTTTATTGGTAAATAAAAGTTT 2603_a12.seq
7367 TCTCCCGTCACTACTTTTTGAATTAATTTTTTATTGGTAAATAAAAGTTT nem316_a12.seq

ATAATCTTCATTAATTCCTTGAAGTTCAAACGCTAGCTCCTTTGAGAAGCA Majority
          7560          7570          7580          7590          7600
7420 ATAATCTTCATTAATTCCTTGAAGTTCAAACGCTAGCTCCTTTGAGAAGCA 2603_a12.seq
7417 ATAATCTTCATTAATTCCTTGAAGTTCAAACGCTAGCTCCTTTGAGAAGCA nem316_a12.seq

ACTTATTATTATCTTTATCAACTTTTTGTAAATTC AATTTACCTA AACTTC Majority
          7610          7620          7630          7640          7650
7470 ACTTATTATTATCTTTATCAACTTTTTGTAAATTC AATTTACCTA AACTTC 2603_a12.seq
7467 ACTTATTATTATCTTTATCAACTTTTTGTAAATTC AATTTACCTA AACTTC nem316_a12.seq

TTCTCGTTTTTAATCGTTAATTTGTAAGGATATTTCTCTCACATCACC GAATTTT Majority
          7660          7670          7680          7690          7700
7520 TTCTCGTTTTTAATCGTTAATTTGTAAGGATATTTCTCTCACATCACC GAATTTT 2603_a12.seq
7517 TTCTCGTTTTTAATCGTTAATTTGTAAGGATATTTCTCTCACATCACC GAATTTT nem316_a12.seq

AGGGATTGGAAAAATCTCTAAGTGTATTAGGATCCTCTGATTTAGGATTCA Majority
          7710          7720          7730          7740          7750
7570 AGGGATTGGAAAAATCTCTAAGTGTATTAGGATCCTCTGATTTAGGATTCA 2603_a12.seq
7567 AGGGATTGGAAAAATCTCTAAGTGTATTAGGATCCTCTGATTTAGGATTCA nem316_a12.seq

ATGTTGTTCTACCATTAGTGT CATAGAATTTGTTACTTATAAAA CTGTCA Majority
          7760          7770          7780          7790          7800
7620 ATGTTGTTCTACCATTAGTGT CATAGAATTTGTTACTTATAAAA CTGTCA 2603_a12.seq
7617 ATGTTGTTCTACCATTAGTGT CATAGAATTTGTTACTTATAAAA CTGTCA nem316_a12.seq

```

FIGURE 20K

100/487

	7810	7820	7830	7840	7850	
	TCTAGTTTTCACATCATATGTGAGTGTTACTTTTTGACCTTCTCCTAAGTT					Majority
7670	TCTAGTTTTCACATCATATGTGAGTGTTACTTTTTGACCTTCTCCTAAGTT					2603_a12.seq
7667	TCTAGTTTTCACATCATATGTGAGTGTTACTTTTTGTCCTCCTAAGTT					nen316_a12.seq
	CAAACCTCTAACCTAGAGTTTATTTTTGATGTATTCTAATTTAACCCCTT					Majority
	7860	7870	7880	7890	7900	
7720	CAAACCTCTAACCTAGAGTTTATTTTTGATGTATTCTAATTTAACCCCTT					2603_a12.seq
7717	CAAACCTCTAACCTAGAGTTTATTTTTGATGTATTCTAATTTAACCCCTT					nen316_a12.seq
	TAAGTATTCACCATCATTATTAGGCCACCAGTTGCAATGCTATCTTTC					Majority
	7910	7920	7930	7940	7950	
7770	TAAGTATTCACCATCATTATTAGGCCACCAGTTGCAATGCTATCTTTC					2603_a12.seq
7767	TAAGTATTCACCATCATTATTAGGCCACCAGTTGCAATGCTATCTTTC					nen316_a12.seq
	ATTATACTTCCATCATTCCCTGTAAAGTATAATCACTTGCTTGTAAATGT					Majority
	7960	7970	7980	7990	8000	
7820	ATTATACTTCCATCATTCCCTGTAAAGTATAATCACTTGCTTGTAAATGT					2603_a12.seq
7817	ATTATACTTCCATCATTCCCTGTAAAGTATAATCACTTGCTTGTAAATGT					nen316_a12.seq
	TTGTCCGTTGCCAAGCTGTAAATTGATTTTGTCAACCATAGGATCTTCTA					Majority
	8010	8020	8030	8040	8050	
7870	TTGTCCGTTGCCAAGCTGTAAATTGATTTTGTCAACCATAGGATCTTCTA					2603_a12.seq
7867	TTGTCCGTTGCCAAGCTGTAAATTGATTTTGTCAACCATAGGATCTTCTA					nen316_a12.seq
	TAGTTCCATTAACAATTGAGTTTTCTTTTGTAAATCTTTTCAAATTTGT					Majority
	8060	8070	8080	8090	8100	
7920	TAGTTCCATTAACAATTGAGTTTTCTTTTGTAAATCTTTTCAAATTTGT					2603_a12.seq
7917	TAGTTCCATTAACAATTGAGTTTTCTTTTGTAAATCTTTTCAAATTTGT					nen316_a12.seq
	TGCTGAATTTTAGATAAAATTTCACTTGTAGATGATCGGCTGAAGTTAC					Majority
	8110	8120	8130	8140	8150	
7970	TGCTGAATTTTAGATAAAATTTCACTTGTAGATGATCGGCTGAAGTTAC					2603_a12.seq
7967	TGCTGAATTTTAGATAAAATTTCACTTGTAGATGATCGGCTGAAGTTAC					nen316_a12.seq
	TATCGGGGTGTAGTACTCAGGTTTGGAAAGAGAATGACTTCATTAGTTCTG					Majority
	8160	8170	8180	8190	8200	
8020	TATCGGGGTGTAGTACTCAGGTTTGGAAAGAGAATGACTTCATTAGTTCTG					2603_a12.seq
8017	TATCGGGGTGTAGTACTCAGGTTTGGAAAGAGAATGACTTCATTAGTTCTG					nen316_a12.seq
	TTATTTCTCCATCTGAAAGTTTTAAAGCTTCCCTTTTCAATTTTTTGAAA					Majority
	8210	8220	8230	8240	8250	
8070	TTATTTCTCCATCTGAAAGTTTTAAAGCTTCCCTTTTCAATTTTTTGAAA					2603_a12.seq
8067	TTATTTCTCCATCTGAAAGTTTTAAAGCTTCCCTTTTCAATTTTTTGAAA					nen316_a12.seq
	GTACCATCTTGATTTTTCTTATACTCCTCATTATAAACTTGTCTAAAAGC					Majority
	8260	8270	8280	8290	8300	
8120	GTACCATCTTGATTTTTCTTATACTCCTCATTATAAACTTGTCTAAAAGC					2603_a12.seq
8117	GTACCATCTTGATTTTTCTTATACTCCTCATTATAAACTTGTCTAAAAGC					nen316_a12.seq
	AGATATATCTATACCAAAATTAAGATGTCATAATTTTTCTGTTTTTAAAC					Majority
	8310	8320	8330	8340	8350	
8170	AGATATATCTATACCAAAATTAAGATGTCATAATTTTTCTGTTTTTAAAC					2603_a12.seq
8167	AGATATATCTATACCAAAATTAAGATGTCATAATTTTTCTGTTTTTAAAC					nen316_a12.seq
	TATTTATATAAAGTTTGGTTGGTGTCCATGTTCTTTTACTGGTCCATTT					Majority
	8360	8370	8380	8390	8400	
8220	TATTTATATAAAGTTTGGTTGGTGTCCATGTTCTTTTACTGGTCCATTT					2603_a12.seq
8217	TATTTATATAAAGTTTGGTTGGTGTCCATGTTCTTTTACTGGTCCATTT					nen316_a12.seq
	CGATAAATTTGACCTTTAGGGTAATTAAGATTTAAATCTAAATAATGAAG					Majority
	8410	8420	8430	8440	8450	
8270	CGATAAATTTGACCTTTAGGGTAATTAAGATTTAAATCTAAATAATGAAG					2603_a12.seq
8267	CGATAAATTTGACCTTTAGGGTAATTAAGATTTAAATCTAAATAATGAAG					nen316_a12.seq

FIGURE 20L

101/487

I I I I T T G C T A A G C T T T C C A G A G A T T A T C T G T G T T T G A T A A C T A T C T A A G G G G A A Majority
 8460 8470 8480 8490 8500
 8320 T T T T T G T A A G T T T C C A G A G A T T A T C T G T G T T T G A T A A C T A T C T A A G G G G A A 2603_ai2.seq
 8317 T T T T T G T A A G T T T C C A G A G A T T A T C T G T G T T T G A T A A C T A T C T A A G G G G A A nem316_ai2.seq
 A C A A A A A G T A A C T C T C C C C A T T T C C T T T T A T A T C C T C G G G C T T A T C A G T A Majority
 8510 8520 8530 8540 8550
 8370 A C A A A A A G T A A C T C T C C C C A T T T C C T T T T A T A T C C T C G G G C T T A T C A G T A 2603_ai2.seq
 8367 A C A A A A A G T A A C T C T C C C C A T T T C C T T T T A T A T C C T C G G G C T T A T C A G T A nem316_ai2.seq
 A G T A G A A A A T T A C T T T T A T T T A G A T A T C C A T T T T T T T T C A T T T G T T C A A A Majority
 8560 8570 8580 8590 8600
 8420 A G T A G A A A A T T A C T T T T A T T T A G A T A T C C A T T T T T T T T C A T T T G T T C A A A 2603_ai2.seq
 8417 A G T A G A A A A T T A C T T T T A T T T A G A T A T C C A T T T T T T T T C A T T T G T T C A A A nem316_ai2.seq
 T T G G C T T T C A T A T G A T G C A C C C A G T T T A A A A T T A T T A A T A G C A T A T G A T C Majority
 8610 8620 8630 8640 8650
 8470 T T G G C T T T C A T A T G A T G C A C C C A G T T T A A A A T T A T T A A T A G C A T A T G A T C 2603_ai2.seq
 8467 T T G G C T T T C A T A T G A T G C A C C C A T T T T A A A A T T A T T A A T A G C A T A T G A T C nem316_ai2.seq
 T T G T T G G A A C A C C A T C A G T T A T A T G A A C A A T A A T T T T T T G A C T A T T T C G A Majority
 8660 8670 8680 8690 8700
 8520 T T G T T G G A A C A C C A T C A G T T A T A T G A A C A A T A A T T T T T T G A C T A T T T C G A 2603_ai2.seq
 8517 T T G T T G G A A C A C C A T C A G T T A T A T G A A C A A T A A T T T T T T G A C T A T T T C G A nem316_ai2.seq
 T T T A C T T G A C T C A A A A T A T C A T C T G C C T C C A T G A A G G C T T T C A T A G T A A A Majority
 8710 8720 8730 8740 8750
 8570 T T T A C T T G A C T C A A A A T A T C A T C T G C C T C C A T G A A G G C T T T C A T A G T A A A 2603_ai2.seq
 8567 T T T A C T T G A C T C A A A A T A T C A T C T G C C T C C A T G A A G G C T T T C A T A G T A A A nem316_ai2.seq
 T G T T T C T C C T A C T T T A C T A A G A T A G T A C T G C T T T T G T T C C T C T G G A G T T A Majority
 8760 8770 8780 8790 8800
 8620 T G T T T C T C C T A C T T T A C T A A G A T A G T A C T G C T T T T G T T G C T C T G G A G T T A 2603_ai2.seq
 8617 T G T T T C T C C T A C T T T A C T A A G A T A G T A C T G C T T T T G T T G C T C T G G A G T T A nem316_ai2.seq
 G T C C G T T T G T A G T T G A T C C C A T T T A G C T T T A G G A G C T T C T G T C G G A A T C Majority
 8810 8820 8830 8840 8850
 8670 A T C C A T T T G T A G T T G A T C C C C A T T T A G C T T T A G G A G C T T C T G T C G G A A T C 2603_ai2.seq
 8667 G T C C G T T T G T A G T T G A T C C C C A T T T A G C T T T A G G A G C T T C T G T A G G A A T C nem316_ai2.seq
 C T T T T T A T A A T C T C T T C A G C A T T A T T T G T T A A T T G T T T A T G A C T A T A A T T Majority
 8860 8870 8880 8890 8900
 8720 C T T T T T A T A A T C T C T T C A G C A T T A T T T G T T A A T T G T T T A T G A C T A T A A T T 2603_ai2.seq
 8717 C T T T T T A T A A T C T C T T C A G C A T T A T T T G T T A A T T G T T T A T G A C T A T A A T T nem316_ai2.seq
 C T C T G T C T G A A T T G T G A A C T T A G T T T G A A G G C C A T A A T A T T T A T C A T C T T Majority
 8910 8920 8930 8940 8950
 8770 C T C T G T C T G A A T T G T G A A C T T A G T T T G A A G G C C A T A A T A T T T A T C A T C T T 2603_ai2.seq
 8767 C T C T G T C T G A A T T G T G A A C T T A G T T T G A A G G C C A T A A T A T T T A T C A T C T T nem316_ai2.seq
 C T T T A A A T C C T T T T A C G A C A T C T A C A C T C C T A C C A T C A A A A A T A T C T G A A Majority
 8960 8970 8980 8990 9000
 8820 C T T T A A A T C C T T T T A C G A C A T C T A C A C T C C T A C C A T C A A A A A T A T C T G A A 2603_ai2.seq
 8817 C T T T A A A T C C T T T T A C G A C A T C T A C A C T C C T A C C A T C A A A A A T A T C T G A A nem316_ai2.seq
 C C A T A G G T A A C T A A T G C A A C C C T A T T A T C A C T G T T T G C T C C T A A A A T A T C Majority
 9010 9020 9030 9040 9050
 8870 C C A T A G G T A A C T A A T G C A A C C C T A T T A T C A C T G T T T G C T C C T A A A A T A T C 2603_ai2.seq
 8867 C C A T A G G T A A C T A A T G C A A C C C T A T T A T C A C T G T T T G C T C C T A A A A T A T C nem316_ai2.seq
 T T T T A C T G C C G T C C C A A G A G C T T C G G C A G C T T T C T T G G C T T T A T T A T G C C Majority
 9060 9070 9080 9090 9100
 8920 T T T T A C T G C C G T C C C A A G A G C T T C G G C A G C T T T C T T G G C T T T A T T A T G C C 2603_ai2.seq
 8917 T T T T A C T G C C G T C C C A A G A G C T T C G G C A G C T T T C T T G G C T T T A T T A T G C C nem316_ai2.seq

FIGURE 20M

102/487



FIGURE 20N

103/487

A C G G T A C T T T C C C C T A A A A C A T T G G T A T T A A G C G G T A T T T G C G A C A A A C A Majority
 9760 9770 9780 9790 9800
 9620 A C G G T A C T T T C C C C T A A A A C A T T G G T A T T A A G C G G T A T T T G C G A C A A A C A 2603_al2.seq
 9617 A C G G T A C T T T C C C C T A A A A C A T T G G T A T T A A G C G G T A T T T G C G A C A A A C A nem316_al2.seq
 A A A A A G A C T T A A C G T C A A T A T T T T A G A A A A T T T T T G G T A T T T T C T C A T T T Majority
 9810 9820 9830 9840 9850
 9670 A A A A A G A C T T A A C G T C A A T A T T T T A G A A A A T T T T T G G T A T T T T C T C A T T T 2603_al2.seq
 9667 A A A A A G A C T T A A C G T C A A T A T T T T A G A A A A T T T T T G G T A T T T T C T C A T T T nem316_al2.seq
 T A C A A C T C C T A T T G T G C C G A A A T G T C G T T T C T A A A T C T A A G A T C A G A T A C Majority
 9860 9870 9880 9890 9900
 9720 T A C A A C T C C T A T T G T G C C G A A A T G T C G T T T C T A A A T C T A A G A T C A G A T A C 2603_al2.seq
 9717 T A C A A C T C C T A T T G T G C C G A A A T G T C G T T T C T A A A T C T A A G A T C A G A T A C nem316_al2.seq
 A G A A T A T C C T A G A A T A T A C A A A C T A T C A C T T A T T A T G A T A T C A A T A A T T T Majority
 9910 9920 9930 9940 9950
 9770 A G A A T A T C C T A G A A T A T A C A A A C T A T C A C T T A T T A T G A T A T C A A T A A T T T 2603_al2.seq
 9767 A G A A T A T C C T A G A A T A T A C A A A C T A T C A C T T A T T A T G A T A T C A A T A A T T T nem316_al2.seq
 C T T A T T A T A A G G T A T G G A A T T T T A A T G T T T T T C C C A A T T T T T G A A T G A T Majority
 9960 9970 9980 9990 10000
 9820 C T T A T T A T A A G G T A T G G A A T T T T A A T G T T T T T C C C A A T T T T T G A A T A T 2603_al2.seq
 9817 C T T A T T A T A A G G T A T G G A A T T T T A A T G T T T T T C C C A A T T T T T G A A T G A T nem316_al2.seq
 T T T T C T T T T A T T T G A T A A T C T T A T T T T T A T T A T C T T A G A A A T A T T T C A Majority
 10010 10020 10030 10040 10050
 9870 T T T T C T T T T A T T T G A T A A T C T T A T T T T T A T T A T C T T A G A A A T A T T T C A 2603_al2.seq
 9867 T T T T C T T T T A T T T G A T A A T C T T A T T T T T A T T A T C T T A G A A A T A T T T C A nem316_al2.seq
 A T T A G C T T A A G T A G T T G A T T T T T C T T T T T A T G T T T T A A A A T A T T G C T T Majority
 10060 10070 10080 10090 10100
 9920 A T T A G C T T A A G T A G T T G A T T T T T C T T T T T A T G T T T T A A A A T A T T G C T T 2603_al2.seq
 9917 A T T A G C T T A A G T A G T T G A T T T T T C T T T T T A T G T T T T A A A A T A T T G C T T nem316_al2.seq
 A A A A A T A A T G T T T G A G A G A G A G T T T A C T G A A T T G A T T G A A A A T T A T T T A C Majority
 10110 10120 10130 10140 10150
 9970 A A A A A T A A T G T T T G A G A G A G A G T T T A C T G A A T T G A T T G A A A A T T A T T T A G 2603_al2.seq
 9967 A A A A A T A A T G T T T G A G A G A G A G T T T A C T G A A T T G A T T G A A A A T T A T T T A C nem316_al2.seq
 A A A A A G A C A T C C T T A A T C A A A T A A A A C T T C T A A C T T T A T G C T A T G A T T A C Majority
 10160 10170 10180 10190 10200
 10018 A A A A A G A C A T C C T T A A T C A A A T A A A A C T T C T A A C T T T A T G C T A T G A T T A C 2603_al2.seq
 10017 A A A A A G A C A T C C T T A A T C A A A T A A A A C T T C T A A C T T T A T G C T A T G A T T A C nem316_al2.seq
 T A C C C T T C C A T T A C T C T A G A C A A A T C A T G T C A T C A A C T T G G T T T A T C T G A Majority
 10210 10220 10230 10240 10250
 10068 T A C C C T T C C A T T A C T C T A G A C A A A T C A T G T C A T C A A C T T G G T T T A T C T G A 2603_al2.seq
 10067 T A C C C T T C C A T T A C T C T A G A C A A A T C A T G T C A T C A A C T T G G T T T A T C T G A nem316_al2.seq
 A C T A C T T A T T A G G A A A T A T T G T C A T G A T T T A A C A A C T T T A T T T A A C A G T C Majority
 10260 10270 10280 10290 10300
 10118 A C T A C T T A T T A G G A A A T A T T G T C A T G A T T T A A C A A C T T T A T T T A A C A G T C 2603_al2.seq
 10117 A C T A C T T A T T A G G A A A T A T T G T C A T G A T T T A A C A A C T T T A T T T A A C A G T C nem316_al2.seq
 A A C T C T C T C T G A A T A T C G A A A A G A G T A C A A T A G T C T A C C A A T C T A A T G G T Majority
 10310 10320 10330 10340 10350
 10168 A A C T C T C T C T G A A T A T C G A A A A G A G T A C A A T A G T C T A C C A A T C T A A T G G T 2603_al2.seq
 10167 A A C T C T C T C T G A A T A T C G A A A A G A G T A C A A T A G T C T A C C A A T C T A A T G G T nem316_al2.seq
 G T A A C T A G A G A A C A A G C T T T C A A A T A T A T T T A T C A T C A A T C A C A C G T T T T Majority
 10360 10370 10380 10390 10400
 10218 G T A A C T A G A G A A C A A G C T T T C A A A T A T A T T T A T C A T C A A T C A C A C G T T T T 2603_al2.seq
 10217 G T A A C T A G A G A A C A A G C T T T C A A A T A T A T T T A T C A T C A A T C A C A C G T T T T nem316_al2.seq

FIGURE 200

104/487

A C A A C G T T T T A A A A T T T T T G A T C A C G A A T G A T T C A G G C A G G T T A C C T T T A A Majority
 10410 10420 10430 10440 10450
 10268 A C A A C T T T T A A A A T T T T T G A T C A C G A A T G A T T C A G G C A G G T T A C C T T T A A 2603_ai2.seq
 10267 A C A A C T T T T A A A A T T T T T G A T C A C G A A T G A T T C A G G C A G G T T A C C T T T A A nem316_ai2.seq
 C T T A C T T T A G T G A A A A A T T T G G A C T A T C T T G T G C A A C T G C T T A T C G C A T A Majority
 10460 10470 10480 10490 10500
 10318 C T T A C T T T A G T G A A A A A T T T G G A C T A T C T T G T G C A A C T G C T T A T C G C A T A 2603_ai2.seq
 10317 C T T A C T T T A G T G A A A A A T T T G G A C T A T C T T G T G C A A C T G C T T A T C G C A T A nem316_ai2.seq
 C G A A A A C A T A T T A G T C C G T T A C T A G A A A A A C T T G G A T T T C A G A T T T T C A A Majority
 10510 10520 10530 10540 10550
 10368 C G A A A A C A T A T T A G T C C A T T A C T A G A A A A A C T T G G A T T T C A G A T T T T C A A 2603_ai2.seq
 10367 C G A A A A C A T A T T A G T C C G T T A C T A G A A A A A C T T G G A T T T A A G A T T T T C A A nem316_ai2.seq
 A A A T A C T A T T A C C G G T G A C C A G T A T C G A A T T C G C T A T T T A A T C G C A T T T T Majority
 10560 10570 10580 10590 10600
 10418 A A A T A C T A T T A C C G G T G A C C A G T A T C G A A T T C C C T A T T T A A T C G C A T T T T 2603_ai2.seq
 10417 A A A T A C T A T T A C C G G T G A C C A G T A T C G A A T T C G C T A T T T A A T C G C A C A T T T nem316_ai2.seq
 T A A A T G C T C G A T T T G G T A T A G A A G T T T A T C C C T T G T C T A A G A T G G A T A A A Majority
 10610 10620 10630 10640 10650
 10468 T A A A T G C T C A A T T T G G T A T A G A A G T T T A T C C C A T G T C T A A G A T G G A T A A A 2603_ai2.seq
 10467 T A A A T G C T C G A T T T G G T A T A G A A G T T T A T C C C T T A T C T A A G A T G G A T A A A nem316_ai2.seq
 T T G C T T A T C A A A C G A T T G T T A T T A G A A T A C T C A A C T A C T T T T A C T G C T T C Majority
 10660 10670 10680 10690 10700
 10518 T T G C T T A T C A A A C G A T T G T T A T T A G A A A T A C T C A A C T A C T T T T A C T G C T T C 2603_ai2.seq
 10517 T T G C T T A T C A A A C G A T T G T T A T T A G A A T A C T C A A C T A C T T T T A C T G C T T C nem316_ai2.seq
 T C A T T A C T T C C C A A A T A C A T T T A T T T T C T T T G A T A C A T T G T T G T C T C T A T Majority
 10710 10720 10730 10740 10750
 10568 T C A T T A C T T C C C A A A T A C A T T T A T T T T C T T T G A T A C A T T G T T G T C T C T A T 2603_ai2.seq
 10567 T C A T T A C T T C C C A A A T A C A T T T A T T T T C T T T G A T A C A T T A T T T G T C T C T A T nem316_ai2.seq
 C A T G G A A A C G T A T T A A T T A T A A T G T A G T T G T C C C T T A C T C A T C C C T T T T C Majority
 10760 10770 10780 10790 10800
 10618 C A T G G A A A C G T A T T A A T T A A A T G T A G T T G T C C C T T A C T C A T C C C T T T T C 2603_ai2.seq
 10617 C A T G G A A A C G T A T T A A T T A A A T G T A G T T G T C C C T T A C T C A T C C C T T T T C nem316_ai2.seq
 A T T G A A C T A C A A A A T A T A T T T A T C T A T G A T A C A T T A C A A T A T T G T G T C A A Majority
 10810 10820 10830 10840 10850
 10668 A T T G A A C T A C A A A A T A T A T T T A T C T A T G A T A C A T T A C A A T A T T G T G T C A A 2603_ai2.seq
 10667 A T T G A A C T A C A A A A T A T A T T T A T C T A T G A T A C A T T A C A A T A T T G T G T C A A nem316_ai2.seq
 A A A T G T T A T T A T A G A T T C C T T T A A A A T T A A T T T A A A A A A A G A C G A T A T A G Majority
 10860 10870 10880 10890 10900
 10718 A A A T G T T A T T A T A G A T T C C T T T A A A A T T A A T T T A A A A A A A G A C G A T A T A G 2603_ai2.seq
 10717 A A A T G T T A T T A T A G A T T C C T T T A A A A T T A A T T T A A A A A A A G A C G A T A T A G nem316_ai2.seq
 A C T A T A T T T T C T T G C T T A C G T T A C T T C C C A T A A C T C T T T T T C T A A T C C A Majority
 10910 10920 10930 10940 10950
 10768 A C T A T A T T T T C T T G C T T A C C T T A C T T C C C A T A A C T C T T T T T C T A A T C C A 2603_ai2.seq
 10767 A C T A T A T T T T C T T G C T T A C C T T A C T T C C C A T A A C T C T T T T T C T A A T C C A nem316_ai2.seq
 A A T T G C A C T G A G A A G C G T A T C G A T A A T G T A A T A G C T A T T T T C G A A A A T T A Majority
 10960 10970 10980 10990 11000
 10818 A A T T G C A C T G A G A A G C G T A T C G A T A A T G T A A T A G C T A T T T T C G A A A A T T A 2603_ai2.seq
 10817 A A T T G C A C T G A G A A G C G T A T C G A T A A T G T A A T A G C T A T T T T C G A A A A T T A nem316_ai2.seq
 T C C C A A A T T C C A A A A T T A T T A C A G C C A C T C A A A G A T G C T C T T C C C T T A T Majority
 11010 11020 11030 11040 11050
 10868 T C C C A A A T T C C A A A A T T A T T A C A G C C A C T C A A A G A T G C T C T T C C C T T A T 2603_ai2.seq
 10867 T C C C A A A T T C C A A A A T T A T T A C A G C C A C T C A A A G A T G C T C T T C C C T T A T nem316_ai2.seq

FIGURE 20P

CTGGCTCCTATCATGAGTTGGTAAAGTTGCTATCATTITTTTCCGA Majority
 11060 11070 11080 11090 11100
 10918 CTGGCTCCTATCATGAGTTGGTAAAGTTGCTATCATTITTTTCCGA 2603_a12.seq
 10917 CTGGCTCCTATCATGAGTTGGTAAAGTTGCTATCATTITTTTCCGA nem316_a12.seq
 ACATTTATTTTAGGATTAATCAATTAATCCCTGAAACAATTTTCATTTCC Majority
 11110 11120 11130 11140 11150
 10967 ACATTTATTTTAGGATTAATCAATTAATCCCTGAAACAATTTTCATTTCC 2603_a12.seq
 10967 ACATTTATTTTAGGATTAATCAATTAATCCCTGAAACAATTTTCATTTCC nem316_a12.seq
 TTCATGGAACATCATAGACATGATAAATTA ACTACTATTCTCCGACCGA Majority
 11160 11170 11180 11190 11200
 11017 TTCATGGAACATCATAGACATGATAAATTA ACTACTATTCTCCGACCGA 2603_a12.seq
 11017 TTCATGGAACATCATAGACATGATAAATTA ACTACTATTCTCCGACCGA nem316_a12.seq
 TAATTACAAATTGGTTAAGTGA AATTGGAGAATACACGTTTAAGGAACAA Majority
 11210 11220 11230 11240 11250
 11067 TAATTACAAATTGGTTAAGTGA AATTGGAGAATACACGTTTAAGGAACAA 2603_a12.seq
 11067 TAATTACAAATTGGTTAAGTGA AATTGGAGAATACACGTTTAAGGAACAA nem316_a12.seq
 CATTITTTCTTCTCCTTTTGTGCTCATCTAGAAAGAATTATCAAAAATCATAT Majority
 11260 11270 11280 11290 11300
 11117 CATTITTTCTTCTCCTTTTGTGCTCATCTAGAAAGAATTATCAAAAATCATAT 2603_a12.seq
 11117 CATTITTTCTTCTCCTTTTGTGCTCATCTAGAAAGAATTATCAAAAATCATAT nem316_a12.seq
 TCCTCCGATACAGATAGCCGFACTA ACTACAGACTTTATTAATAACCAA Majority
 11310 11320 11330 11340 11350
 11167 TCCTCCGATACAGATAGCCGFACTA ACTACAGACTTTATTAATAACCAA 2603_a12.seq
 11167 TCCTCCGATACAGATAGCCGFACTA ACTACAGACTTTATTAATAACCAA nem316_a12.seq
 TTTTAACAGAAATGTTTATTACAGAGGTTTTCTTCTAAACAGATTCATTTCC Majority
 11360 11370 11380 11390 11400
 11217 TTTTAACAGAAATGTTTATTACAGAGGTTTTCTTCTAAACAGATTCATTTCC 2603_a12.seq
 11217 TTTTAACAGAAATGTTTATTACAGAGGTTTTCTTCTAAACAGATTCATTTCC nem316_a12.seq
 CACCCTTACTATTTATTA AACTGATGATCTTTCCAATATTACTAATCTTAA Majority
 11410 11420 11430 11440 11450
 11267 CACCCTTACTATTTATTA AACTGATGATCTTTCCAATATTACTAATCTTAA 2603_a12.seq
 11267 CACCCTTACTATTTATTA AACTGATGATCTTTCCAATATTACTAATCTTAA nem316_a12.seq
 FCCAGATATTATTATTACCAATCCAAAGCTTTCTTCTTTATCAAACATG Majority
 11460 11470 11480 11490 11500
 11317 FCCAGATATTATTATTACCAATCCAAAGCTTTCTTCTTTATCAAACATG 2603_a12.seq
 11317 FCCAGATATTATTATTACCAATCCAAAGCTTTCTTCTTTATCAAACATG nem316_a12.seq
 AGATTTCTTTCAGAGAGTTTAATTACATATATTGATTGATTCATACTTTCA Majority
 11510 11520 11530 11540 11550
 11367 AGATTTCTTTCAGAGAGTTTAATTACATATATTGATTGATTCATACTTTCA 2603_a12.seq
 11367 AGATTTCTTTCAGAGAGTTTAATTACATATATTGATTGATTCATACTTTCA nem316_a12.seq
 GACCAGATCAATCAAATCCAAGCAATTATTTTCATCAATACAGGAAGAAA Majority
 11560 11570 11580 11590 11600
 11417 GACCAGATCAATCAAATCCAAGCAATTATTTTCATCAATACAGGAAGAAA 2603_a12.seq
 11417 GACCAGATCAATCAAATCCAAGCAATTATTTTCATCAATACAGGAAGAAA nem316_a12.seq
 ATATTGTAAACTTTTTTGCAAAAACATAATGAAATAACTACTCGTAGCTCCT Majority
 11610 11620 11630 11640 11650
 11467 ATATTGTAAACTTTTTTGCAAAAACATAATGAAATAACTACTCGTAGCTCCT 2603_a12.seq
 11467 ATATTGTAAACTTTTTTGCAAAAACATAATGAAATAACTACTCGTAGCTCCT nem316_a12.seq
 ATAACCTTTAAAAAATTAACATTA AAAAGCTAGAGCATTGCTGTAATGCTCT Majority
 11660 11670 11680 11690 11700
 11517 ATAACCTTTAAAAAATTAACATTA AAAAGCTAGAGCATTGCTGTAATGCTCT 2603_a12.seq
 11517 ATAACCTTTAAAAAATTAACATTA AAAAGCTAGAGCATTGCTGTAATGCTCT nem316_a12.seq

FIGURE 20Q

106/487

A G C T T T T T T A A T G T T A A T T T T T T T G A A T A A T A T A T A A T C C A A C T T T T T C A A C T G Majority
 11710 11720 11730 11740 11750
 11567 A G C T T T T T T A A T G T T A A T T T T T T T G A A T A A T A T A T A A T C C A A C T T T T T C A A C T G 2603_al2.seq
 11567 A G C T T T T T T A A T G T T A A T T T T T T T G A A T A A T A T A T A A T C C A A C T T T T T C A A C T G nem316_al2.seq
T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G T Majority
 11760 11770 11780 11790 11800
 11617 T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G T 2603_al2.seq
 11617 T T T T T T C C C A T G T G A A A T G T T C T T T A A T T C T T T T A G C A A T A T T C T G T T G T nem316_al2.seq
A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T G Majority
 11810 11820 11830 11840 11850
 11667 A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T G 2603_al2.seq
 11667 A G T T T C T C T C T T A A T G C C T T A T C T T T T A C T A A T A A A T C A A G A G A T T C A T G nem316_al2.seq
G A G T G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A T C A A Majority
 11860 11870 11880 11890 11900
 11717 G A G T G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A T C A A 2603_al2.seq
 11717 G A G T G A C T G A G T A T T T T C T T C C A T G A T G A T T C C T A A C T C A G G G C T A T C A A nem316_al2.seq
T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C A C T T G A A A G T Majority
 11910 11920 11930 11940 11950
 11767 T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C A C T T G A A A G T 2603_al2.seq
 11767 T A A C T T C A A C T G T T C C A C C G C G A T C T G T T G C A A T A A T A G C A C T T G A A A G T nem316_al2.seq
A G A C C A G C T T C T A A A A T A G A G G T T G G T A A T C C C T C T G G A T A C A T T G A A G G Majority
 11960 11970 11980 11990 12000
 11817 A G A C C A G C T T C T A A A A T A G A G G T T G G T A A T C C C T C T G G A T A C A T T G A A G G 2603_al2.seq
 11817 A G A C C A G C T T C T A A A A T A G A G G T T G G T A A T C C C T C T G G A T A C A T T G A A G G nem316_al2.seq
G T A A A C A A A G A T A T C A G T C T G T G C C A T T A A A G A C A T A G T C T G T T C A A A G T Majority
 12010 12020 12030 12040 12050
 11867 G T A A A C A A A G A T A T C A G T C T G T G C C A T T A A A G A C A T A G T C T G T T C A A A G T 2603_al2.seq
 11867 G T A A A C A A A G A T A T C A G T C T G T G C C A T T A A A G A C A T A G T C T G T T C A A A G T nem316_al2.seq
T T A A T T T C C C C A A A A A G T T A A T C T G T T T G G A C T G A T A T T T C T C T T T C A A A Majority
 12060 12070 12080 12090 12100
 11917 T T A A T T T C C C C A A A A A G T T A A T C T G T T T G G A C T G A T A T T T C T C T T T C A A A 2603_al2.seq
 11917 T T A A T T T C C C C A A A A A G T T A A T C T G T T T G G A C T G A T A T T T C T C T T T C A A A nem316_al2.seq
T G T G C T A A A T T C A G G T C C G T C T C C T G C A A T C T G T A A A T A A A C A T T T T C A G A Majority
 12110 12120 12130 12140 12150
 11967 T G T G C T A A A T T C A G G T C C G T C T C C T G C A A T C T G T A A A T A A A C A T T T T C A G A 2603_al2.seq
 11967 T G T G C T A A A T T C A G G T C C G T C T C C T G C A A T C T G T A A A T A A A C A T T T T C A G A nem316_al2.seq
G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A T T C A A T G C C T T T T T C T T Majority
 12160 12170 12180 12190 12200
 12017 G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A T T C A A T G C C T T T T T C T T 2603_al2.seq
 12017 G T A C T G T G A C A T C G A A A A T G C T T C T A A G A G C A A T T C A A T G C C T T T T T C T T nem316_al2.seq
T A A T A A T T C T A C C A G C A T A A A G T G A T G A A A A T A T C A T C A G C A G A T T T T T C A Majority
 12210 12220 12230 12240 12250
 12067 T A A T A A T T C T A C C A G C A T A A A G T G A T G A A A A T A T C A T C A G C A G A T T T T T C A 2603_al2.seq
 12067 T A A T A A T T C T A C C A G C A T A A A G T G A T G A A A A T A T C A T C A G C A G A T T T T T C A nem316_al2.seq
A G G T A A G C C G T A C C A G C A A A A T C A G A G C C T A G A C T T T C A G A T A C C G A A T T Majority
 12260 12270 12280 12290 12300
 12117 A G G T A A G C C G T A C C A G C A A A A T C A G A G C C T A G A C T T T C A G A T A C C G A A T T 2603_al2.seq
 12117 A G G T A A G C C G T A C C A G C A A A A T C A G A G C C T A G A C T T T C A G A T A C C G A A T T nem316_al2.seq
A T A A A T A A C T C C T T T A G C T T C T A T A T T A A A A T G T T T T A A C C A T T C A A C G C Majority
 12310 12320 12330 12340 12350
 12167 A T A A A T A A C T C C T T T A G C T T C T A T A T T A A A A T G T T T T A A C C A T T C A A C G C 2603_al2.seq
 12167 A T A A A T A A C T C C T T T A G C T T C T A T A T T A A A A T G T T T T A A C C A T T C A A C G C nem316_al2.seq

FIGURE 20R

107/487

TTCTCTTTGGATACCGCATAAAAATCTGGACGATAATGCTTAAACACGCGCT Majority
 12360 12370 12380 12390 12400

12217 TTCTCTTTGGATACCGCATAAAAATCTGGACGATAATGCTTAAACACGCGCT 2603_a12.seq
 12217 TTCTCTTTGGATACCGCATAAAAATCTGGACGATAATGCTTAAACACGCGCT nem316_a12.seq

GTGAGAAGATGTTTCATAGATAGCTCCAAAGAAATCTAAAAAACGATTATT Majority
 12410 12420 12430 12440 12450

12267 GTGAGAAGATGTTTCATAGATAGCTCCAAAGAAATCTAAAAAACGATTATT 2603_a12.seq
 12267 GTGAGAAGATGTTTCATAGATAGCTCCAAAGAAATCTAAAAAACGATTATT nem316_a12.seq

GACAGAAAAATGACTTTGACCCATGGTCTAAAAACAATACTAGGTAATGGT Majority
 12460 12470 12480 12490 12500

12317 GACAGAAAAATGACTTTGACCCATGGTCTAAAAACAATACTAGGTAATGGT 2603_a12.seq
 12317 GACAGAAAAATGACTTTGACCCATGGTCTAAAAACAATACTAGGTAATGGT nem316_a12.seq

GATTCCTTTGCAAAAAGATAGCCCTTCTAGCGTTGTTAACTGAAAACCTGTA Majority
 12510 12520 12530 12540 12550

12367 GATTCCTTTGCAAAAAGATAGCCCTTCTAGCGTTGTTAACTGAAAACCTGTA 2603_a12.seq
 12367 GATTCCTTTGCAAAAAGATAGCCCTTCTAGCGTTGTTAACTGAAAACCTGTA nem316_a12.seq

TTACAAATCACAAAATCAATATTTTTCATCTGAAACATATTTTCATCAGCGT Majority
 12560 12570 12580 12590 12600

12417 TTACAAATCACAAAATCAATATTTTTCATCTGAAACATATTTTCATCAGCGT 2603_a12.seq
 12417 TTACAAATCACAAAATCAATATTTTTCATCTGAAACATATTTTCATCAGCGT nem316_a12.seq

GTGTATTCTCGATTTTTGTTAATAATAGGATAGCGCTGCTTGACAATAT Majority
 12610 12620 12630 12640 12650

12467 GTGTATTCTCGATTTTTGTTAATAATAGGATAGCGCTGCTTGACAATAT 2603_a12.seq
 12467 GTGTATTCTCGATTTTTGTTAATAATAGGATAGCGCTGCTTGACAATAT nem316_a12.seq

TTTTGGTCGGTAAACGGTAAATTTTTCTACCCCTTGTCTTCATCTATAATC Majority
 12660 12670 12680 12690 12700

12517 TTTTGGTCGGTAAACGGTAAATTTTTCTACCCCTTGTCTTCATCTATAATC 2603_a12.seq
 12517 TTTTGGTCGGTAAACGGTAAATTTTTCTACCCCTTGTCTTCATCTATAATC nem316_a12.seq

GGTAAATCACCATGATTAGTTGTTACAATAACAACACGGTAGCCACGCTT Majority
 12710 12720 12730 12740 12750

12567 GGTAAATCACCATGATTAGTTGTTACAATAACAACACGGTAGCCACGCTT 2603_a12.seq
 12567 GGTAAATCACCATGATTAGTTGTTACAATAACAACACGGTAGCCACGCTT nem316_a12.seq

AACCAAATCTGCTGTCATTTTTATCTGTATAACGTTCAATACCTCCGAGGA Majority
 12760 12770 12780 12790 12800

12617 AACCAAATCTGCTGTCATTTTTATCTGTATAACGTTCAATACCTCCGAGGA 2603_a12.seq
 12617 AACCAAATCTGCTGTCATTTTTATCTGTATAACGTTCAATACCTCCGAGGA nem316_a12.seq

AGGGTAGATAAATATCCTGAGAAAACAGCAACTGTTTTTACCTTATTTTCC Majority
 12810 12820 12830 12840 12850

12667 AGGGTAGATAAATATCCTGAGAAAACAGCAACTGTTTTTACCTTATTTTCC 2603_a12.seq
 12667 AGGGTAGATAAATATCCTGAGAAAACAGCAACTGTTTTTACCTTATTTTCC nem316_a12.seq

ATATTTATCCACTTTCATCAATAAGCCATCTTTTAAGCCTTTAATCATAG Majority
 12860 12870 12880 12890 12900

12717 ATATTTATCCACTTTCATCAATAAGCCATCTTTTAAGCCTTTAATCATAG 2603_a12.seq
 12717 ATATTTATCCACTTTCATCAATAAGCCATCTTTTAAGCCTTTAATCATAG nem316_a12.seq

CAACTATTTTTTTGCTCTTTTCTCTCTTCTGCTACCAACA CTGGAACAAAAT Majority
 12910 12920 12930 12940 12950

12767 CAACTATTTTTTTGCTCTTTTCTCTCTTCTGCTACCAACA CTGGAACAAAAT 2603_a12.seq
 12767 CAACTATTTTTTTGCTCTTTTCTCTCTTCTGCTACCAACA CTGGAACAAAAT nem316_a12.seq

TCATTTTCGCATAAAATACTAAATATTTGTATCGCTTCTTCTTACCATAATTT Majority
 12960 12970 12980 12990 13000

12817 TCATTTTCGCATAAAATACTAAATATTTGTATCGCTTCTTCTTACCATAATTT 2603_a12.seq
 12817 TCATTTTCGCATAAAATACTAAATATTTGTATCGCTTCTTCTTACCATAATTT nem316_a12.seq

FIGURE 20S

108/487

TTTATAAATATAGATCGCATTGCGTATCATGTAATATTTTCGAAATGGTG Majority
 13010 13020 13030 13040 13050

12867 TTTATAAATATAGATCGCATTGCGTATCATGTAATATTTTCGAAATGGTG 2603_a12.seq
 12867 TTTATAAATATAGATCGCATTGCGTATCATGTAATATTTTCGAAATGGTG nem316_a12.seq

AATGATTCAATACATGAAAAACATGGCCAAATTTTTTAACCTCGTGAAGAG Majority
 13060 13070 13080 13090 13100

12917 AATGATTCAATACATGAAAAACATGGCCAAATTTTTTAACCTCGTGAAGAG 2603_a12.seq
 12917 AATGATTCAATACATGAAAAACATGGCCAAATTTTTTAACCTCGTGAAGAG nem316_a12.seq

TGTCCAATTTTCGTGTAACAGACCAATAAAATTAACCTGATAAGTCTTATA Majority
 13110 13120 13130 13140 13150

12967 TGTCCAATTTTCGTGTAACAGACCAATAAAATTAACCTGATAAGTCTTATA 2603_a12.seq
 12967 TGTCCAATTTTCGTGTAACAGACCAATAAAATTAACCTGATAAGTCTTATA nem316_a12.seq

TCCCATCTCTGACAGACGATAAATTCATTTTCAGAGTCAACAATAATCAATAA Majority
 13160 13170 13180 13190 13200

13017 TCCCATCTCTGACAGACGATAAATTCATTTTCAGAGTCAACAATAATCAATAA 2603_a12.seq
 13017 TCCCATCTCTGACAGACGATAAATTCATTTTCAGAGTCAACAATAATCAATAA nem316_a12.seq

ACATCTCTTCTGCAAAGCCAGATGTTTCTTCGAAAACGCTCGTTTTTCATT Majority
 13210 13220 13230 13240 13250

13067 ACATCTCTTCTGCAAAGCCAGATGTTTCTTCGAAAACGCTCGTTTTTCATT 2603_a12.seq
 13067 ACATCTCTTCTGCAAAGCCAGATGTTTCTTCGAAAACGCTCGTTTTTCATT nem316_a12.seq

AAAGCAGCCGAAGTAATACACTCTTCAATTTCTTTATAGTCAAATTCCTTG Majority
 13260 13270 13280 13290 13300

13117 AAAGCAGCCGAAGTAATACACTCTTCAATTTCTTTATAGTCAAATTCCTTG 2603_a12.seq
 13117 AAAGCAGCCGAAGTAATACACTCTTCAATTTCTTTATAGTCAAATTCCTTG nem316_a12.seq

CATCACTAAAATTTTCACGGTTCATATCTTGATACAAACAAGATAACATAC Majority
 13310 13320 13330 13340 13350

13167 CATCACTAAAATTTTCACGGTTCATATCTTGATACAAACAAGATAACATAC 2603_a12.seq
 13167 CATCACTAAAATTTTCACGGTTCATATCTTGATACAAACAAGATAACATAC nem316_a12.seq

CGACCTTAGGTAAAATGAAGGTAATTTTTCATAATTATCTATCAAATCACCT Majority
 13360 13370 13380 13390 13400

13217 CGACCTTAGGTAAAATGAAGGTAATTTTTCATAATTATCTATCAAATCACCT 2603_a12.seq
 13217 CGACCTTAGGTAAAATGAAGGTAATTTTTCATAATTATCTATCAAATCACCT nem316_a12.seq

AGGACAACCGAATCTTGATCTAAAGTCAA GAACCAATCAAATTCCTTGTC Majority
 13410 13420 13430 13440 13450

13267 AGGACAACCGAATCTTGATCTAAAGTCAA GAACCAATCAAATTCCTTGTC 2603_a12.seq
 13267 AGGACAACCGAATCTTGATCTAAAGTCAA GAACCAATCAAATTCCTTGTC nem316_a12.seq

TACTGCAAATTEGACCGATACAGTTCAAAGCATATGCAATCCCTTTATTTT Majority
 13460 13470 13480 13490 13500

13317 TACTGCAAATTEGACCGATACAGTTCAAAGCATATGCAATCCCTTTATTTT 2603_a12.seq
 13317 TACTGCAAATTEGACCGATACAGTTCAAAGCATATGCAATCCCTTTATTTT nem316_a12.seq

CTGTTAAATAATCAACAGTTAGGGTCCCTCTTCAATATAATCGGCTACT Majority
 13510 13520 13530 13540 13550

13367 CTGTTAAATAATCAACAGTTAGGGTCCCTCTTCAATATAATCGGCTACT 2603_a12.seq
 13367 CTGTTAAATAATCAACAGTTAGGGTCCCTCTTCAATATAATCGGCTACT nem316_a12.seq

AATTGAGAAAATTTCTTCTTATTTTTTCGAGCCATTATCTACGATATAGAT Majority
 13560 13570 13580 13590 13600


13417 AATTGAGAAAATTTCTTCTTATTTTTTCGAGCCATTATCTACGATATAGAT 2603_a12.seq
 13417 AATTGAGAAAATTTCTTCTTATTTTTTCGAGCCATTATCTACGATATAGAT nem316_a12.seq

GTGGCTTACTTGAGGATAAAATTCCTCGAATGTTCTGATCTAAGCGTTCAA Majority
 13610 13620 13630 13640 13650

13467 GTGGCTTACTTGAGGATAAAATTCCTCGAATGTTCTGATCTAAGCGTTCAA 2603_a12.seq
 13467 GTGGCTTACTTGAGGATAAAATTCCTCGAATGTTCTGATCTAAGCGTTCAA nem316_a12.seq

FIGURE 20T

109/487



Decoration 'Decoration #1': Shade (with solid black) residues that differ from the Consensus.

FIGURE 20U

110/487

```

T C C A C A T C G G T C C A A T T A A C A T A T G A C G T G G C G C A T C A C C A G T A A T T C G G Majority
      10          20          30          40          50
1 T C C A C A T C G G T C C A A T T A A C A T A T G A C G T G G C G C A T C A C C A G T A A T T C G G coh1_a12.seq
1 T C C A C A T C G G T C C A A T T A A C A T A T G A C G T G G C G C A T C A C C A G T A A T T C G G a909_a12.seq

T G A A T A A C A A T A T G T T T T G G A A T A A T C T C C A G T T G G T C A C A A A T A A T C G A Majority
      60          70          80          90          100
51 T G A A T A A C A A T A T G T T T T G G A A T A A T C T C C A G T T G G T C A C A A A T A A T C G A coh1_a12.seq
51 T G A A T A A C A A T A T G T T T T G G A A T A A T C T C C A G T T G G T C A C A A A T A A T C G A a909_a12.seq

A A T A T A G T C T T C T T G A C T T A A C A A A C G T A A A C G A C C T T C A T G G T A A T T C T C Majority
      110         120         130         140         150
101 A A T A T A G T C T T C T T G A C T T A A C A A A C G T A A A C G A C C T T C A T G G T A A T T C T C coh1_a12.seq
101 A A T A T A G T C T T C T T G A C T T A A C A A A C G T A A A C G A C C T T C A T G G T A A T T C T C a909_a12.seq

T C T G C A T T C T T G T A T T A G T C A T A A G A T G C A G A A G G T G T A A T T T T A T A C C C Majority
      160         170         180         190         200
151 T C T G C A T T C T T G T A T T A G T C A T A A G A T G C A G A A G G T G T A A T T T T A T A C C C coh1_a12.seq
151 T C T G C A T T C T T G T A T T A G T C A T A A G A T G C A G A A G G T G T A A T T T T A T A C C C a909_a12.seq

T G A A T A T C A T T A T C C G T A A C A C A T C G A C G A A C A T T T T C C A C C A T C A T A T C Majority
      210         220         230         240         250
201 T G A A T A T C A T T A T C C G T A A C A C A T C G A C G A A C A T T T T C C A C C A T C A T A T C coh1_a12.seq
201 T G A A T A T C A T T A T C C G T A A C A C A T C G A C G A A C A T T T T C C A C C A T C A T A T C a909_a12.seq

A T G T G T C T C C C C T G G G A G A C C A T T T A T T A G G T G A G A A A C G A T T T C T A C T T Majority
      260         270         280         290         300
251 A T G T G T C T C C C C T G G G A G A C C A T T T A T T A G G T G A G A A A C G A T T T C T A C T T coh1_a12.seq
251 A T G T G T C T C C C C T G G G A G A C C A T T T A T T A G G T G A G A A A C G A T T T C T A C T T a909_a12.seq

T A G G A G C T A A T T C T C G T A T T C T C T T A A C A G T T T T T T G T A A A G G T C A T A T Majority
      310         320         330         340         350
301 T A G G A G C T A A T T C T C G T A T T C T C T T A A C A G T T T T T T G T A A A G G T C A T A T coh1_a12.seq
301 T A G G A G C T A A T T C T C G T A T T C T C T T A A C A G T T T T T T G T A A A G G T C A T A T a909_a12.seq

G A A T G T G C T C T A T T T A T T A A T G C A G A A G T T G C T T C A T A A G T T G T C T G A A G Majority
      360         370         380         390         400
351 G A A T G T G C T C T A T T T A T T A A T G C A G A A G T T G C T T C A T A A G T T G T C T G A A G coh1_a12.seq
351 G A A T G T G C T C T A T T T A T T A A T G C A G A A G T T G C T T C A T A A G T T G T C T G A A G a909_a12.seq

G C C T A A T T C T A A A G T C A C A T G C A T T C T T T C A G A A A G T T C A G C C G A G A T A G T Majority
      410         420         430         440         450
401 G C C T A A T T C T A A A G T C A C A T G C A T T C T T T C A G A A A G T T C A G C C G A G A T A G T coh1_a12.seq
401 G C C T A A T T C T A A A G T C A C A T G C A T T C T T T C A G A A A G T T C A G C C G A G A T A G T a909_a12.seq

A T A T A G T T T C A T C A G G T A A G C A A T C C G G C C T T G T T C C G A T G T T G A T C C C G Majority
      460         470         480         490         500
451 A T A T A G T T T C A T C A G G T A A G C A A T C C G G C C T T G T T C C G A T G T T G A T C C C G coh1_a12.seq
451 A T A T A G T T T C A T C A G G T A A G C A A T C C G G C C T T G T T C C G A T G T T G A T C C C G a909_a12.seq

A T A A C T C C T G G C T C A T T A A T A G C C T G T T C G T A A C G C T C T T T A A T T A T C T C Majority
      510         520         530         540         550
501 A T A A C T C C T G G C T C A T T A A T A G C C T G T T C G T A A C G C T C T T T A A T T A T C T C coh1_a12.seq
501 A T A A C T C C T G G C T C A T T A A T A G C C T G T T C G T A A C G C T C T T T A A T T A T C T C a909_a12.seq

T A A C T T A G C A T G G G T A T T G G T A A A A T T T T G A A A A T A G A C T A A G T A T T T A T Majority
      560         570         580         590         600
551 T A A C T T A G C A T G G G T A T T G G T A A A A T T T T G A A A A T A G A C T A A G T A T T T A T coh1_a12.seq
551 T A A C T T A G C A T G G G T A T T G G T A A A A T T T T G A A A A T A G A C T A A G T A T T T A T a909_a12.seq

T A A C C T C A G G C C A C T T T C T A T G C A T G A A A T C A A T T T C T T T A T A G A A T T G T Majority
      610         620         630         640         650
601 T A A C C T C A G G C C A C T T T C T A T G C A T G A A A T C A A T T T C T T T A T A G A A T T G T coh1_a12.seq
601 T A A C C T C A G G C C A C T T T C T A T G C A T G A A A T C A A T T T C T T T A T A G A A T T G T a909_a12.seq

```

Figure 21

111/487

	TCACGAAATAGGAGCCTTCTGGAGCAACTATAGCATCCCCTGAACCAGAAAC	Majority
651	TCACGAAATAGGAGCCTTCTGGAGCAACTATAGCATCCCCTGAACCAGAAAC	cohl_a12.seq
651	TCACGAAATAGGAGCCTTCTGGAGCAACTATAGCATCCCCTGAACCAGAAAC	a909_a12.seq
	TGTGCAAAAAGTGCACCCTCCTCTAGCAACTGTTCCATCTCTGTTAGGAC	Majority
701	TGTGCAAAAAGTGCACCCTCCTCTAGCAACTGTTCCATCTCTGTTAGGAC	cohl_a12.seq
701	TGTGCAAAAAGTGCACCCTCCTCTAGCAACTGTTCCATCTCTGTTAGGAC	a909_a12.seq
	AGTCAAAACCAGCATCTATAGGTAATTTAAATATTTTTTCTCCAAAGAGT	Majority
751	AGTCAAAACCAGCATCTATAGGTAATTTAAATATTTTTTCTCCAAAGAGT	cohl_a12.seq
751	AGTCAAAACCAGCATCTATAGGTAATTTAAATATTTTTTCTCCAAAGAGT	a909_a12.seq
	TCTCGATAATAATCATTAAATCGCACGATAACGTTTTTTTCATAGGATAATT	Majority
801	TCTCGATAATAATCATTAAATCGCACGATAACGTTTTTTTCATAGGATAATT	cohl_a12.seq
801	TCTCGATAATAATCATTAAATCGCACGATAACGTTTTTTTCATAGGATAATT	a909_a12.seq
	GTATCACAAATTTTAACTAAAATAACCTCACTACTACAATAAAACTAAAAA	Majority
851	GTATCACAAATTTTAACTAAAATAACCTCACTACTACAATAAAACTAAAAA	cohl_a12.seq
851	GTATCACAAATTTTAACTAAAATAACCTCACTACTACAATAAAACTAAAAA	a909_a12.seq
	AGATTGGAACGTCAGTTAGTTCCAATCTTTTATTTACTTCACTTTCTTTA	Majority
901	AGATTGGAACGTCAGTTAGTTCCAATCTTTTATTTACTTCACTTTCTTTA	cohl_a12.seq
901	AGATTGGAACGTCAGTTAGTTCCAATCTTTTATTTACTTCACTTTCTTTA	a909_a12.seq
	ACCAATCCTTTGGCTAAAAAGATATACGCCAGTTAGATTCAAAATACCATAA	Majority
951	ACCAATCCTTTGGCTAAAAAGATATACGCCAGTTAGATTCAAAATACCATAA	cohl_a12.seq
951	ACCAATCCTTTGGCTAAAAAGATATACGCCAGTTAGATTCAAAATACCATAA	a909_a12.seq
	GCAAGTATAAAAACCAGCTAAAACATCTGTCCGAAAATGAACCCCTAGGTA	Majority
1001	GCAAGTATAAAAACCAGCTAAAACATCTGTCCGAAAATGAACCCCTAGGTA	cohl_a12.seq
1001	GCAAGTATAAAAACCAGCTAAAACATCTGTCCGAAAATGAACCCCTAGGTA	a909_a12.seq
	AATACGAGATAACCCAATTAAAAAAATGAGCAAACCCAATGTACCTTGGC	Majority
1051	AATACGAGATAACCCAATTAAAAAAATGAGCAAACCCAATGTACCTTGGC	cohl_a12.seq
1051	AATACGAGATAACCCAATTAAAAAAATGAGCAAACCCAATGTACCTTGGC	a909_a12.seq
	ACAACAGTTTCCATATACTCTTAGGCATATAGTACTGCAATAAAATAATA	Majority
1101	ACAACAGTTTCCATATACTCTTAGGCATATAGTACTGCAATAAAATAATA	cohl_a12.seq
1101	ACAACAGTTTCCATATACTCTTAGGCATATAGTACTGCAATAAAATAATA	a909_a12.seq
	CTACTCCCAAATATCATAAATGTTCCCATCGAGTGCCCACTGGCAAACGA	Majority
1151	CTACTCCCAAATATCATAAATGTTCCCATCGAGTGCCCACTGGCAAACGA	cohl_a12.seq
1151	CTACTCCCAAATATCATAAATGTTCCCATCGAGTGCCCACTGGCAAACGA	a909_a12.seq
	ATAGCCACCTGCAAATACTAAATGGGTTAAAGTTGGTCTCACTCTTTGAA	Majority
1201	ATAGCCACCTGCAAATACTAAATGGGTTAAAGTTGGTCTCACTCTTTGAA	cohl_a12.seq
1201	ATAGCCACCTGCAAATACTAAATGGGTTAAAGTTGGTCTCACTCTTTGAA	a909_a12.seq
	AAATAAGTTTTAAAGAAAGTATACATATACCAGAGATAATAGCATTACT	Majority
1251	AAATAAGTTTTAAAGAAAGTATACATATACCAGAGATAATAGCATTACT	cohl_a12.seq
1251	AAATAAGTTTTAAAGAAAGTATACATATACCAGAGATAATAGCATTACT	a909_a12.seq

FIGURE 21A

112/487

	<u>C C G A T A A A T C T A G C T T G A G G A T A C C A C T T C T T A A G G T A A C A G A A A G T G A C</u>	Majority
	1310 1320 1330 1340 1350	
1301	G C G A T A A A T C T A G C T T G A G G A T A C C A C T T C T T A A G G T A A C A G A A A G T G A C	coh1_ai2.seq
1301	G C G A T A A A T C T A G C T T G A G G A T A C C A C T T C T T A A G G T A A C A G A A A G T G A C	a909_ai2.seq
	<u>G C T C A T A A T C G C A A T A G C T A T C T G C C T T A C A G T A T T A C C A A C C A C A G T G A</u>	Majority
	1360 1370 1380 1390 1400	
1351	G C T C A T A A T C G C A A T A G C T A T C T G C C T T A C A G T A T T A C C A A C C A C A G T G A	coh1_ai2.seq
1351	G C T C A T A A T C G C A A T A G C T A T C T G C C T T A C A G T A T T A C C A A C C A C A G T G A	a909_ai2.seq
	<u>T T A A C T T G A A A A A T C T T G T A G A A A G A T T T G G C A A C T G T C C T C T A A C A C T T</u>	Majority
	1410 1420 1430 1440 1450	
1401	T T A A C T T G A A A A A T C T T G T A G A A A G A T T T G G C A A C T G T C C T C T A A C A C T T	coh1_ai2.seq
1401	T T A A C T T G A A A A A T C T T G T A G A A A G A T T T G G C A A C T G T C C T C T A A C A C T T	a909_ai2.seq
	<u>T C T T G A A T A G T T T G G T C A A A T G C G A T T A C A G T G T C G G G C C A A T A T T T G A T</u>	Majority
	1460 1470 1480 1490 1500	
1451	T C T T G A A T A G T T T G G T C A A A T G C G A T T A C A G T G T C G G G C C A A T A T T T G A T	coh1_ai2.seq
1451	T C T T G A A T A G T T T G G T C A A A T G C G A T T A C A G T G T C G G G C C A A T A T T T G A T	a909_ai2.seq
	<u>G A C C A A T C C T A A A C T G A A A A T A A G A T A A T A G C A A T A A A T G C T T G A A T A A</u>	Majority
	1510 1520 1530 1540 1550	
1501	G A C C A A T C C T A A A C T G A A A A T A A G A T A A T A G C A A T A A A T G C T T G A A T A A	coh1_ai2.seq
1501	G A C C A A T C C T A A A C T G A A A A T A A G A T A A T A G C A A T A A A T G C T T G A A T A A	a909_ai2.seq
	<u>G T T T A C T A T T T T G A C G A G A T A A C A T T A G T C T T T T T A T A T C T T T C T A A T A T</u>	Majority
	1560 1570 1580 1590 1600	
1551	G T T T A C T A T T T T G A C G A G A T A A C A T T A G T C T T T T T A T A T C T T T C T A A T A T	coh1_ai2.seq
1551	G T T T A C T A T T T T G A C G A G A T A A C A T T A G T C T T T T T A T A T C T T T C T A A T A T	a909_ai2.seq
	<u>T G G C A A A C A A G C C A C G T A A G T T A G A T A G A A A A C A A T C G A A A T T A A A A T T C</u>	Majority
	1610 1620 1630 1640 1650	
1601	T G G C A A A C A A G C C A C G T A A G T T A G A T A G A A A A C A A T C G A A A T T A A A A T T C	coh1_ai2.seq
1601	T G G C A A A C A A G C C A C G T A A G T T A G A T A G A A A A C A A T C G A A A T T A A A A T T C	a909_ai2.seq
	<u>C C T C A A C G A T A T T A A A T G G A A T A A C C A T T G T T A A A A G G T A A T T G C C T A C A</u>	Majority
	1660 1670 1680 1690 1700	
1651	C C T C A A C G A T A T T A A A T G G A A T A A C C A T T G T T A A A A G G T A A T T G C C T A C A	coh1_ai2.seq
1651	C C T C A A C G A T A T T A A A T G G A A T A A C C A T T G T T A A A A G G T A A T T G C C T A C A	a909_ai2.seq
	<u>C C A A T A A A T G T T C T G A T A T C A A A G T T A G C A A A T A T A G C A T A C A A A G G A A T</u>	Majority
	1710 1720 1730 1740 1750	
1701	C C A A T A A A T G T T C T G A T A T C A A A G T T A G C A A A T A T A G C A T A C A A A G G A A T	coh1_ai2.seq
1701	C C A A T A A A T G T T C T G A T A T C A A A G T T A G C A A A T A T A G C A T A C A A A G G A A T	a909_ai2.seq
	<u>C G C A A A G A C A T A G T T G A G A G C T A C C A T A G A T A C A G T C A A G C T A A C T G T A C</u>	Majority
	1760 1770 1780 1790 1800	
1751	C G C A A A G A C A T A G T T G A G A G C T A C C A T A G A T A C A G T C A A G C T A A C T G T A C	coh1_ai2.seq
1751	C G C A A A G A C A T A G T T G A G A G C T A C C A T A G A T A C A G T C A A G C T A A C T G T A C	a909_ai2.seq
	<u>G A A A T A A A C T A G C T T T A A T A A A A T C T T T T G C A C T C T C T A T T T T T C C A G</u>	Majority
	1810 1820 1830 1840 1850	
1801	G A A A T A A A C T A G C T T T A A T A A A A T C T T T T G C A C T C T C T A T T T T T C C A G	coh1_ai2.seq
1801	G A A A T A A A C T A G C T T T A A T A A A A T C T T T T G C A C T C T C T A T T T T T C C A G	a909_ai2.seq
	<u>A A A A T A G C G A A A C T T G C T A A A A T A G A G C T A G A G C A A C C A T A T T C A T C G G</u>	Majority
	1860 1870 1880 1890 1900	
1851	A A A A T A G C G A A A C T T G C T A A A A T A G A G C T A G A G C A A C C A T A T T C A T C G G	coh1_ai2.seq
1851	A A A A T A G C G A A A C T T G C T A A A A T A G A G C T A G A G C A A C C A T A T T C A T C G G	a909_ai2.seq
	<u>T A A A C C G A T A A A G G T T T C T G G A C C A C G A T T A G C A A G T A T A A C T T T T A A A A</u>	Majority
	1910 1920 1930 1940 1950	
1901	T A A A C C G A T A A A G G T T T C T G G A C C A C G A T T A G C A A G T A T A A C T T T T A A A A	coh1_ai2.seq
1901	T A A A C C G A T A A A G G T T T C T G G A C C A C G A T T A G C A A G T A T A A C T T T T A A A A	a909_ai2.seq

FIGURE 21B

113/487

	1960	1970	1980	1990	2000	
	G T G A T C T T A A T A A G A G T A C A C C A T A A C T T G A T T T C A A A T C A A A T A A A A T A					Majority
1951	G T G A T C T T A A T A A G A G T A C A C C A T A A C T T G A T T T C A A A T C A A A T A A A A T A					cohl_ai2.seq
1951	G T G A T C T T A A T A A G A G T A C A C C A T A A C T T G A T T T C A A A T C A A A T A A A A T A					a909_ai2.seq
	A A A G C A A C T A A C A T C G G A A G G A T T G A A A A T C A A C C T T T A A A A A T T C T G C					Majority
	2010	2020	2030	2040	2050	
2001	A A A G C A A C T A A C A T C G G A A G G A T T G A A A A T C A A C C T T T A A A A A T T C T G C					cohl_ai2.seq
2001	A A A G C A A C T A A C A T C G G A A G G A T T G A A A A T C A A C C T T T A A A A A T T C T G C					a909_ai2.seq
	T C C T G G T A T T A A T G G A A A T G A A A C C A T C A T C A A T A C A A A A G A T A A G G C A G					Majority
	2060	2070	2080	2090	2100	
2051	T C C T G G T A T T A A T G G A A A T G A A A C C A T C A T C A A T A C A A A A G A T A A G G C A G					cohl_ai2.seq
2051	T C C T G G T A T T A A T G G A A A T G A A A C C A T C A T C A A T A C A A A A G A T A A G G C A G					a909_ai2.seq
	A A A G A A T G G C G A T T G T C A C C A T T T T A C G T G T A T T T G T C A T A A A A A A A T T C					Majority
	2110	2120	2130	2140	2150	
2101	A A A G A A T G G C G A T T G T C A C C A T T T T A C G T G T A T T T G T C A T A A A A A A A T T C					cohl_ai2.seq
2101	A A A G A A T G G C G A T T G T C A C C A T T T T A C G T G T A T T T G T C A T A A A A A A A T T C					a909_ai2.seq
	C T C C A A T T T A A A T A A A T T G A A A G A A G C T C C A A A G G T A A G C G T A G G T A C G C					Majority
	2160	2170	2180	2190	2200	
2151	C T C C A A T T T A A A T A A A T T G A A A G A A G C T C C A A A G G T A A G C G T A G G T A C G C					cohl_ai2.seq
2151	C T C C A A T T T A A A T A A A T T G A A A G A A G C T C C A A A G G T A A G C G T A G G T A C G C					a909_ai2.seq
	G A A A A A A A C C T T T T G T C T T C T C C C A T C C A G A C T T T A C T G T C G G T T G T G G A A					Majority
	2210	2220	2230	2240	2250	
2201	G A A A A A A A C C T T T T G T C T T C T C C C A T C C A G A C T T T A C T G T C G G T T G T G G A A					cohl_ai2.seq
2201	G A A A A A A A C C T T T T G T C T T C T C C C A T C C A G A C T T T A C T G T C G G T T G T G G A A					a909_ai2.seq
	T C T C A C C A C A T C A G C T T T C G C T C G C G G A C T G A T G C T T C A C A A C T G A C A A A					Majority
	2260	2270	2280	2290	2300	
2251	T C T C A C C A C A T C A G C T T T C G C T C G C G G A C T G A T G C T T C A C A A C T G A C A A A					cohl_ai2.seq
2251	T C T C A C C A C A T C A G C T T T C G C T C G C G G A C T G A T G C T T C A C A A C T G A C A A A					a909_ai2.seq
	T A A G T T G G A A G C G A T T A C C G C C G T C G G G A A T T A C A C C C T G C C C T G A A G A					Majority
	2310	2320	2330	2340	2350	
2301	T A A G T T G G A A G C G A T T A C C G C C G T C G G G A A T T A C A C C C T G C C C T G A A G A					cohl_ai2.seq
2301	T A A G T T G G A A G C G A T T A C C G C C G T C G G G A A T T A C A C C C T G C C C T G A A G A					a909_ai2.seq
	C A C C T A T A G C A T A A C A A A A A A A A C T T G C A A T T G C A A G T T T T T A A T C A C T					Majority
	2360	2370	2380	2390	2400	
2351	C A C C T A T A G C A T A A C A A A A A A A A C T T G C A A T T G C A A G T T T T T A A T C A C T					cohl_ai2.seq
2351	C A C C T A T A G C A T A A C A A A A A A A A C T T G C A A T T G C A A G T T T T T A A T C A C T					a909_ai2.seq
	A A T T A G T A G T A G A T T G T A T A A T A T T A A T T T T T A A C A T C A A T T A A T T G A C A					Majority
	2410	2420	2430	2440	2450	
2401	A A T T A G T A G T A G A T T G T A T A A T A T T A A T T T T T A A C A T C A A T T A A T T G A C A					cohl_ai2.seq
2401	A A T T A G T A G T A G A T T G T A T A A T A T T A A T T T T T A A C A T C A A T T A A T T G A C A					a909_ai2.seq
	G C G C A C T A A T A C T C T A G C T A C T C C T G C C T T T G T A C A A G T A A A C A A G C T T A					Majority
	2460	2470	2480	2490	2500	
2451	G C G C A C T A A T A C T C T A G C T A C T C C T G C C T T T G T A C A A G T A A A C A A G C T T A					cohl_ai2.seq
2451	G C G C A C T A A T A C T C T A G C T A C T C C T G C C T T T G T A C A A G T A A A C A A G C T T A					a909_ai2.seq
	A G T C C C A A T C A T T G T C T G A T G T G G C A G T T T T A T A A A C T T T T T C A A T C G C T					Majority
	2510	2520	2530	2540	2550	
2501	A G T C C C A A T C A T T G T C T G A T G T G G C A G T T T T A T A A A C T T T T T C A A T C G C T					cohl_ai2.seq
2501	A G T C C C A A T C A T T G T C T G A T G T G G C A G T T T T A T A A A C T T T T T C A A T C G C T					a909_ai2.seq
	G T T G G T T C A A T A A T T T C T C T A T T A C T G A T T T T G T A G T G A T A G A T T T G C C C					Majority
	2560	2570	2580	2590	2600	
2551	G T T G G T T C A A T A A T T T C T C T A T T A C T G A T T T T G T A G T G A T A G A T T T G C C C					cohl_ai2.seq
2551	G T T G G T T C A A T A A T T T C T C T A T T A C T G A T T T T G T A G T G A T A G A T T T G C C C					a909_ai2.seq

FIGURE 21C

114/487




FIGURE 21D

115/487

G A C A T T A G T T C A T A A C C T T G A G C T G T T T A G T C T G A A T A A A T A G A T A A A T Majority
3260 3270 3280 3290 3300

3251 G A C A T T A G T T C A T A A C C T T G A G C T G T T T A G T C T G A A T A A A T A G A T A A A T cohl_a12.seq
3251 G A C A T T A G T T C A T A A C C T T G A G C T G T T T A G T C T G A A T A A A T A G A T A A A T a909_a12.seq

C C C T T G A G G A A G A T T G T T C G C A A C A A T A C C T T C A G C C G G T A A A T T A T C A A Majority
3310 3320 3330 3340 3350

3301 C C C T T G A G G A A G A T T G T T C G C A A C A A T A C C T T C A G C C G G T A A A T T A T C A A cohl_a12.seq
3301 C C C T T G A G G A A G A T T G T T C G C A A C A A T A C C T T C A G C C G G T A A A T T A T C A A a909_a12.seq

A C G T T T G T A A A G G T T G A G T T T T A T G A A C A G C T T T T G T T A G T A G A T T G A C G Majority
3360 3370 3380 3390 3400

3351 A C G T T T G T A A A G G T T G A G T T T T A T G A A C A G C T T T T G T T A G T A G A T T G A C G cohl_a12.seq
3351 A C G T T T G T A A A G G T T G A G T T T T A T G A A C A G C T T T T G T T A G T A G A T T G A C G a909_a12.seq

T A T T T G G C T T G G T T A C T A T C A A G G T T T A C T T G T G T T A G A T C A T C G T C T T T Majority
3410 3420 3430 3440 3450

3401 T A T T T G G C T T G G T T A C T A T C A A G G T T T A C T T G T G T T A G A T C A T C G T C T T T cohl_a12.seq
3401 T A T T T G G C T T G G T T A C T A T C A A G G T T T A C T T G T G T T A A T A T C A T C G T C T T T a909_a12.seq

T A T T C C A A T A C C T T G A A A T G G G G T A G T T A G A G T A A A A A C T T G G T T A C C A T Majority
3460 3470 3480 3490 3500

3451 T A T T C C A A T A C C T T G A A A T G G G G T A G T T A G A G T A A A A A C T T G A T T A C C A T cohl_a12.seq
3451 T A T T C C A A T A C C T T G A A A T G G G G T A G T T A G A G T A A A A A C T T G G T T A C C A T a909_a12.seq

C A A C A T C T T T A G C T T G T G C T A C T T G G T A A A C A A G T A A A T T A C C G C C A G C G Majority
3510 3520 3530 3540 3550

3501 C A A C A T C T T T A G C T T G T G C T A C T T G G T A A A C A A G T A A A T T A C C G C C A G C G cohl_a12.seq
3501 C A A C A T C T T T A G C T T G T G C T A C T T G G T A A A C A A G T A A A T T A C C G C C A G C G a909_a12.seq

A T A C C T T G A T T A T T A T A C T T A T T T T G T A T A G T A A T A G A A C C C G T T T T C A T Majority
3560 3570 3580 3590 3600

3551 A T A C C T T G A T T A T T A T A C T T A T T T T G T A T A G T A A T A G A A C C C G T T T T C A T cohl_a12.seq
3551 A T A C C T T G A T T A T T A T A C T T A T T T T G T A T A G T A A T A G A A C C C G T T T T C A T a909_a12.seq

C T G A T C A T T G G T A T C A G C A G A C A C A A G T T G A G T A C T T A G A C T A A A T A A T A Majority
3610 3620 3630 3640 3650

3601 C T G A T C A T T G G T A T C A G C A G A C A C A A G T T G A G T A C T T A G A C T A A A T A A T A cohl_a12.seq
3601 C T G A T C A T T G G T A T C A G C A G A C A C A A G T T G A G T A C T T A G A C T A A A T A A T A a909_a12.seq

A G A G A A G A G T T A T C T T T A G G A T C T T T T T A T A A A T C A T T G T T C T C T T C C T T Majority
3660 3670 3680 3690 3700

3651 A G A G A A G A G T T A T C T T T A G G A T C T T T T T A T A A A T C A T T G T T C T C T T C C T T cohl_a12.seq
3651 A G A G A A G A G T T A T A T T T A G G A T C T T T T T A T A A A T C A T T G T T C T C T T C C T T a909_a12.seq

T C T C A T T G C T T G T T T T A A A A T T T T C T T A C G T T G A C G T G C T C T C C T A G T T A Majority
3710 3720 3730 3740 3750

3701 T C T C A T T G C T T G T T T T A A A A T T T T C T T A C G T T G A C G T G C T C T C C T A G T T A cohl_a12.seq
3701 T C T C A T T G C T T G T T T T A A A A T T T T C T T A C G T T G A C G T G C T C T C C T A G T T A a909_a12.seq

C T T C T A A A G A G A T T A A A A G T A A A A T C A A A G T A A G G A A A A T A G C G A T A A A T Majority
3760 3770 3780 3790 3800

3751 C T T C T A A A G A G A T T A A A A G T A A A A T C A A A G T A A G G A A A A T A G C G A T A A A T cohl_a12.seq
3751 C T T C T A A A A G A T T A A A A G T A A A A T C A A A G T A A G G A A A A T A G C G A T A A A T a909_a12.seq

G G T G C G A T A T A A A T A G C C T C T A T T T G T A T T G C C T C T G C T A C T A C C A A A G C Majority
3810 3820 3830 3840 3850

3801 G G T G C G A T A T A A A T A G C C T C T A T T T G T A T T G C C T C T G C T A C T A C C A A A G C cohl_a12.seq
3801 G G T G C G A T A T A A A T A G C C T C T A T T T G T A T T G C C T C T G C T A C T A C C A A A G C a909_a12.seq

G T T A C C A T T A T C G T T T G G T A C A C G A T G T C C T C T C A C T A G T A A C C G A T G G C Majority
3860 3870 3880 3890 3900

3851 G T T A C C A T T A T C G T T T G G T A C A C G A T G T C C T C T C A C T A G T A A C C G A T G G C cohl_a12.seq
3851 G T T A C C A T T A T C G T T T G G T A C A C G A T G T C C T C T C A C T A G T A A C C G A T G G C a909_a12.seq

FIGURE 21E

116/487

TATTAACGCGCCATATGGTGTACACGTCACCAAAAGTTTGGTAGTCTTTACCT Majority
 3910 3920 3930 3940 3950

3901 TATTAACGCGCCATATGGTGTACACGTCACCAAAAGTTTGGTAGTCTTTACCT coh1_ai2.seq
 3901 TATTAACGCGCCATATGGTGTACACGTCACCAAAAGTTTGGTAGTCTTTACCT a909_ai2.seq

TTAACAAATTTGTAATCCCTCAAATCATCCGGTTTAACTGTTCTGATTTG Majority
 3960 3970 3980 3990 4000

3951 TTAACAATTTGTAATCCCTCAAATCATCCGGTTTAACTGTTCTGATTTG coh1_ai2.seq
 3951 TTAACAATTTGTAATCCCTCAAATCATCCGGTTTAACTGTTCTGATTTG a909_ai2.seq

ATCCACTTGATAAGTATATGTTTCATTTAAGATACTGACTGTCCAGTGGT Majority
 4010 4020 4030 4040 4050

4001 ATCCACTTGATAAGTATATGTTTCATTTAAGATACTGACTGTCCAGTGGT coh1_ai2.seq
 4001 ATCCACTTGATAAGTATATGTTTCATTTAAGATACTGACTGTCCAGTGGT a909_ai2.seq

CTCCAGCTTTTAACTTATCCAAATCAGAAAAAAGCCTTGAAGAGGGGTAAA Majority
 4060 4070 4080 4090 4100

4051 CTCCAACCTTTTAACTTATCCAAATCAGAAAAAAGCCTTGAAGAGGGGTAAA coh1_ai2.seq
 4051 CTCCAGCTTTTAACTTATCCAAATCAGAAAAAAGCCTTGAAGAGGGGTAAA a909_ai2.seq

CCTCTATGTCCTGATAAAATAGAATGAGTTGAGTCTCCTCCAATTGGAAAG Majority
 4110 4120 4130 4140 4150

4101 CCTCTATGTCCTGATAAAATAGAATGAGTTGAGTCTCCTCCAATTGGAAAG coh1_ai2.seq
 4101 CCTCTATGTCCTGATAAAATAGAATGAGTTGAGTCTCCTCCAATTGGAAAG a909_ai2.seq

ACTACTTCCTTCTAAATGACCAATAGAAGTTTGAAGCACTTTTTCACTTG Majority
 4160 4170 4180 4190 4200

4151 ACTACTTCCTTCTAAATGACCAATAGAAGTTTGAAGCACTTTTTCACTTG coh1_ai2.seq
 4151 ACTACTTCCTTCTAAATGACCAATAGAAGTTTGAAGCACTTTTTCACTTG a909_ai2.seq

TACCATGATAAAGTGGTAATTTTATGTTTATCTTTGCAATTGAAATATAA Majority
 4210 4220 4230 4240 4250

4201 TACCATGATAAAGTGGTAATTTTATGTTTATCTTTGCAATTGAAATATAA coh1_ai2.seq
 4201 TACCATGATAAAGTGGTAATTTTATGTTTATCTTTGCAATTGAAATATAA a909_ai2.seq

CCCATATTAACCGTTTTATCGATAGCCAGTTGGAATTATAATCCAAACG Majority
 4260 4270 4280 4290 4300

4251 CCCATATTAACCGTTTTATCGATAGCCAGTTGGAATTATAATCCAAACG coh1_ai2.seq
 4251 CCCATATTAACCGTTTTATCGATAGCCAGTTGGAATTATAATCCAAACG a909_ai2.seq

CTCTEGGTTAGTCATGTGCCACTTTCATTCTGAAGTTTTAAATTGCTTAT Majority
 4310 4320 4330 4340 4350

4301 CTCTEGGTTAGTCATGTGCCACTTTCATTCTGAAGTTTTAAATTGCTTAT coh1_ai2.seq
 4301 CTCTEGGTTAGTCATGTGCCACTTTCATTCTGAAGTTTTAAATTGCTTAT a909_ai2.seq

TATATTCTTTGGCTCGGTTAATAATTTTTTTATAGTCGTTTTTCATCCATA Majority
 4360 4370 4380 4390 4400

4351 TATATTCTTTGGCTCGGTTAATAATTTTTTTATAGTCGTTTTTCATCCATA coh1_ai2.seq
 4351 TATATTCTTTGGCTCGGTTAATAATTTTTTTATAGTCGTTTTTCATCCATA a909_ai2.seq

TGCGTTACGCGGCTCTTGGTAATCCGATAATCGCTCGAGATTGGTGAAATGA Majority
 4410 4420 4430 4440 4450

4401 TGCGTTACGCGGCTCTTGGTAATCCGATAATCGCTCGAGATTGGTGAAATGA coh1_ai2.seq
 4401 TGCGTTACGCGGCTCTTGGTAATCCGATAATCGCTCGAGATTGGTGAAATGA a909_ai2.seq

ATTCCAATAATTAGCAAGTGAAGGATAAGCCATTAAAGCCTACCCCACTG Majority
 4460 4470 4480 4490 4500

4451 ATTCCAATAATTAGCAAGTGAAGGATAAGCCATTAAAGCCTACCCCACTG coh1_ai2.seq
 4451 ATTCCAATAATTAGCAAGTGAAGGATAAGCCATTAAAGCCTACCCCACTG a909_ai2.seq

CAATTATAGTGACAAGCAAAATGGATACTAAATGTTGCTTATTTTTTTTC Majority
 4510 4520 4530 4540 4550

4501 CAATTATAGTGACAAGCAAAATGGATACTAAATGTTGCTTATTTTTTTTC coh1_ai2.seq
 4501 CAATTATAGTGACAAGCAAAATGGATACTAAATGTTGCTTATTTTTTTTC a909_ai2.seq

FIGURE 21F




FIGURE 21G

118/487

Alignment Report showing sequence alignment for Majority, coh1_ai2.seq, and a909_ai2.seq. The alignment spans from position 5210 to 5850. The Majority sequence is shown at the top, with individual sequences below it. Gaps are indicated by dashes. The alignment is as follows:

```
5210 5220 5230 5240 5250
Majority A A A A A A A G T C A T C A T T A G C T C C A T T T T G A G T A T T T C C G G T T G G A G T A T T G
5201 coh1_ai2.seq A A A A A A A G T C A T C A T T A G C T C C A T T T T G A G T A T T T C C G G T T G G A G T A T T G
5201 a909_ai2.seq A A A A A A A G T C A T C A T T A G C T C C A T T T T G A G T A T T T C C G G T T G G A G T A T T G

5260 5270 5280 5290 5300
Majority G T A G C T G C C C A C G G A A T A G T A A T C G T G A A A T T A T T T T C C T C T A A C A G
5251 coh1_ai2.seq G T A G C T G C C C A C G G A A T A G T A A T C G T G A A A T T A T T T T C C T C T A A C A G
5251 a909_ai2.seq G T A G C T G C C C A C G G A A T A G T A A T C G T G A A A T T A T T T T C C T C T A A C A G

5310 5320 5330 5340 5350
Majority G T T A T A C T T C C C A G T T G C T T T T T C C G A A C C T T G A G T T A G A G T T G T A A T A T
5301 coh1_ai2.seq G T T A T A C T T C C C A G T T G C T T T T T C C G A A C C T T G A G T T A G A G T T G T A A T A T
5301 a909_ai2.seq G T T A T A C T T C C C A G T T G C T T T T T C C G A A C C T T G A G T T A G A G T T G T A A T A T

5360 5370 5380 5390 5400
Majority T C C C T G A T C C A T C A G T A A T A G T T A C T T C A T A A G A C C T T C G T T C A A A T C A
5351 coh1_ai2.seq T C C C T G A T C C A T C A G T A A T A G T T A C T T C A T A A G A C C T T C G T T C A A A T C A
5351 a909_ai2.seq T C C C T G A T C C A T C A G T A A T A G T T A C T T C A T A A G A C C T T C G T T C A A A T C A

5410 5420 5430 5440 5450
Majority A C T A C A G A A G C A G A T G G C A T A G T A T C C T T T A T A A C A T A T T G A T A C A C T T T
5401 coh1_ai2.seq A C T A C A G A A G C A G A T G G C A T A G T A T C C T T T A T A A C A T A T T G A T A C A C T T T
5401 a909_ai2.seq A C T A C A G A A G C A G A T G G C A T A G T A T C C T T T A T A A C A T A T T G A T A C A C T T T

5460 5470 5480 5490 5500
Majority T T C T G T A C C A T G A T A A T T G A C T G C A T T C T T A T A A G T A A T A G T A T A T T T G A
5451 coh1_ai2.seq T T C T G T A C C A T G A T A A T T G A C T G C A T T C T T A T A A G T A A T A G T A T A T T T G A
5451 a909_ai2.seq T T C T G T A C C A T G A T A A T T G A C T G C A T T C T T A T A A G T A A T A G T A T A T T T G A

5510 5520 5530 5540 5550
Majority C T G T A T C A C C A A C C G A G T A C G T T T T T T G A T C T A C A G T T T T T C C A C C A C C A
5501 coh1_ai2.seq C T G T A T C A C C A A C C G A G T A C G T T T T T T G A T C T A C A G T T T T T C C A C C A C C A
5501 a909_ai2.seq C T G T A T C A C C A A C C G A G T A C G T T T T T T G A T C T A C A G T T T T T C C A C C A C C A

5560 5570 5580 5590 5600
Majority T C T C C C C A T G T C G C A T C A G T A T T C T T T T C A T G A A T A G T A G C A T T T G G A G T
5551 coh1_ai2.seq T C T C C C C A T G T C G C A T C A G T A T T C T T T T C A T G A A T A G T A G C A T T T G G A G T
5551 a909_ai2.seq T C T C C C C A T G T C G C A T C A G T A T T C T T T T C A T G A A T A G T A G C A T T T G G A G T

5610 5620 5630 5640 5650
Majority T A C A G A T G T A A C C A T A A T T A C A G C T C C A T T A T T A A C A G T G C T A G A A A C A T
5601 coh1_ai2.seq T A C A G A T G T A A C C A T A A T T A C A G C T C C A T T A T T A A C A G T G C T A G A A A C A T
5601 a909_ai2.seq T A C A G A T G T A A C C A T A A T T A C A G C T C C A T T A T T A A C A G T G C T A G A A A C A T

5660 5670 5680 5690 5700
Majority A A T A A T A T C C A T A T T G G G A A A C A T T A A T A A C C T C A G T A C C A T C A T T A T T T
5651 coh1_ai2.seq A A T A A T A T C C A T A T T G G G A A A C A T T A A T A A C C T C A G T A C C A T C A T T A T T T
5651 a909_ai2.seq A A T A A T A T C C A T A T T G G G A A A C A T T A A T A A C C T C A G T A C C A T C A T T A T T T

5710 5720 5730 5740 5750
Majority G A C T C A G T A A C A G T G G A A A C T G G T G T A G T A T T A G C T G A T A T A G A T T T A G C
5701 coh1_ai2.seq G A C T C A G T A A C A G T G G A A A C T G G T G T A G T A T T A G C T G A T A T A G A T T T A G C
5701 a909_ai2.seq G A C T C A G T A A C A G T G G A A A C T G G T G T A G T A T T A G C T G A T A T A G A T T T A G C

5760 5770 5780 5790 5800
Majority C C A T G T C G C A A T C T C A T T T G C T G A C G C A G T A T C T T T T T T A G T T A C A T A T G
5751 coh1_ai2.seq C C A T G T C G C A A T C T C A T T T G C T G A C G C A G T A T C T T T T T T A G T T A C A T A T G
5751 a909_ai2.seq C C A T G T C G C A A T C T C A T T T G C T G A C G C A G T A T C T T T T T T A G T T A C A T A T G

5810 5820 5830 5840 5850
Majority T T C T C C C T C C A T T A G T A G T T G T C G T A A A A A G A G A A T T A A A A T C A G T T G A A
5801 coh1_ai2.seq T T C T C C C T C C A T T A G T A G T T G T C G T A A A A A G A G A A T T A A A A T C A G T T G A A
5801 a909_ai2.seq T T C T C C C T C C A T T A G T A G T T G T C G T A A A A A G A G A A T T A A A A T C A G T T G A A
```

FIGURE 21H

119/487

G C T T T A T A C T C A G C T T C T T T A C C T T G A G G A A T T A A A T A A G A A G C T C C A T C Majority
5860 5870 5880 5890 5900
5851 G C T T T A T A C T C A G C T T C T T T A C C T T G A G G A A T T A A A T A A G A A G C T C C A T C coh1_ai2.seq
5851 G C T T T A T A C T C A G C T T C T T T A C C T T G A G G A A T T A A A T A A G A A G C T C C A T C a909_ai2.seq
T T T A T T C G A A T C A G A T A C A T T T G C A T T A T C T A T T T C T G C A T C A A A A A C T T Majority
5910 5920 5930 5940 5950
5901 T T T A T T C G A A T C A G A T A C A T T T G C A T T A T C T A T T T C T G C A T C A A A A A C T T coh1_ai2.seq
5901 T T T A T T C G A A T C A G A T A C A T T T G C A T T A T C T A T T T C T G C A T C A A A A A C T T a909_ai2.seq
T G T A T G C T T T A T A G G T T G C G C C T T T T T G A G T A T C T T G A A C T G T A A T T G T C Majority
5960 5970 5980 5990 6000
5951 T A T A T G C T T T A T A G G T T G C G C C T T T T T G A G T A T C T T G A A C T G T A A T T G T C coh1_ai2.seq
5951 T G T A T G C T T T A T A G G T T G C G C C T T T T T G A G T A T C T T G A A C T G T A A T T G T C a909_ai2.seq
C C T G T C T C A G C G G C A A A A G C T A T C G G C G T A A C T G G T G A T A C A G C C A T A C C Majority
6010 6020 6030 6040 6050
6001 C C T G T C T C A G C G G C A A A A G C T A T C G G C G T A A C T G G T G A T A C A G C C A T A C C coh1_ai2.seq
6001 C C T G T C T C A G C G G C A A A A G C T A T C G G C G T A A C T G G T G A T A C A G C C A T A C C a909_ai2.seq
A A A T G C T A A A C T C G C C A C T A A C A G C G A T T G A A T C A T T T T C T T T T T C A T T G Majority
6060 6070 6080 6090 6100
6051 A A A T G C T A A A C T C G C C A C T A A C A G C G A T T G A A T C A T T T T C T T T T T C A T T G coh1_ai2.seq
6051 A A A T G C T A A A C T C G C C A C T A A C A G C G A T T G A A T C A T T T T C T T T T T C A T T G a909_ai2.seq
A A A T C T T T T C C T A A A A T C A T A T T G A T G A A T G A T T A A T T C A T A T T T T T T Majority
6110 6120 6130 6140 6150
6101 A A A T C T T T T C C T A A A A T C A T A T T G A T G A A T G A T T A A T T C A T A T T T T T T coh1_ai2.seq
6101 A A A T C T T T T C C T A A A A T C A T A T T G A T G A A T G A T T A A T T C A T A T T T T T T a909_ai2.seq
T C G A T A G T A T A A T A T T A A T C C T G A T G G T A G A G C T A A A G C T A A A C C A A C T A Majority
6160 6170 6180 6190 6200
6151 T C G A T A G T A T A A T A T T A A T C C T G A T G G T A G A G C T A A A G C T A A A C C A A C T A coh1_ai2.seq
6151 T C G A T A G T A T A A T A T T A A T C C T G A T G G T A G A G C T A A A G C T A A A C C A A C T A a909_ai2.seq
G G A T A T A A A T G T G T T C C A A T A C C T C C A G T A C T A G G C A A T T C T G T T C C T Majority
6210 6220 6230 6240 6250
6201 G G A T A T A A A T G T G T T C C A A T A C C T C C A G T A C T A G G C A A T T C T G T T C C T coh1_ai2.seq
6201 G G A T A T A A A T G T G T T C C A A T A C C T C C A G T A C T A G G C A A T T C T G T T C C T a909_ai2.seq
T T A C T G T T A G T A A T T T T A A A A G T A T A T A C T G T A C T T C C A T C T A C T A A A T T Majority
6260 6270 6280 6290 6300
6251 T T A C T G T T A G T A A T T T T A A A A G T A T A T A C T G T A C T T C C A T C T A C T A A A T T coh1_ai2.seq
6251 T T A C T G T T A G T A A T T T T A A A A G T A T A T A C T G T A C T T C C A T C T A C T A A A T T a909_ai2.seq
C T C T T T T A T T G G T G T C G C A T T A T T A C C A T T T T G T T C A A A G G T A A C T C C C G Majority
6310 6320 6330 6340 6350
6301 C T C T T T T A T T G G T G T C G C A T T A T T A C C A T T T T G T T C A A A G G T A A C T C C C G coh1_ai2.seq
6301 C T C T T T T A T T G G T G T C G C A T T A T T A C C A T T T T G T T C A A A G G T A A C T C C C G a909_ai2.seq
T A G A A A T C A C T A A T A C T G A T A T A T C A T T T T A G C T A G T A G G T A C C C T G G A Majority
6360 6370 6380 6390 6400
6351 T A G A A A T C A C T A A T A C T G A T A T A T C A T T T T A G C T A G T A G G T A E C C T G G A coh1_ai2.seq
6351 T A G A A A T C A C T A A T A C T G A T A T A T C A T T T T A G C T A G T A G G T A C C C T G G A a909_ai2.seq
G G G G C C T T T G T C T C T G T T A G G T A G T A T T T T C C T A C T G G C A A A C T G A G G T A Majority
6410 6420 6430 6440 6450
6401 G G G G C C T T T G T C T C T G T T A G G T A G T A T T T T C C T A C T G G C A A A C T G A G G T A coh1_ai2.seq
6401 G G G G C C T T T G T C T C T G T T A G G T A G T A T T T T C C T A C T G G C A A A C T G A G G T A a909_ai2.seq
G T T A T T A G C A T C C A C T A A T A A C A A G C C T T T A T C G T T T G T C A C C A G C C C T G Majority
6460 6470 6480 6490 6500
6451 G T T A T T A G C A T C C A C T A A T A A C A A G C C T T T A T C G T T T G T C A C C A G C C C T G coh1_ai2.seq
6451 G T T A T T A G C A T C C A C T A A T A A C A A G C C T T T A T C G T T T G T C A C C A G C C C T G a909_ai2.seq

FIGURE 21I

AAATACATAGGATGTGAAGCTTTATTCCATTAGCATCTGATTCATAAAATA Majority
6510 6520 6530 6540 6550
6501 AAATACATAGGATGTGAAGCTTTATTCCATTAGCATCTGATTCATAAAATA coh1_ai2.seq
6501 AAATACATAGGATGTGAAGCTTTATTCCATTAGCATCTGATTCATAAAATA a909_ai2.seq
TCAAAAACTGCACCTGCTAAAAAATTATTATCATTITTCGACATTAACCTTT Majority
6560 6570 6580 6590 6600
6551 TCAAAAACTGCACCTGCTAAAAAATTATTATCATTITTCGACATTAACCTTT coh1_ai2.seq
6551 TCAAAAACTGCACCTGCTAAAAAATTATTATCATTITTCGACATTAACCTTT a909_ai2.seq
CTGTAGTCGTACTTTTTTGCTTGATACGGTGTATTGGTAAAGCTAATAATCTA Majority
6610 6620 6630 6640 6650
6601 CTGTAGTCGTACTTTTTTGCTTGATACGGTGTATTGGTAAAGCTAATAATCTA coh1_ai2.seq
6601 CTGTAGTCGTACTTTTTTGCTTGATACGGTGTATTGGTAAAGCTAATAATCTA a909_ai2.seq
CGTCTCCTGAAACTGTCAGCGGATTGTAAGCCGGTAGCATCATAAGTTTTA Majority
6660 6670 6680 6690 6700
6651 CGTCTCCTGAAACTGTCAGCGGATTGTAAGCCGGTAGCATCATAAGTTTTA coh1_ai2.seq
6651 CGTCTCCTGAAACTGTAAGCGGATTGTAAGCCGGTAGCATCATAAGTTTTA a909_ai2.seq
TCAGCTTCACCAGTTGCTAGATTTTTTCTGTAATTGACTCAGATACTTT Majority
6710 6720 6730 6740 6750
6701 TCAGCTTCACCAGTTGCTAGATTTTTTCTGTAATTGACTCAGATACTTT coh1_ai2.seq
6701 TCAGCTTCACCAGTTGCTAGATTTTTTCTGTAATTGACTCAGATACTTT a909_ai2.seq
AAATTCATCGTAGGCTTGTTCATCTATTGATATAGAAGTTCATAAGGTA Majority
6760 6770 6780 6790 6800
6751 AAATTCATCGTAGGCTTGTTCATCTATTGATATAGAAGTTCATAAGGTA coh1_ai2.seq
6751 AAATTCATCGTAGGCTTGTTCATCTATTGATATAGAAGTTCATAAGGTA a909_ai2.seq
CTTTAAATTCCTTAGTCTGACCATCTCTCAGCGGAAAATTCTCTTGTTGC Majority
6810 6820 6830 6840 6850
6801 CTTTAAATTCCTTAGTCTGACCATCTCTCAGCGGAAAATTCTCTTGTTGC coh1_ai2.seq
6801 CTTTAAATTCCTTAGTCTGACCATCTCTCAGCGGAAAATTCTCTTGTTGC a909_ai2.seq
AACGTTTCACTTGGATTAACAAGAAGTCTTTTCGCTTATCTTCATCTAG Majority
6860 6870 6880 6890 6900
6851 AACGTTTCACTTGGATTAACAAGAAGTCTTTTCGCTTATCTTCATCTAG coh1_ai2.seq
6851 AACGTTTCACTTGGATTAACAAGAAGTCTTTTCGCTTATCTTCATCTAG a909_ai2.seq
TCCAACGACAGTTTTACTTACTCTGACGGTGTATTCTTTAGGTTGCCAAA Majority
6910 6920 6930 6940 6950
6901 TCCAACGACAGTTTTACTTACTCTGACGGTGTATTCTTTAGGTTGCCAAA coh1_ai2.seq
6901 TCCAACGACAGTTTTACTTACTCTGACGGTGTATTCTTTAGGTTGCCAAA a909_ai2.seq
CAGCATATAAGGTATTTGTTGCATCAGGGTTGTTATCAATACCTATTGAT Majority
6960 6970 6980 6990 7000
6951 CAGCATATAAGGTATTTGTTGCATCAGGGTTGTTATCAATACCTATTGAT coh1_ai2.seq
6951 CAGCATATAAGGTATTTGTTGCATCAGGGTTGTTATCAATACCTATTGAT a909_ai2.seq
TGACCTGCTGTAATTCACACCGTCTGTATCAGCTAAAATCCTTATCATG Majority
7010 7020 7030 7040 7050
7001 TGACCTGCTGTAATTCACACCGTCTGTATCAGCTAAAATCCTTATCATG coh1_ai2.seq
7001 TGACCTGCTGTAATTCACACCGTCTGTATCAGCTAAAATCCTTATCATG a909_ai2.seq
ATGCCAACCAATAAGGTTGTAACTGCTCCTTGTAAAGTATTGGTTTTTCAG Majority
7060 7070 7080 7090 7100
7051 ATGCCAACCAATAAGGTTGTAACTGCTCCTTGTAAAGTATTGGTTTTTCAG coh1_ai2.seq
7051 ATGCCAACCAATAAGGTTGTAACTGCTCCTTGTAAAGTATTGGTTTTTCAG a909_ai2.seq
GAATTGTAGTTGTGCTATTCAACTCCATACCGCGTGTCTCTACTTGTGTT Majority
7110 7120 7130 7140 7150
7101 GAATTGTAGTTGTGCTATTCAACTCCATACCGCGTGTCTCTACTTGTGTT coh1_ai2.seq
7101 GAATTGTAGTTGTGCTATTCAACTCCATACCGCGTGTCTCTACTTGTGTT a909_ai2.seq

FIGURE 21J

121/487

```

ACCA G A L T A C C A T T T T C T A C T C T A G T A C C A C C G T T A C C A T T G T A T T T G A T Majority
7160 7170 7180 7190 7200
7151 ACCACATTACCATTTTCTACTCTAGTACCACCGTTACCATTGTATTTGAT cohl_a12.seq
7151 ACCACATTACCATTTTCTACTCTAGTACCACCGTTACCATTGTATTTGAT a909_a12.seq

TGAGGTA T C T T C T A A T T T G A T A T C T C C T A C T G G A A T A A T G A C A G G T T T T A Majority
7210 7220 7230 7240 7250
7201 TGAGGTA T C T T C T A A T T T G A T A T C T C C T A C T G G A A T A A T G A C A G G T T T T A cohl_a12.seq
7201 TGAGGTA T C T T C T A A T T T G A T A T C T C C T A C T G G A A T A A T G A C A G G T T T T A a909_a12.seq

TGGTGAT A T T T T T A T T A G C A T C T G C T A A A T G G G C G T C A A T A T C A A T G G A A Majority
7260 7270 7280 7290 7300
7251 TGGTGAT A T T T T T A T T A G C A T C T G C T A A A T G G G C G T C A A T A T C A A T G G A A cohl_a12.seq
7251 TGGTGAT A T T T T T A T T A G C A T C T G C T A A A T G G G C G T C A A T A T C A A T G G A A a909_a12.seq

TCATATGGGTTATAAAATTTTACCATTGTACCACCAGCCACGGAAACGATA Majority
7310 7320 7330 7340 7350
7301 TCATATGGGTTATAAAATTTTACCATTGTACCACCAGCCACGGAAACGATA cohl_a12.seq
7301 TCATATGGGTTATAAAATTTTACCATTGTACCACCAGCCACGGAAACGATA a909_a12.seq

GCCATCTGGCATTGTCGGACGCTCTCAGTAAAGGCTGAATGGGAGCCATCGT Majority
7360 7370 7380 7390 7400
7351 GCCATCTGGCATTGTCGGACGCTCTCAGTAAAGGCTGAATGGGAGCCATCGT cohl_a12.seq
7351 GCCATCTGGCATTGTCGGACGCTCTCAGTAAAGGCTGAATGGGAGCCATCGT a909_a12.seq

CATAGGAATCAGGGTCAGTAGGCTCATTACTTGTGTAATTGCTGACCA Majority
7410 7420 7430 7440 7450
7401 CATAGGAATCAGGGTCAGTAGGCTCATTACTTGTGTAATTGCTGACCA cohl_a12.seq
7401 CATAGGAATCAGGGTCAGTAGGCTCATTACTTGTGTAATTGCTGACCA a909_a12.seq

GAAGCATCCAATGCTGGCTTTCCATCTGTACCAACAGCATCATGCTGTA Majority
7460 7470 7480 7490 7500
7451 GAAGCATCCAATGCTGGCTTTCCATCTGTACCAACAGCATCATGCTGTA cohl_a12.seq
7451 GAAGCATCCAATGCTGGCTTTCCATCTGTACCAACAGCATCATGCTGTA a909_a12.seq

TATAATATGATAAATCTCCAGCCTTTCCGCCAAATAGCTCTTAAATTGATAT Majority
7510 7520 7530 7540 7550
7501 TATAATATGATAAATCTCCAGCCTTTCCGCCAAATAGCTCTTAAATTGATAT cohl_a12.seq
7501 TATAATATGATAAATCTCCAGCCTTTCCGCCAAATAGCTCTTAAATTGATAT a909_a12.seq

CTTGAGTTACAGCACCTGAAAAGTTATAAGGTCTAATACTACCATCTGGA Majority
7560 7570 7580 7590 7600
7551 CTTGAGTTACAGCACCTGAAAAGTTATAAGGTCTAATACTACCATCTGGA cohl_a12.seq
7551 CTTGAGTTACAGCACCTGAAAAGTTATAAGGTCTAATACTACCATCTGGA a909_a12.seq

TTAACATAATAACCAACCGACTAATTTGTAAGCGTCTTTTACGTACTTGT A Majority
7610 7620 7630 7640 7650
7601 TTAACATAATAACCAACCGACTAATTTGTAAGCGTCTTTTACGTACTTGT A cohl_a12.seq
7601 TTAACATAATAACCAACCGACTAATTTGTAAGCGTCTTTTACGTACTTGT A a909_a12.seq

ETTAGTTGTTGATCAACATTTGAGAGACTAGTATCTGTCGTATAAATAGG Majority
7660 7670 7680 7690 7700
7651 ETTAGTTGTTGATCAACATTTGAGAGACTAGTATCTGTCGTATAAATAGG cohl_a12.seq
7651 ETTAGTTGTTGATCAACATTTGAGAGACTAGTATCTGTCGTATAAATAGG a909_a12.seq

CATCTTTAGTTGAGTCCGGGATCTTTATCTCGTGAATCATACTTATAATAA Majority
7710 7720 7730 7740 7750
7701 CATCTTTAGTTGAGTCCGGGATCTTTATCTCGTGAATCATACTTATAATAA cohl_a12.seq
7701 CATCTTTAGTTGAGTCCGGGATCTTTATCTCGTGAATCATACTTATAATAA a909_a12.seq

TATGTACCTGAAGCATCTTGGATATAAATCCCTTGTAATATCTGTATAATC Majority
7760 7770 7780 7790 7800
7751 TATGTACCTGAAGCATCTTGGATATAAATCCCTTGTAATATCTGTATAATC cohl_a12.seq
7751 TATGTACCTGAAGCATCTTGGATATAAATCCCTTGTAATATCTGTATAATC a909_a12.seq

```

FIGURE 21K

122/487

CGGAAATCGAATCACTAATATGCAAGTCTAAATAGGTATCATCTGTTTTTC Majority
7810 7820 7830 7840 7850
7801 CGGAATACGATCACCATAAATGCCAAATCTAAATAGGTATCATCTGTTTTTC coh1_ai2.seq
7801 CGGAATACGATCACCATAAATGCCAAAGTCTAAATAGGTATCATCTGTTTTTC a909_ai2.seq

ATAATTGGCCCTCCGTTTGGATCAATATTGACACGATATGTTACCTTTTTC Majority
7860 7870 7880 7890 7900
7851 ATAATTGGCCCTCCGTTTGGATCAATATTGACACGATATGTTACCTTTTTC coh1_ai2.seq
7851 ATAATTGGCCCTCCGTTTGGATCAATATTGACACGATATGTTACCTTTTTC a909_ai2.seq

CAACCTGCATAGACTTTAACATCATGAGGAGGCATAGTCCGTGTTAAAGTC Majority
7910 7920 7930 7940 7950
7901 CAACCTGCATAGACTTTAACATCATGAGGAGGCATAGTCCGTGTTAAAGTC coh1_ai2.seq
7901 CAACCTGCATAGACTTTAACATCATGAGGAGGCATAGTCCGTGTTAAAGTC a909_ai2.seq

AAATACTTGTGTTTTGTGCTTGGTCTTTATACCATTTACCATCCCAAACAT Majority
7960 7970 7980 7990 8000
7951 AAATACTTGTGTTTTGTGCTTGGTCTTTATACCATTTACCATCCCAAACAT coh1_ai2.seq
7951 AAATACTTGTGTTTTGTGCTTGGTCTTTATACCATTTACCATCCCAAACAT a909_ai2.seq

ACCCCTGGTCCGACTAGGTTTTAGGTTGAACCGTTGTCTATCCGGGGCCATAA Majority
8010 8020 8030 8040 8050
8001 ACCCTGGTCCGACTAGGTTTTAGGTTGAACCGTTGTCTATCCGGGGCCATAA coh1_ai2.seq
8001 ACCCTGGTCCGACTAGGTTTTAGGTTGAACCGTTGTCTATCCGGGGCCATAA a909_ai2.seq

GAGGACAAATTTTGGCTCATATAGAACATCCCTTACTGGAAAATTAGGAAG Majority
8060 8070 8080 8090 8100
8051 GAGGACAAATTTTGGCTCATATAGAACATCCCTTACTGGAAAATTAGGAAG coh1_ai2.seq
8051 GAGGACAAATTTTGGCTCATATAGAACATCCCTTACTGGAAAATTAGGAAG a909_ai2.seq

CTCTGTATTATCAACCGGATCTAAATATTTAATCTTGTATGAATTACGTT Majority
8110 8120 8130 8140 8150
8101 CTCTGTATTATCAACCGGATCTAAATATTTAATCTTGTATGAATTACGTT coh1_ai2.seq
8101 CTCTGTATTATCAACCGGATCTAAATATTTAATCTTGTATGAATTACGTT a909_ai2.seq

CATACCATAACCACTAAGTTCAAATAAATCTTTGTCGGTAGTCTCCATATTTA Majority
8160 8170 8180 8190 8200
8151 CATACCATAACCACTAAGTTCAAATAAATCTTTGTCGGTAGTCTCCATATTTA coh1_ai2.seq
8151 CATACCATAACCACTAAGTTCAAATAAATCTTTGTCGGTAGTCTCCATATTTA a909_ai2.seq

TCGTAGTATTCATCTCCGATTGGCACTTTTGTTTTGCACTCGTTTTGTCT Majority
8210 8220 8230 8240 8250
8201 TCGTAGTATTCATCTCCGATTGGCACTTTTGTTTTGCACTCGTTTTGTCT coh1_ai2.seq
8201 TCGTAGTATTCATCTCCGATTGGCACTTTTGTTTTGCACTCGTTTTGTCT a909_ai2.seq

TGGGTTCTGATCAAATAGGTAATTAATCTGGATATAAGCTTTGATAGTATT Majority
8260 8270 8280 8290 8300
8251 TGGGTTCTGATCAAATAGGTAATTAATCTGGATATAAGCTTTGATAGTATT coh1_ai2.seq
8251 TGGGTTCTGATCAAATAGGTAATTAATCTGGATATAAGCTTTGATAGTATT a909_ai2.seq

TAAcATTAAATCCCTAGGATTTTTTCTGTAAGGTAATAATTCGTCCTGCCA Majority
8310 8320 8330 8340 8350
8301 TAAcATTAAATCCCTAGGATTTTTTCTGTAAGGTAATAATTCGTCCTGCCA coh1_ai2.seq
8301 TAAcATTAAATCCCTAGGATTTTTTCTGTAAGGTAATAATTCGTCCTGCCA a909_ai2.seq

GCACCTCCCCTGTGTCTGCTAAAGACTATTTGCCATCTAGTCCTTGTTT Majority
8360 8370 8380 8390 8400
8351 GCACCTCCCCTGTGTCTGCTAAAGACTATTTGCCATCTAGTCCTTGTTT coh1_ai2.seq
8351 GCACCTCCCCTGTGTCTGCTAAAGACTATTTGCCATCTAGTCCTTGTTT a909_ai2.seq

GTAGAACGGATAATTTTGAATTTCTCTTCCCTTTTGGATAGAGTTTTATTT Majority
8410 8420 8430 8440 8450
8401 GAAGAACGGATAATTTTGAATTTCTCTTCCCTTTTGGATAGAGTTTTATTT coh1_ai2.seq
8401 ATAGAAGGATAATTTTGAATTTCTCTTCCCTTTTGGATAGAGTTTTATTT a909_ai2.seq

FIGURE 21L

124/487




FIGURE 21N

125/487

T G T T T T T A A A A G C A A C A T C A C T G C T A G T G T T C T T A G T T T C T G C A G T A T C T T Majority
9760 9770 9780 9790 9800

9739 T G T T T T A A A A G C A A C A T C A C T G C T A G T G T T C T T A G T T T C T G C A G T A T C T T coh1_ai2.seq
9736 T G T T T T A A A A G C A A C A T C A C T G C T A G T G T T C T T A G T T T C T G C A G T A T C T T a909_ai2.seq

T A G A T T T T A A T A C T T C T G T T T G A C C A T C A T C T T T A A A G T G A A C A A C T T T A Majority
9810 9820 9830 9840 9850

9789 T A G A T T T T A A T A C T T C T G T T T G A C C A T C A T C T T T A A A G T G A A C A A C T T T A coh1_ai2.seq
9786 T A G A T T T T A A T A C T T C T G T T T G A C C A T C A T C T T T A A A G T G A A C A A C T T T A a909_ai2.seq

A G G T T T T C A T C T G A A G C T T C T A A T G G C T T A T C A T A G T T G A C C T C T A C T T T Majority
9860 9870 9880 9890 9900

9839 A G G T T T T C A T C T G A A G C T T C T A A T G G C T T A T C A T A G T T A C C T C T A C T T T coh1_ai2.seq
9836 A G G T T T T C A T C T G A A G C T T C T A A T G G C T T A T C A T A G T T G A C C T C T A C T T T a909_ai2.seq

T A C T G G G G C T T G G G G T T C T G C T T C T T T A C C A T T T G A C T C A A T A G T A A T G T Majority
9910 9920 9930 9940 9950

9889 T A C T G G A G C T T G G G G T T C T G C T T C T T T A C C A T T T G A C T C A A T A G T A A T G T coh1_ai2.seq
9886 T A C T G G G G C T T G G G G T T C T G C T T C T T T A C C A T T T G A C T C A A T A G T A A T G T a909_ai2.seq

C A T A G A G T T T G A A G T T T T G A T T T C A C T A T C T T G T T T A G C A A C T T C T G T C Majority
9960 9970 9980 9990 10000

9939 C A T A G A G T T T G A A G T T T T G A T T T C A C T A T C T T G T T T A G C A A C T C T G T C coh1_ai2.seq
9936 C A T A G A G T T T G A A G T T T T G A T T T C A C T A T C T T G T T T A G C A A C T T C T G T C a909_ai2.seq

A A T G C T T T T T T C T T A T A G T C T T T A A A A G T A G C T G A A T T G T C T T T T A A T T C Majority
10010 10020 10030 10040 10050

9989 A A T G C T T T T T T C T T A T A G T C T T T A A A A G T A G C T G A A T T G T C T T T T A A T T C coh1_ai2.seq
9986 A A T G C T T T T T T C T T A T A G T C T T T A A A A G T A G C T G A A T T G T C T T T T A A T T C a909_ai2.seq

C G T C A C C T T T A A A T C A G C A T T T T T A G G A A T C T T A G C T T C T T T G G T C A A A G Majority
10060 10070 10080 10090 10100

10039 C G T C A C C T T T A A A T C A G C A T T T T T A G G A A T C T T A G C T T C T T T G G T C A A A G coh1_ai2.seq
10036 C G T C A C C T T T A A A T C A G C A T T T T T A G G A A T C T T A G C T T C T T T G G T C A A A G a909_ai2.seq

T C A C T G T T A C A G T A T A G T C T G C A C C T C T A A A C A T C A A T G G T T C T T C A C G G Majority
10110 10120 10130 10140 10150

10089 T C A C T G T T A C A G T A T A G T C T G C A C C T C T A A A C A T C A A T G G T T C T T C A C G G coh1_ai2.seq
10086 T C A C T G T T A C A G T A T A G T C T G C A C C T C T A A A C A T C A A T G G T T C T T C A C G G a909_ai2.seq

T A A G C A G C T T C C T C A G A A G A T G A T G T T T C T G T T A C A C T A G A A G C A G G A G T Majority
10160 10170 10180 10190 10200

10139 T A A G C A G C T T C C T C A G A A G A T G A T G T T T C T G T T A C A C T A G A A G C A G G A G T coh1_ai2.seq
10136 T A A G C A G C T T C C T C A G A A G A T G A T G T T T C T G T T A C A C T A G A A G C A G G A G T a909_ai2.seq

C T G T G G C T T G C T C T G C T C A A C A C T T G A T T G A G A A C T A G A T G T T G A T G A A G Majority
10210 10220 10230 10240 10250

10189 C T G T G G C T T G C T C T G C T C A A C A C T T G A T T G A G A A C T A G A T G T T G A T G A A G coh1_ai2.seq
10186 C T G T G G C T T G C T C T G C T C A A C A C T T G A T T G A G A A C T A G A T G T T G A T G A A G a909_ai2.seq

T T A C C T G G C T A G A A T T T T A T T T T C T A A A G T A A T C C C A C A T C A T C T G T C Majority
10260 10270 10280 10290 10300

10239 T T A C C T G G C T A G A A T T T T A T T T T C T A A A G T A A T C C C A C A T C A T C T G T C coh1_ai2.seq
10236 T T A C C T G G C T A G A A T T T T A T T T T C T A A A G T A A T C C C A C A T C A T C T G T C a909_ai2.seq

T T A G T T T C T T C A A C T G T T A T T G C T G G T A G A A T T A A A A A A T A A G T C G T T A A Majority
10310 10320 10330 10340 10350

10289 T T A G T T T C T T C A A C T G T T A T T G C T G G T A G A A T T A A A A A A T A A G T C G T T A A coh1_ai2.seq
10286 T T A G T T T C T T C A A C T G T T A T T G C T G G T A G A A T T A A A A A A T A A G T C G T T A A a909_ai2.seq

A A A A G T T G T T A G G A T C A T C A A T G A C C A C A T G A T A A T T T T C C A C T C T T T A G Majority
10360 10370 10380 10390 10400

10339 A A A A G T T G T T A G G A T C A T C A A T G A C C A C A T G A T A A T T T T C C A C T C T T T A G coh1_ai2.seq
10336 A A A A G T T G T T A G G A T C A T C A A T G A C C A C A T G A T A A T T T T C C A C T C T T T A G a909_ai2.seq

FIGURE 210

126/487

GGTGTCTTTTCTTTTAAATGATTGATTATAAAAAGTTTGACACTTCTTT Majority
10410 10420 10430 10440 10450
10389 GGTGTCTTTTCTTTTAAATGATTGATTATAAAAAGTTTGACACTTCTTT cohl_a12.seq
10386 GGTGTCTTTTCTTTTAAATGATTGATTATAAAAAGTTTGACACTTCTTT a909_a12.seq

AGCATTCTTTCATCCTCCCTAACCTTAATTGATACTACTAATCTTACCTA Majority
10460 10470 10480 10490 10500
10439 AGCATTCTTTCATCCTCCCTAACCTTAATTGATACTACTAATCTTACCTA cohl_a12.seq
10436 AGCATTCTTTCATCCTCCCTAACCTTAATTGATACTACTAATCTTACCTA a909_a12.seq

GAGGCCATATTCTGAAAGAAATTTTACCTACAATTTGTTCTTCTGAAACA Majority
10510 10520 10530 10540 10550
10489 GAGGCCATATTCTGAAAGAAATTTTACCTACAATTTGTTCTTCTGAAACA cohl_a12.seq
10485 GAGGCCATATTCTGAAAGAAATTTTACCTACAATTTGTTCTTCTGAAACA a909_a12.seq

TCTCCTACAGAAGTATTTTCGAGAATCAATTGAAGTTTTTTCGGTTGCTCTCC Majority
10560 10570 10580 10590 10600
10539 TCTCCTACAGAAGTATTTTCGAGAATCAATTGAAGTTTTTTCGGTTGCTCTCC cohl_a12.seq
10535 TCTCCTACAGAAGTATTTTCGAGAATCAATTGAAGTTTTTTCGGTTGCTCTCC a909_a12.seq

TAATACAAAAATTTTTTATCAGGTACTTGATATGGGTATTTTATATTAC Majority
10610 10620 10630 10640 10650
10589 TAATACAAAAATTTTTTATCAGGTACTTGATATGGGTATTTTATATTAC cohl_a12.seq
10585 TAATACAAAAATTTTTTATCAGGTACTTGATATGGGTATTTTATATTAC a909_a12.seq

TATTACCGAGTGCTTTTATGAATAACATATGGTTCTTTCACCTTATGTTGA Majority
10660 10670 10680 10690 10700
10639 TATTACCGAGTGCTTTTATGAATAACATATGGTTCTTTCACCTTATGTTGA cohl_a12.seq
10635 TATTACCGAGTGCTTTTATGAATAACATATGGTTCTTTCACCTTATGTTGA a909_a12.seq

TTCAAGTAAACATCCCCTTGAGAATCAATATTAACCCAGTCTCCTGACTC Majority
10710 10720 10730 10740 10750
10689 TTCAAGTAAACATCCCCTTGAGAATCAATATTAACCCAGTCTCCTGACTC cohl_a12.seq
10685 TTCAAGTAAACATCCCCTTGAGAATCAATATTAACCCAGTCTCCTGACTC a909_a12.seq

TGCAATAAACCCTTGACTAGGACCTTATTATTGTAGTAAAACCGCGACAA Majority
10760 10770 10780 10790 10800
10739 TGCAATAAACCCTTGACTAGGACCTTATTATTGTAGTAAAACCGCGACAA cohl_a12.seq
10735 TGCAATAAACCCTTGACTAGGACCTTATTATTGTAGTAAAACCGCGACAA a909_a12.seq

CGTCTCCAGTTTTTAAAATTTGAACCTTTTACTGTAAAGACTACATCACCT Majority
10810 10820 10830 10840 10850
10789 CGTCTCCAGTTTTTAAAATTTGAACCTTTTACTGTAAAGACTACATCACCT cohl_a12.seq
10785 CGTCTCCAGTTTTTAAAATTTGAACCTTTTACTGTAAAGACTACATCACCT a909_a12.seq

GCACTTAAAGTCTTATTCATTGAAATGTCCTAGATTCTTAATACAGGCCAA Majority
10860 10870 10880 10890 10900
10839 GCACTTAAAGTCTTATTCATTGAAATGTCCTAGATTCTTAATACAGGCCAA cohl_a12.seq
10835 GCACTTAAAGTCTTATTCATTGAAATGTCCTAGATTCTTAATACAGGCCAA a909_a12.seq

CCATAAAACCGCAATTAATAATGGCTTTGAGGCCAACCGCCATCAAGATGT Majority
10910 10920 10930 10940 10950
10889 CCATAAAACCGCAATTAATAATGGCTTTGAGGCCAACCGCCATCAAGATGT cohl_a12.seq
10885 CCATAAAACCGCAATTAATAATGGCTTTGAGGCCAACCGCCATCAAGATGT a909_a12.seq

ATATGGTATTTTTAATGACACTCCAAAAGCGTTTCTGATAAGTTACGCCA Majority
10960 10970 10980 10990 11000
10939 ATATGGTATTTTTAATGACACTCCAAAAGCGTTTCTGATAAGTTACGCCA cohl_a12.seq
10935 ATATGGTATTTTTAATGACACTCCAAAAGCGTTTCTGATAAGTTACGCCA a909_a12.seq

TCCAGTTCTTGAGATAATTTATCTGAACTAATCTGCTTTTTCATTGTCTA Majority
11010 11020 11030 11040 11050
10989 TCCAGTTCTTGAGATAATTTATCTGAACTAATCTGCTTTTTCATTGTCTA cohl_a12.seq
10985 TCCAGTTCTTGAGATAATTTATCTGAACTAATCTGCTTTTTCATTGTCTA a909_a12.seq

FIGURE 21P

127/487

CGCCTCTCTTATCTACTAAATTCCTTTTCTAAATAGGTATCTGCA Majority
 11060 11070 11080 11090 11100
 11039 CGCCTCTCTTATCTACTAAATTCCTTTTCTAAATAGGTATCTGCA coh1_ai2.seq
 11035 CGCCTCTCTTATCTACTAAATTCCTTTTCTAAATAGGTATCTGCA a909_ai2.seq

GCTAACTGAGCAGTCTCAAAAATACCACTAAGCATTAAAGGAAGCTTCGGC Majority
 11110 11120 11130 11140 11150
 11089 GCTAACTGAGCAGTCTCAAAAATACCACTAAGCATTAAAGGAAGCTTCGGC coh1_ai2.seq
 11085 GCTAACTGAGCAGTCTCAAAAATACCACTAAGCATTAAAGGAAGCTTCGGC a909_ai2.seq

AATAGAACCAGCTTTGCTAATTTTGATTTTTTATCATCTAGCGCTTCTT Majority
 11160 11170 11180 11190 11200
 11139 AATAGAACCAGCTTTGCTAATTTTGATTTTTTATCATCTAGCGCTTCTT coh1_ai2.seq
 11135 AATAGAACCAGCTTTGCTAATTTTGATTTTTTATCATCTAGCGCTTCTT a909_ai2.seq

TAAGTTGCTGAATCTCTTTCTCTTGTTTTTCAATAAGAAGTTGCTGTTCT Majority
 11210 11220 11230 11240 11250
 11189 TAAGTTGCTGAATCTCTTTCTCTTGTTTTTCAATAAGAAGTTGCTGTTCT coh1_ai2.seq
 11185 TAAGTTGCTGAATCTCTTTCTCTTGTTTTTCAATAAGAAGTTGCTGTTCT a909_ai2.seq

AACATAAATTTCTAGCAAGTCTTTTCTTTTTAATTTTTTAAATCTTCCAAT Majority
 11260 11270 11280 11290 11300
 11239 AACATAAATTTCTAGCAAGTCTTTTCTTTTTAATTTTTTAAATCTTCCAAT coh1_ai2.seq
 11235 AACATAAATTTCTAGCAAGTCTTTTCTTTTTAATTTTTTAAATCTTCCAAT a909_ai2.seq

CGCGATTACTTCCCTTAACTGAACCTTAAATTATCGTTTAGATATTATATC Majority
 11310 11320 11330 11340 11350
 11289 CGCGATTACTTCCCTTAACTGAACCTTAAATTATCGTTTAGATATTATATC coh1_ai2.seq
 11285 CGCGATTACTTCCCTTAACTGAACCTTAAATTATCGTTTAGATATTATATC a909_ai2.seq

AAAGTTCTAACCTTTAAACTCATTTTTTGTCTGTGTTTTTCTCAAAAAA Majority
 11360 11370 11380 11390 11400
 11339 AAAGTTCTAACCTTTAAACTCATTTTTTGTCTGTGTTTTTCTCAAAAAA coh1_ai2.seq
 11335 AAAGTTCTAACCTTTAAACTCATTTTTTGTCTGTGTTTTTCTCAAAAAA a909_ai2.seq

AGTCTATGCTAAATTAACATTTTTGATAATTTTTTGAAAAATCTCATCGA Majority
 11410 11420 11430 11440 11450
 11389 AGTCTATGCTAAATTAACATTTTTGATAATTTTTTGAAAAATCTCATCGA coh1_ai2.seq
 11385 AGTCTATGCTAAATTAACATTTTTGATAATTTTTTGAAAAATCTCATCGA a909_ai2.seq

AGTCAATTTTCTTTTTGAAAGCTCGAATTCTAGGCATTA AAAAGCCATATA Majority
 11460 11470 11480 11490 11500
 11439 AGTCAATTTTCTTTTTGAAAGCTCGAATTCTAGGCATTA AAAAGCCATATA coh1_ai2.seq
 11435 AGTCAATTTTCTTTTTGAAAGCTCGAATTCTAGGCATTA AAAAGCCATATA a909_ai2.seq

TC AAAATTGATATATAGGCTTTTTTTTATTATTTAAACAAAAGCAATCAATAG Majority
 11510 11520 11530 11540 11550
 11489 TC AAAATTGATATATAGGCTTTTTTTTATTATTTAAACAAAAGCAATCAATAG coh1_ai2.seq
 11476 TC AAAATTGATATATAGGCTTTTTTTTATTATTTAAACAAAAGCAATCAATAG a909_ai2.seq

GACAATAGCGTCAATTTAGTGACATAATCTATTACAGATTAAGTTCTTTT Majority
 11560 11570 11580 11590 11600
 11539 GACAATAGCGTCAATTTAGTGACATAATCTATTACAGATTAAGTTCTTTT coh1_ai2.seq
 11492 GACAATAGCGTCAATTTAGTGACATAATCTATTACAGATTAAGTTCTTTT a909_ai2.seq

TGAATAATATAATCCAACCTTTTCAACTGTTTTTTCCCATGTGAAATGTTT.C Majority
 11610 11620 11630 11640 11650
 11589 TGAATAATATAATCCAACCTTTTCAACTGTTTTTTCCCATGTGAAATGTTT.C coh1_ai2.seq
 11542 TGAATAATATAATCCAACCTTTTCAACTGTTTTTTCCCATGTGAAATGTTT.C a909_ai2.seq

TTTAAATCTTTTAGCAATATTCGTGTGTAGTTTCTCTCTTAATGCCTTAT Majority
 11660 11670 11680 11690 11700
 11639 TTTAAATCTTTTAGCAATATTCGTGTGTAGTTTCTCTCTTAATGCCTTAT coh1_ai2.seq
 11592 TTTAAATCTTTTAGCAATATTCGTGTGTAGTTTCTCTCTTAATGCCTTAT a909_ai2.seq

FIGURE 21Q

128/487

CTTTAACTAAATAAATAAGAGATTTCCTCGACTGAGTATTTTCTTCC Majority
 11710 11720 11730 11740 11750
 11689 CTTTACTAATAAATCAAGAGATTTCATGGAGTCACTGAGTATTTTCTTCC coh1_ai2.seq
 11642 CTTTACTAATAAATCAAGAGATTTCATGGAGTCACTGAGTATTTTCTTCC a909_ai2.seq
 ATGATGATTCCTAACTCAGGGCTATCAATAAATTCAACTGTTCCACCGCG Majority
 11760 11770 11780 11790 11800
 11739 ATGATGATTCCTAACTCAGGGCTATCAATAAATTCAACTGTTCCACCGCG coh1_ai2.seq
 11692 ATGATGATTCCTAACTCAGGGCTATCAATAAATTCAACTGTTCCACCGCG a909_ai2.seq
 ATCTGTTGCAATAATAGCACTCGAAAGTAGACCAGCTTCTAAAATAGAGG Majority
 11810 11820 11830 11840 11850
 11789 ATCTGTTGCAATAATAGCACTCGAAAGTAGACCAGCTTCTAAAATAGAGG coh1_ai2.seq
 11742 ATCTGTTGCAATAATAGCACTCGAAAGTAGACCAGCTTCTAAAATAGAGG a909_ai2.seq
 TTGGTAATCCCTCTGGATACATTGATGGGTAACAAAGATATCTGTCTGT Majority
 11860 11870 11880 11890 11900
 11839 TTGGTAATCCCTCTGGATACATTGATGGGTAACAAAGATATCTGTCTGT coh1_ai2.seq
 11792 TTGGTAATCCCTCTGGATACATTGATGGGTAACAAAGATATCTGTCTGT a909_ai2.seq
 GCCATTAAGACATAGTCTGTTCAAAGTTTAAATTTCCCAAAGTTAAT Majority
 11910 11920 11930 11940 11950
 11889 GCCATTAAGACATAGTCTGTTCAAAGTTTAAATTTCCCAAAGTTAAT coh1_ai2.seq
 11842 GCCATTAAGACATAGTCTGTTCAAAGTTTAAATTTCCCAAAGTTAAT a909_ai2.seq
 CTGTTTGGACTGATATTTCTCTTTCAAATGTGCTAATTCAGGTCCGCTC Majority
 11960 11970 11980 11990 12000
 11939 CTGTTTGGACTGATATTTCTCTTTCAAATGTGCTAATTCAGGTCCGCTC coh1_ai2.seq
 11892 CTGTTTGGACTGATATTTCTCTTTCAAATGTGCTAATTCAGGTCCGCTC a909_ai2.seq
 CTGCAATCTGTAAATAAACATTTTCAGAGTACTGTGACATCGAAAATGCT Majority
 12010 12020 12030 12040 12050
 11989 CTGCAATCTGTAAATAAACATTTTCAGAGTACTGTGACATCGAAAATGCT coh1_ai2.seq
 11942 CTGCAATCTGTAAATAAACATTTTCAGAGTACTGTGACATCGAAAATGCT a909_ai2.seq
 TCTAAGAGCAATTCATGCCTTTTTCTTTAATAATTCTACCAGCATAAGT Majority
 12060 12070 12080 12090 12100
 12039 TCTAAGAGCAATTCATGCCTTTTTCTTTAATAATTCTACCAGCATAAGT coh1_ai2.seq
 11992 TCTAAGAGCAATTCATGCCTTTTTCTTTAATAATTCTACCAGCATAAGT a909_ai2.seq
 GATGAAAATATCATCAGCAGATTTTTCAAGGTAAGCCGTGTCAGCAAAAAT Majority
 12110 12120 12130 12140 12150
 12089 GATGAAAATATCATCAGCAGATTTTTCAAGGTAAGCCGTGTCAGCAAAAAT coh1_ai2.seq
 12042 GATGAAAATATCATCAGCAGATTTTTCAAGGTAAGCCGTGTCAGCAAAAAT a909_ai2.seq
 CAGAGCCTAGACTTTTCAGATACCGAATTATAAATAACTCTTTAGCTTCT Majority
 12160 12170 12180 12190 12200
 12139 CAGAGCCTAGACTTTTCAGATACCGAATTATAAATAACTCTTTAGCTTCT coh1_ai2.seq
 12092 CAGAGCCTAGACTTTTCAGATACCGAATTATAAATAACTCTTTAGCTTCT a909_ai2.seq
 ATATTAATAATGTTTTAAACCATTCAACCGCTTCTCTTGGATACCGCATAAAA Majority
 12210 12220 12230 12240 12250
 12189 ATATTAATAATGTTTTAAACCATTCAACCGCTTCTCTTGGATACCGCATAAAA coh1_ai2.seq
 12142 ATATTAATAATGTTTTAAACCATTCAACCGCTTCTCTTGGATACCGCATAAAA a909_ai2.seq
 ATCTGGACGATAGTGTCTTAAACACCGCGCTGTGAGAAGATGTTTCATAGATAG Majority
 12260 12270 12280 12290 12300
 12239 ATCTGGACGATAGTGTCTTAAACACCGCGCTGTGAGAAGATGTTTCATAGATAG coh1_ai2.seq
 12192 ATCTGGACGATAGTGTCTTAAACACCGCGCTGTGAGAAGATGTTTCATAGATAG a909_ai2.seq
 CTCCAAAAGAAATCTAAAAAACGATTATTGACAGAAAAATGACTTGA'CCCA Majority
 12310 12320 12330 12340 12350
 12289 CTCCAAAAGAAATCTAAAAAACGATTATTGACAGAAAAATGACTTGA'CCCA coh1_ai2.seq
 12242 CTCCAAAAGAAATCTAAAAAACGATTATTGACAGAAAAATGACTTGA'CCCA a909_ai2.seq

FIGURE 21R

129/487




FIGURE 21S

130/487




FIGURE 21T

131/487

```

CTGCTTAACTAAATGACATAATTACCAATGATACTGACATTTGA Majority
13660 13670 13680 13690 13700
13639 CTGCTACTAAACTTTGAAATGACATAATTACCAATGATACTGACATTTGA coh1_a12.seq
13592 CTGCTACTAAACTTTGAAATGACATAATTACCAATGATACTGACATTTGA a909_a12.seq

GTATTGATAATAATAGAGTACAGCTCCACTAAGAGTAGCAGCAATTAATA Majority
13710 13720 13730 13740 13750
13689 GTATTGATAATAATAAGTACAGCTCCACTAAGAGTAGCAGCAATTAATA coh1_a12.seq
13642 GTATTGATAATAATAGAGTACAGCTCCACTAAGAGTAGCAGCAATTAATA a909_a12.seq

GCCCAGCATTCTCTTTGTTAATTCTTTAAAAGTAAATACATCTCTTAAAG Majority
13760 13770 13780 13790 13800
13739 GCCCAGCATTCTCTTTGTTAATTCTTTAAAAGTAAATACATCTCTTAAAG coh1_a12.seq
13692 GCCCAGCATTCTCTTTGTTAATTCTTTAAAAGTAAATACATCTCTTAAAG a909_a12.seq

AGATAGCTTGATATAGGGAGACAATAAATTCAGTAATAACTGTAGAGATA Majority
13810 13820 13830 13840 13850
13789 AGATAGCTTGATAAGGGAGACAATAAATTCAGTAATAACTGTAGAGATA coh1_a12.seq
13742 AGATAGCTTGATATAGGGAGACAATAAATTCAGTAATAACTGTAGAGATA a909_a12.seq

ATAGCTCCCATAGCACCTAAAATFGGTATTTAAAAGTATATTAAGCACAAAC Majority
13860 13870 13880 13890 13900
13839 ATAGCTCCCATAGCACCTAAAATFGGTATTTAAAAGTATATTAAGCACAAAC coh1_a12.seq
13792 ATAGCTCCCATAGCACCTAAAATFGGTATTTAAAAGTATATTAAGCACAAAC a909_a12.seq

ATTTGCCACAAGTCCAATAACTGCAGACATTGTGTAAGCTTTTGTACGTC Majority
13910 13920 13930 13940 13950
13889 ATTTGCCACAAGTCCAATAACTGCAGACATTGTGTAAGCTTTTGTACGTC coh1_a12.seq
13842 ATTTGCCACAAGTCCAATAACTGCAGACATTGTGTAAGCTTTTGTACGTC a909_a12.seq

TTGAAGCCAGTAGATACTGTGTCCCTAAAGCGTTACCATAAGAAATGCAA Majority
13960 13970 13980 13990 14000
13939 TTGAAGCCAGTAGATACTGTGTCCCTAAAGCGTTACCATAAGAAATGCAA coh1_a12.seq
13892 TTGAAGCCAGTAGATACTGTGTCCCTAAAGCGTTACCATAAGAAATGCAA a909_a12.seq

ATGATCATCAAAA Majority
14010
13989 ATGATCATCAAAA coh1_a12.seq
13942 ATGATCATCAAAA a909_a12.seq

```

Decoration 'Decoration #1': Shade (with solid black) residues that differ from the Consensus.

FIGURE 21U

M K L S K K L L F S A A V L T M V A G S T V E P V A Q F A T G M S I V R A A E V S Q E R P A K T T V Majority				
10	20	30	40	50
1	M K L S K K L L F S A A V L T M V A G S T V E P V A Q F A T G M S I V R A A E V S Q E R P A K T T V	sag645_2603.pep		
1	M K L S K K L L F S A A V L T M V A G S T V E P V A Q F A T G M S I V R A A E V S Q E R P A K T T V	sag645_a909.pep		
1	M K L S K K L L F S A A V L T M V A G S T V E P V A Q F A T G M S I V R A A E V S Q E R P A K T T V	sag645_cjb111.pep		
1	M K L S K K L L F S A A V L T M V A G S T V E P V A Q F A T G M S I V R A A E V S Q E R P A K T T V	sag645_coh1.pep		
1	M K L S K K L L F S A A V L T M V A G S T V E P V A Q F A T G M S I V R A A E V S Q E R P A K T T V	sag645_nem316.pep		
N I Y K L Q A D S Y K S E I T S N G G I E N K D G E V I S N Y A K L G D N V K G L Q C V Q F K R Y K Majority				
60	70	80	90	100
51	N I Y K L Q A D S Y K S E I T S N G G I E N K D G E V I S N Y A K L G D N V K G L Q C V Q F K R Y K	sag645_2603.pep		
51	N I Y K L Q A D S Y K S E I T S N G G I E N K D G E V I S N Y A K L G D N V K G L Q C V Q F K R Y K	sag645_a909.pep		
51	N I Y K L Q A D S Y K S E I T S N G G I E N K D G E V I S N Y A K L G D N V K G L Q C V Q F K R Y K	sag645_cjb111.pep		
51	N I Y K L Q A D S Y K S E I T S N G G I E N K D G E V I S N Y A K L G D N V K G L Q C V Q F K R Y K	sag645_coh1.pep		
51	N I Y K L Q A D S Y K S E I T S N G G I E N K D G E V I S N Y A K L G D N V K G L Q C V Q F K R Y K	sag645_nem316.pep		
V K T D I S V D E L K K L T T V E A A D A K V G T I L E E G V S L P Q K T N A Q G L V V D A L D S K Majority				
110	120	130	140	150
01	V K T D I S V D E L K K L T T V E A A D A K V G T I L E E G V S L P Q K T N A Q G L V V D A L D S K	sag645_2603.pep		
01	V K T D I S V D E L K K L T T V E A A D A K V G T I L E E G V S L P Q K T N A Q G L V V D A L D S K	sag645_a909.pep		
01	V K T D I S V D E L K K L T T V E A A D A K V G T I L E E G V S L P Q K T N A Q G L V V D A L D S K	sag645_cjb111.pep		
01	V K T D I S V D E L K K L T T V E A A D A K V G T I L E E G V S L P Q K T N A Q G L V V D A L D S K	sag645_coh1.pep		
01	V K T D I S V D E L K K L T T V E A A D A K V G T I L E E G V S L P Q K T N A Q G L V V D A L D S K	sag645_nem316.pep		
S N V R Y L Y V E D L K N S P S N I T K A Y A V P F V L E L P V A N S T G T G F L S E I N I Y P K N Majority				
160	170	180	190	200
51	S N V R Y L Y V E D L K N S P S N I T K A Y A V P F V L E L P V A N S T G T G F L S E I N I Y P K N	sag645_2603.pep		
51	S N V R Y L Y V E D L K N S P S N I T K A Y A V P F V L E L P V A N S T G T G F L S E I N I Y P K N	sag645_a909.pep		
51	S N V R Y L Y V E D L K N S P S N I T K A Y A V P F V L E L P V A N S T G T G F L S E I N I Y P K N	sag645_cjb111.pep		
51	S N V R Y L Y V E D L K N S P S N I T K A Y A V P F V L E L P V A N S T G T G F L S E I N I Y P K N	sag645_coh1.pep		
51	S N V R Y L Y V E D L K N S P S N I T K A Y A V P F V L E L P V A N S T G T G F L S E I N I Y P K N	sag645_nem316.pep		
V V T D E P K T D K D V K K L G Q D D A G Y T I G E E F K W F L K S T I P A N L G D Y E K F E I T D Majority				
210	220	230	240	250
01	V V T D E P K T D K D V K K L G Q D D A G Y T I G E E F K W F L K S T I P A N L G D Y E K F E I T D	sag645_2603.pep		
01	V V T D E P K T D K D V K K L G Q D D A G Y T I G E E F K W F L K S T I P A N L G D Y E K F E I T D	sag645_a909.pep		
01	V V T D E P K T D K D V K K L G Q D D A G Y T I G E E F K W F L K S T I P A N L G D Y E K F E I T D	sag645_cjb111.pep		
01	V V T D E P K T D K D V K K L G Q D D A G Y T I G E E F K W F L K S T I P A N L G D Y E K F E I T D	sag645_coh1.pep		
01	V V T D E P K T D K D V K K L G Q D D A G Y T I G E E F K W F L K S T I P A N L G D Y E K F E I T D	sag645_nem316.pep		
K F A D G L T Y K S V G K I K I G S K T L N R D E H Y T I D E P T V D N Q N T L K I T F K P E K F K Majority				
260	270	280	290	300
51	K F A D G L T Y K S V G K I K I G S K T L N R D E H Y T I D E P T V D N Q N T L K I T F K P E K F K	sag645_2603.pep		
51	K F A D G L T Y K S V G K I K I G S K T L N R D E H Y T I D E P T V D N Q N T L K I T F K P E K F K	sag645_a909.pep		
51	K F A D G L T Y K S V G K I K I G S K T L N R D E H Y T I D E P T V D N Q N T L K I T F K P E K F K	sag645_cjb111.pep		
51	K F A D G L T Y K S V G K I K I G S K T L N R D E H Y T I D E P T V D N Q N T L K I T F K P E K F K	sag645_coh1.pep		
51	K F A D G L T Y K S V G K I K I G S K T L N R D E H Y T I D E P T V D N Q N T L K I T F K P E K F K	sag645_nem316.pep		
E I A E L L K G M T L V K N Q D A L D K A T A N T D D A A F L E I P V A S T I N E K A V L G K A I E Majority				
310	320	330	340	350
11	E I A E L L K G M T L V K N Q D A L D K A T A N T D D A A F L E I P V A S T I N E K A V L G K A I E	sag645_2603.pep		
11	E I A E L L K G M T L V K N Q D A L D K A T A N T D D A A F L E I P V A S T I N E K A V L G K A I E	sag645_a909.pep		
11	E I A E L L K G M T L V K N Q D A L D K A T A N T D D A A F L E I P V A S T I N E K A V L G K A I E	sag645_cjb111.pep		
11	E I A E L L K G M T L V K N Q D A L D K A T A N T D D A A F L E I P V A S T I N E K A V L G K A I E	sag645_coh1.pep		
11	E I A E L L K G M T L V K N Q D A L D K A T A N T D D A A F L E I P V A S T I N E K A V L G K A I E	sag645_nem316.pep		
N T F E L Q Y D H T P D K A D N P K P S N P P R K P E V H T G G K R F V K K D S T E T Q T L G C A E Majority				
360	370	380	390	400
11	N T F E L Q Y D H T P D K A D N P K P S N P P R K P E V H T G G K R F V K K D S T E T Q T L G C A E	sag645_2603.pep		
11	N T F E L Q Y D H T P D K A D N P K P S N P P R K P E V H T G G K R F V K K D S T E T Q T L G C A E	sag645_a909.pep		
11	N T F E L Q Y D H T P D K A D N P K P S N P P R K P E V H T G G K R F V K K D S T E T Q T L G C A E	sag645_cjb111.pep		
11	N T F E L Q Y D H T P D K A D N P K P S N P P R K P E V H T G G K R F V K K D S T E T Q T L G C A E	sag645_coh1.pep		
11	N T F E L Q Y D H T P D K A D N P K P S N P P R K P E V H T G G K R F V K K D S T E T Q T L G C A E	sag645_nem316.pep		

Figure 22

133/487

F D L L A S D G T A V K W T D A L I K A N T N K N Y I A G E A V T C Q P I K L K S H T D G T F E I K Majority
 410 420 430 440 450
 01 F D L L A S D G T A V K W T D A L I K A N T N K N Y I A G E A V T C Q P I K L K S H T D G T F E I K sag645_2603.pep
 01 F D L L A S D G T A V K W T D A L I K A N T N K N Y I A G E A V T C Q P I K L K S H T D G T F E I K sag645_a909.pep
 01 F D L L A S D G T A V K W T D A L I K A N T N K N Y I A G E A V T C Q P I K L K S H T D G T F E I K sag645_cjb111.pep
 01 F D L L A S D G T A V K W T D A L I K A N T N K N Y I A G E A V T C Q P I K L K S H T D G T F E I K sag645_coh1.pep
 01 F D L L A S D G T A V K W T D A L I K A N T N K N Y I A G E A V T C Q P I K L K S H T D G T F E I K sag645_nem316.pep

G L A Y A V D A N A E G T A V T Y K L K E T K A P E G Y V I P D K E I E F T V S Q T S Y N T K P T D Majority
 460 470 480 490 500
 01 G L A Y A V D A N A E G T A V T Y K L K E T K A P E G Y V I P D K E I E F T V S Q T S Y N T K P T D sag645_2603.pep
 01 G L A Y A V D A N A E G T A V T Y K L K E T K A P E G Y V I P D K E I E F T V S Q T S Y N T K P T D sag645_a909.pep
 01 G L A Y A V D A N A E G T A V T Y K L K E T K A P E G Y V I P D K E I E F T V S Q T S Y N T K P T D sag645_cjb111.pep
 01 G L A Y A V D A N A E G T A V T Y K L K E T K A P E G Y V I P D K E I E F T V S Q T S Y N T K P T D sag645_coh1.pep
 01 G L A Y A V D A N A E G T A V T Y K L K E T K A P E G Y V I P D K E I E F T V S Q T S Y N T K P T D sag645_nem316.pep

I T V D S A D A T P D T I K N N K R P S I P N T G G I G T A I F V A I G A A V M A F A V K G M K R R Majority
 510 520 530 540 550
 01 I T V D S A D A T P D T I K N N K R P S I P N T G G I G T A I F V A I G A A V M A F A V K G M K R R sag645_2603.pep
 01 I T V D S A D A T P D T I K N N K R P S I P N T G G I G T A I F V A I G A A V M A F A V K G M K R R sag645_a909.pep
 01 I T V D S A D A T P D T I K N N K R P S I P N T G G I G T A I F V A I G A A V M A F A V K G M K R R sag645_cjb111.pep
 01 I T V D S A D A T P D T I K N N K R P S I P N T G G I G T A I F V A I G A A V M A F A V K G M K R R sag645_coh1.pep
 01 I T V D S A D A T P D T I K N N K R P S I P N T G G I G T A I F V A I G A A V M A F A V K G M K R R sag645_nem316.pep

T K D N Majority
 51 T K D N sag645_2603.pep
 51 T K D N sag645_a909.pep
 51 T K D N sag645_cjb111.pep
 51 T K D N sag645_coh1.pep
 51 T K D N sag645_nem316.pep

scoration 'Decoration #1': Shade (with solid black) residues that differ from the Consensus.

FIGURE 22A

134/487

M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A Majority				
10	20	30	40	50
1	M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A	sag649_2603.pep		
1	M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A	sag649_coh1.pep		
1	M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A	sag649_cjb111.pep		
1	M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A	sag649_18rs21.pep		
1	M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A	sag649_nem316.pep		
1	M K K R Q K I W R G L S V T L L L I L S Q I P F G I L V Q G E T Q D T N Q A L G K V I V K K T G D N A	sag649_cjb111.pep		
T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G Majority				
60	70	80	90	100
51	T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G	sag649_2603.pep		
51	T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G	sag649_coh1.pep		
51	T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G	sag649_cjb111.pep		
51	T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G	sag649_18rs21.pep		
51	T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G	sag649_nem316.pep		
51	T P L G K A T F V L K N D N D K S E T S H E T V E G S G E A T F E N I K P G D Y T L R E E T A P I G	sag649_cjb111.pep		
Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E Majority				
110	120	130	140	150
101	Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E	sag649_2603.pep		
101	Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E	sag649_coh1.pep		
101	Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E	sag649_cjb111.pep		
101	Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E	sag649_18rs21.pep		
101	Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E	sag649_nem316.pep		
101	Y K K T D K T W K V K V A D N G A T I I E G M D A D K A E K R K E V L N A Q Y P K S A I Y E D T K E	sag649_cjb111.pep		
N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K Majority				
160	170	180	190	200
151	N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K	sag649_2603.pep		
151	N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K	sag649_coh1.pep		
151	N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K	sag649_cjb111.pep		
151	N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K	sag649_18rs21.pep		
151	N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K	sag649_nem316.pep		
151	N Y P L V N V E G S K V G E Q Y K A L N P I N G K D G R R E I A E G W L S K K I T G V N D L D K N K	sag649_cjb111.pep		
Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E Majority				
210	220	230	240	250
201	Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E	sag649_2603.pep		
201	Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E	sag649_coh1.pep		
201	Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E	sag649_cjb111.pep		
201	Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E	sag649_18rs21.pep		
201	Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E	sag649_nem316.pep		
201	Y K I E L T V E G K T T V E T K E L N Q P L D V V V L L D N S N S M N N E R A N N S Q R A L K A G E	sag649_cjb111.pep		
A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V Majority				
260	270	280	290	300
251	A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V	sag649_2603.pep		
251	A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V	sag649_coh1.pep		
251	A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V	sag649_cjb111.pep		
251	A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V	sag649_18rs21.pep		
251	A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V	sag649_nem316.pep		
251	A V E K L I D K I T S N K D N R V A L V T Y A S T I F D G T E A T V S K G V A D Q N G K A L N D S V	sag649_cjb111.pep		
S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q Majority				
310	320	330	340	350
301	S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q	sag649_2603.pep		
301	S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q	sag649_coh1.pep		
301	S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q	sag649_cjb111.pep		
301	S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q	sag649_18rs21.pep		
301	S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q	sag649_nem316.pep		
301	S W D Y H K T T F T A T T H N Y S Y L N L T N D A N E V N I L K S R I P K E A E H I N G D R T L Y Q	sag649_cjb111.pep		
F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S Majority				
360	370	380	390	400
351	F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S	sag649_2603.pep		
351	F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S	sag649_coh1.pep		
351	F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S	sag649_cjb111.pep		
351	F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S	sag649_18rs21.pep		
351	F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S	sag649_nem316.pep		
351	F G A T F T Q K A L M K A N E I L E T Q S S N A R K K L I F H V T D G V P T M S Y A I N F N P Y I S	sag649_cjb111.pep		

Figure 23

135/487

T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V Majority				
410	420	430	440	450
401	T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V	sag649_2603.pep		
401	T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V	sag649_coh1.pep		
401	T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V	sag649_cjb111.pep		
401	T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V	sag649_18rs21.pep		
401	T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V	sag649_nem316.pep		
401	T S Y Q N Q F N S F L N K I P D R S G I L Q E D F I I N G D D Y Q I V K G D G E S F K L F S D R K V	sag649_cjb111.pep		
P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T Majority				
460	470	480	490	500
451	P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T	sag649_2603.pep		
451	P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T	sag649_coh1.pep		
451	P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T	sag649_cjb111.pep		
451	P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T	sag649_18rs21.pep		
451	P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T	sag649_nem316.pep		
451	P V T G G T T Q A A Y R V P Q N Q L S V M S N E G Y A I N S G Y I Y L Y W R D Y N W V Y P F D P K T	sag649_cjb111.pep		
K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E Majority				
510	520	530	540	550
501	K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E	sag649_2603.pep		
501	K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E	sag649_coh1.pep		
501	K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E	sag649_cjb111.pep		
501	K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E	sag649_18rs21.pep		
501	K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E	sag649_nem316.pep		
501	K K V S A T K Q I K T H G E P T T L Y F N G N I R P K G Y D I F T V G I G V N G D P G A T P L E A E	sag649_cjb111.pep		
K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G Majority				
560	570	580	590	600
551	K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G	sag649_2603.pep		
551	K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G	sag649_coh1.pep		
551	K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G	sag649_cjb111.pep		
551	K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G	sag649_18rs21.pep		
551	K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G	sag649_nem316.pep		
551	K F M Q S I S S K T E N Y T N V D D T N K I Y D E L N K Y F K T I V E E K H S I V D G N V T D P M G	sag649_cjb111.pep		
E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T Majority				
610	620	630	640	650
601	E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T	sag649_2603.pep		
601	E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T	sag649_coh1.pep		
601	E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T	sag649_cjb111.pep		
601	E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T	sag649_18rs21.pep		
601	E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T	sag649_nem316.pep		
601	E M I E F Q L K N G Q S F T H D D Y V L V G N D G S Q L K N G V A L G G P N S D G G I L K D V T V T	sag649_cjb111.pep		
Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K Majority				
660	670	680	690	700
651	Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K	sag649_2603.pep		
651	Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K	sag649_coh1.pep		
651	Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K	sag649_cjb111.pep		
651	Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K	sag649_18rs21.pep		
651	Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K	sag649_nem316.pep		
651	Y D K T S Q T I K I N H L N L G S G Q K V V L T Y D V R L K D N Y I S N K F Y N T N N R T T L S P K	sag649_cjb111.pep		
S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L Majority				
710	720	730	740	750
701	S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L	sag649_2603.pep		
701	S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L	sag649_coh1.pep		
701	S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L	sag649_cjb111.pep		
701	S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L	sag649_18rs21.pep		
701	S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L	sag649_nem316.pep		
701	S E K E P N T I R D F P I P K I R D V R E F P V L T I S N Q K K M G E V E F I K V N K D K H S E S L	sag649_cjb111.pep		
L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S Majority				
760	770	780	790	800
751	L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S	sag649_2603.pep		
751	L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S	sag649_coh1.pep		
751	L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S	sag649_cjb111.pep		
751	L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S	sag649_18rs21.pep		
751	L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S	sag649_nem316.pep		
751	L G A K F Q L Q I E K D F S G Y K Q F V P E G S D V T T K N D G K I Y F K A L Q D G N Y K L Y E I S	sag649_cjb111.pep		

FIGURE 23A

136/487

	810	820	830	840	850	Majority
	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					
801	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					sag649_2603.pep
801	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					sag649_coh1.pep
801	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					sag649_cjb111.pep
801	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					sag649_18rs21.pep
801	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					sag649_new316.pep
801	SPDGYIEVKTTPVVTFTIQNGEVTNLKADPNANKNQIGYLEGNGKHLITN					sag649_cjb111.pep
	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					Majority
	860	870	880	890		
851	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					sag649_2603.pep
851	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					sag649_coh1.pep
851	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					sag649_cjb111.pep
851	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					sag649_18rs21.pep
851	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					sag649_new316.pep
851	TPKRPPGVFPKTTGGIGTIVYILVGSSTFMILTICSFRRKQL					sag649_cjb111.pep

Decoration 'Decoration #1': Shade (with solid black) residues that differ from the Consensus.

FIGURE 23B

137/487

	10	20	30	40	50	Majority
	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					
1	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					sag1408_2603.pep
1	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					sag1408_515.pep
1	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					sag1408_18rs21.seq
1	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					sag1408_cjb111.pep
1	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					sag1408_h36b.pep
1	MRKYQKFSKILTLSLFCLSQIPLNTNVLGESTVPENGA K G K L V V K K T D D Q					sag1408_nem316.pep
	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					Majority
	60	70	80	90	100	
51	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					sag1408_2603.pep
51	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					sag1408_515.pep
51	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					sag1408_18rs21.seq
51	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					sag1408_cjb111.pep
51	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					sag1408_h36b.pep
51	NKPLSKATFVLKTTAHPE SKIEKVTAELTGEATFDNLIPGDYTLSEETAP					sag1408_nem316.pep
	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					Majority
	110	120	130	140	150	
101	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					sag1408_2603.pep
101	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					sag1408_515.pep
101	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					sag1408_18rs21.seq
101	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					sag1408_cjb111.pep
101	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					sag1408_h36b.pep
101	EGYKKTNTQWQVKVESNGKTTIQNSGDKNSTIGQNEELD K Q Y P P T G I Y E					sag1408_nem316.pep
	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					Majority
	160	170	180	190	200	
151	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					sag1408_2603.pep
151	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					sag1408_515.pep
151	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					sag1408_18rs21.seq
151	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					sag1408_cjb111.pep
151	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					sag1408_h36b.pep
151	DTKESYKLEHVKGSVPNGKSEAKAVNPYSSEGEHIREIPEGTLSKRIS E V					sag1408_nem316.pep
	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					Majority
	210	220	230	240	250	
201	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					sag1408_2603.pep
201	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					sag1408_515.pep
201	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					sag1408_18rs21.seq
201	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					sag1408_cjb111.pep
201	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					sag1408_h36b.pep
201	GDLAHNKYKIELTVSGKTI V K P V D K Q K P L D V V F V L D N S N S M N N D G P N F Q R					sag1408_nem316.pep
	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					Majority
	260	270	280	290	300	
251	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					sag1408_2603.pep
251	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					sag1408_515.pep
251	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					sag1408_18rs21.seq
251	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					sag1408_cjb111.pep
247	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					sag1408_h36b.pep
251	HNKAKKAAEALGTAVKDILGANS DNRVALV TYGSDIFDGRSVDVVKGFKE					sag1408_nem316.pep
	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					Majority
	310	320	330	340	350	
301	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					sag1408_2603.pep
301	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					sag1408_515.pep
301	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					sag1408_18rs21.seq
301	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					sag1408_cjb111.pep
297	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					sag1408_h36b.pep
301	DDKY YGLQTKFTIQTENYSHKQLTNNAEEI IKRIPTEAPKAKWGSTTNGL					sag1408_nem316.pep
	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					Majority
	360	370	380	390	400	
351	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					sag1408_2603.pep
351	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					sag1408_515.pep
351	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					sag1408_18rs21.seq
351	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					sag1408_cjb111.pep
346	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					sag1408_h36b.pep
351	TPEQQKEYYLSKVG E T F T M K A F M E A D D I L S Q V N R N S Q K I I V H V T D G V P T R					sag1408_nem316.pep

Figure 24

138/487

S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F Majority				
410	420	430	440	450
401	S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F	sag1408_2603.pep		
401	S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F	sag1408_515.pep		
401	S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F	sag1408_18rs21.seq		
396	S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F	sag1408_cjb111.pep		
401	S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F	sag1408_h36b.pep		
401	S Y A I N N F K L G A S Y E S Q F E Q M K K N G Y L N K S N F L L T D K P E D I K G N G E S Y F L F	sag1408_nem316.pep		
P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S Majority				
460	470	480	490	500
451	P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S	sag1408_2603.pep		
451	P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S	sag1408_515.pep		
451	P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S	sag1408_18rs21.seq		
451	P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S	sag1408_cjb111.pep		
446	P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S	sag1408_h36b.pep		
451	P L D S Y Q T Q I I S G N L Q K L H Y L D L N L N Y P K G T I Y R N G P V K E H G T P T K L Y I N S	sag1408_nem316.pep		
L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T Majority				
510	520	530	540	550
501	L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T	sag1408_2603.pep		
501	L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T	sag1408_515.pep		
501	L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T	sag1408_18rs21.seq		
501	L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T	sag1408_cjb111.pep		
496	L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T	sag1408_h36b.pep		
501	L K Q K N Y D I F N F G I D I S G F R Q V Y N E D Y K K N Q D G T F Q K L K E E A F E L S D G E I T	sag1408_nem316.pep		
E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I Majority				
560	570	580	590	600
551	E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I	sag1408_2603.pep		
551	E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I	sag1408_515.pep		
551	E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I	sag1408_18rs21.seq		
551	E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I	sag1408_cjb111.pep		
546	E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I	sag1408_h36b.pep		
551	E L M R S F S S K P E Y Y T P I V T S A D T S N N E I L S K I Q Q Q F E T I L T K E N S I V N G T I	sag1408_nem316.pep		
E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K Majority				
610	620	630	640	650
601	E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K	sag1408_2603.pep		
601	E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K	sag1408_515.pep		
601	E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K	sag1408_18rs21.seq		
601	E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K	sag1408_cjb111.pep		
596	E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K	sag1408_h36b.pep		
601	E D P M G D K I N L Q L G N G Q T L Q P S D Y T L Q G N D G S V M K D G I A T G G P N N D G G I L K	sag1408_nem316.pep		
G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L Majority				
660	670	680	690	700
651	G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L	sag1408_2603.pep		
651	G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L	sag1408_515.pep		
651	G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L	sag1408_18rs21.seq		
651	G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L	sag1408_cjb111.pep		
646	G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L	sag1408_h36b.pep		
651	G V K L E Y I G N K L Y V R G L N L G E G Q K V T L T Y D V K L D D S F I S N K F Y D T N G R T T L	sag1408_nem316.pep		
N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L Majority				
710	720	730	740	750
701	N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L	sag1408_2603.pep		
701	N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L	sag1408_515.pep		
701	N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L	sag1408_18rs21.seq		
701	N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L	sag1408_cjb111.pep		
696	N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L	sag1408_h36b.pep		
701	N P K S E D P N T L R D F P I P K I R D V R E Y P T I T I K N E K K L G E I E F I K V D K D N N K L	sag1408_nem316.pep		
L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I Majority				
760	770	780	790	800
751	L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I	sag1408_2603.pep		
751	L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I	sag1408_515.pep		
751	L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I	sag1408_18rs21.seq		
751	L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I	sag1408_cjb111.pep		
746	L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I	sag1408_h36b.pep		
751	L L K G A T F E L Q E F N E D Y K L Y L P I K N N N S K V V T G E N G K I S Y K D L K D G K Y Q L I	sag1408_nem316.pep		

FIGURE 24A


139/487

		E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N Majority										
		810		820		830		840		850		
801	E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N											sag1408_2603.pep
801	E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N											sag1408_515.pep
801	E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N											sag1408_18rs21.seq
801	E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N											sag1408_cjb111.pep
796	E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N											sag1408_h36b.pep
801	E A V S P E D Y Q K I T N K P I L T F E V V K G S I Q N I I A V N K Q I S E Y H E E G D K H L I T N											sag1408_nem316.pep
		T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K Majority										
		860		870		880		890		900		
851	T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K											sag1408_2603.pep
851	T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K											sag1408_515.pep
851	T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K											sag1408_18rs21.seq
851	T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K											sag1408_cjb111.pep
846	T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K											sag1408_h36b.pep
851	T H I P P K G I I P M T G G K G I L S F I L I G G A M M S I A G G I Y I W K R Y K K S S D M S I E K											sag1408_nem316.pep
D												
Majority												
901	D											sag1408_2603.pep
901	D											sag1408_515.pep
901	D											sag1408_18rs21.seq
901	D											sag1408_cjb111.pep
896	D											sag1408_h36b.pep
901	D											sag1408_nem316.pep

Decoration 'Decoration #1': Shade (with solid black) residues that differ from the Consensus.


FIGURE 24B

Figure 25: GBS closely associate with tight junctions and cross the monolayer by a paracellular route



Transmission Electron Microscopy images of GBS infection of ME180 cervical epithelial cells.


Figure 26: GBS infection of ME180 cells
GBS infection of ME180 cells



141/487

PCT/US05/27239/142/487

Figure 27



PCT/US05/27239 143/487

Figure 28




Figure 29






Figure 30



PCT/US2005/027239

Figure 31



PCT/US2005/027239/47/487

Figure 32





Figure 33

COH1

2603 V/R




PCT/US05/27239 149/487

GBS STRAIN COH1 over GBS80

Negative staining EM

Figure 34



GBS STRAIN COH1 over GBS80

IEM anti-GBS80 (gold particles 10nm)





Figure 35

GBS STRAIN COH1 over GBS80


Figure 36

IEM anti-GBS80 (gold particles 10nm)



GBS STRAIN COH1 over GBS80
IEM anti-GBS80 (gold particles 20nm)


Figure 37



GBS STRAIN COH1 over GBS80

IEM anti-GBS104 (gold particles 10nm)

Figure 38



GBS STRAIN COH1 over GBS80

Figure 39

IEM anti-GBS80 (gold particles 20nm) anti-GBS104 (gold particles 10nm)







Figure 40 **GBS STRAIN COH1 over GBS80**

IEM anti-GBS80 (gold particles 20nm) anti-GBS104 (gold particles 10nm)





Figure 41: GBS 80 is necessary for polymer formation, GBS104 and sortase SAG0648 are necessary for efficient assembly



PCT/US05/27239 157/487

Figure 42: Gbs67 is part of a second pilus;

Gbs80 is polymerized in strain 515

(515 lacks sortase 647-8, but has AI-2 sortases)





Figure 43: Two macro-molecules are visible in Coh1 at >1000 kDa, one is the Gbs80 pilin



Conservative size estimate:
240 kDa + 14 subunits of
Gbs80 = ~ 1000 kDa




Figure 44




Figure 45: Gbs52 is a minor component of the GBS pilus




Figure 46: The pilus is found in the supernatant of the bacterial culture





Figure 47: The pilus is found in all growth phases of cultures in all growth phases




TCA precipitation of 1 ml of THB culture supernatant run on 3-8% SDS-PAGE. OD600 nm are noted above samples, "f" indicates supernatant was filtered (0.2 μ M syringe filter).

Left five samples: Coh1.

Right five samples: 179 (Δ Gbs80/pGbs80).

Figure 48: In Coh1, only the gbs80 protein and one sortase (sag0647 or sag0648) is required for polymerization



Over expression of gbs80 in various strain backgrounds (two clones each).

Total protein extract preparations.

Only the double sortase mutant does not polymerize gbs80.

Gbs80 is polymerized in the DK515 strain background (lacks adhesin island 1, adhesin island 2 is 2603-like). Presumably, sag1405&sag1406 are responsible for polymerization.

GBS STRAIN JM9030013
IEM anti-GBS80









FIGURE 49



GBS STRAIN JM9030013
IEM anti-GBS104

FIGURE 50

PCT/US05/27239

GI-19224135	1	MNNK YOK QDAPR-VSNR RP ----- K Q L T W T L G V F L M F L L S S M R G A Q S I F G E E K
ORF78	1	----- Q K R D K T N Y G S A N N K R ----- R O T T I G L L K V E L T F V A L I G ----- I V G
GI-21909634	1	----- Q K R D K T N Y G S A N N K R ----- R O T T I G L L K V E L T F V A L I G I V G F S I R A F G -----
GI-28810257	1	----- Q K R D K T N Y G S A N N K R ----- R O T T I G L L K V E L T F V A L I G I V G F S I R A F G -----
GI-19745301	1	----- Q K R D K T N Y G S A N N K R ----- R O T T I G L L K V E L T F V A L I G I V G F S I R A F G -----
GAS15	1	LRGE K M T R F F N K L N T L N T O R V L S K N S R F L W T L G V F L M F A L V T S L V G A K T V E C-----
GI-19224135	53	R I E V S V E K I K S P D D -- A Y P W Y G Y D S Y D S S H P Y E R F W A H D L R V N L N G S R S Y O V Y C F N L
ORF78	39	-----
GI-21909634	46	- A E O S V P N K O S S V O -- D Y P W Y G Y D S Y S K G Y E D Y S P L T Y N L K V N L D G S R E Y O A Y C F N L
GI-28810257	46	- A E O S V P N K O S S V O -- D Y P W Y G Y D S Y S K G Y E D Y S P L T Y N L K V N L D G S R E Y O A Y C F N L
GI-19745301	46	- A E O S T -----
GAS15	58	- L V E S T E N A I N P D S S S E V R I N G Y E S Y V R G H E V Y K O F W A H D L R V N L E G S R S Y O V Y C F N L
GI-19224135	111	N S L E N E K N A F S K O M E N R V D G T G E V E T N Y S O T P K I R G E S L M N K L S I M Y N A F P K N A N G V M
ORF78	39	-----
GI-21909634	103	T K H F F S K S D S V R S O W Y K N L E G T N E N F I K L A D K P R I E D G L O O N L R I T Y N G Y P N D R N G I M
GI-28810257	103	T K H F F S K S D S V R S O W Y K N L E G T N E N F I K L A D K P R I E D G L O O N L R I T Y N G Y P N D R N G I M
GI-19745301	52	-----
GAS15	117	K N A F L G S D S S V K K Y N R H D G I S T R E D Y M S P R I T G D E L N O K T R A M I N G H P O N A N G I M
GI-19224135	171	D K L E P L N A I L V T O A A W Y S D S S Y G N - I K T L W A S E L K D G K T D F E O K L M R E A Y S K L S D D
ORF78	39	----- F S I R A G
GI-21909634	163	K G I D P L N A I L V T O N A I W Y D S S Y L S D T S K A F Q O E T D L K D S O L O L M R N A L K L L I N E K
GI-28810257	163	K G I D P L N A I L V T O N A I W Y D S S Y L S D T S K A F Q O E T D L K D S O L O L M R N A L K L L I N E K
GI-19745301	52	-----
GAS15	177	E G L E P L N A I R V T O B A W Y S D N A P L S N P D E S E K R E S E S N L Y S I S O L S L M R G A L N O L I D E N
GI-19224135	230	L E E T S K N K L F O G S K L N I E V P O D N S ----- V O N L L S A E Y V P E S P E A G O S E E P E V O T K N T
ORF78	46	----- A E E K S T E T K R T
GI-21909634	223	E V E S L P N O V F A N Y O L S I F O S S D N T ----- F O N L L S A E Y V D T P P K P G ----- E B F F A K T E K T
GI-28810257	223	E V E S L P N O V F A N Y O L S I F O S S D N T ----- F O N L L S A E Y V D T P P K P G ----- E B F F A K T E K T
GI-19745301	52	----- E T R K T
GAS15	237	L A T K M P K O V P D E F O L S I F O S E D N G D K Y N K G Y O N L L S G G I V E T K E T E P G D P P M P P N O P O T T
GI-19224135	284	S V I I R R Y A E G D Y S K L L E G A T L R L I G E D I L L F O E K V F O S N G T G E K I E L S N G T Y T L T E L S S P
ORF78	57	S V I I R R Y A E G D Y S K L L E G A T L R L I G E D I L L F O E K V F O S N G T G E K I E L S N G T Y T L T E L S S P
GI-21909634	275	S V I I R R Y A E G D Y S K L L E G A T L R L I G E S G F O E K I F D S N G E K V E L I N G T Y V L S E L E R E P
GI-28810257	275	S V I I R R Y A E G D Y S K L L E G A T L R L I G E S G F O E K I F D S N G E K V E L I N G T Y V L S E L E R E P
GI-19745301	57	S V I I R R Y A E G D Y S K L L E G A T L R L I G E S G F O E K I F D S N G E K V E L I N G T Y V L S E L E R E P
GAS15	297	S V I I R R Y A E G D Y S K L L E G A T L O L I G D N V N S F O A R V T S E N D I S E R I E L S D G T Y T L T E L S P
GI-19224135	344	D G Y K I A E P I K S R V N K V F I V O R D G S O V E M P N R E V A E P Y S V E Y S D M O D S N Y I N P E T F T P
ORF78	117	D G Y K I A E P I K S R V N K V F I V O R D G S O V E M P N K E L G S P Y I T E A Y N D F E E G L S T O N
GI-21909634	335	D G Y K I A E P I K S R V N K V F I V O R D G S O V E M P N K E L G S P Y I T E A Y N D F E E G L S T O N
GI-28810257	335	D G Y K I A E P I K S R V N K V F I V O R D G S O V E M P N K E L G S P Y I T E A Y N D F E E G L S T O N
GI-19745301	117	D G Y K I A E P I K S R V N K V F I V O R D G S O V E M P N K E L G S P Y I T E A Y N D F E E G L S T O N
GAS15	357	A G Y S I A E P I T F K V E A G N V Y T - I I D G K O T E N P N K E I V E P Y S V E A Y N D F E E F S V L I T O N
GI-19224135	404	Y G R F Y A N N K D K S S O V Y C F N A D L H S P P E S E D G G T I D F L I S T M K E V R Y T H I A G S D L F K Y
ORF78	174	Y A R F Y A N N K D K S S O V Y C F N A N L K S P P D S E D H G A T I N P D F T T E - D I R Y S H I A G S D L I N
GI-21909634	393	Y G R F Y A N N K D K S S O V Y C F N A D L H S P P D S Y D H G A T I D P V S E S K E I R Y T H V S G Y D L K Y
GI-28810257	393	Y G R F Y A N N K D K S S O V Y C F N A D L H S P P D S Y D H G A T I D P V S E S K E I R Y T H V S G Y D L K Y
GI-19745301	177	Y G R F Y A N N K D K S S O V Y C F N A D L H S P P D S L D K E F L D P D F N E G E K I R Y T H I L E A D L F S Y
GAS15	413	Y A R F Y A N N K D K S S O V Y C F N A D L K S P P D S E D G G T I D F L I S T M K E V R Y T H I A G S D L F K Y

FIGURE 52

GI-19224135 464 ALRPRDTNPEDFLKHINKVLEKGYKRRGD--SYNGLTEIFPRAATOLAIYYFTDSIDLK
 ORF78 233 ANTARDEDFQLFKHVKNVIENGYHKKGQAIPYNSLTFEAFRAATOLAIYYFTDSVDL--
 GI-21909634 453 AATPRDKDADFLLKHLKHLDKGYKRRGD--TYKILTEAFRAATOLAIYYFTDSADLIT
 GI-28810257 453 AATPRDKDADFLLKHLKHLDKGYKRRGD--TYKILTEAFRAATOLAIYYFTDSADLIT
 GI-19745301 237 ANNPRASINDELSCVHIVLEKGYRDDST--TYANLTSVEAFRAATOLAIYYFTDSVDLND
 GAS15 472 TVKPRDTDPDITLKHINKVLEKGYREKQAIPYNSLTFEAFRAATOLAIYYFTDSAEID-

GI-19224135 522 LKTYNDNKGYPHGFESWDEKTLAVTKELINYAOD--NSAPQLTNLDFVFPNNSKYOSLIGTE
 ORF78 291 --TKDRLEDFHGFCDMNDOTLGVANKIIVEYALS--DEDSKLTNLDFFVFPNNSKYOSLIGTE
 GI-21909634 511 LKTYNDNKGYPHGFCDKLDLAVVHELTITYAED--VILEMTQNLDFFVFPNNSRYOALIGTO
 GI-28810257 511 LKTYNDNKGYPHGFCDKLDLAVVHELTITYAED--VILEMTQNLDFFVFPNNSRYOALIGTO
 GI-19745301 295 LADY-----HGFALITTEALNATITETVAYADRANLPIISNLDFFVFPNNSKYOSLIGTO
 GAS15 531 ---KDKLNDYHGFCDMNDSTLAVANKILMEYAO--SNEPQLTDLDFVFPNNSKYOSLIGTO

GI-19224135 581 YHPDDLVDVIRMEDNKQEVIPVTHSLTVKRTVVCGLGDMTNGCFQFELBLNDKTKQELIVNT
 ORF78 348 YHPDDLVDVIRMEDNKQEVIPVTHSLTVKRTVVCGLGDMTNGCFQFELBLNDKTKQELIVNT
 GI-21909634 570 YHPNELIDVISWEDNKQEPPIPIITHKLTISKTVGTIADNKKREFNFEIHLNSSDQQAISGT
 GI-28810257 570 YHPNELIDVISWEDNKQEPPIPIITHKLTISKTVGTIADNKKREFNFEIHLNSSDQQAISGT
 GI-19745301 349 YHPESLVDIIRMEDNKQEPPIPIITHKLTISKTVGTIADNKKREFNFEIHLNSSDQQAISGT
 GAS15 587 YHPEDLVDIIRMEDNK--EVIIPVTHSLTVKRTVVCGLGDMTNGCFQFELBLNKNKQELISOT

GI-19224135 641 LKTNNOQLVAKDGRYSFNLRHGDTIRIEGLEFGYSYTKETE--KDYIIVTVVNNVSOEAO
 ORF78 408 LKTNNOQLVAKDGRYSFNLRHGDTIRIEGLEFGYSYTKETE--KDYIIVTVVNNVSOEAO
 GI-21909634 630 YFTNSGELTVIDGKATEFLINDGESLIVEGLPSCGYSYEITETGASDYEVSVNGKNAPDGNA
 GI-28810257 630 YFTNSGELTVIDGKATEFLINDGESLIVEGLPSCGYSYEITETGASDYEVSVNGKNAPDGNA
 GI-19745301 409 YFTNSGELTVIDGKATEFLINDGESLIVEGLPSCGYSYEITETGASDYEVSVNGKNAPDGNA
 GAS15 646 VKIDKTNLEFRDGRATINLRHGDSLLOGLEFGYSYTKETE--SEGKVKVNSQEVANATV

GI-19224135 701 ASENVTADKEVTFENRNDLVPTGCLTIDGCAIYLWLLLLVFFGLLWHLFGRKGLKND--
 ORF78 468 ASENVTADKEVTFENRNDLVPTGCLTIDGCAIYLWLLLLVFFGLLWHLFGRKGLKND--
 GI-21909634 690 TKASVKEDETVTFENRNDLVPTGCLTIDGCAIYLWLLLLVFFGLLWHLFGRKGLKND--
 GI-28810257 690 TKASVKEDETVTFENRNDLVPTGCLTIDGCAIYLWLLLLVFFGLLWHLFGRKGLKND--
 GI-19745301 469 TKASVKEDETVTFENRNDLVPTGCLTIDGCAIYLWLLLLVFFGLLWHLFGRKGLKND--
 GAS15 706 SKTGITTSDETFAPENRNDLVPTGCLDQKINGYLALTEVAGTSLGHLGHTTIRTKHD

FIGURE 52A

169/487

GI-1922WO 2006/078318

PCT/US2005/027239

GI-50913503 SYMFARGEKMNKIPLNKEAGFLVHTKRRRNFVTLVGVFTLLACAGAIQFGQVAY
MVSSYMFVARGEKMNKIPLNKEASFLAHTKRRRNFVTLVGVFTLLACAGAIQFGQVAY

GI-19224134 61 AADERTVFNFKSPDPDYPIYGYDSV-----RCLEARYHNLIKVNLIKGSREYQAYCFNITK
GI-50913503 61 AADERTVPSHSENFPEFFMYGYDAYGREYPCYNLWIRYHDLRVNLSGSRSYQVYCFNIOQ

GI-19224134 115 YEFPRPTYSTTNMFKKIDGSGSAFKSYAANPFLDENLDKLEKNILNLTNGVKSNAQCF
GI-50913503 121 NNPSSQKNSFIKNNWKKIEGNCCKSFVDYAHTTKGKKE---ELEQRELSSELYNEYPNDANGY

GI-19224134 175 MNCLEEDLNATLVTONATHIYSDSAPLNDVNRKMERREVRNCEISESOVTLMREALKKLIDP
GI-50913503 178 MKGLEHNLNATLVTONATHIYSDNS-QYQFETLHESEANEKILSRSOVTLMREALKKLIDP

GI-19224134 235 NLEATAANKIPSGYRLNIFKSENEYONLLSAEYVPPDDPPKPGDTSEHNPKTPELDGTP
GI-50913503 237 NLEATAVANKIPSGYRLNIFSENEAYONLLSAEYVPPDDPPKPGETSEHNPKTPELDGTP

GI-19224134 295 PEDPKHPDESSEFALPPLMPPELDGEEVPEVPSSELEPALPPLMPPELDGEEVPEVPSSELE
GI-50913503 297 PEDPKHPDDNLEPTLPPVM-----

GI-19224134 355 PALPPLMPPELDGEEVPEVPSSELEPALPPLMPPELDGEEVPEVPSSELEPALPPLMPPELDG
GI-50913503 316 -----LDGEEVPEVPSSELEPALPPLMPPELDG

GI-19224134 415 EEVPEKPSVDLPFIEVPRYEFNNKQDSPLAGESGETEYITEVYGNQONPVDIDKILPNETG
GI-50913503 343 QEVPEKPSIDLPIEVPRYEFNNKQDSPLAGESGETEYITEVYGNQONPVDIDKILPNETG

GI-19224134 475 FSGNMVETEDTKPEPEVLMGGQSESVEFTKDTQTGMSCGOTTPQVETEDTKPEPEVLMGGQSE
GI-50913503 403 FSGNMVETEDTKPEPEVLMGGQSESVEFTKDTQTGMSCGOTTPQVETEDTKPEPEVLMGGQSE

GI-19224134 535 SVEFTKDTQTGMSCGOTTPQVETEDTKPEPEVLMGGQSESVEFTKDTQTGMSCGOTTPQVETE
GI-50913503 463 SVEFTKDTQTGMSCGOTTPQVETEDTKPEPEVLMGGQSESVEFTKDTQTGMSCGOTTPQVETE

GI-19224134 595 DTKEPEVLMGGQSESVEFTKDTQTGMSCGFSETATVVEDTRPKLVPHFDNNEPKVEENREK
GI-50913503 523 DTKEPEVLMGGQSESVEFTKDTQTGMSCGFSETATVVEDTRPKLVPHFDNNEPKVEENREK

GI-19224134 655 PTKNITPILPATGDIENVLAFGLILILSVLSIFSLLNKONNKV-
GI-50913503 583 PTKNITPILPATGDIENVLAFGLILILSVLSIFSLLNKONNKV

FIGURE 53

170/487

GI-19745307 1 MTQKNSYKLSFLLSLTGFILGLLLVFIGLSGVSVGHAEFRNGANKQCA
 ORF84 WO 2006/078318 NSYKLSFLLSLTGFILGLLLVFIGLSGVSVGHAEFRNGANKQCA PCT/US2005/027239
 GI-28810263 1 MTQKNSYKLSFLLSLTGFILGLLLVFIGLSGVSVGHAEFRNGANKQCAFEIKKN
 GI-21909640 1 MTQKNSYKLSFLLSLTGFILGLLLVFIGLSGVSVGHAEFRNGANKQCAFEIKKN
 GI-19224141 1 MTQKNSYKLSFLLSLTGFILGLLLVFIGLSGVSVGHAEFRNGANKQCSFEIKKVDQNNKP

GI-19745307 55 ----- KSOBEYNYE
 ORF84 55 ----- KSOBEYNYE
 GI-28810263 55 ----- KSOBEYNYE
 GI-21909640 1 -----
 GI-19224141 61 LPGATFSLTSKDGKGTSVQTFSTNDKGI VDAQNLQPGTYTLKEETAPDGYDKSRITVTVT

GI-19745307 64 VYDN ----- RNI
 ORF84 64 VYDN ----- RNI
 GI-28810263 64 VYDN ----- RNI
 GI-21909640 1 -----
 GI-19224141 121 VYENGYTKLVENPYNGEII SKAGSKDVSSSLQLENPKMSVVSKYKTEVSSGAADFYENH

GI-19745307 71 LODGEHKLEIKRVDGCTGKTYQG FCFQLTNFF TAQGVSKKLYKKLSS
 ORF84 71 LODGEHKLEIKRVDGCTGKTYQG FCFQLTNFF TAQGVSKKLYKKLSS
 GI-28810263 71 LODGEHKLEIKRVDGCTGKTYQG FCFQLTNFF TAQGVSKKLYKKLSS
 GI-21909640 1 -----
 GI-19224141 181 AAYFKMSFENKOKDKSETINEGDTSEVLQDRRLNPKGISODEPITRYDSANSPLAIGKYH

GI-19745307 118 ----- SDEETLK
 ORF84 118 ----- SDEETLK
 GI-28810263 118 ----- SDEETLK
 GI-21909640 4 ----- SDEETLK
 GI-19224141 241 AENHQLIYTFDYIAGLDKVLQSAELSLFLENKEVLENTSISNFKSTIGGQEITYKGTVN

GI-19745307 125 QYASKYTSNRRGDTSC
 ORF84 125 QYASKYTSNRRGDTSC
 GI-28810263 125 QYASKYTSNRRGDTSC
 GI-21909640 11 QYASKYTSNRRGDTSC
 GI-19224141 301 VLYGNESTKESNYHTNGLSNVCGSIESYNTETGEFVWVYVNPNTNI PYATMNLWGFR

GI-19745307 141 ----- NLKQIAKVLTEGYPT
 ORF84 141 ----- NLKQIAKVLTEGYPT
 GI-28810263 141 ----- NLKQIAKVLTEGYPT
 GI-21909640 27 ----- NLKQIAKVLTEGYPT
 GI-19224141 361 ARSNTSDLENDANTSSAELGEIOVYEVPEGEKLPSSYGVDVTKLTLRDLITAGLNGTOM

GI-19745307 157 NKS DWLN GLTENENIEVTQDAIWE
 ORF84 157 NKS DWLN GLTENENIEVTQDAIWE
 GI-28810263 157 NKS DWLN GLTENENIEVTQDAIWE
 GI-21909640 43 NKS DWLN GLTENENIEVTQDAIWE
 GI-19224141 421 TRRQRIDFCNNIQNKAFIIVKVTGKTQSGKPLVVQSNLASFRGASEYAAFTPVGGNVYEQ

GI-19745307 182 TETTVPADR SYTNRNVNSQRMKEVYOKLIDTTDID KYEDVQFDLFVPQDTN
 ORF84 182 TETTVPADR SYTNRNVNSQRMKEVYOKLIDTTDID KYEDVQFDLFVPQDTN
 GI-28810263 182 TETTVPADR SYTNRNVNSQRMKEVYOKLIDTTDID KYEDVQFDLFVPQDTN
 GI-21909640 68 TETTVPADR SYTNRNVNSQRMKEVYOKLIDTTDID KYEDVQFDLFVPQDTN
 GI-19224141 481 NEIALSPSKGSGSKSEFTKPSITVANLRVAQLRFKRMSTDNVPLEEAAAEFLRSSVGN

GI-19745307 233 LQAVISVEPVIESLPITS LRPIAQNDITANN
 ORF84 233 LQAVISVEPVIESLPITS LRPIAQNDITANN
 GI-28810263 233 LQAVISVEPVIESLPITS LRPIAQNDITANN
 GI-21909640 119 LQAVISVEPVIESLPITS LRPIAQNDITANN
 GI-19224141 541 QKLEASSNTQGEVHFKDLTSGTYDLYETKAPKGYQQVTEKLETVTVDTTINPAEEMVTWGS

FIGURE 54